title,summary,description,subject,return,daily_alpha,action
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference,AC Immune Announces Upcoming Presentations at the 16th CTAD Conference,AC Immune Announces Upcoming Presentations at the 16th CTAD Conference,Calendar of Events,0.014981259,0.022388861,long
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline,AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline,AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline,Calendar of Events,0.009009,0.00693203,long
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43,AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43,AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43,Health,0.012658317,0.015000731,long
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic,PRESS RELEASE,PRESS RELEASE,Company Announcement,-0.072413804,-0.076389115,short
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease,AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease,AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease,Company Announcement,0.042553254,0.039435822,long
"AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease","AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease","AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease",Clinical Study,0.116161625,0.114052401,long
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update,AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update,AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update,Interim information,0,0.002230822,long
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update,AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update,AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update,Earnings Releases and Operating Results,0,0.006319337,long
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update,AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update,AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update,Clinical Study,0.069204084,0.065015498,long
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update,AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update,AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update,Earnings Releases and Operating Results,0.038869306,0.033344177,long
AC Immune SA Appoints New Chief Medical Officer,AC Immune SA Appoints New Chief Medical Officer,AC Immune SA Appoints New Chief Medical Officer,Management Changes,0.006825932,0.008955743,long
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial,AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial,AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial,Clinical Study,0.106837611,0.09989369,long
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development,AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development,AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development,Clinical Study,0.091603061,0.090945269,long
AC Immune Showcasing Precision Medicine Programs at AAIC 2023,AC Immune Showcasing Precision Medicine Programs at AAIC 2023,AC Immune Showcasing Precision Medicine Programs at AAIC 2023,Clinical Study,-0.005076097,-0.004264002,short
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease,AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease,AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease,Calendar of Events,-0.015659888,-0.013800173,short
"AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023","AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023","AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023",Clinical Study,0.003389827,-0.005884727,short
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023,AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023,AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023,Calendar of Events,0,-0.007491911,short
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023,AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023,AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023,Calendar of Events,0.011450462,0.012156953,long
AC Immune to Present at the Jefferies 2023 London Healthcare Conference,AC Immune to Present at the Jefferies 2023 London Healthcare Conference,AC Immune to Present at the Jefferies 2023 London Healthcare Conference,Calendar of Events,-0.009293716,-0.009293716,short
AC Immune to Present at the SVB Securities Global Biopharma Conference,AC Immune to Present at the SVB Securities Global Biopharma Conference,AC Immune to Present at the SVB Securities Global Biopharma Conference,Calendar of Events,-0.016064242,-0.025947391,short
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference,"Lausanne, Switzerland, November 23, 2022 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the upcoming presentations of its vaccine technology SupraAntigen®, and of its anti-Tau and anti-Abeta investigational candidates, at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, California (United States) and online, on November 29 – December 2, 2022.","Lausanne, Switzerland, November 23, 2022 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the upcoming presentations of its vaccine technology SupraAntigen®, and of its anti-Tau and anti-Abeta investigational candidates, at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, California (United States) and online, on November 29 – December 2, 2022.",Clinical Study,0.018518501,0.019393735,long
"AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023","AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023","AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023",Calendar of Events,-0.004132227,-0.004433595,short
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update,"- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy –","- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy –",Earnings Releases and Operating Results,0.00847467,0.007055668,long
DBV Technologies participera au prochain congrès de l’EAACI 2023,"Montrouge, France, 8 juin 2023","Montrouge, France, 8 juin 2023",European Regulatory News,,,
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate,"SAN DIEGO and SUZHOU, China, May  04, 2023  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced achievement of a milestone in its ongoing collaboration with Exelixis for development of novel masked antibody-drug conjugate (ADC) candidates leveraging Adagene’s proprietary SAFEbody precision masking technology.","SAN DIEGO and SUZHOU, China, May  04, 2023  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced achievement of a milestone in its ongoing collaboration with Exelixis for development of novel masked antibody-drug conjugate (ADC) candidates leveraging Adagene’s proprietary SAFEbody precision masking technology.",Product / Services Announcement,0,0.002671429,long
"Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors","- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four cycles both as monotherapy and in combination with anti-PD-1 therapy -","- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four cycles both as monotherapy and in combination with anti-PD-1 therapy -",Calendar of Events,-0.023579865,-0.060786138,short
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial,"- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology -","- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology -",Clinical Study,0.024999976,0.019099108,long
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting,- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort –,- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort –,Calendar of Events,0.033557015,0.032113109,long
Adagene Announces Updates to its Board of Directors,"SAN DIEGO and SUZHOU, China, April  28, 2023  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced updates to its board of directors (the “Board”), including the following:","SAN DIEGO and SUZHOU, China, April  28, 2023  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced updates to its board of directors (the “Board”), including the following:",Directors and Officers,0,0.002230822,long
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors,"- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave way for dose expansion in specific tumors -","- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave way for dose expansion in specific tumors -",Clinical Study,0.048275814,0.044313926,long
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023,"- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab –","- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab –",Product / Services Announcement,0.015037579,0.011459088,long
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
天演药业将在第38届SITC年会上以海报形式公布其精准掩蔽型抗CTLA-4安全抗体SAFEbody® ADG126剂量优化试验结果,-数据将展示ADG126的作用机制及与帕博利珠单抗联用连续给药的剂量优化，10 mg/kg每3周一次的方案目前正在微卫星稳定型晚期结直肠癌中进行队列扩展研究,-数据将展示ADG126的作用机制及与帕博利珠单抗联用连续给药的剂量优化，10 mg/kg每3周一次的方案目前正在微卫星稳定型晚期结直肠癌中进行队列扩展研究,Calendar of Events,0.033557015,0.032113109,long
"Aditxt, Inc. to Present at 8th Annual Dawson James Conference","Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023 Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023","Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023 Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023",Advisory,-0.023769078,-0.017809128,short
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in  Q2 2024,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex Announces Participation in the Bio-Europe 2023 Conference,"Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, and Dr. Mikhail Kalinichev, Head of Translational Science, will be attending the Bio-Europe 2023 Conference (November 6 – 8, 2023) in Munich, Germany.","Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, and Dr. Mikhail Kalinichev, Head of Translational Science, will be attending the Bio-Europe 2023 Conference (November 6 – 8, 2023) in Munich, Germany.",European Regulatory News,,,
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference,"Geneva, Switzerland, September 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will be attending the H.C. Wainwright 25th Annual Global Investment Conference (September 11 – 13, 2023) in New York.","Geneva, Switzerland, September 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will be attending the H.C. Wainwright 25th Annual Global Investment Conference (September 11 – 13, 2023) in New York.",European Regulatory News,,,
Addex Announces Plan to Implement ADS Ratio Change, Ad Hoc Announcement Pursuant to Art. 53 LR, Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex Completes $5.0 Million Equity Financing,Proceeds to advance allosteric modulator therapeutic pipeline,Proceeds to advance allosteric modulator therapeutic pipeline,European Regulatory News,,,
Addex Completes ADS Ratio Change, Ad Hoc Announcement Pursuant to Art. 53 LR, Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex Convenes Annual General Meeting 2023,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex Increases Issued Share Capital to Create Treasury Shares,Ad Hoc Announcement Pursuant to Art. 53 LR ,Ad Hoc Announcement Pursuant to Art. 53 LR ,European Regulatory News,,,
Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex Raises $5.0 Million in Equity Financing,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency,Ad Hoc Announcement Pursuant to Art. 53 LR ,Ad Hoc Announcement Pursuant to Art. 53 LR ,European Regulatory News,,,
Addex Regains Nasdaq Listing Compliance,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex Reports Full Year 2022 Financial Results and Provides Corporate Update,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex Reports Q1 2023 Financial Results and Provides Corporate Update,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain,Ad Hoc Announcement Pursuant to Art. 53 LR,Ad Hoc Announcement Pursuant to Art. 53 LR,European Regulatory News,,,
Addex Shareholders Approve All Resolutions at Annual General Meeting,Ad Hoc Announcement Pursuant to Art. 53 LR ,Ad Hoc Announcement Pursuant to Art. 53 LR ,European Regulatory News,,,
"Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023","Geneva, Switzerland, August 3, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2023 Financial Results on August 10, 2023. Tim Dyer, CEO,  Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.","Geneva, Switzerland, August 3, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2023 Financial Results on August 10, 2023. Tim Dyer, CEO,  Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.",European Regulatory News,,,
"Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023","Geneva, Switzerland, May 4, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Q1 2023 financial results on Thursday, May 11, 2023. Tim Dyer, CEO and Robert Lütjens, Head of Discovery – Biology, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.","Geneva, Switzerland, May 4, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Q1 2023 financial results on Thursday, May 11, 2023. Tim Dyer, CEO and Robert Lütjens, Head of Discovery – Biology, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.",European Regulatory News,,,
"Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy","SOUTH SAN FRANCISCO, Calif., Jan.  10, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy.","SOUTH SAN FRANCISCO, Calif., Jan.  10, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy.",Management Changes,0.003855708,0.005428403,long
"Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023","Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023. Tim Dyer, CEO , Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day.","Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023. Tim Dyer, CEO , Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day.",European Regulatory News,,,
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®,"IRVINE, Calif., Aug.  29, 2023  (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced the presentation of positive results from its Phase 2 clinical study of ABP-450 for the treatment of cervical dystonia (CD), a chronic and debilitating neurologic condition affecting the muscles of the neck, at the International Parkinson and Movement Disorders Society Congress® (IP-MDS), which is being held at the Bella Center in Copenhagen, Denmark, from August 27 – 31, 2023. The data was previously released by the Company in September 2022.","IRVINE, Calif., Aug.  29, 2023  (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced the presentation of positive results from its Phase 2 clinical study of ABP-450 for the treatment of cervical dystonia (CD), a chronic and debilitating neurologic condition affecting the muscles of the neck, at the International Parkinson and Movement Disorders Society Congress® (IP-MDS), which is being held at the Bella Center in Copenhagen, Denmark, from August 27 – 31, 2023. The data was previously released by the Company in September 2022.",Research Analysis and Reports,0.038929402,0.039177879,long
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache,"IRVINE, Calif., Aug.  24, 2023  (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent Application No. 17/006,685, titled “Neurotoxin Compositions for Use in Treating Headache” (the “Application”), which involves the Company’s lead asset, ABP-450 (prabotulinumtoxinA) injection. The soon to issue patent will provide protection in the United States for the claimed methods of use of ABP-450 into 2041.","IRVINE, Calif., Aug.  24, 2023  (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent Application No. 17/006,685, titled “Neurotoxin Compositions for Use in Treating Headache” (the “Application”), which involves the Company’s lead asset, ABP-450 (prabotulinumtoxinA) injection. The soon to issue patent will provide protection in the United States for the claimed methods of use of ABP-450 into 2041.",Patents,0.029810269,0.026063336,long
AEON Biopharma Reports Third Quarter 2023 Financial Results,– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study –,– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study –,Earnings Releases and Operating Results,-0.043062162,-0.039930198,short
"Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma","The 7,380,394 AEON shares reflected in the Form 4 filed on August 14th were transferred to limited partners of Strathspey Crown","The 7,380,394 AEON shares reflected in the Form 4 filed on August 14th were transferred to limited partners of Strathspey Crown",Regulatory information,0.119221352,0.1201923,long
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology,"As previously reported, the study met its primary endpoint of improvement in liver fibrosis without worsening of NASH at week 24, and key secondary endpoints including NASH resolution without worsening of fibrosis","As previously reported, the study met its primary endpoint of improvement in liver fibrosis without worsening of NASH at week 24, and key secondary endpoints including NASH resolution without worsening of fibrosis",Clinical Study,0.007585348,0.006446775,long
MDxHealth Announces its Extraordinary General Shareholders’ Meeting,    ,    ,European Regulatory News,,,
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease,"Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone","Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone",Clinical Study,-0.018403608,-0.019244853,short
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology,Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses,Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses,Calendar of Events,-0.007883097,0.000318358,long
"Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins","22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo","22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo",Clinical Study,-0.59064688,-0.592150486,short
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update,"-- Results from Cohort D, an expansion cohort of type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 agonist, to be reported during the second quarter of 2023 -- -- SYNCHRONY Phase 3 studies on track to begin enrolling in the second half of this year --","-- Results from Cohort D, an expansion cohort of type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 agonist, to be reported during the second quarter of 2023 -- -- SYNCHRONY Phase 3 studies on track to begin enrolling in the second half of this year --",Earnings Releases and Operating Results,-0.010144641,-0.011675302,short
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results,"SOUTH SAN FRANCISCO, Calif., March  17, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2022.","SOUTH SAN FRANCISCO, Calif., March  17, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2022.",Earnings Releases and Operating Results,0.005787608,0.013083521,long
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update,"-- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov.  13, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.","-- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov.  13, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.",Earnings Releases and Operating Results,-0.001412394,0.001719569,long
Akoya to Participate at Three Upcoming Investor Conferences,"MARLBOROUGH, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences.","MARLBOROUGH, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences.",Calendar of Events,0.026392936,0.017118382,long
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference,"SOUTH SAN FRANCISCO, Calif., Jan.  04, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA.","SOUTH SAN FRANCISCO, Calif., Jan.  04, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA.",Trade Show,0.002020579,-0.004176536,short
Akero Therapeutics to Present at the Jefferies Healthcare Conference,"SAN FRANCISCO, May  31, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced that management will present at the Jefferies Healthcare Conference Wednesday, June 7, 2023, at 10:30 a.m. (ET) in New York, NY.","SAN FRANCISCO, May  31, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced that management will present at the Jefferies Healthcare Conference Wednesday, June 7, 2023, at 10:30 a.m. (ET) in New York, NY.",Calendar of Events,-0.001822693,0.002699164,long
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November,"SOUTH SAN FRANCISCO, Calif., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present at the following investor conferences this month:","SOUTH SAN FRANCISCO, Calif., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present at the following investor conferences this month:",Calendar of Events,-0.003211255,-0.004630235,short
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September,"SOUTH SAN FRANCISCO, Calif., Aug.  31, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the following investor conferences this month:","SOUTH SAN FRANCISCO, Calif., Aug.  31, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the following investor conferences this month:",Calendar of Events,-0.001609294,-0.003028296,short
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023,"Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due to NASH/MASH","Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due to NASH/MASH",Clinical Study,0.018465925,0.013533198,long
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022,Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category,Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category,Calendar of Events,0.023908576,0.020294957,long
"Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023","MARLBOROUGH, Mass., April  06, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.","MARLBOROUGH, Mass., April  06, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.",Calendar of Events,0.004026874,0.006063226,long
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023,"SOUTH SAN FRANCISCO, Calif., Aug.  28, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that all samples and data required for a readout of topline results from the Phase 2b SYMMETRY study have been collected, which supports the expected timing of readout in October of this year. The topline week 36 results from the study, evaluating treatment of patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH), will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins as well as safety and tolerability.","SOUTH SAN FRANCISCO, Calif., Aug.  28, 2023  (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that all samples and data required for a readout of topline results from the Phase 2b SYMMETRY study have been collected, which supports the expected timing of readout in October of this year. The topline week 36 results from the study, evaluating treatment of patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH), will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins as well as safety and tolerability.",Product / Services Announcement,0.037940372,0.032780954,long
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH,Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks,Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks,Product / Services Announcement,0.00925046,0.004214314,long
Akoya Biosciences and Enable Medicine Introduce Cloud Platform to Power Faster Analysis of PhenoCycler-Fusion Data,"MARLBOROUGH, Mass., April  12, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced they are partnering with Enable Medicine to introduce a cloud platform capable of significantly accelerating the analysis of high plex spatial image datasets generated by Akoya’s PhenoCycler-Fusion system. Demos of the cloud platform will be available at the Akoya booth (#1713) at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, April 14-19, 2023.","MARLBOROUGH, Mass., April  12, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced they are partnering with Enable Medicine to introduce a cloud platform capable of significantly accelerating the analysis of high plex spatial image datasets generated by Akoya’s PhenoCycler-Fusion system. Demos of the cloud platform will be available at the Akoya booth (#1713) at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, April 14-19, 2023.",Partnerships,0.027586181,0.022338709,long
Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel,"MARLBOROUGH, Mass., Feb.  28, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight.","MARLBOROUGH, Mass., Feb.  28, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight.",Directors and Officers,0,0.001257134,long
"Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies","MARLBOROUGH, Mass., Aug.  07, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced   a momentous achievement - publication of the 1,000th peer-reviewed article citing use of the company’s technology, the largest publication volume in the industry. Approximately 80% of these articles have been published in the last 2.5 years, reflecting the exponential growth in adoption of Akoya's solutions.","MARLBOROUGH, Mass., Aug.  07, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced   a momentous achievement - publication of the 1,000th peer-reviewed article citing use of the company’s technology, the largest publication volume in the industry. Approximately 80% of these articles have been published in the last 2.5 years, reflecting the exponential growth in adoption of Akoya's solutions.",Product / Services Announcement,-0.003100772,-0.007353125,short
Eurobio Scientific: GenDx reduces organ matching time to 3 hours,Eurobio Scientific: GenDx reduces organ matching time to 3 hours,Eurobio Scientific: GenDx reduces organ matching time to 3 hours,European Regulatory News,0.004285744,-0.003130885,short
Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures,"MARLBOROUGH, Mass., Oct.  17, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that researchers from Akoya Biosciences and The University of Queensland’s Frazer Institute have comprehensively mapped the spatial proteome of head and neck squamous cell carcinoma (HNSCC) using ultrahigh-plex spatial phenotyping. Spatial phenotyping consists of whole-slide imaging of tissue sections at single-cell resolution to visualize and quantitate biomarker expression and reveal how cells interact and organize across the entire tissue landscape.","MARLBOROUGH, Mass., Oct.  17, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that researchers from Akoya Biosciences and The University of Queensland’s Frazer Institute have comprehensively mapped the spatial proteome of head and neck squamous cell carcinoma (HNSCC) using ultrahigh-plex spatial phenotyping. Spatial phenotyping consists of whole-slide imaging of tissue sections at single-cell resolution to visualize and quantitate biomarker expression and reveal how cells interact and organize across the entire tissue landscape.",Research Analysis and Reports,0.072463767,0.065047137,long
Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow,"MARLBOROUGH, Mass., April  12, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the launch of PhenoCode™ Discovery Panels, which simplify spatial biology workflows performed on the company’s PhenoCycler-Fusion platform, at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, April 14-19, 2023.","MARLBOROUGH, Mass., April  12, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the launch of PhenoCode™ Discovery Panels, which simplify spatial biology workflows performed on the company’s PhenoCycler-Fusion platform, at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, April 14-19, 2023.",Product / Services Announcement,0.027586181,0.022338709,long
Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms,"MARLBOROUGH, Mass., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today highlighted the industry-leading scale and speed in whole-slide, spatial biology workflows enabled by the recently launched PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platform upgrades. Enhancements to the PhenoCycler-Fusion 2.0 System allow customers to process twice as many samples per week, making it the highest throughput spatial discovery platform on the market. The PhenoImager 2.0 platform delivers a 5x workflow improvement by enabling rapid real-time image analysis directly on the HT instrument. With an unprecedented ability to perform whole-slide spatial biology at scale, Akoya’s customers can accelerate progress towards new discoveries, identification of clinically relevant biomarkers, and development of novel spatial signatures.","MARLBOROUGH, Mass., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today highlighted the industry-leading scale and speed in whole-slide, spatial biology workflows enabled by the recently launched PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platform upgrades. Enhancements to the PhenoCycler-Fusion 2.0 System allow customers to process twice as many samples per week, making it the highest throughput spatial discovery platform on the market. The PhenoImager 2.0 platform delivers a 5x workflow improvement by enabling rapid real-time image analysis directly on the HT instrument. With an unprecedented ability to perform whole-slide spatial biology at scale, Akoya’s customers can accelerate progress towards new discoveries, identification of clinically relevant biomarkers, and development of novel spatial signatures.",Product / Services Announcement,0.009434066,0.011575518,long
Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting,Simultaneous detection of proteins and RNA markers across 23 different tissue samples demonstrate robust and scalable capabilities of company’s multiomics solution Simultaneous detection of proteins and RNA markers across 23 different tissue samples demonstrate robust and scalable capabilities of company’s multiomics solution,Simultaneous detection of proteins and RNA markers across 23 different tissue samples demonstrate robust and scalable capabilities of company’s multiomics solution Simultaneous detection of proteins and RNA markers across 23 different tissue samples demonstrate robust and scalable capabilities of company’s multiomics solution,Health,0.004444461,0.007568894,long
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023,Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale,Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale,Calendar of Events,-0.002941174,-0.004360833,short
EUROBIO : ACCÉLÉRATION DU DÉPLOIEMENT STRATÉGIQUE AU PREMIER SEMESTRE 2023,ACCÉLÉRATION DU DÉPLOIEMENT STRATÉGIQUE AU PREMIER SEMESTRE 2023,ACCÉLÉRATION DU DÉPLOIEMENT STRATÉGIQUE AU PREMIER SEMESTRE 2023,European Regulatory News,-0.005291,-0.007121772,short
EUROBIO : ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023,ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023,ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023,European Regulatory News,-0.005291,-0.007121772,short
Eurobio Scientific : 2022 ANNUAL RESULTS - Very strong performance and strengthening of the Core Business,2022 ANNUAL RESULTS,2022 ANNUAL RESULTS,European Regulatory News,-0.001234596,-0.000474631,short
Eurobio Scientific: all resolutions approved at the Annual General Meeting,Eurobio Scientific: all resolutions approved at the Annual General Meeting,Eurobio Scientific: all resolutions approved at the Annual General Meeting,European Regulatory News,-0.004087222,0.003948527,long
Eurobio Scientific becomes one of the first European companies to obtain IVDR1 CE marking of PCR tests,Eurobio Scientific becomes one of the first European companies to obtainIVDR1 CE marking of PCR tests,Eurobio Scientific becomes one of the first European companies to obtainIVDR1 CE marking of PCR tests,European Regulatory News,0.011904808,0.019073673,long
Eurobio Scientific : bilan semestriel du contrat de liquidité,BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE,BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE,European Regulatory News,0.015602788,0.015056635,long
Eurobio Scientific: CATHERINE COURBOILLET TO JOIN EUROBIO SCIENTIFIC BOARD AS AN INDEPENDENT MEMBER,CATHERINE COURBOILLET TO JOIN EUROBIO SCIENTIFIC BOARD AS AN INDEPENDENT MEMBER,CATHERINE COURBOILLET TO JOIN EUROBIO SCIENTIFIC BOARD AS AN INDEPENDENT MEMBER,European Regulatory News,0.030967712,0.028121675,long
Eurobio Scientific devient une des premières sociétés européennes à obtenir le marquage CE IVDR1 de tests PCR,Eurobio Scientific devient une des premières sociétés européennes à obtenir le marquage CE IVDR1 de tests PCR,Eurobio Scientific devient une des premières sociétés européennes à obtenir le marquage CE IVDR1 de tests PCR,European Regulatory News,0.011904808,0.019073673,long
Eurobio Scientific formalises the appointment of Anne-Sophie Hérelle as Group CFO,EUROBIO SCIENTIFIC FORMALISES THE APPOINTMENT OF ANNE-SOPHIE HERELLE AS GROUP CFO,EUROBIO SCIENTIFIC FORMALISES THE APPOINTMENT OF ANNE-SOPHIE HERELLE AS GROUP CFO,European Regulatory News,0.011725349,0.017728328,long
Eurobio Scientific : GenDx réduit à 3h la durée des tests de compatibilité d’organes,Eurobio Scientific : GenDx réduit à 3h la durée des tests de compatibilité d’organes,Eurobio Scientific : GenDx réduit à 3h la durée des tests de compatibilité d’organes,European Regulatory News,0.004285744,-0.003130885,short
Eurobio Scientific : l’assemblée générale approuve l’ensemble des résolutions,Eurobio Scientific : l’assemblée générale approuve l’ensemble des résolutions,Eurobio Scientific : l’assemblée générale approuve l’ensemble des résolutions,European Regulatory News,-0.004087222,0.003948527,long
Eurobio Scientific : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2022,MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2022,MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2022,European Regulatory News,-0.004884,-0.015674062,short
Eurobio Scientific - MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2023,MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2023,MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2023,European Regulatory News,0.011612923,0.006704327,long
Eurobio Scientific : NOMINATION DE CATHERINE COURBOILLET EN TANT QU’ADMINISTRATRICE INDEPENDANTE,NOMINATION DE CATHERINE COURBOILLET EN TANT QU’ADMINISTRATRICE INDEPENDANTE,NOMINATION DE CATHERINE COURBOILLET EN TANT QU’ADMINISTRATRICE INDEPENDANTE,European Regulatory News,0.030967712,0.028121675,long
EUROBIO SCIENTIFIC : RAPPORT FINANCIER ANNUEL 2022,EUROBIO SCIENTIFIC : RAPPORT FINANCIER ANNUEL 2022,EUROBIO SCIENTIFIC : RAPPORT FINANCIER ANNUEL 2022,European Regulatory News,-0.004884,-0.015674062,short
Eurobio Scientific: RESULTATS ANNUELS 2022 - Très solide performance et renforcement du Cœur d’Activité,RESULTATS ANNUELS 2022,RESULTATS ANNUELS 2022,European Regulatory News,-0.001234596,-0.000474631,short
EUROBIO SCIENTIFIC : RESULTATS DU 1ER SEMESTRE 2023,RESULTATS DU 1ER SEMESTRE 2023,RESULTATS DU 1ER SEMESTRE 2023,European Regulatory News,0,-0.001560905,short
Eurobio Scientific : Results for the First Half of 2023, , ,European Regulatory News,0,-0.001560905,short
"Eurobio Scientific : Wietse Mulder, CEO de GenDx,  détient 2% du capital","Wietse Mulder, CEO de GenDx, détient 2% du capital d’Eurobio Scientific ","Wietse Mulder, CEO de GenDx, détient 2% du capital d’Eurobio Scientific ",European Regulatory News,-0.002724858,-0.006129255,short
"Eurobio Scientific: Wietse Mulder, CEO of GenDx, holds a 2% stake","WIETSE MULDER, CEO OF GENDX, HOLDS A 2% STAKE IN EUROBIO SCIENTIFIC","WIETSE MULDER, CEO OF GENDX, HOLDS A 2% STAKE IN EUROBIO SCIENTIFIC",European Regulatory News,-0.002724858,-0.006129255,short
Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland,"Alvotech (Nasdaq: ALVO) and Íslandsbanki hf. (“Islandsbanki”) have entered into a market making agreement. According to the market making agreement, Islandsbanki places bids and offers for ALVO shares trading on the Nasdaq Iceland Main Market (the “Exchange”) for a minimum amount with a fixed spread between the bid and offer price.","Alvotech (Nasdaq: ALVO) and Íslandsbanki hf. (“Islandsbanki”) have entered into a market making agreement. According to the market making agreement, Islandsbanki places bids and offers for ALVO shares trading on the Nasdaq Iceland Main Market (the “Exchange”) for a minimum amount with a fixed spread between the bid and offer price.",European Regulatory News,-0.021505355,-0.021835298,short
"Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer","-- Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct.  31, 2023  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company's new Executive Vice President, Chief Legal & Compliance Officer. He will join the Company on November 15.","-- Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct.  31, 2023  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company's new Executive Vice President, Chief Legal & Compliance Officer. He will join the Company on November 15.",Directors and Officers,0.029411736,0.02455802,long
"Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)","Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group (“JAMP Pharma”), a Canadian owned pharmaceutical organization headquartered in the Greater Montreal area, announced today that Health Canada has granted JAMP Pharma marketing authorization for AVT04, a biosimilar to Stelara® (ustekinumab) developed by Alvotech. AVT04 will be marketed under the brand name JamtekiTM.","Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group (“JAMP Pharma”), a Canadian owned pharmaceutical organization headquartered in the Greater Montreal area, announced today that Health Canada has granted JAMP Pharma marketing authorization for AVT04, a biosimilar to Stelara® (ustekinumab) developed by Alvotech. AVT04 will be marketed under the brand name JamtekiTM.",European Regulatory News,0.003325913,-0.010599903,short
"Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)",PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada.,PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada.,Licensing Agreements,0.003325913,-0.010599903,short
Alvotech Announces Changes to the Leadership Team,"Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Faysal Kalmoua has been appointed Alvotech’s Chief Operating Officer and Hafrun Fridriksdottir is stepping down following resubmission of the Biologics License Application (BLA) for AVT02, Alvotech’s proposed high-concentration interchangeable biosimilar to Humira® (adalimumab).","Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Faysal Kalmoua has been appointed Alvotech’s Chief Operating Officer and Hafrun Fridriksdottir is stepping down following resubmission of the Biologics License Application (BLA) for AVT02, Alvotech’s proposed high-concentration interchangeable biosimilar to Humira® (adalimumab).",European Regulatory News,-0.004036323,-0.000730529,short
Alvotech Announces Changes to the Leadership Team," REYKJAVIK, Iceland, Sept.  05, 2023  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Faysal Kalmoua has been appointed Alvotech’s Chief Operating Officer and Hafrun Fridriksdottir is stepping down following resubmission of the Biologics License Application (BLA) for AVT02, Alvotech’s proposed high-concentration interchangeable biosimilar to Humira® (adalimumab)."," REYKJAVIK, Iceland, Sept.  05, 2023  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Faysal Kalmoua has been appointed Alvotech’s Chief Operating Officer and Hafrun Fridriksdottir is stepping down following resubmission of the Biologics License Application (BLA) for AVT02, Alvotech’s proposed high-concentration interchangeable biosimilar to Humira® (adalimumab).",Management Changes,-0.004036323,-0.000730529,short
Alvotech mun birta uppgjör fyrstu níu mánaða 2023 þann 28. nóvember og streyma uppgjörsfundi 29. nóvember kl. 13:00 að íslenskum tíma,"Alvotech (NASDAQ: ALVO) mun birta uppgjör fyrir fyrstu níu mánuði ársins 2023 eftir lokun markaða í Bandaríkjunum, þriðjudaginn 28. nóvember 2023.  Þá mun Alvotech halda kynningarfund fyrir fjárfesta í beinu streymi miðvikudaginn 29. nóvember nk. kl. 13:00 að íslenskum tíma.","Alvotech (NASDAQ: ALVO) mun birta uppgjör fyrir fyrstu níu mánuði ársins 2023 eftir lokun markaða í Bandaríkjunum, þriðjudaginn 28. nóvember 2023.  Þá mun Alvotech halda kynningarfund fyrir fjárfesta í beinu streymi miðvikudaginn 29. nóvember nk. kl. 13:00 að íslenskum tíma.",European Regulatory News,-0.020787804,-0.018410273,short
Alvotech og Íslandsbanki gera samning um viðskiptavakt með hlutabréf í Kauphöllinni,"Alvotech (NASDAQ: ALVO) og Íslandbanki hf. hafa gert samning um viðskiptavakt á hlutabréfum Alvotech á Aðalmarkaði Nasdaq Iceland („Kauphöllinni“).  Samkvæmt samningnum gefur Íslandsbanki út virk kaup og sölutilboð fyrir hlutabréf í Alvotech á Nasdaq Iceland markaðnum („Kauphöllinni“), fyrir ákveðna lágmarksfjárhæð með föstu bili milli kaup og söluverðs.","Alvotech (NASDAQ: ALVO) og Íslandbanki hf. hafa gert samning um viðskiptavakt á hlutabréfum Alvotech á Aðalmarkaði Nasdaq Iceland („Kauphöllinni“).  Samkvæmt samningnum gefur Íslandsbanki út virk kaup og sölutilboð fyrir hlutabréf í Alvotech á Nasdaq Iceland markaðnum („Kauphöllinni“), fyrir ákveðna lágmarksfjárhæð með föstu bili milli kaup og söluverðs.",European Regulatory News,-0.021505355,-0.021835298,short
DBV Technologies présente ses résultats financiers du premier semestre 2023 et fait le point sur ses activités,"Montrouge, France, le 25 juillet (22h30 CET)","Montrouge, France, le 25 juillet (22h30 CET)",European Regulatory News,,,
"Alvotech og JAMP Pharma hljóta markaðsleyfi í Kanada fyrir Jamteki, líftæknilyfjahliðstæðu við Stelara","Alvotech (NASDAQ: ALVO) og JAMP Pharma Group („JAMP Pharma“) tilkynntu í dag Heilbrigðisstofnun Kanada, Health Canada, hafi veitt JAMP Pharma leyfi til markaðsetningar á AVT04, líftæknilyfjahliðstæðu við Stelara (ustekinumab) sem þróuð var af Alvotech. AVT04 verður markaðsett undir vörumerkinu Jamteki og er framleidd af Alvotech í Reykjavík.","Alvotech (NASDAQ: ALVO) og JAMP Pharma Group („JAMP Pharma“) tilkynntu í dag Heilbrigðisstofnun Kanada, Health Canada, hafi veitt JAMP Pharma leyfi til markaðsetningar á AVT04, líftæknilyfjahliðstæðu við Stelara (ustekinumab) sem þróuð var af Alvotech. AVT04 verður markaðsett undir vörumerkinu Jamteki og er framleidd af Alvotech í Reykjavík.",European Regulatory News,0.003325913,-0.010599903,short
Alvotech og STADA fyrst til að hljóta jákvæða afgreiðslu lyfjastofnunar Evrópu á umsókn um markaðsleyfi fyrir líftæknilyfjahliðstæðu við Stelara,"Alvotech (NASDAQ: ALVO) og STADA Arzneimittel (STADA) tilkynntu í dag að mannalyfjanefnd Lyfjastofnunar Evrópu (CHMP) hafi veitt jákvæða umsögn vegna umsóknar um markaðsleyfi fyrir Uzpruvo (AVT04), líftæknilyfjahliðstæðu við Stelara (ustekinumab) sem Alvotech hefur þróað.","Alvotech (NASDAQ: ALVO) og STADA Arzneimittel (STADA) tilkynntu í dag að mannalyfjanefnd Lyfjastofnunar Evrópu (CHMP) hafi veitt jákvæða umsögn vegna umsóknar um markaðsleyfi fyrir Uzpruvo (AVT04), líftæknilyfjahliðstæðu við Stelara (ustekinumab) sem Alvotech hefur þróað.",European Regulatory News,0.035632233,0.025012539,long
Alvotech tekur þátt í heilbrigðisráðstefnu Jefferies í London,"Alvotech (NASDAQ: ALVO) tekur þátt í heilbrigðisráðstefnu fjárfestingabankans Jefferies, sem haldin verður í London dagana 14.- 16. nóvember n.k. Stjórnendur Alvotech munu þar kynna starfsemi félagsins og funda með fjárfestum. ","Alvotech (NASDAQ: ALVO) tekur þátt í heilbrigðisráðstefnu fjárfestingabankans Jefferies, sem haldin verður í London dagana 14.- 16. nóvember n.k. Stjórnendur Alvotech munu þar kynna starfsemi félagsins og funda með fjárfestum. ",European Regulatory News,-0.001161356,-0.001161356,short
Alvotech tilkynnir um breytingar í framkvæmdastjórn,"Alvotech (NASDAQ: ALVO, „félagið“) tilkynnti í dag um breytingar í framkvæmdastjórn félagsins. Faysal Kalmoua hefur verið skipaður framkvæmdastjóri rekstrar og Hafrún Friðriksdóttir lætur af störfum. Breytingar fylgja í kjölfar þess að félagið hefur lagt inn endurnýjaða umsókn um markaðsleyfi í Bankaríkjunum fyrir AVT02, fyrirhugaða líftæknilyfjahliðstæðu með útskiptileika við Humira (adalimumab) í háum styrk.","Alvotech (NASDAQ: ALVO, „félagið“) tilkynnti í dag um breytingar í framkvæmdastjórn félagsins. Faysal Kalmoua hefur verið skipaður framkvæmdastjóri rekstrar og Hafrún Friðriksdóttir lætur af störfum. Breytingar fylgja í kjölfar þess að félagið hefur lagt inn endurnýjaða umsókn um markaðsleyfi í Bankaríkjunum fyrir AVT02, fyrirhugaða líftæknilyfjahliðstæðu með útskiptileika við Humira (adalimumab) í háum styrk.",European Regulatory News,-0.004036323,-0.000730529,short
Alvotech to Present at the Jefferies 2023 London Healthcare Conference,"Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference taking place in London on November 14-16, 2023. ","Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference taking place in London on November 14-16, 2023. ",European Regulatory News,-0.001161356,-0.001161356,short
Alvotech to Present at the Jefferies 2023 London Healthcare Conference,"REYKJAVIK, Iceland, Nov.  07, 2023  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference taking place in London on November 14-16, 2023.","REYKJAVIK, Iceland, Nov.  07, 2023  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference taking place in London on November 14-16, 2023.",Health,-0.001161356,-0.001161356,short
"Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET","Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of 2023, after U.S. markets close on Tuesday, November 28, 2023.","Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of 2023, after U.S. markets close on Tuesday, November 28, 2023.",European Regulatory News,-0.020787804,-0.018410273,short
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara,"BAD VILBEL, Germany and REYKJAVIK, Iceland, Nov.  10, 2023  (GLOBE NEWSWIRE) -- Partners STADA and Alvotech today announced that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) has adopted a positive opinion for Uzpruvo (AVT04), a biosimilar candidate to Stelara® (ustekinumab).","BAD VILBEL, Germany and REYKJAVIK, Iceland, Nov.  10, 2023  (GLOBE NEWSWIRE) -- Partners STADA and Alvotech today announced that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) has adopted a positive opinion for Uzpruvo (AVT04), a biosimilar candidate to Stelara® (ustekinumab).",Health,0.035632233,0.025012539,long
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara,"Partners STADA and Alvotech today announced that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency’s (EMA) has adopted a positive opinion for Uzpruvo (AVT04), a biosimilar candidate to Stelara® (ustekinumab).","Partners STADA and Alvotech today announced that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency’s (EMA) has adopted a positive opinion for Uzpruvo (AVT04), a biosimilar candidate to Stelara® (ustekinumab).",European Regulatory News,0.035632233,0.025012539,long
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea,Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the Region Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the Region,Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the Region Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the Region,Partnerships,0,-0.001072376,short
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel,-- Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –-,-- Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –-,Product / Services Announcement,-0.008695644,-0.002860395,short
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA),-- VASCEPA® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT-- -- VASCEPA Becomes First and Only Approved Medication in KSA for Reducing CV Risk Beyond Cholesterol Lowering Therapy in High-Risk Statin Treated Patients with Elevated and High Triglyceride Levels --,-- VASCEPA® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT-- -- VASCEPA Becomes First and Only Approved Medication in KSA for Reducing CV Risk Beyond Cholesterol Lowering Therapy in High-Risk Statin Treated Patients with Elevated and High Triglyceride Levels --,Product / Services Announcement,-0.008403453,-0.006070343,short
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health,-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –-,-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –-,Product / Services Announcement,-0.006711403,-0.00834173,short
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt,– Agreement Underscores Board’s Commitment to Aligning Executive Compensation with Shareholder Returns –,– Agreement Underscores Board’s Commitment to Aligning Executive Compensation with Shareholder Returns –,Directors and Officers,0.02777775,0.030040489,long
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events,— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression —,— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression —,Health,0.024999975,0.029426508,long
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors,"DUBLIN, Ireland and BRIDGEWATER, N.J., April  17, 2023  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer (CEO). In addition, the board has appointed Oliver O’Connor as a new independent Director of the company. Both appointments are effective immediately.","DUBLIN, Ireland and BRIDGEWATER, N.J., April  17, 2023  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer (CEO). In addition, the board has appointed Oliver O’Connor as a new independent Director of the company. Both appointments are effective immediately.",Directors and Officers,0,0.000218194,long
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update,-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing --,-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing --,Earnings Releases and Operating Results,0.014184384,0.012918711,long
Amarin Reports Second Quarter 2023 Financial Results,"-- Company Reported Total Net Revenues of $80 Million in Second Quarter 2023; Total Net Revenues Included Net Product Revenues of $65 Million, $15 Million in License and Royalty Revenues, of Which $11 Million is Non-Cash -- -- Delivered Positive Cash Flow of $9 Million in the Quarter with a Cash Position of $313 Million --","-- Company Reported Total Net Revenues of $80 Million in Second Quarter 2023; Total Net Revenues Included Net Product Revenues of $65 Million, $15 Million in License and Royalty Revenues, of Which $11 Million is Non-Cash -- -- Delivered Positive Cash Flow of $9 Million in the Quarter with a Cash Position of $313 Million --",Earnings Releases and Operating Results,-0.025210159,-0.01813425,short
Amarin Reports Third Quarter 2023 Financial Results,"-- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 --  -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position of $321 Million --","-- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 --  -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position of $321 Million --",Earnings Releases and Operating Results,0,-0.0023912,short
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress,"DUBLIN, Ireland and BRIDGEWATER, N.J., July  26, 2023  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023. This new research includes, along with other topics, the review of the contribution of eicosapentaenoic acid (EPA) and other biomarkers to MACE reduction by icosapent ethyl (IPE).","DUBLIN, Ireland and BRIDGEWATER, N.J., July  26, 2023  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023. This new research includes, along with other topics, the review of the contribution of eicosapentaenoic acid (EPA) and other biomarkers to MACE reduction by icosapent ethyl (IPE).",Clinical Study,0,0.002129811,long
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023,-- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting -- -- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting --,-- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting -- -- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting --,Clinical Study,-0.028168988,-0.025534631,short
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1),"-- VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHSScotland, as secondary prevention in adult statin-treated patients at high cardiovascular risk1 -- -- VAZKEPA® already commercially available in England, Wales, and Northern Ireland where NICE recommended its reimbursement and use across the National Health Service (NHS) in July 2022 --","-- VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHSScotland, as secondary prevention in adult statin-treated patients at high cardiovascular risk1 -- -- VAZKEPA® already commercially available in England, Wales, and Northern Ireland where NICE recommended its reimbursement and use across the National Health Service (NHS) in July 2022 --",Product / Services Announcement,0,-0.004252353,short
"Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25","SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25.","SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25.",Product / Services Announcement,0.060779225,0.065342297,long
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP),"SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares. Investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab. Top-line data also demonstrate a favorable safety and tolerability profile.","SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares. Investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab. Top-line data also demonstrate a favorable safety and tolerability profile.",Product / Services Announcement,0.060779225,0.065342297,long
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer,"SAN DIEGO, Dec.  02, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 trial of JEMPERLI (dostarlimab) plus standard of care chemotherapy compared to chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer, met its primary endpoint of investigator-assessed progression-free survival (PFS). The JEMPERLI regimen showed a statistically significant and clinically meaningful benefit in the prespecified mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) patient subgroup and in the overall population. A clinically relevant benefit in PFS was also observed in the mismatch repair proficient (MMRp)/microsatellite stable (MSS) patient subgroup.","SAN DIEGO, Dec.  02, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 trial of JEMPERLI (dostarlimab) plus standard of care chemotherapy compared to chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer, met its primary endpoint of investigator-assessed progression-free survival (PFS). The JEMPERLI regimen showed a statistically significant and clinically meaningful benefit in the prespecified mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) patient subgroup and in the overall population. A clinically relevant benefit in PFS was also observed in the mismatch repair proficient (MMRp)/microsatellite stable (MSS) patient subgroup.",Health,-0.010630532,0.001962145,long
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer,"SAN DIEGO, July  31, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. The supplemental Biologics License Application (sBLA) supporting this new indication received Priority Review and was approved ahead of the Sept. 23, 2023 Prescription Drug User Fee Act action date.","SAN DIEGO, July  31, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. The supplemental Biologics License Application (sBLA) supporting this new indication received Priority Review and was approved ahead of the Sept. 23, 2023 Prescription Drug User Fee Act action date.",Health,0.145264389,0.144433614,long
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP),"SAN DIEGO, May  02, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the publication of data from the open-label, single-arm Phase 2 GALLOP study evaluating the efficacy, tolerability and safety of imsidolimab, its investigational anti-interleukin-36 receptor (IL-36R) IgG4 antibody for the treatment of generalized pustular psoriasis (GPP), in the British Journal of Dermatology. Patients with GPP who received a single dose of imsidolimab demonstrated a rapid and sustained improvement of symptoms and pustular eruptions of GPP flare within days after initiating treatment.","SAN DIEGO, May  02, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the publication of data from the open-label, single-arm Phase 2 GALLOP study evaluating the efficacy, tolerability and safety of imsidolimab, its investigational anti-interleukin-36 receptor (IL-36R) IgG4 antibody for the treatment of generalized pustular psoriasis (GPP), in the British Journal of Dermatology. Patients with GPP who received a single dose of imsidolimab demonstrated a rapid and sustained improvement of symptoms and pustular eruptions of GPP flare within days after initiating treatment.",Clinical Study,-0.002361797,-0.000580803,short
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS),ANX005 Granted Orphan Drug Designation by the European Medicines Agency for the Treatment of GBS,ANX005 Granted Orphan Drug Designation by the European Medicines Agency for the Treatment of GBS,Clinical Study,,,
AnaptysBio Announces Stock Repurchase Plan,"SAN DIEGO, Jan.  13, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share. With cash, cash equivalents and investments greater than $575 million as of December 31, 2022, notwithstanding the potential full execution of the Stock Repurchase Plan, the company reiterates its previous guidance that it anticipates having approximately 4 years of capital to execute against its non-risk adjusted research and development plan, excluding potential future royalties from its GSK immuno-oncology financial collaboration.","SAN DIEGO, Jan.  13, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share. With cash, cash equivalents and investments greater than $575 million as of December 31, 2022, notwithstanding the potential full execution of the Stock Repurchase Plan, the company reiterates its previous guidance that it anticipates having approximately 4 years of capital to execute against its non-risk adjusted research and development plan, excluding potential future royalties from its GSK immuno-oncology financial collaboration.",Stock Market News,0.040745581,0.049159518,long
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference,"SAN DIEGO, Nov.  21, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, interim chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday November 29th, 2022, at 8:10 a.m. ET / 5:10 a.m. PT.","SAN DIEGO, Nov.  21, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, interim chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday November 29th, 2022, at 8:10 a.m. ET / 5:10 a.m. PT.",Calendar of Events,-0.010972905,-0.010846161,short
AnaptysBio to Participate in Upcoming November Investor Conferences,"SAN DIEGO, Nov.  09, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m. PT; members of its senior management team will also be hosting investor meetings at the Jefferies London Healthcare Conference on November 16th, 2022.","SAN DIEGO, Nov.  09, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m. PT; members of its senior management team will also be hosting investor meetings at the Jefferies London Healthcare Conference on November 16th, 2022.",Calendar of Events,-0.016123599,-0.000857661,short
"Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress","SAN DIEGO, Oct.  11, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032’s Phase 2b study in moderate to severe atopic dermatitis.","SAN DIEGO, Oct.  11, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032’s Phase 2b study in moderate to severe atopic dermatitis.",Clinical Study,-0.001531429,-0.004062855,short
DBV Technologies présente ses résultats financiers du troisième trimestre 2023 et fait le point sur ses activités,"Montrouge, France, le 27 octobre (22h30 CET)","Montrouge, France, le 27 octobre (22h30 CET)",European Regulatory News,,,
"Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio","BRISBANE, Calif., Jan.  06, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Dean “Rick” Artis, Ph.D., has been appointed as chief scientific officer (CSO), succeeding Larry C. Mattheakis, Ph.D. Dr. Artis most recently served as CSO at Octant Bio and earlier, led efforts at Annexon for the discovery of the company’s small molecule classical complement inhibitors, including ANX1502.","BRISBANE, Calif., Jan.  06, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Dean “Rick” Artis, Ph.D., has been appointed as chief scientific officer (CSO), succeeding Larry C. Mattheakis, Ph.D. Dr. Artis most recently served as CSO at Octant Bio and earlier, led efforts at Annexon for the discovery of the company’s small molecule classical complement inhibitors, including ANX1502.",Directors and Officers,,,
"Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer","BRISBANE, Calif., July  27, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the appointment of Jamie Dananberg, M.D., as chief medical officer.","BRISBANE, Calif., July  27, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the appointment of Jamie Dananberg, M.D., as chief medical officer.",Management Changes,,,
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference,"BRISBANE, Calif., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 8:10 a.m. ET in NYC.","BRISBANE, Calif., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 8:10 a.m. ET in NYC.",Calendar of Events,,,
BioCorRx Reports Business Update for the Third Quarter of 2023,"ANAHEIM, CA, Nov.  14, 2023  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, and reported on recent corporate developments.","ANAHEIM, CA, Nov.  14, 2023  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, and reported on recent corporate developments.",Earnings Releases and Operating Results,-0.145833354,-0.151233075,short
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference,"BRISBANE, Calif., Nov.  22, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 2:10 p.m. ET in Miami.","BRISBANE, Calif., Nov.  22, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 2:10 p.m. ET in Miami.",Calendar of Events,,,
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results,ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward,ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward,Earnings Releases and Operating Results,,,
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises,"Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications","Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications",Calendar of Events,,,
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy,Additional analyses support consistent protection from vision loss,Additional analyses support consistent protection from vision loss,Product / Services Announcement,,,
Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy,"PRIME Designation Granted Based on Phase 2 ARCHER Trial Results, which Showed Meaningful Preservation of Visual Function in Patients with Geographic Atrophy","PRIME Designation Granted Based on Phase 2 ARCHER Trial Results, which Showed Meaningful Preservation of Visual Function in Patients with Geographic Atrophy",Health,,,
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress,Initial Clinical Data Expected from the Phase 2 ARCHER Trial of ANX007 in Geographic Atrophy in Mid-2023,Initial Clinical Data Expected from the Phase 2 ARCHER Trial of ANX007 in Geographic Atrophy in Mid-2023,Earnings Releases and Operating Results,,,
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones,Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023,Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023,Earnings Releases and Operating Results,,,
Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium,"BERWYN, Pa., Nov.  16, 2020  (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D. and CFO, Jeff McGroarty, MBA, CPA, will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19, 2020. ","BERWYN, Pa., Nov.  16, 2020  (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D. and CFO, Jeff McGroarty, MBA, CPA, will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19, 2020. ",Calendar of Events,0.033057819,0.025015359,long
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4),"BRISBANE, Calif., Feb.  16, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted equity inducement awards to four new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on February 15, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).","BRISBANE, Calif., Feb.  16, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted equity inducement awards to four new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on February 15, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).",Stock Market News,,,
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4),"BRISBANE, Calif., May  16, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 15, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).","BRISBANE, Calif., May  16, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 15, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).",Contests/Awards,,,
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4),"BRISBANE, Calif., Oct.  18, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 17, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).","BRISBANE, Calif., Oct.  18, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 17, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).",Changes in company's own shares,,,
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4),"BRISBANE, Calif., Aug.  02, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted an equity inducement award to Jamie Dananberg, M.D., the company’s Chief Medical Officer, under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on July 22, 2023, effective August 1, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).","BRISBANE, Calif., Aug.  02, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted an equity inducement award to Jamie Dananberg, M.D., the company’s Chief Medical Officer, under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on July 22, 2023, effective August 1, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).",Stock Market News,,,
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4),"BRISBANE, Calif., Jan.  17, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted an equity inducement award to Dean “Rick” Artis, Ph.D., chief scientific officer, under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on January 4, 2023, effective January 15, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).","BRISBANE, Calif., Jan.  17, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted an equity inducement award to Dean “Rick” Artis, Ph.D., chief scientific officer, under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on January 4, 2023, effective January 15, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).",Stock Market News,,,
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results,"Montrouge, France, July 31, 2023","Montrouge, France, July 31, 2023",European Regulatory News,,,
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4),"BRISBANE, Calif., Nov.  17, 2022  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted an equity inducement award to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on November 16, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).","BRISBANE, Calif., Nov.  17, 2022  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted an equity inducement award to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on November 16, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).",Major shareholder announcements,,,
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4),"BRISBANE, Calif., Sept.  18, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on September 14, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).","BRISBANE, Calif., Sept.  18, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on September 14, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).",Changes in company's own shares,,,
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results,"Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ","Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ",Earnings Releases and Operating Results,,,
"Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function","ARCHER data support ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection against vision loss in both foveal and non-foveal patients through 12 months","ARCHER data support ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection against vision loss in both foveal and non-foveal patients through 12 months",Clinical Study,,,
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference,"BRISBANE, Calif., Jan.  04, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT in San Francisco.","BRISBANE, Calif., Jan.  04, 2023  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT in San Francisco.",Calendar of Events,,,
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023,"Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET","Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET",Clinical Study,,,
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study,"Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer’s Disease (AD) is sufficiently powered to continue as planned without any additional patients Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer’s Disease (AD) is sufficiently powered to continue as planned without any additional patients","Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer’s Disease (AD) is sufficiently powered to continue as planned without any additional patients Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer’s Disease (AD) is sufficiently powered to continue as planned without any additional patients",Clinical Study,0.038961065,0.037517159,long
Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference,"BERWYN, Pa., Dec.  03, 2020  (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference on Friday, December 4, 2020.","BERWYN, Pa., Dec.  03, 2020  (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference on Friday, December 4, 2020.",Calendar of Events,-0.024074095,-0.023774152,short
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for  Topical Roflumilast in Greater China and Southeast Asia,"WESTLAKE VILLAGE, Calif. and HANGZHOU, China, Aug.  10, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, and Hangzhou Zhongmei Huadong Pharmaceutical Co, a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), today announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and Southeast Asia (Indonesia, Singapore, The Philippines, Thailand, Myanmar, Brunei, Cambodia, Laos, Malaysia, and Vietnam). Huadong will receive an exclusive license for both the cream and foam formulations of topical roflumilast, a next generation phosphodiesterase type 4 (PDE4) inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, and potentially additional dermatological conditions in the future.","WESTLAKE VILLAGE, Calif. and HANGZHOU, China, Aug.  10, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, and Hangzhou Zhongmei Huadong Pharmaceutical Co, a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), today announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and Southeast Asia (Indonesia, Singapore, The Philippines, Thailand, Myanmar, Brunei, Cambodia, Laos, Malaysia, and Vietnam). Huadong will receive an exclusive license for both the cream and foam formulations of topical roflumilast, a next generation phosphodiesterase type 4 (PDE4) inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, and potentially additional dermatological conditions in the future.",Licensing Agreements,0.001064885,-0.00440904,short
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD),"WESTLAKE VILLAGE, Calif., Sept.  07, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced interim results from the INTEGUMENT-OLE long-term open-label study of roflumilast cream 0.15% in adults and children ages 6 years and older with atopic dermatitis. In the study, roflumilast cream was well-tolerated, with no new safety signals observed during treatment up to 56 weeks in duration. Efficacy was not only maintained but improved over time, with 46.1% and 51.0% of participants who rolled over from the roflumilast cream treatment arm in INTEGUMENT-1 or -2 achieving validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) success, defined as vIGA-AD value of 0 or 1 plus a 2-grade improvement from baseline, at Weeks 28 and 56, respectively.","WESTLAKE VILLAGE, Calif., Sept.  07, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced interim results from the INTEGUMENT-OLE long-term open-label study of roflumilast cream 0.15% in adults and children ages 6 years and older with atopic dermatitis. In the study, roflumilast cream was well-tolerated, with no new safety signals observed during treatment up to 56 weeks in duration. Efficacy was not only maintained but improved over time, with 46.1% and 51.0% of participants who rolled over from the roflumilast cream treatment arm in INTEGUMENT-1 or -2 achieving validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) success, defined as vIGA-AD value of 0 or 1 plus a 2-grade improvement from baseline, at Weeks 28 and 56, respectively.",Clinical Study,0.04516134,0.052131031,long
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5,"WESTLAKE VILLAGE, Calif., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the INTEGUMENT-PED pivotal Phase 3 trial of roflumilast cream 0.05%, in children ages 2 to 5 years with mild to moderate atopic dermatitis (AD) met its primary endpoint and all secondary endpoints. In the study, 25.4% of children treated with roflumilast cream 0.05% achieved IGA Success, defined as a validated Investigator Global Assessment – Atopic Dermatitis (vIGA-AD) score of ‘clear’ or ‘almost clear’ plus a 2-grade improvement from baseline at Week 4, compared to 10.7% treated with vehicle (P<0.0001), with significant improvements seen as early as Week 1.Roflumilast cream 0.05% is a once-daily steroid-free topical cream in development, that is formulated to deliver drug without disrupting the skin barrier. INTEGUMENT-PED enrolled 652 children ages 2 to 5, with a mean Body Surface Area (BSA) of 22% overall, and a range from 3% to 82%. The data reinforce the well-established efficacy, safety and tolerability profile of roflumilast cream in atopic dermatitis across the INTEGUMENT program.","WESTLAKE VILLAGE, Calif., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the INTEGUMENT-PED pivotal Phase 3 trial of roflumilast cream 0.05%, in children ages 2 to 5 years with mild to moderate atopic dermatitis (AD) met its primary endpoint and all secondary endpoints. In the study, 25.4% of children treated with roflumilast cream 0.05% achieved IGA Success, defined as a validated Investigator Global Assessment – Atopic Dermatitis (vIGA-AD) score of ‘clear’ or ‘almost clear’ plus a 2-grade improvement from baseline at Week 4, compared to 10.7% treated with vehicle (P<0.0001), with significant improvements seen as early as Week 1.Roflumilast cream 0.05% is a once-daily steroid-free topical cream in development, that is formulated to deliver drug without disrupting the skin barrier. INTEGUMENT-PED enrolled 652 children ages 2 to 5, with a mean Body Surface Area (BSA) of 22% overall, and a range from 3% to 82%. The data reinforce the well-established efficacy, safety and tolerability profile of roflumilast cream in atopic dermatitis across the INTEGUMENT program.",Clinical Study,-0.010886423,-0.008744971,short
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark,"WESTLAKE VILLAGE, Calif., July  17, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies effective July 5. These national formularies provide access to an additional 20 million commercial lives in the United States.","WESTLAKE VILLAGE, Calif., July  17, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies effective July 5. These national formularies provide access to an additional 20 million commercial lives in the United States.",Product / Services Announcement,0.03813566,0.038469514,long
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer,"WESTLAKE VILLAGE, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie.","WESTLAKE VILLAGE, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie.",Directors and Officers,-0.012006809,-0.014847965,short
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%,"WESTLAKE VILLAGE, Calif., Aug.  29, 2023  (GLOBE NEWSWIRE) --  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the launch of The Cream That Can, the first commercial direct-to-consumer ad for ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents. The Cream That Can campaign invites individuals with psoriasis to reimagine a steroid-free cream for their psoriasis.","WESTLAKE VILLAGE, Calif., Aug.  29, 2023  (GLOBE NEWSWIRE) --  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the launch of The Cream That Can, the first commercial direct-to-consumer ad for ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents. The Cream That Can campaign invites individuals with psoriasis to reimagine a steroid-free cream for their psoriasis.",Product / Services Announcement,0.016209371,0.016457848,long
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress,Arcutis announced new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% for treatment of adults/adolescents with scalp/body psoriasis.,Arcutis announced new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% for treatment of adults/adolescents with scalp/body psoriasis.,Clinical Study,-0.09020622,-0.09378042,short
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform,Phase 1-ready device shows 100% success in human functional study of twelve subjects to date Phase 1-ready device shows 100% success in human functional study of twelve subjects to date,Phase 1-ready device shows 100% success in human functional study of twelve subjects to date Phase 1-ready device shows 100% success in human functional study of twelve subjects to date,Clinical Study,-0.008196713,-0.015902316,short
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older,"WESTLAKE VILLAGE, Calif., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis (AD) in adults and children ages 6 years and older.","WESTLAKE VILLAGE, Calif., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis (AD) in adults and children ages 6 years and older.",Regulatory information,0.001283726,0.004628581,long
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11,Arcutis today announced the FDA has approved an sNDA to expand the indication of ZORYVE (roflumilast) cream 0.3%.,Arcutis today announced the FDA has approved an sNDA to expand the indication of ZORYVE (roflumilast) cream 0.3%.,Product / Services Announcement,0.011286725,0.017246675,long
"New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis",Arcutis announced the launch of an educational campaign designed to elevate understanding and connection for those living with seborrheic dermatitis.,Arcutis announced the launch of an educational campaign designed to elevate understanding and connection for those living with seborrheic dermatitis.,Health,0.026022279,0.02892642,long
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials,New individual patient response data showed nearly all individuals (95%) treated with ZORYVE® (roflumilast) cream 0.3% had a measurable improvement in PASI,New individual patient response data showed nearly all individuals (95%) treated with ZORYVE® (roflumilast) cream 0.3% had a measurable improvement in PASI,Clinical Study,-0.204620426,-0.203565196,short
BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index,"SAN DIEGO, June  26, 2023  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company has been added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. markets open on June 26, 2023, as part of the 2023 Russell indexes reconstitution in the broad-market Russell 3000® Index. The stock also was automatically added to the appropriate growth and value indexes.","SAN DIEGO, June  26, 2023  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company has been added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. markets open on June 26, 2023, as part of the 2023 Russell indexes reconstitution in the broad-market Russell 3000® Index. The stock also was automatically added to the appropriate growth and value indexes.",Trading information,-0.014285701,-0.012923783,short
BioAtla Announces $65 Million Underwritten Offering of its Common Stock,"SAN DIEGO, Nov.  04, 2022  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has agreed to sell 9,745,128 shares of its common stock at a price of $6.67 per share in an underwritten offering. The gross proceeds of the offering to BioAtla before deducting estimated underwriting discount and commissions and estimated offering expenses are expected to be approximately $65 million. The offering is expected to close on or about November 8, 2022, subject to the satisfaction of customary closing conditions.","SAN DIEGO, Nov.  04, 2022  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has agreed to sell 9,745,128 shares of its common stock at a price of $6.67 per share in an underwritten offering. The gross proceeds of the offering to BioAtla before deducting estimated underwriting discount and commissions and estimated offering expenses are expected to be approximately $65 million. The offering is expected to close on or about November 8, 2022, subject to the satisfaction of customary closing conditions.",Stock Market News,0.26886785,0.252722759,long
Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform,Intellectual property relates to key features of the company’s liquid jet injection technology Intellectual property relates to key features of the company’s liquid jet injection technology,Intellectual property relates to key features of the company’s liquid jet injection technology Intellectual property relates to key features of the company’s liquid jet injection technology,Patents,-0.0051948,-0.000551705,short
BioAtla Announces Change in Executive Leadership,"SAN DIEGO, Feb.  27, 2023  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, will be leaving the Company to pursue a new opportunity as Chief Executive Officer at Viatris (Nasdaq: VTRS), a large, global healthcare pharmaceutical company. Scott will continue his relationship with BioAtla by serving as a Board of Directors member for the Company.","SAN DIEGO, Feb.  27, 2023  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, will be leaving the Company to pursue a new opportunity as Chief Executive Officer at Viatris (Nasdaq: VTRS), a large, global healthcare pharmaceutical company. Scott will continue his relationship with BioAtla by serving as a Board of Directors member for the Company.",Directors and Officers,0,-0.008804658,short
"BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma","SAN DIEGO, Feb.  23, 2023  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3182 (CAB-EpCAMxCAB-CD3 bispecific T-cell engager) for the treatment of advanced adenocarcinoma. BioAtla plans to initiate and advance a Phase 1 dose-escalation and expansion clinical study in 2023.","SAN DIEGO, Feb.  23, 2023  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3182 (CAB-EpCAMxCAB-CD3 bispecific T-cell engager) for the treatment of advanced adenocarcinoma. BioAtla plans to initiate and advance a Phase 1 dose-escalation and expansion clinical study in 2023.",Clinical Study,-0.006309142,-0.013886773,short
BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones,"SAN DIEGO, Jan.  10, 2023  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its recent accomplishments for its clinical pipeline and provided upcoming 2023 milestones. Company updates and 2023 milestones will be presented in a fireside chat at 41st Annual J.P. Morgan Healthcare Conference, January 10, 2023.","SAN DIEGO, Jan.  10, 2023  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its recent accomplishments for its clinical pipeline and provided upcoming 2023 milestones. Company updates and 2023 milestones will be presented in a fireside chat at 41st Annual J.P. Morgan Healthcare Conference, January 10, 2023.",Clinical Study,-0.352331589,-0.350758894,short
"BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award",Award recognizes Dr. Short’s contribution to science innovation Award recognizes Dr. Short’s contribution to science innovation,Award recognizes Dr. Short’s contribution to science innovation Award recognizes Dr. Short’s contribution to science innovation,Contests/Awards,0.005464476,0.00402057,long
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform,"SAN DIEGO, June  28, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development.","SAN DIEGO, June  28, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development.",Patents,0,0.002567865,long
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program,BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis,BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis,Health,0,0.00290414,long
BioAtla to Participate in the Jefferies Healthcare Conference,"SAN DIEGO, May  31, 2023  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the Jefferies Healthcare Conference, to be held in New York, NY June 7-9, 2023.","SAN DIEGO, May  31, 2023  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the Jefferies Healthcare Conference, to be held in New York, NY June 7-9, 2023.",Trade Show,-0.006600654,-0.002078797,short
BioAtla to Participate in the Jefferies London Healthcare Conference,"SAN DIEGO, Nov.  08, 2022  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Scott Smith, President and Sheri Lydick, Senior Vice President, Commercial Strategy will participate in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held in London, UK November 15-17, 2022.","SAN DIEGO, Nov.  08, 2022  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Scott Smith, President and Sheri Lydick, Senior Vice President, Commercial Strategy will participate in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held in London, UK November 15-17, 2022.",Calendar of Events,0,-0.003052963,short
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules,"SUNNYVALE, Calif., Nov.  16, 2023  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about November 20, 2023, subject to the satisfaction of customary closing conditions.","SUNNYVALE, Calif., Nov.  16, 2023  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about November 20, 2023, subject to the satisfaction of customary closing conditions.",Stock Market News,-0.047619004,-0.049867367,short
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs,"SUNNYVALE, Calif., Sept.  06, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced a clarification and next steps on its autologous CardiAMP cell therapy programs. ","SUNNYVALE, Calif., Sept.  06, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced a clarification and next steps on its autologous CardiAMP cell therapy programs. ",Clinical Study,-0.05172409,-0.049854274,short
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected,"SUNNYVALE, Calif., July  24, 2023  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP® Cell Therapy Heart Failure Trial (clinicaltrials.gov Identifier: NCT02438306), for which FDA granted Breakthrough Designation. Pursuant to the DSMB recommendation, BioCardia is pausing the trial pending the one-year follow-up outcomes analysis for patients that have been treated and those that have been enrolled but not yet treated.","SUNNYVALE, Calif., July  24, 2023  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP® Cell Therapy Heart Failure Trial (clinicaltrials.gov Identifier: NCT02438306), for which FDA granted Breakthrough Designation. Pursuant to the DSMB recommendation, BioCardia is pausing the trial pending the one-year follow-up outcomes analysis for patients that have been treated and those that have been enrolled but not yet treated.",Product / Services Announcement,-0.333333313,-0.335965014,short
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure,"SUNNYVALE, Calif., Nov.  14, 2023  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.","SUNNYVALE, Calif., Nov.  14, 2023  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.",Health,2.224999857,2.211074041,long
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan,"SUNNYVALE, Calif., June  08, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Japan Patent Office has granted Patent No: JP7282649B2 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on September 30, 2034.  ","SUNNYVALE, Calif., June  08, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Japan Patent Office has granted Patent No: JP7282649B2 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on September 30, 2034.  ",Patents,0.030150725,0.0299866,long
BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies,"SUNNYVALE, Calif., April  04, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies.","SUNNYVALE, Calif., April  04, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies.",Patents,-0.019999981,-0.021630308,short
BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study,"SUNNYVALE, Calif., May  23, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeting for the CardiAMP Cell Therapy Trial for Heart Failure is scheduled to take place on July 12th. The Company expects the FDA’s response to its adaptive statistical analysis plan supplement early to mid-June and anticipates approval of the plan and completion of all tasks to implement the plan, including all data monitoring, in advance of the DSMB meeting.","SUNNYVALE, Calif., May  23, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeting for the CardiAMP Cell Therapy Trial for Heart Failure is scheduled to take place on July 12th. The Company expects the FDA’s response to its adaptive statistical analysis plan supplement early to mid-June and anticipates approval of the plan and completion of all tasks to implement the plan, including all data monitoring, in advance of the DSMB meeting.",Calendar of Events,0.005917154,0.010000398,long
BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications,"SUNNYVALE, Calif., May  09, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,642,377: titled, “ Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications”, with a patent term that will expire in 2039.    ","SUNNYVALE, Calif., May  09, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,642,377: titled, “ Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications”, with a patent term that will expire in 2039.    ",Patents,-0.014705869,-0.010805143,short
BioCardia Letter to Shareholders,"SUNNYVALE, Calif., Dec.  22, 2022  (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders:","SUNNYVALE, Calif., Dec.  22, 2022  (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders:",Health,-0.011173174,-0.002939678,short
BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available,"SUNNYVALE, Calif., April  28, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases has made available two presentations from the “Next Generation Cardiovascular Drug Development Summit on Executing Cell and Gene Therapy for Cardiac Regeneration” which took place this week on April 26-27, 2023 in Boston, MA.","SUNNYVALE, Calif., April  28, 2023  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases has made available two presentations from the “Next Generation Cardiovascular Drug Development Summit on Executing Cell and Gene Therapy for Cardiac Regeneration” which took place this week on April 26-27, 2023 in Boston, MA.",Calendar of Events,0.009900981,0.012131803,long
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting,New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years,New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years,Law & Legal Issues,-0.022222201,-0.024349877,short
"BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.","ANAHEIM, CA, Nov.  22, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that its board of directors has authorized the exploration of a potential spin-off of BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage drug development company, into a separate publicly traded company on a major exchange.","ANAHEIM, CA, Nov.  22, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that its board of directors has authorized the exploration of a potential spin-off of BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage drug development company, into a separate publicly traded company on a major exchange.",Company Announcement,0,-0.005169945,short
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting,"ANAHEIM, CA, March  07, 2023  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:  BICX) (the “Company”), a clinical-stage developer and provider of innovative treatment programs for substance use and related disorders, has announced interim positive safety and pharmacokinetic (PK) results for the Phase I clinical trial of the Company’s BICX104 implantable naltrexone pellet. Dr. Andrew P. Mallon, PhD, the principal investigator of BioCorRx’s Phase I study, funded by the National Institute on Drug Abuse (NIDA) through the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, presented the interim findings on February 21, 2023, at the 4th Annual HEAL Investigator Meeting.  ","ANAHEIM, CA, March  07, 2023  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:  BICX) (the “Company”), a clinical-stage developer and provider of innovative treatment programs for substance use and related disorders, has announced interim positive safety and pharmacokinetic (PK) results for the Phase I clinical trial of the Company’s BICX104 implantable naltrexone pellet. Dr. Andrew P. Mallon, PhD, the principal investigator of BioCorRx’s Phase I study, funded by the National Institute on Drug Abuse (NIDA) through the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, presented the interim findings on February 21, 2023, at the 4th Annual HEAL Investigator Meeting.  ",Clinical Study,-0.003205125,0.012001898,long
"BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","ANAHEIM, CA, Jan.  19, 2023  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced an update from the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage pharmaceutical company.","ANAHEIM, CA, Jan.  19, 2023  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced an update from the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage pharmaceutical company.",Company Announcement,0.032520294,0.037961058,long
"BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","ANAHEIM, CA, June  30, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the first subject has been dosed in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage pharmaceutical company.","ANAHEIM, CA, June  30, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the first subject has been dosed in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage pharmaceutical company.",Health,0.064377725,0.07515757,long
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors,"ANAHEIM, CA, Jan.  24, 2023  (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced that Mr. Harsha Murthy was appointed to the Company’s Board of Directors.","ANAHEIM, CA, Jan.  24, 2023  (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced that Mr. Harsha Murthy was appointed to the Company’s Board of Directors.",Directors and Officers,0.090909111,0.095277231,long
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data,"ANAHEIM, CA, Feb.  23, 2023  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Dr. Andrew Mallon, CSO and Grant Principal Investigator on the  Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), attended and presented a poster on BICX104 interim data at the 4th Annual NIH HEAL Initiative Investigator Meeting, which was held February 21-22nd, 2023.","ANAHEIM, CA, Feb.  23, 2023  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Dr. Andrew Mallon, CSO and Grant Principal Investigator on the  Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), attended and presented a poster on BICX104 interim data at the 4th Annual NIH HEAL Initiative Investigator Meeting, which was held February 21-22nd, 2023.",Company Announcement,0,-0.007577631,short
"BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","ANAHEIM, CA, Oct.  13, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the last subject has been enrolled in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage pharmaceutical company.","ANAHEIM, CA, Oct.  13, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the last subject has been enrolled in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage pharmaceutical company.",Clinical Study,0.002506263,0.023119922,long
BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States,"ANAHEIM, CA, Dec.  07, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has partnered with Government Plus LLC, a leading provider of private sector healthcare to veterans, to nationally expand its Beat Addiction Recovery Program.","ANAHEIM, CA, Dec.  07, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has partnered with Government Plus LLC, a leading provider of private sector healthcare to veterans, to nationally expand its Beat Addiction Recovery Program.",Partnerships,0.136363643,0.138623461,long
BioCorRx Provides Business Update for 2022,Revenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics,Revenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics,Annual report,0,0.001319056,long
BioCorRx Provides Business Update for the First Quarter of 2023,Revenue Increases 97%,Revenue Increases 97%,Company Announcement,0.032432401,0.035216896,long
BioCorRx Provides Business Update for the Second Quarter of 2022,"ANAHEIM, CA, Aug.  16, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and reported on recent corporate developments.","ANAHEIM, CA, Aug.  16, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and reported on recent corporate developments.",Company Announcement,0,0.002634833,long
BioCorRx Provides Business Update for the Third Quarter of 2022,"ANAHEIM, CA, Nov.  15, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September 30, 2022 and reported on recent corporate developments.","ANAHEIM, CA, Nov.  15, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September 30, 2022 and reported on recent corporate developments.",Earnings Releases and Operating Results,0,-0.015261184,short
DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results,"Montrouge, France, October 31, 2023","Montrouge, France, October 31, 2023",European Regulatory News,,,
BioCorRx to Participate in the Benzinga All Access Event on July 15th,"ANAHEIM, CA, July  13, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady Granier, President and Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be participating in the Benzinga All Access event taking place on July 15, 2022.","ANAHEIM, CA, July  13, 2022  (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady Granier, President and Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be participating in the Benzinga All Access event taking place on July 15, 2022.",Calendar of Events,0,0.015046033,long
Biogen Appoints Adam Keeney as Head of Corporate Development,"CAMBRIDGE, Mass., April  04, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen’s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer.","CAMBRIDGE, Mass., April  04, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen’s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer.",Directors and Officers,-0.000829347,-0.002459674,short
Biogen Appoints Jane Grogan as Head of Research,"CAMBRIDGE, Mass., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member of Biogen’s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer.","CAMBRIDGE, Mass., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member of Biogen’s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer.",Management Changes,0.000675927,0.002545744,long
Biogen Appoints Monish Patolawala to its Board of Directors,Biogen Appoints Monish Patolawala to its Board of Directors,Biogen Appoints Monish Patolawala to its Board of Directors,Directors and Officers,0,-0.001794379,short
Biogen Completes Acquisition of Reata Pharmaceuticals,"CAMBRIDGE, Mass., Sept.  26, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs.","CAMBRIDGE, Mass., Sept.  26, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs.",Mergers and Acquisitions,-0.000196075,0.007068609,long
Biogen to Acquire Reata Pharmaceuticals,"CAMBRIDGE, Mass. and PLANO, Texas, July  28, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.","CAMBRIDGE, Mass. and PLANO, Texas, July  28, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.",Health,0.001940634,-0.005551277,short
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting,"CAMBRIDGE, Mass., Oct.  19, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer’s disease portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) meeting taking place October 24-27 in Boston, Mass. The presentations will advance the understanding of Alzheimer’s disease with data on different treatment approaches, predictive analysis of disease progression, and clinical meaningfulness of amyloid removal for patients and their caregivers.","CAMBRIDGE, Mass., Oct.  19, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer’s disease portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) meeting taking place October 24-27 in Boston, Mass. The presentations will advance the understanding of Alzheimer’s disease with data on different treatment approaches, predictive analysis of disease progression, and clinical meaningfulness of amyloid removal for patients and their caregivers.",Clinical Study,-0.000189707,-0.001909845,short
"FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS","CAMBRIDGE, Mass., April  25, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).1 The ongoing Phase 3 ATLAS study of tofersen in people with presymptomatic SOD1-ALS will serve as the confirmatory trial.1","CAMBRIDGE, Mass., April  25, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).1 The ongoing Phase 3 ATLAS study of tofersen in people with presymptomatic SOD1-ALS will serve as the confirmatory trial.1",Clinical Study,-0.029685568,-0.018725462,short
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease,"CAMBRIDGE, Mass., Oct.  25, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in mild Alzheimer’s disease (AD). The data showed favorable trends on multiple exploratory endpoints of cognition and activities of daily living in AD (n=46), building upon prior results which showed a reduction of tau protein in the cerebral spinal fluid (CSF t-tau) and tau positron emission tomography (PET) across brain regions. The late-breaking results were presented at the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) meeting held in Boston, MA from October 24-27.","CAMBRIDGE, Mass., Oct.  25, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in mild Alzheimer’s disease (AD). The data showed favorable trends on multiple exploratory endpoints of cognition and activities of daily living in AD (n=46), building upon prior results which showed a reduction of tau protein in the cerebral spinal fluid (CSF t-tau) and tau positron emission tomography (PET) across brain regions. The late-breaking results were presented at the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) meeting held in Boston, MA from October 24-27.",Clinical Study,-0.012685574,-0.002398469,short
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease,"CAMBRIDGE, Mass., March  29, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new promising Phase 1b clinical data showing that the investigational antisense oligonucleotide (ASO) therapy, BIIB080, reduced soluble tau protein in cerebrospinal fluid (CSF) in a dose-dependent and sustained manner in patients with early-stage Alzheimer’s disease (AD). BIIB080 also reduced aggregated tau pathology, as measured by positron emission tomography (PET) in all brain composites assessed. The primary endpoint of the Phase 1b trial (week 25) and open-label long-term extension study (through week 100) was safety and tolerability, with biomarker data as an exploratory endpoint. The results were presented at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2023) held in Gothenburg, Sweden from March 28 – April 1.","CAMBRIDGE, Mass., March  29, 2023  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new promising Phase 1b clinical data showing that the investigational antisense oligonucleotide (ASO) therapy, BIIB080, reduced soluble tau protein in cerebrospinal fluid (CSF) in a dose-dependent and sustained manner in patients with early-stage Alzheimer’s disease (AD). BIIB080 also reduced aggregated tau pathology, as measured by positron emission tomography (PET) in all brain composites assessed. The primary endpoint of the Phase 1b trial (week 25) and open-label long-term extension study (through week 100) was safety and tolerability, with biomarker data as an exploratory endpoint. The results were presented at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2023) held in Gothenburg, Sweden from March 28 – April 1.",Clinical Study,0.003219223,-0.007726142,short
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,"SAN DIEGO, June  13, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced that it has entered into a definitive agreement for the purchase and sale of 1,509,434 shares of the Company’s common stock at an offering price of $5.30 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 3,018,868 shares of common stock. The warrants have an exercise price of $5.05 per share, will be exercisable upon issuance, and will expire three years following issuance. The closing of the offering is expected to occur on or about June 14, 2023, subject to the satisfaction of customary closing conditions.","SAN DIEGO, June  13, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced that it has entered into a definitive agreement for the purchase and sale of 1,509,434 shares of the Company’s common stock at an offering price of $5.30 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 3,018,868 shares of common stock. The warrants have an exercise price of $5.05 per share, will be exercisable upon issuance, and will expire three years following issuance. The closing of the offering is expected to occur on or about June 14, 2023, subject to the satisfaction of customary closing conditions.",Initial Public Offerings,-0.197431784,-0.200935748,short
DBV Technologies to Participate in Upcoming EAACI Congress 2023,"Montrouge, France, June 8, 2023","Montrouge, France, June 8, 2023",European Regulatory News,,,
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer,"SAN DIEGO, May  01, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies.","SAN DIEGO, May  01, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies.",Management Changes,-0.012345667,-0.011239732,short
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes,Autonomous device exceeded performance targets for oral delivery of large molecules in three recent preclinical studies,Autonomous device exceeded performance targets for oral delivery of large molecules in three recent preclinical studies,Health,0.004587151,0.005293642,long
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure,"Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023","Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023",Interim information,0.05741633,0.059557781,long
Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference,"SAN DIEGO, Aug.  02, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that management will be attending the Canaccord Genuity 43rd Annual Growth Conference in Boston.","SAN DIEGO, Aug.  02, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that management will be attending the Canaccord Genuity 43rd Annual Growth Conference in Boston.",Calendar of Events,0,0.007075909,long
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference,"SAN DIEGO, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York City.","SAN DIEGO, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York City.",Calendar of Events,0.01742167,0.011316442,long
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes,"SAN DIEGO, June  08, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.","SAN DIEGO, June  08, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.",Calendar of Events,0.00784313,0.007679005,long
DBV Technologies to Participate in Upcoming Investor Conference,"Montrouge, France, June 06, 2023","Montrouge, France, June 06, 2023",European Regulatory News,,,
"Correction: BioSenic S.A.  : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS", REGULATED INFORMATION, REGULATED INFORMATION,European Regulatory News,0,0.007407602,long
BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease,"CARSON CITY, Nev., Sept.  26, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the last patient has completed the last visit at week 30 in its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer’s Disease (AD).","CARSON CITY, Nev., Sept.  26, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the last patient has completed the last visit at week 30 in its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer’s Disease (AD).",Clinical Study,0.00615384,0.013418525,long
BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023,"CARSON CITY, Nev., April  17, 2023  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data abstracts from its Phase 2 trials evaluating NE7107 in degenerative dementias and Parkinson’s Disease will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, to be held virtually and in Boston, MA, April 22-27, 2023.","CARSON CITY, Nev., April  17, 2023  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data abstracts from its Phase 2 trials evaluating NE7107 in degenerative dementias and Parkinson’s Disease will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, to be held virtually and in Boston, MA, April 22-27, 2023.",Trade Show,-0.005031442,-0.004813248,short
BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023,"CARSON CITY, Nev., March  21, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from its Phase 2 Parkinson’s Disease (PD) trial will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023), to be held March 28 – April 1, 2023 in Gothenburg, Sweden.","CARSON CITY, Nev., March  21, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from its Phase 2 Parkinson’s Disease (PD) trial will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023), to be held March 28 – April 1, 2023 in Gothenburg, Sweden.",Health,0.019480553,0.010591438,long
BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023,"CARSON CITY, Nev., Oct.  26, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that clinical safety data from the Company’s Phase 2 open-label study evaluating the efficacy and safety of BIV201, terlipressin administered as a continuous infusion, in patients with refractory ascites due to cirrhosis, will be highlighted in a late-breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2023, taking place from November 10-14, 2023 in Boston, MA.  ","CARSON CITY, Nev., Oct.  26, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that clinical safety data from the Company’s Phase 2 open-label study evaluating the efficacy and safety of BIV201, terlipressin administered as a continuous infusion, in patients with refractory ascites due to cirrhosis, will be highlighted in a late-breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2023, taking place from November 10-14, 2023 in Boston, MA.  ",Calendar of Events,-0.034920676,-0.03228632,short
"BioVie Announces Registration Details for ""BioVie Day"" Webinar","Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time","Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time",Calendar of Events,0.033898272,0.020560056,long
"BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial",Patients treated with BIV201 experienced reduced ascites fluid buildup (p<0.005) Patients treated with BIV201 experienced reduced ascites fluid buildup (p<0.005),Patients treated with BIV201 experienced reduced ascites fluid buildup (p<0.005) Patients treated with BIV201 experienced reduced ascites fluid buildup (p<0.005),Product / Services Announcement,-0.024539855,-0.013915601,short
BioVie Issues Letter to Shareholders,"CARSON CITY, Nev., July  18, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today issued the following letter to shareholders:","CARSON CITY, Nev., July  18, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today issued the following letter to shareholders:",Advisory,0.037549419,0.038303559,long
BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders,"CARSON CITY, Nev., Aug.  28, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced details of three presentations given from studies of NE3107 in the treatment of Parkinson’s Disease (PD) at the 2023 International Congress of Parkinson’s Disease and Movement Disorders (MDS), being held in Copenhagen, Denmark August 27-31, 2023.","CARSON CITY, Nev., Aug.  28, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced details of three presentations given from studies of NE3107 in the treatment of Parkinson’s Disease (PD) at the 2023 International Congress of Parkinson’s Disease and Movement Disorders (MDS), being held in Copenhagen, Denmark August 27-31, 2023.",Health,0.002967427,-0.002191991,short
BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease,Data from Phase 3 Trial of NE3107 Presented as Poster at the 148th American Neurological Association Annual Meeting,Data from Phase 3 Trial of NE3107 Presented as Poster at the 148th American Neurological Association Annual Meeting,Clinical Study,0.040697635,0.034592407,long
BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease,Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the American Diabetes Association Annual Meeting Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the American Diabetes Association Annual Meeting,Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the American Diabetes Association Annual Meeting Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the American Diabetes Association Annual Meeting,Calendar of Events,-0.042881647,-0.04151973,short
BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease,"CARSON CITY, Nev., July  17, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from a poster detailing the epigenetic basis for how in a Phase 2 exploratory biomarker study its drug candidate NE3107 may have potentially regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements. The poster was presented yesterday at the Alzheimer’s Associate’s International Conference (AAIC) held in Amsterdam July 16-20, 2023.","CARSON CITY, Nev., July  17, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from a poster detailing the epigenetic basis for how in a Phase 2 exploratory biomarker study its drug candidate NE3107 may have potentially regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements. The poster was presented yesterday at the Alzheimer’s Associate’s International Conference (AAIC) held in Amsterdam July 16-20, 2023.",Clinical Study,-0.005940635,-0.005606781,short
BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023,Data Show that BIV201 in Combination with Standard of Care (SOC) is Well Tolerated with No Major Difference in Treatment-Emergent Adverse Events (TEAEs) Compared to SOC Alone,Data Show that BIV201 in Combination with Standard of Care (SOC) is Well Tolerated with No Major Difference in Treatment-Emergent Adverse Events (TEAEs) Compared to SOC Alone,Clinical Study,-0.045731664,-0.042599701,short
BioVie Set to Join the Russell 2000® and Russell 3000® Indexes,"CARSON CITY, Nev., June  23, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the Company will be added as a member of the US small-cap Russell 2000® and Russell 3000® Indexes, effective after the US market opens on June 26, as part of the 2023 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. The stock also was automatically added to the appropriate growth and value indexes.","CARSON CITY, Nev., June  23, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the Company will be added as a member of the US small-cap Russell 2000® and Russell 3000® Indexes, effective after the US market opens on June 26, as part of the 2023 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. The stock also was automatically added to the appropriate growth and value indexes.",Major shareholder announcements,0,0.008201455,long
"BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023","CARSON CITY, Nev., Aug.  31, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced it will host a virtual KOL event titled NE3107―Putting Data in Context, ahead of the upcoming Phase 3 results in Alzheimer’s Disease. The event will take place on Thursday, September 7, 2023 at 2:30pm ET. To register, click here.","CARSON CITY, Nev., Aug.  31, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced it will host a virtual KOL event titled NE3107―Putting Data in Context, ahead of the upcoming Phase 3 results in Alzheimer’s Disease. The event will take place on Thursday, September 7, 2023 at 2:30pm ET. To register, click here.",Health,0.009009001,0.007589999,long
BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights,"IGALMI™ (dexmedetomidine) commercial momentum accelerating with doubling of formulary wins, unlocking more than $55 million in targeted market opportunity, and an additional $255 million scheduled to vote","IGALMI™ (dexmedetomidine) commercial momentum accelerating with doubling of formulary wins, unlocking more than $55 million in targeted market opportunity, and an additional $255 million scheduled to vote",Earnings Releases and Operating Results,-0.093655592,-0.094479566,short
BioVie to Participate in the Truist Securities BioPharma Symposium,"CARSON CITY, Nev., Nov.  02, 2023  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the participation of its management team in the Truist Securities BioPharma Symposium, to be held in New York, NY, November 8- 9, 2023.","CARSON CITY, Nev., Nov.  02, 2023  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the participation of its management team in the Truist Securities BioPharma Symposium, to be held in New York, NY, November 8- 9, 2023.",Calendar of Events,-0.010869503,-0.020144057,short
BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD,"CARSON CITY, Nev., Oct.  19, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer’s Disease will be presented during an oral presentation at the upcoming 16th Clinical Trials on Alzheimer's Disease (CTAD), to be held in Boston, MA from October 24-27, 2023.","CARSON CITY, Nev., Oct.  19, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer’s Disease will be presented during an oral presentation at the upcoming 16th Clinical Trials on Alzheimer's Disease (CTAD), to be held in Boston, MA from October 24-27, 2023.",Clinical Study,-0.018927501,-0.02064764,short
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting,"CARSON CITY, Nev., April  20, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a data abstract from its Phase 2 open label trial evaluating NE7107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to be held in San Diego, CA April 27-29, 2023.","CARSON CITY, Nev., April  20, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a data abstract from its Phase 2 open label trial evaluating NE7107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to be held in San Diego, CA April 27-29, 2023.",Clinical Study,-0.007325942,-0.000250985,short
BioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease,"CARSON CITY, Nev., July  10, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster detailing the genetic basis for how its drug candidate NE3107 regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements will be presented this weekend at the Alzheimer’s Associate’s International Conference (AAIC) to be held in Amsterdam July 16-20, 2023.","CARSON CITY, Nev., July  10, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster detailing the genetic basis for how its drug candidate NE3107 regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements will be presented this weekend at the Alzheimer’s Associate’s International Conference (AAIC) to be held in Amsterdam July 16-20, 2023.",Clinical Study,0.002252196,0.003095875,long
BioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association,"CARSON CITY, Nev., June  21, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract highlighting baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer’s disease will be presented as a poster at the 83rd Scientific Sessions of the American Diabetes Association, to be held June 23-26, 2023 in San Diego, CA.","CARSON CITY, Nev., June  21, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract highlighting baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer’s disease will be presented as a poster at the 83rd Scientific Sessions of the American Diabetes Association, to be held June 23-26, 2023 in San Diego, CA.",Product / Services Announcement,0.001814837,0.004147947,long
"Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients","CARSON CITY, Nev., Oct.  25, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, announced that blinded data on cognitive, biomarker and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer’s Disease (AD) were presented today as an oral presentation at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) in Boston, MA,","CARSON CITY, Nev., Oct.  25, 2023  (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, announced that blinded data on cognitive, biomarker and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer’s Disease (AD) were presented today as an oral presentation at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) in Boston, MA,",Research Analysis and Reports,-0.015624985,-0.00533788,short
Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock,"IRVINE, Calif., March  03, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today the pricing of its previously announced underwritten public offering. Biomerica is offering an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share. All shares of common stock in the offering are being offered by Biomerica.","IRVINE, Calif., March  03, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today the pricing of its previously announced underwritten public offering. Biomerica is offering an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share. All shares of common stock in the offering are being offered by Biomerica.",Prospectus/Announcement of Prospectus,-0.100719415,-0.105495549,short
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed,"IRVINE, Calif., March  08, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced the launch of its InFoods® IBS test. The test is being performed in a CLIA-certified, and CAP accredited high-complexity laboratory facility and offered as a laboratory developed test (LDT). The Company further announced all validation testing necessary for the InFoods IBS product to be offered as an LDT has been completed. The first patient samples have been processed.","IRVINE, Calif., March  08, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced the launch of its InFoods® IBS test. The test is being performed in a CLIA-certified, and CAP accredited high-complexity laboratory facility and offered as a laboratory developed test (LDT). The Company further announced all validation testing necessary for the InFoods IBS product to be offered as an LDT has been completed. The first patient samples have been processed.",Health,0.017467233,0.017165865,long
"Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).","IRVINE, Calif., April  17, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic products, is pleased to announce that inFoods® IBS, a revolutionary new approach to alleviate Irritable Bowel Syndrome (IBS) symptoms, is now available at the flagship office of Gastro Health in Miami, with plans expand into the other Gastro Health offices in the future.","IRVINE, Calif., April  17, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic products, is pleased to announce that inFoods® IBS, a revolutionary new approach to alleviate Irritable Bowel Syndrome (IBS) symptoms, is now available at the flagship office of Gastro Health in Miami, with plans expand into the other Gastro Health offices in the future.",Product / Services Announcement,-0.011904751,-0.011686557,short
"Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board","IRVINE, Calif., Jan.  10, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board which is advising the Company on the commercialization of products based on the Biomerica InFoods® Technology platform, beginning with the InFoods® IBS product. InFoods® IBS is the first of its kind diagnostic guided therapy using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of Irritable Bowel Syndrome (IBS) without the use of drugs.","IRVINE, Calif., Jan.  10, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board which is advising the Company on the commercialization of products based on the Biomerica InFoods® Technology platform, beginning with the InFoods® IBS product. InFoods® IBS is the first of its kind diagnostic guided therapy using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of Irritable Bowel Syndrome (IBS) without the use of drugs.",Health,0.017647041,0.019219736,long
Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups,"IRVINE, Calif., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that several new Gastrointestinal (GI) groups have signed up and begun using the Company's revolutionary inFoods® IBS Product. This expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica's influence in providing innovative solutions for Irritable Bowel Syndrome (IBS) while positioning the Company for product revenue growth over the coming quarters. These new groups join Gastro Health, a group with 390 GI physicians which was the Company's first large physician group customer. In addition, several additional Gastro Health office locations have started using the inFoods IBS therapy for their IBS patients.","IRVINE, Calif., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that several new Gastrointestinal (GI) groups have signed up and begun using the Company's revolutionary inFoods® IBS Product. This expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica's influence in providing innovative solutions for Irritable Bowel Syndrome (IBS) while positioning the Company for product revenue growth over the coming quarters. These new groups join Gastro Health, a group with 390 GI physicians which was the Company's first large physician group customer. In addition, several additional Gastro Health office locations have started using the inFoods IBS therapy for their IBS patients.",Health,0.070588236,0.069169256,long
Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting,"IRVINE, Calif., Nov.  02, 2022  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) announced that data derived from a clinical study of InFoods® IBS was presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting in a poster titled “IgG-based Elimination Diets for Patients with IBS: Results From a Prospective, Multi-Center, Double-Blind, Placebo-Controlled Trial.” The poster was selected by ACG as a “Presidential Poster.” Fewer than 5% of accepted ACG abstracts each year receive this distinction, which is awarded for high quality, novel and potentially industry disruptive research.","IRVINE, Calif., Nov.  02, 2022  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) announced that data derived from a clinical study of InFoods® IBS was presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting in a poster titled “IgG-based Elimination Diets for Patients with IBS: Results From a Prospective, Multi-Center, Double-Blind, Placebo-Controlled Trial.” The poster was selected by ACG as a “Presidential Poster.” Fewer than 5% of accepted ACG abstracts each year receive this distinction, which is awarded for high quality, novel and potentially industry disruptive research.",Clinical Study,-0.005882347,-0.00426996,short
Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE,Expands Commercialization Efforts in Areas with High Unmet Needs Expands Commercialization Efforts in Areas with High Unmet Needs,Expands Commercialization Efforts in Areas with High Unmet Needs Expands Commercialization Efforts in Areas with High Unmet Needs,Product / Services Announcement,0.021390354,0.016354208,long
Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients,"IRVINE, Calif., June  21, 2023  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative diagnostic solutions, announced that the China National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a patent application that covers a development stage information technology (“IT”) system that includes an artificial Intelligence (AI) claim aimed at assisting individuals to protect themselves against potential adverse reactions to specific food ingredients. Among other things, the patent claims focus on systems, algorithms and methods to help patients avoid potentially harmful food items based on their unique medical data.","IRVINE, Calif., June  21, 2023  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative diagnostic solutions, announced that the China National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a patent application that covers a development stage information technology (“IT”) system that includes an artificial Intelligence (AI) claim aimed at assisting individuals to protect themselves against potential adverse reactions to specific food ingredients. Among other things, the patent claims focus on systems, algorithms and methods to help patients avoid potentially harmful food items based on their unique medical data.",Patents,0.061349708,0.063682818,long
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights,IGALMI™ (dexmedetomidine) commercial execution fully underway in 2023 with key focus on market access and demand generation through expanded field team,IGALMI™ (dexmedetomidine) commercial execution fully underway in 2023 with key focus on market access and demand generation through expanded field team,Earnings Releases and Operating Results,-0.050775758,-0.05283125,short
Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16,"IRVINE, Calif., Nov.  10, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City. Zackary Irani, Chief Executive Officer of Biomerica will be hosting meetings during the event, which consists of one-on-one and small group meetings.","IRVINE, Calif., Nov.  10, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City. Zackary Irani, Chief Executive Officer of Biomerica will be hosting meetings during the event, which consists of one-on-one and small group meetings.",Calendar of Events,0.032967001,0.028034273,long
CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Disease Screening Test,"IRVINE, Calif., Aug.  03, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that CVS Pharmacy has begun in-store sales rollout of the Company’s EZ Detect™ colorectal disease screening test in over 7,000 stores nationwide throughout the CVS Pharmacy retail system. Biomerica has shipped the EZ Detect product to CVS Health distribution centers in the US, and the product is projected to be on store shelves in September. The Company is also working with CVS Health to introduce an additional Biomerica product to be sold in CVS pharmacies.  ","IRVINE, Calif., Aug.  03, 2023  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that CVS Pharmacy has begun in-store sales rollout of the Company’s EZ Detect™ colorectal disease screening test in over 7,000 stores nationwide throughout the CVS Pharmacy retail system. Biomerica has shipped the EZ Detect product to CVS Health distribution centers in the US, and the product is projected to be on store shelves in September. The Company is also working with CVS Health to introduce an additional Biomerica product to be sold in CVS pharmacies.  ",Product / Services Announcement,0.171232872,0.175875967,long
Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors,"NEWPORT BEACH, Calif., Aug.  28, 2023  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors. Meridian Biosciences (formerly traded on Nasdaq under VIVO) is a leading global provider of diagnostic testing solutions. Meridian Biosciences was acquired on January 31, 2023 by SD Biosensor, Inc. and SJL Partners LLC in an all-cash transaction valued at approximately $1.53 billion.","NEWPORT BEACH, Calif., Aug.  28, 2023  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors. Meridian Biosciences (formerly traded on Nasdaq under VIVO) is a leading global provider of diagnostic testing solutions. Meridian Biosciences was acquired on January 31, 2023 by SD Biosensor, Inc. and SJL Partners LLC in an all-cash transaction valued at approximately $1.53 billion.",Directors and Officers,0,-0.005159418,short
Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening Test,"Simple 2 minute at-home test detects an early warning sign of colorectal cancer, the third most common cancer worldwide Simple 2 minute at-home test detects an early warning sign of colorectal cancer, the third most common cancer worldwide","Simple 2 minute at-home test detects an early warning sign of colorectal cancer, the third most common cancer worldwide Simple 2 minute at-home test detects an early warning sign of colorectal cancer, the third most common cancer worldwide",Clinical Study,0.04854376,0.055808445,long
inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology,"NEWPORT BEACH, Calif., May  18, 2023  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, announced a significant advance in the management of irritable bowel syndrome (IBS). The inFoods® IBS diagnostic test has now been validated for use with finger stick (capillary) patient whole blood samples simplifying sample collection and facilitating wider access to the test.  With this new finger stick blood collection option, any trained medical professional in the doctor’s office can collect the patient’s blood sample during their office visit and forward the sample to the Lab for processing. This workflow enhancement greatly simplifies the process for healthcare providers to order the inFoods IBS test and is much easier for patients.  The InFoods IBS test will continue to be available using blood collected from a patient’s arm (venipuncture) by a trained phlebotomist.","NEWPORT BEACH, Calif., May  18, 2023  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, announced a significant advance in the management of irritable bowel syndrome (IBS). The inFoods® IBS diagnostic test has now been validated for use with finger stick (capillary) patient whole blood samples simplifying sample collection and facilitating wider access to the test.  With this new finger stick blood collection option, any trained medical professional in the doctor’s office can collect the patient’s blood sample during their office visit and forward the sample to the Lab for processing. This workflow enhancement greatly simplifies the process for healthcare providers to order the inFoods IBS test and is much easier for patients.  The InFoods IBS test will continue to be available using blood collected from a patient’s arm (venipuncture) by a trained phlebotomist.",Clinical Study,-0.05000005,-0.049205268,short
REPEAT - Biomerica Reports First Quarter 2024 Financial Results,Biomerica Reports First Quarter 2024 Financial Results.  Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024,Biomerica Reports First Quarter 2024 Financial Results.  Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024,Earnings Releases and Operating Results,0.02777775,0.036302351,long
Walmart to Expand Sales of Biomerica’s Aware® Breast Self Exam; Product will now be available in over 2400 Walmart stores,"IRVINE, Calif., Oct.  14, 2022  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that under a General Merchandise Supplier Agreement with Walmart, the Company’s Aware® Breast Self Exam device will now be sold in over 2400 Walmart’s retail stores. In July, the Company announced that Walmart had begun selling the Aware product online through Walmart.com. Walmart has now determined to also sell Aware in-store, at approximately 50% of their retail store locations. Biomerica has received and shipped an Initial stocking order from Walmart, and the product should be on store shelves within weeks. The product retails for $19.95.","IRVINE, Calif., Oct.  14, 2022  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that under a General Merchandise Supplier Agreement with Walmart, the Company’s Aware® Breast Self Exam device will now be sold in over 2400 Walmart’s retail stores. In July, the Company announced that Walmart had begun selling the Aware product online through Walmart.com. Walmart has now determined to also sell Aware in-store, at approximately 50% of their retail store locations. Biomerica has received and shipped an Initial stocking order from Walmart, and the product should be on store shelves within weeks. The product retails for $19.95.",Product / Services Announcement,0.26262625,0.255576529,long
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder,"ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the successful and favorable outcomes of an End-of-Phase 2 meeting (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of its lead asset BNC210 for the acute treatment of Social Anxiety Disorder (SAD) into Phase 3 registrational studies based on the recently completed Phase 2 PREVAIL dataset.","ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the successful and favorable outcomes of an End-of-Phase 2 meeting (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of its lead asset BNC210 for the acute treatment of Social Anxiety Disorder (SAD) into Phase 3 registrational studies based on the recently completed Phase 2 PREVAIL dataset.",Product / Services Announcement,0.051546341,0.046169731,long
Bionomics to Present at Upcoming June Investor Conferences,"ADELAIDE, Australia and CAMBRIDGE, Mass., June  15, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced that it will present at the following upcoming investor conferences in June:","ADELAIDE, Australia and CAMBRIDGE, Mass., June  15, 2023  (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced that it will present at the following upcoming investor conferences in June:",Calendar of Events,0.020408143,0.022352437,long
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union,"NEW YORK and MAINZ, Germany, August 30, 2023 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) administered as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. The Committee has also recommended the updated vaccine for children 6 months through 4 years of age as part or all of the primary three-dose vaccination series, depending on how many prior doses they received, or as single dose for those with a history of completion of a COVID-19 primary vaccination course or prior SARS-CoV-2 infection. ","NEW YORK and MAINZ, Germany, August 30, 2023 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) administered as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. The Committee has also recommended the updated vaccine for children 6 months through 4 years of age as part or all of the primary three-dose vaccination series, depending on how many prior doses they received, or as single dose for those with a history of completion of a COVID-19 primary vaccination course or prior SARS-CoV-2 infection. ",Company Announcement,0.021061239,0.017724273,long
BioNTech präsentiert positives Daten-Update aus der Phase-1/2-Studie mit dem CAR-T-Zelltherapiekandidat BNT211 bei fortgeschrittenen soliden Tumoren auf dem ESMO-Kongress 2023,"MAINZ, Deutschland, 23. Oktober 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, „BioNTech” oder „das Unternehmen”) gab heute Daten aus der laufenden klinischen Phase-1/2-Studie (NCT04503278; 2019-004323-20) des gegen Claudin-6 (CLDN6)-gerichteten CAR-T-Zelltherapiekandidaten BNT211 bekannt. In der Studie werden die Sicherheit und Wirksamkeit von BNT211 in Patientinnen und Patienten mit CLDN6-positiven rezidivierten oder refraktären fortgeschrittenen soliden Tumoren untersucht. Die Daten zeigen ermutigende Anzeichen für eine klinische Aktivität und eine erhöhte Beständigkeit von krebsspezifischen CAR-T-Zellen in Kombination mit einem CAR-T-Zellen-verstärkenden RNA-Impfstoff („CARVac“). Die Daten wurden von Prof. Dr. Dr. John Haanen, der Onkologe am Niederländischen Krebsinstitut (NKI) in Amsterdam ist, in einer Late-Breaking-Data-Session auf dem ESMO-Kongress 2023 in Madrid präsentiert. Die Ergebnisse bestätigen die positiven Zwischenergebnisse, die zuvor auf der diesjährigen Jahrestagung der American Society of Clinical Oncology („ASCO“) in Chicago (USA), vorgestellt wurden.","MAINZ, Deutschland, 23. Oktober 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, „BioNTech” oder „das Unternehmen”) gab heute Daten aus der laufenden klinischen Phase-1/2-Studie (NCT04503278; 2019-004323-20) des gegen Claudin-6 (CLDN6)-gerichteten CAR-T-Zelltherapiekandidaten BNT211 bekannt. In der Studie werden die Sicherheit und Wirksamkeit von BNT211 in Patientinnen und Patienten mit CLDN6-positiven rezidivierten oder refraktären fortgeschrittenen soliden Tumoren untersucht. Die Daten zeigen ermutigende Anzeichen für eine klinische Aktivität und eine erhöhte Beständigkeit von krebsspezifischen CAR-T-Zellen in Kombination mit einem CAR-T-Zellen-verstärkenden RNA-Impfstoff („CARVac“). Die Daten wurden von Prof. Dr. Dr. John Haanen, der Onkologe am Niederländischen Krebsinstitut (NKI) in Amsterdam ist, in einer Late-Breaking-Data-Session auf dem ESMO-Kongress 2023 in Madrid präsentiert. Die Ergebnisse bestätigen die positiven Zwischenergebnisse, die zuvor auf der diesjährigen Jahrestagung der American Society of Clinical Oncology („ASCO“) in Chicago (USA), vorgestellt wurden.",Company Announcement,0.041071158,0.039045453,long
BioNTech Presents Positive Phase 1/2 Data Update for  CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023,"MAINZ, Germany, October 23, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced follow-up data from its ongoing first-in-human Phase 1/2 trial (NCT04503278; 2019-004323-20) evaluating the safety and efficacy of the Company’s Claudin-6 (CLDN6)-directed CAR-T cell therapy candidate BNT211 in patients with CLDN6-positive refractory/relapsed solid tumors. The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac. At the ESMO Congress 2023 in Madrid, Prof. John Haanen, M.D., Ph.D., Netherlands Cancer Institute (NKI), Amsterdam, Netherlands presented the data in an oral late-breaking data session which confirms the positive interim data presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA.","MAINZ, Germany, October 23, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced follow-up data from its ongoing first-in-human Phase 1/2 trial (NCT04503278; 2019-004323-20) evaluating the safety and efficacy of the Company’s Claudin-6 (CLDN6)-directed CAR-T cell therapy candidate BNT211 in patients with CLDN6-positive refractory/relapsed solid tumors. The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac. At the ESMO Congress 2023 in Madrid, Prof. John Haanen, M.D., Ph.D., Netherlands Cancer Institute (NKI), Amsterdam, Netherlands presented the data in an oral late-breaking data session which confirms the positive interim data presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA.",Company Announcement,0.041071158,0.039045453,long
Pfizer and BioNTech Receive Health Canada Authorization for  XBB.1.5-Adapted Monovalent COVID-19 Vaccine,"KIRKLAND, QUEBEC and MAINZ, GERMANY, September 28, 2023 — Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that Health Canada has authorized the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) for ages 6 months and older. The updated vaccine will be available in Canada as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. For children 6 months through 4 years of age the updated vaccine is authorized for administration as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose for those with a history of completion of a COVID-19 primary vaccination course.","KIRKLAND, QUEBEC and MAINZ, GERMANY, September 28, 2023 — Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that Health Canada has authorized the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) for ages 6 months and older. The updated vaccine will be available in Canada as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. For children 6 months through 4 years of age the updated vaccine is authorized for administration as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose for those with a history of completion of a COVID-19 primary vaccination course.",Company Announcement,-0.012676578,-0.019821398,short
BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film,Meetings scheduled with FDA in October and November for TRANQUILITY and SERENITY III programs,Meetings scheduled with FDA in October and November for TRANQUILITY and SERENITY III programs,Clinical Study,-0.025641002,-0.026779575,short
DBV Technologies to Participate in Upcoming Investor Conference,"Montrouge, France, September 5, 2023","Montrouge, France, September 5, 2023",European Regulatory News,,,
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron XBB.1.5 angepassten COVID-19-Impfstoff in der Europäischen Union,"NEW YORK und MAINZ, Deutschland, 30. August 2023 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, „CHMP“) der Europäischen Arzneimittel-Agentur (European Medicines Agency, „EMA“) eine positive Beurteilung für die Marktzulassung (Marketing Authorization) des an Omikron XBB.1.5 angepassten monovalenten COVID-19-Impfstoffs (COMIRNATY® Omikron XBB.1.5) der Unternehmen ausgesprochen hat. Die Empfehlung gilt für eine Impfstoffdosis bei Personen ab 5 Jahren, unabhängig von deren bisherigen COVID-19-Impfstatus. Der Ausschuss hat den aktualisierten Impfstoff zudem für Kinder im Alter von 6 Monaten bis 4 Jahren als Teil aller primären Impfserien mit drei Dosen empfohlen, abhängig davon, wie viele Dosen bereits verabreicht wurden. Bei Kindern dieser Altersgruppe, die bereits eine vollständige primäre Impfserie mit einem COVID-19-Impfstoff erhalten oder eine SARS-CoV-2-Infektion durchlaufen haben, wird die Verabreichung einer einzelnen Impfstoffdosis mit dem aktualisierten Impfstoff empfohlen.     ","NEW YORK und MAINZ, Deutschland, 30. August 2023 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, „CHMP“) der Europäischen Arzneimittel-Agentur (European Medicines Agency, „EMA“) eine positive Beurteilung für die Marktzulassung (Marketing Authorization) des an Omikron XBB.1.5 angepassten monovalenten COVID-19-Impfstoffs (COMIRNATY® Omikron XBB.1.5) der Unternehmen ausgesprochen hat. Die Empfehlung gilt für eine Impfstoffdosis bei Personen ab 5 Jahren, unabhängig von deren bisherigen COVID-19-Impfstatus. Der Ausschuss hat den aktualisierten Impfstoff zudem für Kinder im Alter von 6 Monaten bis 4 Jahren als Teil aller primären Impfserien mit drei Dosen empfohlen, abhängig davon, wie viele Dosen bereits verabreicht wurden. Bei Kindern dieser Altersgruppe, die bereits eine vollständige primäre Impfserie mit einem COVID-19-Impfstoff erhalten oder eine SARS-CoV-2-Infektion durchlaufen haben, wird die Verabreichung einer einzelnen Impfstoffdosis mit dem aktualisierten Impfstoff empfohlen.     ",Company Announcement,0.021061239,0.017724273,long
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease,Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer’s patients in nursing homes with moderate to severe dementia,Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer’s patients in nursing homes with moderate to severe dementia,Clinical Study,0.009975101,0.009453244,long
BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site,No evidence of misconduct or fraud found beyond instance previously reported1,No evidence of misconduct or fraud found beyond instance previously reported1,Clinical Study,0.311965832,0.316073166,long
BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program,BXCL501 was well tolerated across a broad dose range from 30mcg to 140mcg administered chronically ,BXCL501 was well tolerated across a broad dose range from 30mcg to 140mcg administered chronically ,Health,0.001101751,0.003886247,long
BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia,Clinically meaningful efficacy results observed with half (60mcg) of the approved dose of IGALMI™,Clinically meaningful efficacy results observed with half (60mcg) of the approved dose of IGALMI™,Health,-0.000385663,-0.009264482,short
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer,Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC,Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC,Clinical Study,0.005071887,0.000847337,long
BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD),"Columbia University-led trial expected to add fourth site to target completion of 4-arm, 160-patient trial in 2024","Columbia University-led trial expected to add fourth site to target completion of 4-arm, 160-patient trial in 2024",Health,0.03879317,0.036998791,long
BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services,Standardizes and improves product reimbursement process,Standardizes and improves product reimbursement process,Health,0.006600654,-0.000412118,short
"BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype","Median overall survival of 15.5 months with BXCL701 + KEYTRUDA® (pembrolizumab), compared to 9.6 months with checkpoint inhibitor monotherapy in late-line refractory patients in separate Phase 2 trial1","Median overall survival of 15.5 months with BXCL701 + KEYTRUDA® (pembrolizumab), compared to 9.6 months with checkpoint inhibitor monotherapy in late-line refractory patients in separate Phase 2 trial1",Clinical Study,0.012396682,0.010977702,long
"BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer","Median overall survival of 13.6 months with BXCL701 + KEYTRUDA® (pembrolizumab), compared to 7.6 months with checkpoint inhibitor monotherapy (CPI) in late-line refractory patients in separate, Phase 2 trial1","Median overall survival of 13.6 months with BXCL701 + KEYTRUDA® (pembrolizumab), compared to 7.6 months with checkpoint inhibitor monotherapy (CPI) in late-line refractory patients in separate, Phase 2 trial1",Clinical Study,0.018248158,0.016744552,long
"BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer","NEW HAVEN, Conn., Feb.  08, 2023  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a Key Opinion Leader (KOL) Day focused on its lead immuno-oncology program BXCL701 for the investment community on Tuesday, February 21, 2023 from 1:00 to 3:00 p.m. ET.","NEW HAVEN, Conn., Feb.  08, 2023  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a Key Opinion Leader (KOL) Day focused on its lead immuno-oncology program BXCL701 for the investment community on Tuesday, February 21, 2023 from 1:00 to 3:00 p.m. ET.",Product / Services Announcement,0.02769633,0.032657908,long
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences,"NEW HAVEN, Conn., June  01, 2023  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in fireside chats at two upcoming investor conferences. He will be joined by Robert Risinger, M.D., Chief Medical Officer, Neuroscience, and Matt Wiley, Chief Commercial Officer.","NEW HAVEN, Conn., June  01, 2023  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in fireside chats at two upcoming investor conferences. He will be joined by Robert Risinger, M.D., Chief Medical Officer, Neuroscience, and Matt Wiley, Chief Commercial Officer.",Calendar of Events,-0.001114853,-0.001689198,short
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference,"NEW HAVEN, Conn., Dec.  22, 2022  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present corporate updates and anticipated milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 9:45 a.m. PST.","NEW HAVEN, Conn., Dec.  22, 2022  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present corporate updates and anticipated milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 9:45 a.m. PST.",Calendar of Events,-0.007105709,0.001127787,long
"Baudax Bio Acquires TeraImmune, Inc.","TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax","TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax",Mergers and Acquisitions,0.230295979,0.222695109,long
BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference,"NEW HAVEN, Conn., May  02, 2023  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas on Tuesday, May 9, 2023 at 10:15 a.m. PT. He will be joined by Robert Risinger, M.D., Chief Medical Officer, Neuroscience, and Matt Wiley, Chief Commercial Officer.","NEW HAVEN, Conn., May  02, 2023  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas on Tuesday, May 9, 2023 at 10:15 a.m. PT. He will be joined by Robert Risinger, M.D., Chief Medical Officer, Neuroscience, and Matt Wiley, Chief Commercial Officer.",Trade Show,0,0.001780994,long
"BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023","NEW HAVEN, Conn., Feb.  23, 2023  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company’s financial results and to provide a general business update.","NEW HAVEN, Conn., Feb.  23, 2023  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company’s financial results and to provide a general business update.",Calendar of Events,0.018531426,0.010953795,long
"BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023","NEW HAVEN, Conn., Oct.  31, 2023  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will release its third quarter 2023 financial results on Tuesday, November 14, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company’s financial results and to provide a general business update.","NEW HAVEN, Conn., Oct.  31, 2023  (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will release its third quarter 2023 financial results on Tuesday, November 14, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company’s financial results and to provide a general business update.",Calendar of Events,-0.017543843,-0.018963502,short
Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules,"MALVERN, Pa., Aug.  17, 2023  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromuscular Blocking Agents and an associated reversal agent, today announced that it has entered into definitive agreements for the purchase and sale of 2,006,544 shares of its common stock and 1,395,243 Series E pre-funded warrants at a purchase price of $0.56 per share of common stock (or $0.55 per prefunded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series A-7 common stock purchase warrants (the “warrants”) to purchase up to 3,401,787 shares of common stock. The warrants have an initial exercise price of $0.56 per share and are not exercisable until the shareholders of the Company approve the issuance of the underlying shares (the “Approval”). The warrants are exercisable for a period of five years commencing from the date the Approval is obtained. Additionally, the exercise price of the warrants will be adjusted upon the Company effecting a reverse stock split, if the post-reverse stock split exercise price of the warrants is higher than the lowest daily VWAP of the common stock during the five trading days following the reverse stock split (the “Adjustment”). If the Adjustment is applicable, the exercise price of the warrants will be reduced to the lowest daily VWAP of the common stock during the five trading days following such reverse stock split, and the number of shares issuable upon exercise of the warrants shall increase such that the aggregate exercise price payable as a result of such Adjustment shall be equal to the aggregate exercise price payable prior to such Adjustment. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about August 21, 2023, subject to the satisfaction of customary closing conditions.","MALVERN, Pa., Aug.  17, 2023  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromuscular Blocking Agents and an associated reversal agent, today announced that it has entered into definitive agreements for the purchase and sale of 2,006,544 shares of its common stock and 1,395,243 Series E pre-funded warrants at a purchase price of $0.56 per share of common stock (or $0.55 per prefunded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series A-7 common stock purchase warrants (the “warrants”) to purchase up to 3,401,787 shares of common stock. The warrants have an initial exercise price of $0.56 per share and are not exercisable until the shareholders of the Company approve the issuance of the underlying shares (the “Approval”). The warrants are exercisable for a period of five years commencing from the date the Approval is obtained. Additionally, the exercise price of the warrants will be adjusted upon the Company effecting a reverse stock split, if the post-reverse stock split exercise price of the warrants is higher than the lowest daily VWAP of the common stock during the five trading days following the reverse stock split (the “Adjustment”). If the Adjustment is applicable, the exercise price of the warrants will be reduced to the lowest daily VWAP of the common stock during the five trading days following such reverse stock split, and the number of shares issuable upon exercise of the warrants shall increase such that the aggregate exercise price payable as a result of such Adjustment shall be equal to the aggregate exercise price payable prior to such Adjustment. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about August 21, 2023, subject to the satisfaction of customary closing conditions.",Warrants and Certificates,-0.069285716,-0.072743065,short
"Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000","Secondary Efficacy Analyses, Including of Neuromuscular Blockade and Spontaneous Reversal, Support Earlier Reported Clinical Results with BX1000 Secondary Efficacy Analyses, Including of Neuromuscular Blockade and Spontaneous Reversal, Support Earlier Reported Clinical Results with BX1000","Secondary Efficacy Analyses, Including of Neuromuscular Blockade and Spontaneous Reversal, Support Earlier Reported Clinical Results with BX1000 Secondary Efficacy Analyses, Including of Neuromuscular Blockade and Spontaneous Reversal, Support Earlier Reported Clinical Results with BX1000",Clinical Study,0.071620002,0.070662117,long
Baudax Bio Announces Corporate Update,Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition,Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition,Corporate Action,0.384499946,0.388696971,long
Baudax Bio Announces Date of Reconvened Annual Meeting,"Annual Meeting to be reconvened on June 23, 2023 Annual Meeting to be reconvened on June 23, 2023","Annual Meeting to be reconvened on June 23, 2023 Annual Meeting to be reconvened on June 23, 2023",Calendar of Events,0.0185185,0.019525273,long
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock,"MALVERN, Pa., Aug.  23, 2023  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on September 5, 2023. The shares of Series C Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on September 7, 2023. The outstanding shares of Series C Preferred Stock will vote together with the outstanding shares of the Company’s common stock, as a single class, exclusively with respect to a proposal to approve a reverse stock split, as well as any proposal to adjourn any meeting of shareholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Pennsylvania Business Corporation Law. Subject to certain limitations, each outstanding share of Series C Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series C Preferred Stock).","MALVERN, Pa., Aug.  23, 2023  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on September 5, 2023. The shares of Series C Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on September 7, 2023. The outstanding shares of Series C Preferred Stock will vote together with the outstanding shares of the Company’s common stock, as a single class, exclusively with respect to a proposal to approve a reverse stock split, as well as any proposal to adjourn any meeting of shareholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Pennsylvania Business Corporation Law. Subject to certain limitations, each outstanding share of Series C Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series C Preferred Stock).",Dividend Reports and Estimates,0.060267811,0.057757241,long
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update,Transformative Period Led by Acquisition of TeraImmune,Transformative Period Led by Acquisition of TeraImmune,Earnings Releases and Operating Results,0.025908484,0.026879432,long
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference,"MALVERN, Pa., Sept.  07, 2023  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13, 2023 in New York, NY.","MALVERN, Pa., Sept.  07, 2023  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13, 2023 in New York, NY.",Calendar of Events,-0.02500005,-0.018030359,short
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer,"NEEDHAM, Mass., Nov.  03, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced initial positive interim survival and immunological biomarker data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug) together with standard of care (SoC) chemoradiation followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC). Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting.","NEEDHAM, Mass., Nov.  03, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced initial positive interim survival and immunological biomarker data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug) together with standard of care (SoC) chemoradiation followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC). Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting.",Clinical Study,-0.249999967,-0.253578458,short
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024,"NEEDHAM, Mass., June  13, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that, in the second quarter of 2024, it expects to report topline overall survival data from its ongoing, open-label, phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor treatment (ICI) in patients with non-resectable, stage III/IV non-small cell lung cancer (NSCLC) who progressed while on treatment with PD-(L)1 inhibitor therapy (Cohort 2).","NEEDHAM, Mass., June  13, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that, in the second quarter of 2024, it expects to report topline overall survival data from its ongoing, open-label, phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor treatment (ICI) in patients with non-resectable, stage III/IV non-small cell lung cancer (NSCLC) who progressed while on treatment with PD-(L)1 inhibitor therapy (Cohort 2).",Clinical Study,-0.022289121,-0.025793085,short
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma,"NEEDHAM, Mass., Nov.  11, 2022  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced presentation of late-breaking data from a phase 1 mechanistic clinical trial of CAN-2409, Candel’s lead viral immunotherapy in development, in combination with nivolumab and standard of care treatment in patients with high-grade glioma. Data were presented at the 37th Annual Meeting of Society for Immunotherapy of Cancer (SITC) today in Boston.","NEEDHAM, Mass., Nov.  11, 2022  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced presentation of late-breaking data from a phase 1 mechanistic clinical trial of CAN-2409, Candel’s lead viral immunotherapy in development, in combination with nivolumab and standard of care treatment in patients with high-grade glioma. Data were presented at the 37th Annual Meeting of Society for Immunotherapy of Cancer (SITC) today in Boston.",Product / Services Announcement,0.025949372,0.018567958,long
"Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors","Nicoletta Loggia, PhD, RPh, biopharma executive with more than two decades of technical expertise in the biopharmaceutical industry Nicoletta Loggia, PhD, RPh, biopharma executive with more than two decades of technical expertise in the biopharmaceutical industry","Nicoletta Loggia, PhD, RPh, biopharma executive with more than two decades of technical expertise in the biopharmaceutical industry Nicoletta Loggia, PhD, RPh, biopharma executive with more than two decades of technical expertise in the biopharmaceutical industry",Directors and Officers,0.019867531,0.019703406,long
DBV Technologies to Present New Data at ACAAI 2023,"Montrouge, France, November 2, 2023","Montrouge, France, November 2, 2023",European Regulatory News,,,
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110,"NEEDHAM, Mass., Oct.  18, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Nature published results from the ongoing first-in-human phase 1 investigator-sponsored clinical trial of CAN-3110, a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate, in patients with recurrent high-grade glioma (HGG), of which 86.7% were glioblastoma, that had returned after standard of care (SoC) treatment.","NEEDHAM, Mass., Oct.  18, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Nature published results from the ongoing first-in-human phase 1 investigator-sponsored clinical trial of CAN-3110, a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate, in patients with recurrent high-grade glioma (HGG), of which 86.7% were glioblastoma, that had returned after standard of care (SoC) treatment.",Clinical Study,0.033333369,0.042499888,long
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting,"NEEDHAM, Mass., May  19, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced new data from an ongoing phase 1 investigator-sponsored clinical trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients with high-grade glioma that has recurred after standard of care (SoC) treatment. The data were presented today in an Oral Presentation Session at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).","NEEDHAM, Mass., May  19, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced new data from an ongoing phase 1 investigator-sponsored clinical trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients with high-grade glioma that has recurred after standard of care (SoC) treatment. The data were presented today in an Oral Presentation Session at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).",Clinical Study,0.006436534,0.004194323,long
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting,"NEEDHAM, Mass., Nov.  18, 2022  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced presentation of updated data from a phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma (rHGG). An overview of this data will be presented in-person at the Society for Neuro-Oncology (SNO) 27th Annual Meeting today starting at 5:30 pm ET in Tampa, Florida.","NEEDHAM, Mass., Nov.  18, 2022  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced presentation of updated data from a phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma (rHGG). An overview of this data will be presented in-person at the Society for Neuro-Oncology (SNO) 27th Annual Meeting today starting at 5:30 pm ET in Tampa, Florida.",Clinical Study,0.010869555,0.001991714,long
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting,"NEEDHAM, Mass., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the Company will present three posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 in San Diego, CA and virtually.","NEEDHAM, Mass., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the Company will present three posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 in San Diego, CA and virtually.",Clinical Study,-0.089999974,-0.08756487,short
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer,Fast track designation has the potential to facilitate the development and expedite the U.S. FDA review of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small cell lung cancer who are resistant to first line PD-(L)1 inhibitor therapy and who do not have molecular driver mutations Fast track designation has the potential to facilitate the development and expedite the U.S. FDA review of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small cell lung cancer who are resistant to first line PD-(L)1 inhibitor therapy and who do not have molecular driver mutations,Fast track designation has the potential to facilitate the development and expedite the U.S. FDA review of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small cell lung cancer who are resistant to first line PD-(L)1 inhibitor therapy and who do not have molecular driver mutations Fast track designation has the potential to facilitate the development and expedite the U.S. FDA review of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small cell lung cancer who are resistant to first line PD-(L)1 inhibitor therapy and who do not have molecular driver mutations,Regulatory information,0.098591542,0.098809736,long
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer,"NEEDHAM, Mass., Sept.  26, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced updated activity data from its ongoing, open-label, phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage III/IV non-small cell lung cancer (NSCLC), who have an inadequate response to front line anti-PD(L)1 therapy. These patients historically have had an expected median overall survival of 10-13 months (Reckamp K et al. J Clin Onc 2022;40:2295-2306). The aim of the CAN-2409 immunotherapy antitumor strategy is to raise the tail on the survival curve by increasing the number of long survivors beyond 10-13 months.","NEEDHAM, Mass., Sept.  26, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced updated activity data from its ongoing, open-label, phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage III/IV non-small cell lung cancer (NSCLC), who have an inadequate response to front line anti-PD(L)1 therapy. These patients historically have had an expected median overall survival of 10-13 months (Reckamp K et al. J Clin Onc 2022;40:2295-2306). The aim of the CAN-2409 immunotherapy antitumor strategy is to raise the tail on the survival curve by increasing the number of long survivors beyond 10-13 months.",Clinical Study,0.017857126,0.02512181,long
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights,"NEEDHAM, Mass., May  11, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.","NEEDHAM, Mass., May  11, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.",Earnings Releases and Operating Results,-0.044943778,-0.042763824,short
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights,"NEEDHAM, Mass., March  30, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.","NEEDHAM, Mass., March  30, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.",Earnings Releases and Operating Results,-0.007795916,-0.01462285,short
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights,"NEEDHAM, Mass., Aug.  10, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.","NEEDHAM, Mass., Aug.  10, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.",Earnings Releases and Operating Results,-0.090909111,-0.096383036,short
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights,"NEEDHAM, Mass., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.","NEEDHAM, Mass., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.",Clinical Study,0.080000043,0.077301375,long
"Candel Therapeutics to Host Virtual R&D Day on December 6, 2022","NEEDHAM, Mass., Nov.  29, 2022  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced it will host a virtual Research and Development (R&D) Day from 11:00 am – 1:30 pm ET on Tuesday, December 6, 2022.","NEEDHAM, Mass., Nov.  29, 2022  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced it will host a virtual Research and Development (R&D) Day from 11:00 am – 1:30 pm ET on Tuesday, December 6, 2022.",Calendar of Events,0.052631528,0.052277952,long
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference,"NEEDHAM, Mass., June  05, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will give a corporate presentation at the upcoming Jefferies Healthcare Conference, taking place June 7 – 9, 2023, in New York City.","NEEDHAM, Mass., June  05, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will give a corporate presentation at the upcoming Jefferies Healthcare Conference, taking place June 7 – 9, 2023, in New York City.",Calendar of Events,0.019607825,0.01876658,long
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference,"NEEDHAM, Mass., Aug.  02, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Canaccord Genuity 43rd Annual Growth Conference, taking place August 7-10, 2023, in Boston.","NEEDHAM, Mass., Aug.  02, 2023  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Canaccord Genuity 43rd Annual Growth Conference, taking place August 7-10, 2023, in Boston.",Health,0.019047715,0.026123624,long
Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform,-Capricor’s StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics- -Capricor’s StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics-,-Capricor’s StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics- -Capricor’s StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics-,Product / Services Announcement,0.007594929,0.001066057,long
Capricor Therapeutics Announces $23 Million Registered Direct Offering,"SAN DIEGO, Sept.  29, 2023  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that it has entered into definitive agreements with its commercial partner, Nippon Shinyaku, Co., Ltd. and funds associated with Highbridge Capital Management, LLC. for the issuance and sale of 4,935,621 shares of its common stock in a registered direct offering. Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $5.70 per share. Each warrant will be exercisable beginning six months after issuance and will expire seven years from the date of issuance. The combined offering price per share of common stock and accompanying warrant is $4.66. The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.","SAN DIEGO, Sept.  29, 2023  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that it has entered into definitive agreements with its commercial partner, Nippon Shinyaku, Co., Ltd. and funds associated with Highbridge Capital Management, LLC. for the issuance and sale of 4,935,621 shares of its common stock in a registered direct offering. Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $5.70 per share. Each warrant will be exercisable beginning six months after issuance and will expire seven years from the date of issuance. The combined offering price per share of common stock and accompanying warrant is $4.66. The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.",Partnerships,-0.338488008,-0.345838948,short
"Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors",-John Hopkins School of Medicine Clinical Director Joins Capricor’s Board of Directors with over 30 Years of Internal Medicine and Infectious Disease Experience-,-John Hopkins School of Medicine Clinical Director Joins Capricor’s Board of Directors with over 30 Years of Internal Medicine and Infectious Disease Experience-,Directors and Officers,0.01809953,0.013884461,long
"Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors","SAN DIEGO, July  24, 2023  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment of Philip J. Gotwals, Ph.D., to its Board of Directors, effective immediately. Dr. Gotwals, most recently the Global Head, Vice President of Business Development and Licensing at Novartis Institutes for Biomedical Research, brings his strategic vision for research, innovation for drug development and valuable industry experience to the Company.","SAN DIEGO, July  24, 2023  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced the appointment of Philip J. Gotwals, Ph.D., to its Board of Directors, effective immediately. Dr. Gotwals, most recently the Global Head, Vice President of Business Development and Licensing at Novartis Institutes for Biomedical Research, brings his strategic vision for research, innovation for drug development and valuable industry experience to the Company.",Management Changes,0.015384548,0.012752847,long
Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy,Upcoming Meeting Planned in Early Q3 2023 to Discuss CAP-1002’s Pathway Towards Potential Biologics License Application Submission Upcoming Meeting Planned in Early Q3 2023 to Discuss CAP-1002’s Pathway Towards Potential Biologics License Application Submission,Upcoming Meeting Planned in Early Q3 2023 to Discuss CAP-1002’s Pathway Towards Potential Biologics License Application Submission Upcoming Meeting Planned in Early Q3 2023 to Discuss CAP-1002’s Pathway Towards Potential Biologics License Application Submission,Calendar of Events,0.017353562,0.016395677,long
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society,-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy-,-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy-,Health,-0.007194238,-0.008697844,short
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients,"-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function-","-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function-",Clinical Study,-0.052631529,-0.04201184,short
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors,"SAN DIEGO, Calif., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry.","SAN DIEGO, Calif., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry.",Directors and Officers,0.004886028,0.006755844,long
Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award,-HOPE-2 Trial Recognized as an Outstanding Accomplishment in Research Advancement- -HOPE-2 Trial Recognized as an Outstanding Accomplishment in Research Advancement-,-HOPE-2 Trial Recognized as an Outstanding Accomplishment in Research Advancement- -HOPE-2 Trial Recognized as an Outstanding Accomplishment in Research Advancement-,Contests/Awards,0.003976139,0.009194758,long
Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11,"Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ET Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ET","Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ET Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ET",Calendar of Events,-0.007812493,-0.005141064,short
CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis,"NEWARK, Calif., Nov.  01, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that two-year safety and efficacy results of seladelpar for primary biliary cholangitis (PBC) have been published in Alimentary Pharmacology & Therapeutics:","NEWARK, Calif., Nov.  01, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that two-year safety and efficacy results of seladelpar for primary biliary cholangitis (PBC) have been published in Alimentary Pharmacology & Therapeutics:",Clinical Study,0.001221029,-0.001170171,short
"CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis","AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation","AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation",Clinical Study,-0.016393492,-0.009690951,short
CymaBay Names Harish Shantharam Chief Financial Officer,Proven Leader in Building Financial Organizations to Prepare Company for Successful Commercialization,Proven Leader in Building Financial Organizations to Prepare Company for Successful Commercialization,Directors and Officers,-0.010794864,-0.006894138,short
CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023,"Results from the RESPONSE registrational study to be highlighted in oral presentation on Monday, November 13th","Results from the RESPONSE registrational study to be highlighted in oral presentation on Monday, November 13th",Clinical Study,-0.009756121,-0.005559097,short
"CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)","NEWARK, Calif., April  21, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the ENHANCE phase 3 global study evaluating seladelpar for primary biliary cholangitis (PBC) have been published in Hepatology:","NEWARK, Calif., April  21, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the ENHANCE phase 3 global study evaluating seladelpar for primary biliary cholangitis (PBC) have been published in Hepatology:",Research Analysis and Reports,0.006809402,0.006056761,long
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ,"NEWARK, Calif., April  17, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ.","NEWARK, Calif., April  17, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ.",Trade Show,0.007856307,0.008074501,long
CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference,"NEWARK, Calif., March  01, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer 33rd Annual Healthcare Conference.","NEWARK, Calif., March  01, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer 33rd Annual Healthcare Conference.",Trade Show,0.008749962,0.010895033,long
CymaBay Therapeutics to Present at Upcoming Investment Conferences,"NEWARK, Calif., Nov.  06, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the UBS Biopharma Conference, November 8-9th in Miami Beach, FL, the Piper Sandler 35th Annual Healthcare Conference, November 28-30th, in New York, NY, and the Evercore ISI 6th Annual HealthCONx Conference, November 28-30th, in Miami, Florida.","NEWARK, Calif., Nov.  06, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the UBS Biopharma Conference, November 8-9th in Miami Beach, FL, the Piper Sandler 35th Annual Healthcare Conference, November 28-30th, in New York, NY, and the Evercore ISI 6th Annual HealthCONx Conference, November 28-30th, in Miami, Florida.",Calendar of Events,0.020171144,0.018376764,long
"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023","NEWARK, Calif., May  10, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update.","NEWARK, Calif., May  10, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update.",Calendar of Events,0.001917498,-0.00526137,short
Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis,"NEWARK, Calif., Oct.  23, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) has revised the originally granted Breakthrough Therapy Designation for seladelpar to now reflect treatment of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A). Seladelpar is the only potent, selective, orally active PPARδ agonist, or delpar, with phase 3 results demonstrating a statistically significant improvement in PBC-related cholestatic pruritus.","NEWARK, Calif., Oct.  23, 2023  (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) has revised the originally granted Breakthrough Therapy Designation for seladelpar to now reflect treatment of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A). Seladelpar is the only potent, selective, orally active PPARδ agonist, or delpar, with phase 3 results demonstrating a statistically significant improvement in PBC-related cholestatic pruritus.",Research Analysis and Reports,-0.001469471,0.002281845,long
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines,"Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone","Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone",Research Analysis and Reports,0.008928634,0.003027767,long
"C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors","WATERTOWN, Mass., Jan.  30, 2023  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of CFT1946, an orally bioavailable mutant-selective BiDAC™ degrader for the treatment of BRAF V600 mutant solid tumors.","WATERTOWN, Mass., Jan.  30, 2023  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of CFT1946, an orally bioavailable mutant-selective BiDAC™ degrader for the treatment of BRAF V600 mutant solid tumors.",Clinical Study,-0.007653054,-0.00055385,short
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights,"– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial –","– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial –",Earnings Releases and Operating Results,-0.008226618,-0.00803355,short
CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®,-Update provided for both Part A (single dose with optional re-dosing) and Part B (consolidation dosing) of the Phase 1 CARBON™ clinical trial-,-Update provided for both Part A (single dose with optional re-dosing) and Part B (consolidation dosing) of the Phase 1 CARBON™ clinical trial-,Clinical Study,0.037172493,0.024891589,long
"C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors","WATERTOWN, Mass., May  16, 2022  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of CFT8634, an orally bioavailable BiDAC™ degrader targeting BRD9 for the treatment of SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors.","WATERTOWN, Mass., May  16, 2022  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of CFT8634, an orally bioavailable BiDAC™ degrader targeting BRD9 for the treatment of SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors.",Health,-0.015384634,-0.011053283,short
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"WATERTOWN, Mass., July  17, 2023  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 351,000 shares of the Company’s common stock to two new employees (the “Inducement Grants”), with grants made on July 10 and July 17, 2023 (the “Grant Dates”). The Inducement Grants were granted as inducements material to these individuals entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).","WATERTOWN, Mass., July  17, 2023  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 351,000 shares of the Company’s common stock to two new employees (the “Inducement Grants”), with grants made on July 10 and July 17, 2023 (the “Grant Dates”). The Inducement Grants were granted as inducements material to these individuals entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).",Management statements,0,0.000333854,long
"C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma","CFT8634 Phase 1 Dose Escalation Data to be Presented at the Connective Tissue Oncology Society Annual Meeting on November 2, 2023","CFT8634 Phase 1 Dose Escalation Data to be Presented at the Connective Tissue Oncology Society Annual Meeting on November 2, 2023",Health,0.015873001,0.013341574,long
"C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors",– Dr. Laura Bessen Brings More Than Two Decades of Experience Across Medical Affairs and Clinical Development in Support of Successful Product Launches –,– Dr. Laura Bessen Brings More Than Two Decades of Experience Across Medical Affairs and Clinical Development in Support of Successful Product Launches –,Directors and Officers,-0.020042151,-0.016025319,short
"C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers","Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022 Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022","Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022 Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022",Regulatory information,-0.011123407,-0.001083731,short
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights,Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC™ Degrader; Phase 1/2 Clinical Trial Enrolling Patients,Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC™ Degrader; Phase 1/2 Clinical Trial Enrolling Patients,Earnings Releases and Operating Results,0.00318471,0.005856139,long
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights,"Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023","Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023",Calendar of Events,-0.0135135,-0.021091131,short
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights,"Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared","Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared",Earnings Releases and Operating Results,-0.005681813,0.000153436,long
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights,"The Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Continue to Enroll Patients and Advance Through Dose Escalation","The Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Continue to Enroll Patients and Advance Through Dose Escalation",Earnings Releases and Operating Results,-0.030927855,-0.021858061,short
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights,"Portfolio Decision to Prioritize Ongoing Phase 1/2 Trials of CFT7455, an IKZF1/3 Degrader, and CFT1946, a BRAF V600 Degrader","Portfolio Decision to Prioritize Ongoing Phase 1/2 Trials of CFT7455, an IKZF1/3 Degrader, and CFT1946, a BRAF V600 Degrader",Earnings Releases and Operating Results,0.087248318,0.084857118,long
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment,"Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors","Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors",Directors and Officers,0.022099493,0.02267628,long
C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022,"WATERTOWN, Mass., Sept.  26, 2022  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat at the virtual Bank of America Securities Precision Oncology Conference 2022.","WATERTOWN, Mass., Sept.  26, 2022  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat at the virtual Bank of America Securities Precision Oncology Conference 2022.",Calendar of Events,0,0.004185374,long
C4 Therapeutics to Present at Two Virtual February 2023 Conferences,"WATERTOWN, Mass., Feb.  08, 2023  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat and a panel discussion at two upcoming virtual conferences in February.","WATERTOWN, Mass., Feb.  08, 2023  (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat and a panel discussion at two upcoming virtual conferences in February.",Calendar of Events,0,0.004961578,long
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year,Asserts Certara’s leadership in advancing the development and approval of new drugs for patients Asserts Certara’s leadership in advancing the development and approval of new drugs for patients,Asserts Certara’s leadership in advancing the development and approval of new drugs for patients Asserts Certara’s leadership in advancing the development and approval of new drugs for patients,Health,0.008768229,0.002239357,long
"Avid Bioservices Appoints Michael Alston, Jr. as Vice President, Operations",Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company’s Ongoing Facility Expansion Projects Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company’s Ongoing Facility Expansion Projects,Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company’s Ongoing Facility Expansion Projects Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company’s Ongoing Facility Expansion Projects,Directors and Officers,-0.023001099,-0.020854704,short
"Avid Bioservices Appoints Oksana Lukash as Vice President, People","TUSTIN, Calif., Nov.  16, 2022  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial organizations across a range of industries.","TUSTIN, Calif., Nov.  16, 2022  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial organizations across a range of industries.",Management statements,-0.009590829,-0.005299651,short
"Avid Bioservices Appoints Pramthesh (Prem) Patel, Ph.D., as Vice President, Process Development for Mammalian Cell Business",Biopharmaceutical Executive with More than 30 Years of Experience With Top Global Big Pharma Companies GSK and Bristol Myers Squibb Biopharmaceutical Executive with More than 30 Years of Experience With Top Global Big Pharma Companies GSK and Bristol Myers Squibb,Biopharmaceutical Executive with More than 30 Years of Experience With Top Global Big Pharma Companies GSK and Bristol Myers Squibb Biopharmaceutical Executive with More than 30 Years of Experience With Top Global Big Pharma Companies GSK and Bristol Myers Squibb,Management Changes,-0.00871078,-0.002916007,short
"Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing Facility",Avid completes construction of cell and gene theapy facility bringing total revenue generating capacity to up to ~$400 Million annually,Avid completes construction of cell and gene theapy facility bringing total revenue generating capacity to up to ~$400 Million annually,Product / Services Announcement,-0.004866175,0.002541427,long
Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs,CIRM-Funded Programs to Receive Access to Avid’s Suite of World-Class CGT CDMO Services to Support Clinical Development Activities CIRM-Funded Programs to Receive Access to Avid’s Suite of World-Class CGT CDMO Services to Support Clinical Development Activities,CIRM-Funded Programs to Receive Access to Avid’s Suite of World-Class CGT CDMO Services to Support Clinical Development Activities CIRM-Funded Programs to Receive Access to Avid’s Suite of World-Class CGT CDMO Services to Support Clinical Development Activities,Product / Services Announcement,0.001703617,0.000284636,long
Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers,Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing Suites within Myford Facility,Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing Suites within Myford Facility,Health,0.012799988,0.011169661,long
Cidara Therapeutics Added to Russell Microcap® Index,"SAN DIEGO, June  26, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, announced today it has joined the broad market Russell Microcap® Index at the conclusion of the Russell U.S. Indexes annual reconstitution. The newly reconstituted Index will become effective after the U.S. equity market opens on Monday, June 26, 2023.","SAN DIEGO, June  26, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, announced today it has joined the broad market Russell Microcap® Index at the conclusion of the Russell U.S. Indexes annual reconstitution. The newly reconstituted Index will become effective after the U.S. equity market opens on Monday, June 26, 2023.",Stock Market News,0.008620682,0.009982599,long
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update,"Montrouge, France, July 25, 2023","Montrouge, France, July 25, 2023",European Regulatory News,,,
Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1),"SAN DIEGO and CAMBRIDGE, England, Oct.  13, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, and Mundipharma today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.1","SAN DIEGO and CAMBRIDGE, England, Oct.  13, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, and Mundipharma today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.1",Product / Services Announcement,0.038374763,0.046899364,long
"Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development","Dr. Davarpanah will lead Cidara’s oncology efforts, focusing on strategy to advance development candidates ","Dr. Davarpanah will lead Cidara’s oncology efforts, focusing on strategy to advance development candidates ",Company Announcement,-0.00660791,-0.005636962,short
Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza,Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials,Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials,Business Contracts,0.185372028,0.187241844,long
Cidara Therapeutics Named as a San Diego Metro Area Top Workplace,"SAN DIEGO, Nov.  20, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it has been named a Top Workplace by The San Diego Union-Tribune. Cidara was among the top 100 companies and organizations included in the 2023 Top Workplace list.","SAN DIEGO, Nov.  20, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it has been named a Top Workplace by The San Diego Union-Tribune. Cidara was among the top 100 companies and organizations included in the 2023 Top Workplace list.",Contests/Awards,-0.012820501,-0.012243714,short
Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023,"SAN DIEGO, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new data on its drug-Fc conjugate (DFC) candidate, CD388, at IDWeek 2023. The conference is taking place both in-person at the Boston Convention and Exhibition Center in Boston, MA and virtually from October 11 – 15, 2023.","SAN DIEGO, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new data on its drug-Fc conjugate (DFC) candidate, CD388, at IDWeek 2023. The conference is taking place both in-person at the Boston Convention and Exhibition Center in Boston, MA and virtually from October 11 – 15, 2023.",Health,0.025906774,0.023375347,long
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting,"SAN DIEGO, Nov.  03, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting. The conference is taking place November 1-5, 2023, both virtually and in-person in San Diego, CA.","SAN DIEGO, Nov.  03, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting. The conference is taking place November 1-5, 2023, both virtually and in-person in San Diego, CA.",Clinical Study,-0.089887623,-0.093466114,short
DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update,"Montrouge, France, October 27, 2023","Montrouge, France, October 27, 2023",European Regulatory News,,,
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results,"SAN DIEGO, March  23, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year ended December 31, 2022 and provided an update on its corporate activities and product pipeline.","SAN DIEGO, March  23, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year ended December 31, 2022 and provided an update on its corporate activities and product pipeline.",Earnings Releases and Operating Results,-0.105263122,-0.112863058,short
Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™,– U.S. launch of REZZAYO by Melinta expected in mid-2023 –– Company eligible to receive up to an additional $47 million in milestones from multiple existing partnerships based on successful completion of activities planned over the next year –,– U.S. launch of REZZAYO by Melinta expected in mid-2023 –– Company eligible to receive up to an additional $47 million in milestones from multiple existing partnerships based on successful completion of activities planned over the next year –,Product / Services Announcement,0,0.000509515,long
"Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B","SAN DIEGO, June  22, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CD388, Cidara’s novel drug-Fc conjugate (DFC) candidate. CD388 is being developed in collaboration with Janssen Pharmaceuticals for the prevention of influenza A and B infection in adults who are at high risk of severe influenza, including those for whom vaccines are either ineffective or contraindicated.","SAN DIEGO, June  22, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CD388, Cidara’s novel drug-Fc conjugate (DFC) candidate. CD388 is being developed in collaboration with Janssen Pharmaceuticals for the prevention of influenza A and B infection in adults who are at high risk of severe influenza, including those for whom vaccines are either ineffective or contraindicated.",Product / Services Announcement,0.100000011,0.102276164,long
"Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023","• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza from Janssen Pharmaceuticals, Inc. leadership following Election to Proceed notification","• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza from Janssen Pharmaceuticals, Inc. leadership following Election to Proceed notification",Calendar of Events,-0.023999989,-0.017030297,short
Cidara Therapeutics to Participate in Upcoming Investor Conferences,"SAN DIEGO, March  31, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, is scheduled to participate in the following upcoming investor conferences.","SAN DIEGO, March  31, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, is scheduled to participate in the following upcoming investor conferences.",Calendar of Events,-0.015624985,-0.018002968,short
Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit,"SAN DIEGO, June  13, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting DFC candidate, as well as the development of its novel drug-Fc conjugates (DFCs) from Cidara’s Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023.  ","SAN DIEGO, June  13, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting DFC candidate, as well as the development of its novel drug-Fc conjugates (DFCs) from Cidara’s Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023.  ",Health,-0.008130073,-0.011634037,short
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023,"SAN DIEGO, Sept.  27, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it will present new data on its drug-Fc conjugate (DFC) candidate, CD388, in an oral presentation and two poster presentations at IDWeek 2023. The conference will take place both in-person at the Boston Convention and Exhibition Center in Boston, MA and virtually from October 11 – 15, 2023.","SAN DIEGO, Sept.  27, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it will present new data on its drug-Fc conjugate (DFC) candidate, CD388, in an oral presentation and two poster presentations at IDWeek 2023. The conference will take place both in-person at the Boston Convention and Exhibition Center in Boston, MA and virtually from October 11 – 15, 2023.",Calendar of Events,-0.007142887,-0.009984043,short
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit,"SAN DIEGO, June  20, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting drug-Fc conjugate (DFC), as well as the development of its novel DFCs from Cidara’s Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023.","SAN DIEGO, June  20, 2023  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting drug-Fc conjugate (DFC), as well as the development of its novel DFCs from Cidara’s Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023.",Clinical Study,0.027272701,0.027889959,long
Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications,"FLORHAM PARK, N.J. and TAMPA, Fla., July  27, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Verséa Ophthalmics, LLC (“Verséa Ophthalmics”), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, today announced that the companies have entered into an exclusive U.S. commercialization agreement in which Verséa Ophthalmics will distribute Celularity’s BIOVANCE® and BIOVANCE® 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications.","FLORHAM PARK, N.J. and TAMPA, Fla., July  27, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Verséa Ophthalmics, LLC (“Verséa Ophthalmics”), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, today announced that the companies have entered into an exclusive U.S. commercialization agreement in which Verséa Ophthalmics will distribute Celularity’s BIOVANCE® and BIOVANCE® 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications.",Product / Services Announcement,-0.014285701,-0.021991304,short
"Celularity Announces $45 Million Purchase Order,  First Middle East Private Label Agreement For  Celularity’s Halal-Certified Biomaterial Products","FLORHAM PARK, N.J., May  23, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has received a $45 million purchase order for Celularity private label Halal-Certified biomaterial products from Jamjoom Medical Store (Jamjoom). Dr. Walid Swelim will serve as marketing manager for promotion and distribution of the products. This marks the first purchase order received by Celularity under its recently announced expansion into the Middle East market, as part of Celularity’s global market strategy.","FLORHAM PARK, N.J., May  23, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has received a $45 million purchase order for Celularity private label Halal-Certified biomaterial products from Jamjoom Medical Store (Jamjoom). Dr. Walid Swelim will serve as marketing manager for promotion and distribution of the products. This marks the first purchase order received by Celularity under its recently announced expansion into the Middle East market, as part of Celularity’s global market strategy.",Product / Services Announcement,0.037037001,0.041120245,long
DBV Technologies va présenter de nouvelles données à l’ACAAI 2023,"Montrouge, France, le 2 novembre (21h30 CET) 2023","Montrouge, France, le 2 novembre (21h30 CET) 2023",European Regulatory News,,,
Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting,"FLORHAM PARK, N.J., April  04, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today an oral and poster presentation at the upcoming 2023 Annual Meeting Society for Biomaterials (“SFB”), which will be held April 19th – 22nd in San Diego, CA. The oral presentation and poster highlights the role decellularized dehydrated human amniotic membranes plays in supporting human tenocytes in vitro.","FLORHAM PARK, N.J., April  04, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today an oral and poster presentation at the upcoming 2023 Annual Meeting Society for Biomaterials (“SFB”), which will be held April 19th – 22nd in San Diego, CA. The oral presentation and poster highlights the role decellularized dehydrated human amniotic membranes plays in supporting human tenocytes in vitro.",Calendar of Events,0.027027001,0.025396674,long
Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products,"FLORHAM PARK, N.J., May  10, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has been advised by Farouk, Maamoun Tamer & Co. (Tamer Group), the exclusive distributor for Celularity's branded Halal-Certified biomaterial products in the Kingdom of Saudi Arabia, that it expects to submit purchase orders through the end of 2023 in the range of $60 million to $80 million.","FLORHAM PARK, N.J., May  10, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has been advised by Farouk, Maamoun Tamer & Co. (Tamer Group), the exclusive distributor for Celularity's branded Halal-Certified biomaterial products in the Kingdom of Saudi Arabia, that it expects to submit purchase orders through the end of 2023 in the range of $60 million to $80 million.",Management statements,0.05200942,0.044830552,long
Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt,"AD Ports Logistics, subsidiary of AD Ports Group’s Logistics Cluster, chosen as the Exclusive Distributor for United Arab Emirates, Qatar, Bahrain, Oman, Kuwait and Egypt","AD Ports Logistics, subsidiary of AD Ports Group’s Logistics Cluster, chosen as the Exclusive Distributor for United Arab Emirates, Qatar, Bahrain, Oman, Kuwait and Egypt",Partnerships,0.116487445,0.118303383,long
Celularity Announces Clinical Data on  Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia,"FLORHAM PARK, N.J., April  27, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced preliminary results from its Phase 1 trial of CYNK-001, its investigational unmodified natural killer (NK) cell therapy in development for the treatment of R/R AML and MRD positive AML.","FLORHAM PARK, N.J., April  27, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced preliminary results from its Phase 1 trial of CYNK-001, its investigational unmodified natural killer (NK) cell therapy in development for the treatment of R/R AML and MRD positive AML.",Clinical Study,0.023622025,0.017093153,long
Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification,SFDA Classification Establishes Clear Regulatory Pathway for Importation of Celularity’s Commercial Biomaterial Products into the Kingdom of Saudi Arabia,SFDA Classification Establishes Clear Regulatory Pathway for Importation of Celularity’s Commercial Biomaterial Products into the Kingdom of Saudi Arabia,Regulatory information,-0.003115317,0.001081707,long
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron,"FLORHAM PARK, N.J., Aug.  29, 2023  (GLOBE NEWSWIRE) --  Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc. (Regeneron) to support the research of Regeneron’s allogeneic cell therapy candidates.","FLORHAM PARK, N.J., Aug.  29, 2023  (GLOBE NEWSWIRE) --  Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc. (Regeneron) to support the research of Regeneron’s allogeneic cell therapy candidates.",Calendar of Events,0.139860104,0.140108582,long
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF,"AMF Regulated InformationMontrouge, France, July 10, 2023","AMF Regulated InformationMontrouge, France, July 10, 2023",European Regulatory News,,,
Celularity Human Placental-Derived  Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies,"Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental-derived biomaterials at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental-derived biomaterials at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering","Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental-derived biomaterials at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental-derived biomaterials at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering",Clinical Study,0.004081641,0.004835781,long
Celularity Inc. Announces $3 Million Registered Direct Offering,"FLORHAM PARK, N.J., July  27, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock together with warrants to purchase up to 8,571,428 shares of its Class A common stock at a combined purchase price of $0.35 per share and accompanying warrant (together the “Securities”), pursuant to a registered direct offering resulting in total gross proceeds of approximately $3 million before deducting placement agent commissions and other estimated offering expenses. The warrants will have an exercise price of $0.35, will be exercisable beginning six months after the date of issuance and will expire five years following the initial exercise date. The closing of the offering and sale of the Securities is expected to occur on or about July 31, 2023, subject to the satisfaction of customary closing conditions.","FLORHAM PARK, N.J., July  27, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock together with warrants to purchase up to 8,571,428 shares of its Class A common stock at a combined purchase price of $0.35 per share and accompanying warrant (together the “Securities”), pursuant to a registered direct offering resulting in total gross proceeds of approximately $3 million before deducting placement agent commissions and other estimated offering expenses. The warrants will have an exercise price of $0.35, will be exercisable beginning six months after the date of issuance and will expire five years following the initial exercise date. The closing of the offering and sale of the Securities is expected to occur on or about July 31, 2023, subject to the satisfaction of customary closing conditions.",Stock Market News,-0.014285701,-0.021991304,short
Celularity Inc. Announces $6 Million Registered Direct Offering,"FLORHAM PARK, N.J., April  05, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 9,230,770 shares of its Class A common stock together with warrants to purchase up to 9,230,770 shares of its Class A common stock at a combined purchase price of $0.65 per share and accompanying warrant (together the “Securities”), pursuant to a registered direct offering resulting in total gross proceeds of approximately $6 million before deducting placement agent commissions and other estimated offering expenses. The warrants will have an exercise price of $0.75, will be exercisable beginning six months after the date of issuance and will expire five years following the initial exercise date. The closing of the offering and sale of the Securities is expected to occur on or about April 10, 2023, subject to the satisfaction of customary closing conditions.","FLORHAM PARK, N.J., April  05, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 9,230,770 shares of its Class A common stock together with warrants to purchase up to 9,230,770 shares of its Class A common stock at a combined purchase price of $0.65 per share and accompanying warrant (together the “Securities”), pursuant to a registered direct offering resulting in total gross proceeds of approximately $6 million before deducting placement agent commissions and other estimated offering expenses. The warrants will have an exercise price of $0.75, will be exercisable beginning six months after the date of issuance and will expire five years following the initial exercise date. The closing of the offering and sale of the Securities is expected to occur on or about April 10, 2023, subject to the satisfaction of customary closing conditions.",Financing Agreements,-0.123809549,-0.121949834,short
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing,"FLORHAM PARK, N.J., Nov.  24, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today that on November 21, 2023, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq’s continued listing requirements of the Company’s failure to timely file a Form 10-Q for the third quarter of 2023.","FLORHAM PARK, N.J., Nov.  24, 2023  (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today that on November 21, 2023, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq’s continued listing requirements of the Company’s failure to timely file a Form 10-Q for the third quarter of 2023.",Exchange Members,0.069999992,0.069494618,long
Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health,Celularity’s Pre-Request for Designation (Pre-RFD) is based on data demonstrating 100 percent biochemical characterization of the product,Celularity’s Pre-Request for Designation (Pre-RFD) is based on data demonstrating 100 percent biochemical characterization of the product,Product / Services Announcement,0.016129017,0.017448073,long
"Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types",Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies,Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies,Product / Services Announcement,-0.006989731,-0.006866143,short
Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”,"Hariri, Celularity’s CEO, Chairman and Founder, will open the meeting with the keynote address highlighting recent progress and important next steps for the science of longevity together with Scott Gottlieb, M.D., Senior Fellow of the American Enterprise Institute and former Commissioner of the U.S. Food and Drug Administration","Hariri, Celularity’s CEO, Chairman and Founder, will open the meeting with the keynote address highlighting recent progress and important next steps for the science of longevity together with Scott Gottlieb, M.D., Senior Fellow of the American Enterprise Institute and former Commissioner of the U.S. Food and Drug Administration",Calendar of Events,0.071975484,0.066728013,long
Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability,"Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower tissue factor (TF) expression, activity, and thrombotic effects, providing a feasible strategy potentially to improve the safety of ASC-based cell therapy ","Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower tissue factor (TF) expression, activity, and thrombotic effects, providing a feasible strategy potentially to improve the safety of ASC-based cell therapy ",Clinical Study,0.026315765,0.025741419,long
Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated  as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH),Celularity’s Pre-Request for Designation (Pre-RFD) is based on data showing CTW contains 100 percent extracellular matrix,Celularity’s Pre-Request for Designation (Pre-RFD) is based on data showing CTW contains 100 percent extracellular matrix,Licensing Agreements,-0.016447353,-0.026330502,short
A.I. Coming to Certara’s D360 Scientific Informatics Software,"New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses. New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses.","New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses. New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses.",Product / Services Announcement,0.005644352,0.003588861,long
Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase,Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares,Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares,Changes in company's own shares,0.128638581,0.125024963,long
"Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation",Certara improves software capabilities by expanding into deep learning and data fabric Certara improves software capabilities by expanding into deep learning and data fabric,Certara improves software capabilities by expanding into deep learning and data fabric Certara improves software capabilities by expanding into deep learning and data fabric,Mergers and Acquisitions,0.026477852,0.020280737,long
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software,Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines,Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines,Management statements,0.000715324,0.002856776,long
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day,- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments -,- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments -,Health,0.016042765,0.018054593,long
Certara Simcyp™ Group Awarded Two New Grants from US FDA,Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations,Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations,Health,-0.00125631,-0.001007833,short
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections,"YONKERS, N.Y., Nov.  28, 2022  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that ANSM, the French National Agency for the Safety of Medicines and Health Products, has authorized its Clinical Trial Application (CTA) for the study of intra-articularly administered exebacase, in the setting of a minimally-invasive arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infection (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).","YONKERS, N.Y., Nov.  28, 2022  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that ANSM, the French National Agency for the Safety of Medicines and Health Products, has authorized its Clinical Trial Application (CTA) for the study of intra-articularly administered exebacase, in the setting of a minimally-invasive arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infection (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).",Clinical Study,0.118881177,0.126934243,long
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study,CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial,CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial,Product / Services Announcement,0.179261858,0.173885248,long
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee,"YONKERS, N.Y., April  26, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces the first patient has been dosed in the Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).","YONKERS, N.Y., April  26, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces the first patient has been dosed in the Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).",Health,0.006410327,0.004834247,long
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee,"YONKERS, New York, April  03, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the initiation of a Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).","YONKERS, New York, April  03, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the initiation of a Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).",Product / Services Announcement,-0.027322443,-0.026003386,short
ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting,Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa,Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa,Calendar of Events,-0.004184096,-0.002147744,short
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections,"YONKERS, N.Y., Sept.  12, 2022  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the publication of an editorial in the Journal of Bone and Joint Infection discussing the potential for each of the Company’s lysins, exebacase and CF-296, as additional agents in the treatment armamentarium against bone and joint infections (BJIs) due to their in vitro activity against coagulase-negative staphylococci (CoNS), the bacteria most frequently involved in implant-associated BJIs, and their potential for both local and systemic anti-biofilm activity. The authors conclude that these advantages could compensate for the treatment challenges with current antibiotic treatments against staphylococcal BJIs alone.","YONKERS, N.Y., Sept.  12, 2022  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the publication of an editorial in the Journal of Bone and Joint Infection discussing the potential for each of the Company’s lysins, exebacase and CF-296, as additional agents in the treatment armamentarium against bone and joint infections (BJIs) due to their in vitro activity against coagulase-negative staphylococci (CoNS), the bacteria most frequently involved in implant-associated BJIs, and their potential for both local and systemic anti-biofilm activity. The authors conclude that these advantages could compensate for the treatment challenges with current antibiotic treatments against staphylococcal BJIs alone.",Health,0.020833313,0.015471796,long
ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement,"YONKERS, N.Y., Feb.  28, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $10.0 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The combined effective purchase price for each share of common stock (or pre-funded warrant to purchase common stock in lieu thereof) and associated warrants will be $4.00.","YONKERS, N.Y., Feb.  28, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $10.0 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The combined effective purchase price for each share of common stock (or pre-funded warrant to purchase common stock in lieu thereof) and associated warrants will be $4.00.",Stock Market News,-0.272151854,-0.270894719,short
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement,"YONKERS, N.Y., Dec.  13, 2022  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $7.0 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The combined effective purchase price for each share of common stock (or pre-funded warrant to purchase common stock in lieu thereof) and associated warrants will be $0.129.","YONKERS, N.Y., Dec.  13, 2022  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $7.0 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The combined effective purchase price for each share of common stock (or pre-funded warrant to purchase common stock in lieu thereof) and associated warrants will be $0.129.",Management statements,0,-0.028249126,short
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370,"YONKERS, N.Y., Sept.  18, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).","YONKERS, N.Y., Sept.  18, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).",Regulatory information,0.095406398,0.09612816,long
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens,"YONKERS, N.Y., April  20, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing CF-370 is highly efficacious in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Pseudomonas aeruginosa (P. aeruginosa).These data were recently presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting held from April 15-18, 2023 in Copenhagen, Denmark.","YONKERS, N.Y., April  20, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing CF-370 is highly efficacious in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Pseudomonas aeruginosa (P. aeruginosa).These data were recently presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting held from April 15-18, 2023 in Copenhagen, Denmark.",Clinical Study,0.164772706,0.171847664,long
Coherus Completes Surface Oncology Acquisition,"– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment –","– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment –",Mergers and Acquisitions,0.012269927,0.012157557,long
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million,"YONKERS, N.Y., June  27, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 7.0 million shares of the company's common stock. In consideration for the immediate exercise of the existing warrants for cash, the exercising holder received new unregistered warrants to purchase an aggregate of 7.0 million shares of the company's common stock. In connection with the exercise, the company also agreed to reduce the exercise price of such existing warrants to $1.36, which is equal to the most recent closing price of the company's common stock on The Nasdaq Capital Market prior to the execution of the warrant exercise agreement.","YONKERS, N.Y., June  27, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 7.0 million shares of the company's common stock. In consideration for the immediate exercise of the existing warrants for cash, the exercising holder received new unregistered warrants to purchase an aggregate of 7.0 million shares of the company's common stock. In connection with the exercise, the company also agreed to reduce the exercise price of such existing warrants to $1.36, which is equal to the most recent closing price of the company's common stock on The Nasdaq Capital Market prior to the execution of the warrant exercise agreement.",Stock Market News,-0.037037089,-0.039146313,short
ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update,"YONKERS, N.Y., May  15, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the first quarter ended March 31, 2023.","YONKERS, N.Y., May  15, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the first quarter ended March 31, 2023.",Earnings Releases and Operating Results,0.126666705,0.125136044,long
ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update,"YONKERS, N.Y., March  31, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the fourth quarter and full year ended December 31, 2022.","YONKERS, N.Y., March  31, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the fourth quarter and full year ended December 31, 2022.",Earnings Releases and Operating Results,-0.022831028,-0.02520901,short
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update,"YONKERS, N.Y., Aug.  14, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the second quarter ended June 30, 2023.","YONKERS, N.Y., Aug.  14, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the second quarter ended June 30, 2023.",Company Announcement,0.030927805,0.033059481,long
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update,Continued execution to advance exebacase and CF-370 into new clinical studies Continued execution to advance exebacase and CF-370 into new clinical studies,Continued execution to advance exebacase and CF-370 into new clinical studies Continued execution to advance exebacase and CF-370 into new clinical studies,Earnings Releases and Operating Results,-0.027777833,-0.023135525,short
"Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.",–$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85% compared to Humira® –,–$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85% compared to Humira® –,Product / Services Announcement,0.023419182,0.024231276,long
Evelo Biosciences Closes $25.5 Million Private Placement,Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors,Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors,Financing Agreements,0.005917154,-0.002965058,short
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development,"YONKERS, New York, Sept.  19, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company’s Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023.","YONKERS, New York, Sept.  19, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company’s Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023.",Calendar of Events,0.001697771,0.003839223,long
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023,"YONKERS, N.Y., Aug.  28, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Garrett Nichols, M.D., M.S., the Company’s Interim Chief Medical Officer, will be presenting an updated overview of the Company’s DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial (AMR) Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.","YONKERS, N.Y., Aug.  28, 2023  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Garrett Nichols, M.D., M.S., the Company’s Interim Chief Medical Officer, will be presenting an updated overview of the Company’s DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial (AMR) Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.",Calendar of Events,0.044568253,0.039408835,long
"CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch",– CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* –,– CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* –,Product / Services Announcement,0.011940359,0.010801786,long
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC),–  LOQTORZI is the first and only FDA-approved treatment for NPC –,–  LOQTORZI is the first and only FDA-approved treatment for NPC –,Clinical Study,-0.060498164,-0.052023769,short
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™,"REDWOOD CITY, Calif., July  13, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and specialty pharmacy Superior Biologics, Inc. (“Superior Biologics”) today announced a national distribution agreement for YUSIMRY™ (adalimumab-aqvh) at a price of $995 per carton of two autoinjectors, a discount of more than 85% compared to Humira® (adalimumab), currently priced at $6,922 per carton of two pens.“Coherus is pleased to work with Superior Biologics for nationwide distribution of YUSIMRY, providing patients and their plan sponsors access to a high-quality, safe, and effective treatment at significant savings compared to Humira,” said Denny Lanfear, Coherus’ Chairman and Chief Executive Officer. “Superior Biologics is an ideal partner for the distribution of YUSIMRY based on their commitment to quality patient service and care, their extensive experience working with manufacturers, patients, physicians, and plan sponsors, and their nationwide reach. Through this unique distribution partnership, we can bring YUSIMRY immediately to patients throughout the United States.”","REDWOOD CITY, Calif., July  13, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and specialty pharmacy Superior Biologics, Inc. (“Superior Biologics”) today announced a national distribution agreement for YUSIMRY™ (adalimumab-aqvh) at a price of $995 per carton of two autoinjectors, a discount of more than 85% compared to Humira® (adalimumab), currently priced at $6,922 per carton of two pens.“Coherus is pleased to work with Superior Biologics for nationwide distribution of YUSIMRY, providing patients and their plan sponsors access to a high-quality, safe, and effective treatment at significant savings compared to Humira,” said Denny Lanfear, Coherus’ Chairman and Chief Executive Officer. “Superior Biologics is an ideal partner for the distribution of YUSIMRY based on their commitment to quality patient service and care, their extensive experience working with manufacturers, patients, physicians, and plan sponsors, and their nationwide reach. Through this unique distribution partnership, we can bring YUSIMRY immediately to patients throughout the United States.”",Product / Services Announcement,0.007830051,0.003614982,long
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™,– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler –,– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler –,Product / Services Announcement,0.025236568,0.025943059,long
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC),"REDWOOD CITY, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 - 5, 2023 at the San Diego Convention Center in San Diego, CA.","REDWOOD CITY, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 - 5, 2023 at the San Diego Convention Center in San Diego, CA.",Health,0.007537741,0.004696585,long
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC),"– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug –","– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug –",Health,0.015060227,0.009535097,long
Coherus to Acquire Surface Oncology,– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues –,– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues –,Mergers and Acquisitions,-0.120593713,-0.121542612,short
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections,"– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL –","– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL –",Product / Services Announcement,-0.022421503,-0.019517363,short
"Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients",–  YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  –,–  YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  –,Product / Services Announcement,0.019559883,0.018985537,long
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market,"WALTHAM, Mass., July  31, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,236,248 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,236,248 shares of common stock and Series B warrants to purchase up to 3,236,248 shares of common stock, at a purchase price of $3.09 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants, in a registered direct offering priced at-the-market.","WALTHAM, Mass., July  31, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,236,248 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,236,248 shares of common stock and Series B warrants to purchase up to 3,236,248 shares of common stock, at a purchase price of $3.09 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants, in a registered direct offering priced at-the-market.",Stock Market News,-0.161290328,-0.162362704,short
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,"WALTHAM, Mass., May  23, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,256,269 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,256,269 shares of common stock and Series B warrants to purchase up to 3,256,269 shares of common stock, at a purchase price of $3.071 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants, in a registered direct offering priced at-the-market under Nasdaq rules.","WALTHAM, Mass., May  23, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,256,269 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,256,269 shares of common stock and Series B warrants to purchase up to 3,256,269 shares of common stock, at a purchase price of $3.071 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants, in a registered direct offering priced at-the-market under Nasdaq rules.",Stock Market News,-0.034602124,-0.03051888,short
Cytek® Biosciences Launches Educational Roadshow Focused on Spectral Flow Cytometry,The Cytek Reveal Roadshow Will Provide Insights to Accelerate Discoveries – from Basic Science to Highly Complex Assays The Cytek Reveal Roadshow Will Provide Insights to Accelerate Discoveries – from Basic Science to Highly Complex Assays,The Cytek Reveal Roadshow Will Provide Insights to Accelerate Discoveries – from Basic Science to Highly Complex Assays The Cytek Reveal Roadshow Will Provide Insights to Accelerate Discoveries – from Basic Science to Highly Complex Assays,Calendar of Events,0.009641831,0.003908482,long
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,"WALTHAM, Mass., March  31, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,700,000 shares of its common stock at a purchase price of $3.60 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.","WALTHAM, Mass., March  31, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,700,000 shares of its common stock at a purchase price of $3.60 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.",Stock Market News,-0.098507443,-0.100885425,short
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,"WALTHAM, Mass., Dec.  15, 2022  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 1,734,105 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 1,734,105 shares of common stock and Series B warrants to purchase up to 1,734,105 shares of common stock, at a purchase price of $4.325 per share of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants, in a registered direct offering priced at-the-market under Nasdaq rules. The Series A warrants will be exercisable immediately upon issuance and will expire five years following the issuance date and have an exercise price of $4.075 per share and the Series B warrants will be exercisable immediately upon issuance and will expire eighteen months following the issuance date and have an exercise price of $4.075 per share.","WALTHAM, Mass., Dec.  15, 2022  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 1,734,105 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 1,734,105 shares of common stock and Series B warrants to purchase up to 1,734,105 shares of common stock, at a purchase price of $4.325 per share of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants, in a registered direct offering priced at-the-market under Nasdaq rules. The Series A warrants will be exercisable immediately upon issuance and will expire five years following the issuance date and have an exercise price of $4.075 per share and the Series B warrants will be exercisable immediately upon issuance and will expire eighteen months following the issuance date and have an exercise price of $4.075 per share.",Stock Market News,-0.118257293,-0.105488124,short
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma,55% objective response rate; 23% complete response rate in locally advanced cSCC,55% objective response rate; 23% complete response rate in locally advanced cSCC,Clinical Study,0.024464809,0.016759206,long
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds,"WALTHAM, Mass., Oct.  02, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding (i) Series A warrants to purchase up to an aggregate of 1,734,105 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,734,105 shares of common stock, each having an exercise price of $4.075 per share, issued by Checkpoint on December 16, 2022 and (ii) Series A warrants to purchase up to an aggregate of 1,428,572 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,428,572 shares of common stock issued by Checkpoint on February 22, 2023, each having an exercise price of $5.00 per share, at a reduced exercise price of $1.76 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File No. 333-251005) and Form S-3 (File No. 333-270474), respectively. The gross proceeds to Checkpoint from the exercise of the warrants are expected to be approximately $11.13 million, prior to deducting placement agent fees and estimated offering expenses. The closing of the offering is expected to occur on or about October 4, 2023, subject to satisfaction of customary closing conditions.","WALTHAM, Mass., Oct.  02, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding (i) Series A warrants to purchase up to an aggregate of 1,734,105 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,734,105 shares of common stock, each having an exercise price of $4.075 per share, issued by Checkpoint on December 16, 2022 and (ii) Series A warrants to purchase up to an aggregate of 1,428,572 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,428,572 shares of common stock issued by Checkpoint on February 22, 2023, each having an exercise price of $5.00 per share, at a reduced exercise price of $1.76 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File No. 333-251005) and Form S-3 (File No. 333-270474), respectively. The gross proceeds to Checkpoint from the exercise of the warrants are expected to be approximately $11.13 million, prior to deducting placement agent fees and estimated offering expenses. The closing of the offering is expected to occur on or about October 4, 2023, subject to satisfaction of customary closing conditions.",Financing Agreements,-0.079999992,-0.081617362,short
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma,"Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024 FDA indicates that it does not currently plan to hold an advisory committee meeting","Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024 FDA indicates that it does not currently plan to hold an advisory committee meeting",Health,0.048780441,0.053999059,long
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing,Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens,Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens,Clinical Study,0.004255315,0.00682318,long
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer,"Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous squamous cell carcinoma","Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous squamous cell carcinoma",Clinical Study,0.041237073,0.045434097,long
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma,Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indications Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indications,Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indications Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indications,Company Announcement,0.037459287,0.031262172,long
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences,"WALTHAM, Mass., Sept.  22, 2022  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows:","WALTHAM, Mass., Sept.  22, 2022  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows:",Calendar of Events,0.009174347,0.011320742,long
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference,"WALTHAM, Mass., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 2:30 p.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference.","WALTHAM, Mass., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 2:30 p.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference.",Calendar of Events,-0.004999995,-0.003130179,short
"CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline",Enabling Rapid and Reliable Diagnosis and Research of Rare Genetic Diseases Around the World,Enabling Rapid and Reliable Diagnosis and Research of Rare Genetic Diseases Around the World,Product / Services Announcement,0.012269927,0.010693847,long
"CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment","CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and RIYADH, Saudi Arabia, June  27, 2023  (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF), today announced a strategic collaboration with the formation of a Joint Venture (JV) to increase local and regional access and rapid delivery of world-class multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council (GCC). Under the terms of the collaboration, CENTOGENE will receive a $30 million mandatory convertible loan from Lifera.","CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and RIYADH, Saudi Arabia, June  27, 2023  (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF), today announced a strategic collaboration with the formation of a Joint Venture (JV) to increase local and regional access and rapid delivery of world-class multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council (GCC). Under the terms of the collaboration, CENTOGENE will receive a $30 million mandatory convertible loan from Lifera.",Financing Agreements,0.419437349,0.417328125,long
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting,- IND filing for CX-801 anticipated by the end of 2023 -,- IND filing for CX-801 anticipated by the end of 2023 -,Calendar of Events,0.028037355,0.021024584,long
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients,"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept.  01, 2023  (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data confirming the utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher disease (GD). The findings from this landmark study which were published in Diagnostics in a paper titled, “Insights into the value of lyso-Gb1 as a predictive biomarker in treatment-naïve patients with Gaucher disease type 1 in the LYSO-PROOF study,” also indicate lyso-Gb1 could help to predict the clinical course of patients and improve personalized care of GD patients in the future.","CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept.  01, 2023  (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data confirming the utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher disease (GD). The findings from this landmark study which were published in Diagnostics in a paper titled, “Insights into the value of lyso-Gb1 as a predictive biomarker in treatment-naïve patients with Gaucher disease type 1 in the LYSO-PROOF study,” also indicate lyso-Gb1 could help to predict the clinical course of patients and improve personalized care of GD patients in the future.",Clinical Study,0.008403353,0.00214154,long
CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort,Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options,Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options,Clinical Study,0.012903291,0.004021079,long
CENTOGENE to Participate in Upcoming Conferences in April,"CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April  14, 2023  (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for April 2023. CENTOGENE representatives will be attending events in Spain, the U.S., and Germany and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.","CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April  14, 2023  (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for April 2023. CENTOGENE representatives will be attending events in Spain, the U.S., and Germany and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.",Calendar of Events,0,0.001596255,long
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference,"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that CENTOGENE CEO Kim Stratton will present in the virtual track at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, and invites investors to participate via virtual one-on-one meetings with Ms. Stratton and CENTOGENE CFO Miguel Coego Rios.","CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that CENTOGENE CEO Kim Stratton will present in the virtual track at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, and invites investors to participate via virtual one-on-one meetings with Ms. Stratton and CENTOGENE CFO Miguel Coego Rios.",Calendar of Events,-0.045454609,-0.051559838,short
"CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism",Results From Landmark Study Published in Brain Journal Results From Landmark Study Published in Brain Journal,Results From Landmark Study Published in Brain Journal Results From Landmark Study Published in Brain Journal,Clinical Study,0.10256411,0.088638295,long
Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023,"NORWOOD, Mass., Oct.  17, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced results of a pre-clinical study on its CRB-913 cannabinoid type-1 receptor (CB1) inverse agonist have been selected for oral presentation at the 11th annual Obesity Journal Symposium, held during the 2023 Obesity Week Conference in Dallas, Texas October 14-17, 2023. In addition, the work has also been selected as a late breaking poster. ","NORWOOD, Mass., Oct.  17, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced results of a pre-clinical study on its CRB-913 cannabinoid type-1 receptor (CB1) inverse agonist have been selected for oral presentation at the 11th annual Obesity Journal Symposium, held during the 2023 Obesity Week Conference in Dallas, Texas October 14-17, 2023. In addition, the work has also been selected as a late breaking poster. ",Clinical Study,-0.003322256,0.004085346,long
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting,"NORWOOD, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal antibody were presented as posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in San Diego, CA November 1-5, 2023.","NORWOOD, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal antibody were presented as posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in San Diego, CA November 1-5, 2023.",Clinical Study,0.036831656,0.027557102,long
Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701,"NORWOOD, Mass., Oct.  16, 2023  (GLOBE NEWSWIRE) --  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next generation antibody drug conjugate (ADC) targeting nectin-4 was presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Boston on October 14th 2023.","NORWOOD, Mass., Oct.  16, 2023  (GLOBE NEWSWIRE) --  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next generation antibody drug conjugate (ADC) targeting nectin-4 was presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Boston on October 14th 2023.",Health,0.024875558,0.019498948,long
CRISPR Therapeutics Proposes New Appointment to the Board of Directors,"ZUG, Switzerland and BOSTON, Oct.  16, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Sandy Mahatme, LL.M. to its Board of Directors at the Company’s next annual general meeting to be held in 2024.","ZUG, Switzerland and BOSTON, Oct.  16, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Sandy Mahatme, LL.M. to its Board of Directors at the Company’s next annual general meeting to be held in 2024.",Directors and Officers,0,-0.00537661,short
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update,"NORWOOD, Mass., Nov.  07, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the third quarter of 2023.","NORWOOD, Mass., Nov.  07, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the third quarter of 2023.",Earnings Releases and Operating Results,-0.071428598,-0.071428598,short
"Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023","NORWOOD, Mass., Oct.  03, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (""Corbus"" or the ""Company""), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here.","NORWOOD, Mass., Oct.  03, 2023  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (""Corbus"" or the ""Company""), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here.",Calendar of Events,0,0.005265498,long
CRISPR Therapeutics Announces Departure of Board Member,"ZUG, Switzerland and BOSTON, March  29, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Directors after nearly a decade of service.","ZUG, Switzerland and BOSTON, March  29, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Directors after nearly a decade of service.",Directors and Officers,0.011630608,0.000685243,long
CRISPR Therapeutics Announces Leadership Transition,"-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023--Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue serving as CEO of the Company-","-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023--Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue serving as CEO of the Company-",Directors and Officers,-0.041103904,-0.034134212,short
"CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development","ZUG, Switzerland and BOSTON, Dec.  19, 2022  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023. Dr. Harding brings extensive leadership experience in biopharma business development and corporate strategy and joins CRISPR Therapeutics to lead the Company’s business development operations.","ZUG, Switzerland and BOSTON, Dec.  19, 2022  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023. Dr. Harding brings extensive leadership experience in biopharma business development and corporate strategy and joins CRISPR Therapeutics to lead the Company’s business development operations.",Directors and Officers,0.001939241,0.001417383,long
CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference,"ZUG, Switzerland and BOSTON, Aug.  30, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at Citi's 18th Annual Biopharma Conference being held from September 6-7, 2023.","ZUG, Switzerland and BOSTON, Aug.  30, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at Citi's 18th Annual Biopharma Conference being held from September 6-7, 2023.",Calendar of Events,-0.000197713,-0.000976958,short
CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference,"ZUG, Switzerland and BOSTON, Feb.  27, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at 43rd Annual Cowen Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET.","ZUG, Switzerland and BOSTON, Feb.  27, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at 43rd Annual Cowen Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET.",Health,0.02436481,0.015560152,long
CRISPR Therapeutics to Participate in Upcoming Investor Conferences,"ZUG, Switzerland and CAMBRIDGE, Mass., Feb.  08, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in fireside chats at the following investor conferences in February.","ZUG, Switzerland and CAMBRIDGE, Mass., Feb.  08, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in fireside chats at the following investor conferences in February.",Calendar of Events,8.98E-05,0.005051352,long
DBV Technologies invitée à participer à une prochaine Conférence Investisseur,"Montrouge, France, le 5 septembre (23 :00 CET) 2023","Montrouge, France, le 5 septembre (23 :00 CET) 2023",European Regulatory News,,,
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference,"ZUG, Switzerland and BOSTON, Dec.  01, 2022  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 2022 BMO Growth & ESG Conference on Wednesday, December 7, 2022, at 1:00 p.m. ET.","ZUG, Switzerland and BOSTON, Dec.  01, 2022  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 2022 BMO Growth & ESG Conference on Wednesday, December 7, 2022, at 1:00 p.m. ET.",Calendar of Events,-0.011133429,-0.013807086,short
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting,"ZUG, Switzerland and BOSTON, Sept.  27, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023.","ZUG, Switzerland and BOSTON, Sept.  27, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023.",Calendar of Events,0.016265452,0.013424296,long
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD),"ZUG, Switzerland and BOSTON, Oct.  31, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the Company’s common stock.","ZUG, Switzerland and BOSTON, Oct.  31, 2023  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the Company’s common stock.",Management statements,0,-0.00141966,short
Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’,The Cytek® Aurora™ CS system has been selected as the “Cell Sorting Product of the Year” in the third annual BioTech Breakthrough Awards program.,The Cytek® Aurora™ CS system has been selected as the “Cell Sorting Product of the Year” in the third annual BioTech Breakthrough Awards program.,Product / Services Announcement,-0.14606739,-0.14748637,short
Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters,"Certification Validates Company’s Commitment to Quality in all Areas, Helping to Advance Roadmap for Translational and Clinical Markets in the United States Certification Validates Company’s Commitment to Quality in all Areas, Helping to Advance Roadmap for Translational and Clinical Markets in the United States","Certification Validates Company’s Commitment to Quality in all Areas, Helping to Advance Roadmap for Translational and Clinical Markets in the United States Certification Validates Company’s Commitment to Quality in all Areas, Helping to Advance Roadmap for Translational and Clinical Markets in the United States",Company Announcement,0.006309142,0.003467986,long
Cytek Biosciences Announces $50 Million Stock Repurchase Program,"FREMONT, Calif., May  19, 2023  (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law. The Company’s common stock is listed on The Nasdaq Global Select Market under the symbol “CTKB”. The repurchase program will continue until the end of the fiscal year unless extended or shortened by the Board of Directors.","FREMONT, Calif., May  19, 2023  (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law. The Company’s common stock is listed on The Nasdaq Global Select Market under the symbol “CTKB”. The repurchase program will continue until the end of the fiscal year unless extended or shortened by the Board of Directors.",Stock Market News,0.028400606,0.026158395,long
Cytek® Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and Europe,Company to Lead Symposiums at ICCS and ESCCA Company to Lead Symposiums at ICCS and ESCCA,Company to Lead Symposiums at ICCS and ESCCA Company to Lead Symposiums at ICCS and ESCCA,Health,0.004672856,0.001736355,long
DBV Technologies invitée à participer à une prochaine Conférence Investisseur,"Montrouge, France, le 6 juin (23 :00 CET) 2023 ","Montrouge, France, le 6 juin (23 :00 CET) 2023 ",European Regulatory News,,,
Cytek® Biosciences Marks Shipment of Its 100th Cell Sorter as the Company Continues to Lead Cell Analysis Forward,"FREMONT, Calif., May  16, 2023  (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that it has shipped its 100th Cytek Aurora CS system. This milestone is a clear indication of the company’s continuing momentum – and of the scientific community’s desire for Full Spectrum Profiling™ (FSP™) technology that streamlines workflows, accelerates discoveries and maximizes efficiency.","FREMONT, Calif., May  16, 2023  (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that it has shipped its 100th Cytek Aurora CS system. This milestone is a clear indication of the company’s continuing momentum – and of the scientific community’s desire for Full Spectrum Profiling™ (FSP™) technology that streamlines workflows, accelerates discoveries and maximizes efficiency.",Product / Services Announcement,-0.017857158,-0.015072663,short
Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed,"SALUGGIA, Italy, and FREMONT, Calif., Feb.  28, 2023  (GLOBE NEWSWIRE) -- DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit to Cytek for approximately USD 46.5 million.","SALUGGIA, Italy, and FREMONT, Calif., Feb.  28, 2023  (GLOBE NEWSWIRE) -- DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit to Cytek for approximately USD 46.5 million.",Mergers and Acquisitions,0,0.001257134,long
CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.,"- Financing is expected to extend cash runway into the 2nd half of 2025 based on current operating plans, enabling the Company to reach multiple clinical milestones -","- Financing is expected to extend cash runway into the 2nd half of 2025 based on current operating plans, enabling the Company to reach multiple clinical milestones -",Management statements,0.163120585,0.155519715,long
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas,-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX-,-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX-,Health,0.045801576,0.038857655,long
CytomX Therapeutics Announces New Employment Inducement Grants,"SOUTH SAN FRANCISCO, Calif., July  20, 2023  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that on July 19, 2023, the Company granted its recently appointed Senior Vice President, Chief Medical Officer, Yu-Waye (Wayne) Chu, M.D., an option to purchase 375,000 shares of the Company’s common stock and also granted an additional new employee options to purchase 2,500 shares of the Company’s common stock, at an exercise price per share equal to $1.82, which was the closing trading price on July 19, 2023, the date of the grants.","SOUTH SAN FRANCISCO, Calif., July  20, 2023  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that on July 19, 2023, the Company granted its recently appointed Senior Vice President, Chief Medical Officer, Yu-Waye (Wayne) Chu, M.D., an option to purchase 375,000 shares of the Company’s common stock and also granted an additional new employee options to purchase 2,500 shares of the Company’s common stock, at an exercise price per share equal to $1.82, which was the closing trading price on July 19, 2023, the date of the grants.",Changes in company's own shares,0.010989,0.013251739,long
"CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer","SOUTH SAN FRANCISCO, Calif., July  17, 2023  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO). In this role, Dr. Chu will oversee clinical development of the Company’s diversified portfolio of Probody® therapeutic candidates.","SOUTH SAN FRANCISCO, Calif., July  17, 2023  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO). In this role, Dr. Chu will oversee clinical development of the Company’s diversified portfolio of Probody® therapeutic candidates.",Directors and Officers,0.021978,0.022311854,long
CytomX Therapeutics to Present at Upcoming November Investor Conferences,"SOUTH SAN FRANCISCO, Calif., Nov.  01, 2023  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in November.","SOUTH SAN FRANCISCO, Calif., Nov.  01, 2023  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in November.",Calendar of Events,-0.0090909,-0.011482101,short
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF,"Informations RéglementéesMontrouge, France, le 10 juillet (22 :30 CET) 2023","Informations RéglementéesMontrouge, France, le 10 juillet (22 :30 CET) 2023",European Regulatory News,,,
DBV Technologies annonce la nomination de Virginie Boucinha au poste de Directrice Financière,"Montrouge, France, 16 octobre 2023","Montrouge, France, 16 octobre 2023",European Regulatory News,,,
DBV Technologies annonce la publication par le New England Journal of Medicine des données de l’étude EPITOPE de phase 3 évaluant Viaskin™ Peanut chez les enfants de 1 à 3 ans,"Montrouge, France, le 10 mai (23 :30 CET) 2023 ","Montrouge, France, le 10 mai (23 :30 CET) 2023 ",European Regulatory News,,,
"DBV Technologies annonce les résultats à 2 ans d’EPOPEX, étude de prolongation ouverte de phase 3 en cours de l’étude EPITOPE Viaskin™ Peanut chez les jeunes enfants","Montrouge, France, le 9 novembre (22h30 CET) 2023","Montrouge, France, le 9 novembre (22h30 CET) 2023",European Regulatory News,,,
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers,"Montrouge, France, November 9, 2023","Montrouge, France, November 9, 2023",European Regulatory News,,,
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer,"Montrouge, France, October 16, 2023","Montrouge, France, October 16, 2023",European Regulatory News,,,
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers,"Montrouge, France, May 10, 2023","Montrouge, France, May 10, 2023",European Regulatory News,,,
DBV Technologies a reçu la réponse attendue de la FDA sur certains éléments de conception du protocole pour les études de sécurité COMFORT et publie ses résultats financiers du troisième trimestre 2023,"Montrouge, France, le 31 octobre (21h30 CET) 2023","Montrouge, France, le 31 octobre (21h30 CET) 2023",European Regulatory News,,,
DBV Technologies a reçu les commentaires de la FDA sur les éléments de conception des études de sécurité de Viaskin Peanut et publie ses résultats financiers du deuxième trimestre et du premier semestre 2023.,"Montrouge, France, le 31 juillet 2023","Montrouge, France, le 31 juillet 2023",European Regulatory News,,,
Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 30 juin 2023,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Information mensuelle relative au nombre total des droits de vote etd’actions composant le capital social au 30 juin 2023,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Information mensuelle relative au nombre total des droits de vote etd’actions composant le capital social au 30 juin 2023,European Regulatory News,,,
Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 30 septembre 2023,          Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2023,          Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2023,European Regulatory News,,,
Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 31 mai 2023,Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 mai 2023,Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 mai 2023,European Regulatory News,,,
Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 31 octobre 2023,Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2023,Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2023,European Regulatory News,,,
"Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023",Monthly information regarding the total number of voting rights and ,Monthly information regarding the total number of voting rights and ,European Regulatory News,,,
"Monthly information regarding the total number of voting rights and  total number of shares of the Company as of May 31, 2023", , ,European Regulatory News,,,
"Monthly information regarding the total number of voting rights and  total number of shares of the Company as of October 31, 2023","Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023","Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023",European Regulatory News,,,
"Monthly information regarding the total number of voting rights and  total number of shares of the Company as of September 30, 2023","                  Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023","                  Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023",European Regulatory News,,,
"Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells","JUPITER, Fla. and PARIS, Sept.  26, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (""bYoRNA"") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (""mRNA""). Dyadic is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health. bYoRNA is a French biotechnology company focused on producing affordable therapeutic mRNA, at scale, for human and animal health.","JUPITER, Fla. and PARIS, Sept.  26, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (""bYoRNA"") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (""mRNA""). Dyadic is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health. bYoRNA is a French biotechnology company focused on producing affordable therapeutic mRNA, at scale, for human and animal health.",Partnerships,0.009615376,0.01688006,long
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity,"JUPITER, Fla. and DHAKA, Bangladesh, June  21, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it has entered into a Memorandum of Understanding (“MoU”) with Essential Drugs Company Limited (EDCL), the state owned pharmaceutical company under the Ministry of Health and Family Welfare of Bangladesh to facilitate biopharmaceutical research, pre-clinical development, cGMP production, clinical trials, regulatory and other relevant areas of interest in Bangladesh.","JUPITER, Fla. and DHAKA, Bangladesh, June  21, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it has entered into a Memorandum of Understanding (“MoU”) with Essential Drugs Company Limited (EDCL), the state owned pharmaceutical company under the Ministry of Health and Family Welfare of Bangladesh to facilitate biopharmaceutical research, pre-clinical development, cGMP production, clinical trials, regulatory and other relevant areas of interest in Bangladesh.",Business Contracts,0.029126187,0.031459297,long
Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™,"JUPITER, Fla., May  08, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a co-development and marketing agreement with Fermbox Bio Inc (“Fermbox”).","JUPITER, Fla., May  08, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a co-development and marketing agreement with Fermbox Bio Inc (“Fermbox”).",Health,0.024242474,0.0234185,long
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin,"JUPITER, Fla., Aug.  07, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and manufacture biopharmaceuticals and alternative proteins for food, nutrition, health and wellness at flexible commercial scales affordably, today announced positive results from third party analytical testing of the company’s animal-free recombinant serum albumin.","JUPITER, Fla., Aug.  07, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and manufacture biopharmaceuticals and alternative proteins for food, nutrition, health and wellness at flexible commercial scales affordably, today announced positive results from third party analytical testing of the company’s animal-free recombinant serum albumin.",Product / Services Announcement,-0.011627896,-0.015880249,short
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™,"JUPITER, Fla., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus™.","JUPITER, Fla., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus™.",Licensing Agreements,-0.016304397,-0.014162945,short
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases,"JUPITER, Fla., Oct.  05, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it has entered into a research collaboration agreement with the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital, as part of VIC’s collaboration with Voltron Therapeutics, Inc. (“Voltron”), to use Dyadic’s proprietary C1 protein production platform to express vaccine antigens for influenza A and other infectious diseases.","JUPITER, Fla., Oct.  05, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it has entered into a research collaboration agreement with the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital, as part of VIC’s collaboration with Voltron Therapeutics, Inc. (“Voltron”), to use Dyadic’s proprietary C1 protein production platform to express vaccine antigens for influenza A and other infectious diseases.",Health,0.059406003,0.060112493,long
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent,"JUPITER, Fla., April  12, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (""Dyadic"", ""we"", ""us"", ""our"", or the ""Company"") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced it signed an expanded licensing agreement for its C1-cell protein expression platform with South Africa’s Rubic One Health (“Rubic”) to develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved African countries.","JUPITER, Fla., April  12, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (""Dyadic"", ""we"", ""us"", ""our"", or the ""Company"") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced it signed an expanded licensing agreement for its C1-cell protein expression platform with South Africa’s Rubic One Health (“Rubic”) to develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved African countries.",Licensing Agreements,0.015625048,0.010377576,long
Dyadic Appoints Doug Pace to Its Executive Leadership Team,"JUPITER, Fla., Oct.  09, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic’s management team is in response to the increased interest in the Company’s microbial platforms, specifically the C1 technology for infectious disease and other recombinant vaccines and antibodies for human and animal pharmaceutical use, and the Dapibus™ platform for non-pharmaceutical applications for large nutritional markets such as dairy proteins and enzymes as well as cell culture markets for recombinant serum albumin.","JUPITER, Fla., Oct.  09, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic’s management team is in response to the increased interest in the Company’s microbial platforms, specifically the C1 technology for infectious disease and other recombinant vaccines and antibodies for human and animal pharmaceutical use, and the Dapibus™ platform for non-pharmaceutical applications for large nutritional markets such as dairy proteins and enzymes as well as cell culture markets for recombinant serum albumin.",Health,-0.024509781,-0.019946709,short
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate,"JUPITER, Fla., July  24, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate.","JUPITER, Fla., July  24, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate.",Clinical Study,0.048387114,0.045755414,long
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform,"JUPITER, Fla., April  18, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/640,483, titled ""PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA"" (the “Patent”), and is expected to provide patent protection through 2038.","JUPITER, Fla., April  18, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/640,483, titled ""PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA"" (the “Patent”), and is expected to provide patent protection through 2038.",Patents,0.032967001,0.029005112,long
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa,"JUPITER, Fla., Nov.  20, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (""Dyadic"", ""we"", ""us"", ""our"", or the ""Company"") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today applauds the signing of an agreement between Dyadic’s African licensee, Rubic One Health (“Rubic”) and Afreximaxbank to fund the project preparatory facility for the manufacture of vaccines using Dyadic’s C1 protein production platform in South Africa for the entire continent.","JUPITER, Fla., Nov.  20, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (""Dyadic"", ""we"", ""us"", ""our"", or the ""Company"") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today applauds the signing of an agreement between Dyadic’s African licensee, Rubic One Health (“Rubic”) and Afreximaxbank to fund the project preparatory facility for the manufacture of vaccines using Dyadic’s C1 protein production platform in South Africa for the entire continent.",Product / Services Announcement,0.017543843,0.018120629,long
Dyadic to Participate at Two Industry Events in May,"JUPITER, Fla., May  10, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that they will be participating in the following events during the month of May.","JUPITER, Fla., May  10, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that they will be participating in the following events during the month of May.",Product / Services Announcement,-0.00555555,-0.012734418,short
Dyadic to Participate at Upcoming Events in June,"JUPITER, Fla., June  01, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating in the following events during the month of June.","JUPITER, Fla., June  01, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating in the following events during the month of June.",Calendar of Events,-0.013157882,-0.013732228,short
Dyadic to Present at Industry and Investor Events in October,Dyadic to Present at Industry and Investor Events in October,Dyadic to Present at Industry and Investor Events in October,Product / Services Announcement,0,-0.007350939,short
Dyadic to Present at Industry Events in November,Dyadic to Present at Industry Events in November,Dyadic to Present at Industry Events in November,Calendar of Events,-0.026143766,-0.033156538,short
Dyadic to Present at World Vaccine Congress Washington 2023,"JUPITER, Fla., March  30, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Washington, D.C.","JUPITER, Fla., March  30, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Washington, D.C.",Calendar of Events,0.020134209,0.013307274,long
Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress,“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH),“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH),Clinical Study,-0.017605618,-0.019109224,short
Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting,Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia,Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia,Research Analysis and Reports,-0.025547421,-0.030756008,short
"Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023","ROCKAWAY, N.J., Nov.  15, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “Accessing the Power of Vagus Nerve Stimulation with gammaCore™” on November 21, 2023 at 1:30pm EST. The webinar will cover the nVNS mechanism of action and potential pipeline of indications using the company’s proprietary nVNS technology platform that is embodied in its gammaCore product.","ROCKAWAY, N.J., Nov.  15, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “Accessing the Power of Vagus Nerve Stimulation with gammaCore™” on November 21, 2023 at 1:30pm EST. The webinar will cover the nVNS mechanism of action and potential pipeline of indications using the company’s proprietary nVNS technology platform that is embodied in its gammaCore product.",Calendar of Events,-0.022660446,-0.025735735,short
electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering,"ROCKAWAY, N.J., Aug.  23, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the securities class actions over the company’s 2018 initial public offering brought in the federal and state courts of New Jersey. The litigation has concluded without any finding of wrongdoing or liability, nor any payment, by electroCore.","ROCKAWAY, N.J., Aug.  23, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the securities class actions over the company’s 2018 initial public offering brought in the federal and state courts of New Jersey. The litigation has concluded without any finding of wrongdoing or liability, nor any payment, by electroCore.",Initial Public Offerings,-0.020876807,-0.023387377,short
electroCore Expands Intellectual Patent Portfolio for nVNS Technology,"ROCKAWAY, N.J., July  18, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office (USPTO) has issued a patent related to non-invasive nerve stimulation with mobile devices.","ROCKAWAY, N.J., July  18, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office (USPTO) has issued a patent related to non-invasive nerve stimulation with mobile devices.",Patents,-0.001095315,-0.000341176,short
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology,"ROCKAWAY, N.J., Oct.  11, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a treatment protocol for nVNS.","ROCKAWAY, N.J., Oct.  11, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a treatment protocol for nVNS.",Product / Services Announcement,-0.003710572,-0.006241998,short
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology,"ROCKAWAY, N.J., Sept.  26, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.","ROCKAWAY, N.J., Sept.  26, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.",Patents,0.004694854,0.011959538,long
"electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC","ROCKAWAY, N.J., July  13, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea and vomiting, will be distributed and billed exclusively by electroCore, Inc. within the Department of Veterans Affairs (VA) and other Federal Supply Schedule (FSS) eligible entities.","ROCKAWAY, N.J., July  13, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea and vomiting, will be distributed and billed exclusively by electroCore, Inc. within the Department of Veterans Affairs (VA) and other Federal Supply Schedule (FSS) eligible entities.",Partnerships,-0.024578219,-0.028793287,short
electroCore Provides Select Second Quarter 2023 Financial Guidance,"Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022 Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022","Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022 Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022",Pre-Release Comments,0.008230445,0.006433582,long
"electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum","ROCKAWAY, N.J., Nov.  07, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin NY Grand Central on November 16, 2023.","ROCKAWAY, N.J., Nov.  07, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin NY Grand Central on November 16, 2023.",Health,-0.001631359,-0.001631359,short
electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference,"ROCKAWAY, N.J., Sept.  07, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the H.C. Wainwright 25th Annual Global Investment Conference.","ROCKAWAY, N.J., Sept.  07, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the H.C. Wainwright 25th Annual Global Investment Conference.",Calendar of Events,-0.000836839,0.006132853,long
electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference,"ROCKAWAY, N.J., Oct.  05, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023.","ROCKAWAY, N.J., Oct.  05, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023.",Calendar of Events,0.004746793,0.005453284,long
electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference,"ROCKAWAY, N.J., Sept.  21, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference. Mr. Goldberger will also be available for one-on-one meetings held throughout the conference on September 26 and 27, 2023.","ROCKAWAY, N.J., Sept.  21, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference. Mr. Goldberger will also be available for one-on-one meetings held throughout the conference on September 26 and 27, 2023.",Calendar of Events,-0.033088203,-0.026385663,short
gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD),"ROCKAWAY, N.J., July  25, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer reviewed manuscript, Effect of Transcutaneous Cervical Vagus Nerve Stimulation on Declarative and Working Memory in Patients with Posttraumatic Stress Disorder (PTSD): A Pilot Study, in the Journal of Affective Disorders. The study was conducted with the support of Emory University, The Georgia Institute of Technology and the Atlanta Veteran’s Affairs Medical Center and was sponsored by a Department of Defense Small Business Technology Transfer grant (DoD STTR).","ROCKAWAY, N.J., July  25, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer reviewed manuscript, Effect of Transcutaneous Cervical Vagus Nerve Stimulation on Declarative and Working Memory in Patients with Posttraumatic Stress Disorder (PTSD): A Pilot Study, in the Journal of Affective Disorders. The study was conducted with the support of Emory University, The Georgia Institute of Technology and the Atlanta Veteran’s Affairs Medical Center and was sponsored by a Department of Defense Small Business Technology Transfer grant (DoD STTR).",Research Analysis and Reports,-0.028601644,-0.027985178,short
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD),"Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD","Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD",Product / Services Announcement,0.010733442,0.007892286,long
gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms,"ROCKAWAY, N.J., July  06, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its gammaCore non-invasive vagus nerve stimulation (“nVNS”) has been selected to be a part of studies on effects of cannabinoids and alternative care on athlete pain management and performance. The NFL and NFLPA are jointly awarding two research grants to independent medical researchers at the American Society of Pain and Neuroscience (ASPN) and Emory University.","ROCKAWAY, N.J., July  06, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its gammaCore non-invasive vagus nerve stimulation (“nVNS”) has been selected to be a part of studies on effects of cannabinoids and alternative care on athlete pain management and performance. The NFL and NFLPA are jointly awarding two research grants to independent medical researchers at the American Society of Pain and Neuroscience (ASPN) and Emory University.",Product / Services Announcement,-0.00322925,0.005142992,long
TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project,"ROCKAWAY, N.J., June  27, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Performance product, has been selected to be a part of the Air Force Research Laboratories (AFRL) Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments (A2PEX) Grant Program. A2PEX is a five-year project led by the Florida Institute for Human and Machine Cognition (IHMC) that includes internationally-recognized leaders in wearable technologies from industry and academia.","ROCKAWAY, N.J., June  27, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Performance product, has been selected to be a part of the Air Force Research Laboratories (AFRL) Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments (A2PEX) Grant Program. A2PEX is a five-year project led by the Florida Institute for Human and Machine Cognition (IHMC) that includes internationally-recognized leaders in wearable technologies from industry and academia.",Product / Services Announcement,-0.010594287,-0.012703511,short
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization,"CAMBRIDGE, Mass., and DEVENS, Mass., July  27, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur Group company, today announced the companies have expanded their multi-year contract to support the scaling of EDIT-301, Editas Medicine’s experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), from approval to commercialization. The expanded agreement includes compliant cleanroom space and labs services at Azzur’s COD site in Devens, Massachusetts. Editas Medicine has utilized Azzur’s services to execute pre-clinical and early-phase clinical manufacturing activities for its cell medicines, including EDIT-301 for the treatment of sickle cell disease and beta thalassemia, since 2020.","CAMBRIDGE, Mass., and DEVENS, Mass., July  27, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur Group company, today announced the companies have expanded their multi-year contract to support the scaling of EDIT-301, Editas Medicine’s experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), from approval to commercialization. The expanded agreement includes compliant cleanroom space and labs services at Azzur’s COD site in Devens, Massachusetts. Editas Medicine has utilized Azzur’s services to execute pre-clinical and early-phase clinical manufacturing activities for its cell medicines, including EDIT-301 for the treatment of sickle cell disease and beta thalassemia, since 2020.",Partnerships,0.013667413,0.00596181,long
Editas Medicine Announces Second Quarter 2023 Results and Business Updates,On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end,On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end,Earnings Releases and Operating Results,-0.017340997,-0.010265088,short
Editas Medicine Announces Third Quarter 2023 Results and Business Updates,Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar,Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar,Earnings Releases and Operating Results,0.031294422,0.025769292,long
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease,"CAMBRIDGE,  Mass., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD).","CAMBRIDGE,  Mass., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD).",Health,-0.002836877,-0.008213487,short
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease,On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end,On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end,Clinical Study,0.008860721,0.002331849,long
Editas Medicine Reports Inducement Grant to New Chief Scientific Officer,"CAMBRIDGE, Mass., July  25, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Scientific Officer, Linda C. Burkly, Ph.D. In connection with Dr. Burkly’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Burkly as an inducement material to Dr. Burkly entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 135,500 shares of Editas Medicine common stock at a price of $8.66 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Dr. Burkly’s employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Burkly’s continued service relationship with Editas Medicine through the applicable vesting dates.","CAMBRIDGE, Mass., July  25, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Scientific Officer, Linda C. Burkly, Ph.D. In connection with Dr. Burkly’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Burkly as an inducement material to Dr. Burkly entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 135,500 shares of Editas Medicine common stock at a price of $8.66 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Dr. Burkly’s employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Burkly’s continued service relationship with Editas Medicine through the applicable vesting dates.",Contests/Awards,0.006928455,0.007544921,long
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer,"CAMBRIDGE, Mass., Sept.  25, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine’s commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company’s current and future pipeline of products.","CAMBRIDGE, Mass., Sept.  25, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine’s commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company’s current and future pipeline of products.",Directors and Officers,-0.012738842,-0.009834701,short
"Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer","CAMBRIDGE, Mass., July  24, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas’ drug discovery team and activities related to Editas Medicine’s pipeline of experimental medicines across all therapeutic areas and indications.","CAMBRIDGE, Mass., July  24, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas’ drug discovery team and activities related to Editas Medicine’s pipeline of experimental medicines across all therapeutic areas and indications.",Directors and Officers,-0.017897075,-0.020528776,short
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia,"CAMBRIDGE, Mass., June  06, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on Monday, June 12, at 8:00 a.m. ET to present clinical data from the RUBY trial of EDIT-301 for the treatment of severe sickle cell disease. The Company will also present initial clinical data from the EDITHAL trial of EDIT-301 for the treatment of transfusion-dependent beta thalassemia.","CAMBRIDGE, Mass., June  06, 2023  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on Monday, June 12, at 8:00 a.m. ET to present clinical data from the RUBY trial of EDIT-301 for the treatment of severe sickle cell disease. The Company will also present initial clinical data from the EDITHAL trial of EDIT-301 for the treatment of transfusion-dependent beta thalassemia.",Clinical Study,0.001059346,0.002066119,long
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar,"Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET","Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET",Product / Services Announcement,0.011594192,0.002319638,long
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress,Company-sponsored webinar to be announced Company-sponsored webinar to be announced,Company-sponsored webinar to be announced Company-sponsored webinar to be announced,Clinical Study,-0.043042979,-0.043479908,short
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,"WATERTOWN, Mass., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock. The warrants will have an exercise price $5.13 per share, will become exercisable immediately upon issuance and have a term of five and one-half years from the date of issuance. The offering is expected to close on or about September 20, 2023, subject to the satisfaction of customary closing conditions.","WATERTOWN, Mass., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock. The warrants will have an exercise price $5.13 per share, will become exercisable immediately upon issuance and have a term of five and one-half years from the date of issuance. The offering is expected to close on or about September 20, 2023, subject to the satisfaction of customary closing conditions.",Prospectus/Announcement of Prospectus,-0.001831544,0.000309908,long
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013,ZKN-013 is in development for potential treatment of recessive dystrophic and junctional epidermolysis bullosa (RDEB and JEB) and Familial Adenomatous Polyposis (FAP),ZKN-013 is in development for potential treatment of recessive dystrophic and junctional epidermolysis bullosa (RDEB and JEB) and Familial Adenomatous Polyposis (FAP),Clinical Study,-0.012931056,-0.011150063,short
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit,Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications,Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications,Product / Services Announcement,0.011049779,0.011893458,long
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement,"Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study","Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study",Exchange Members,0.023880646,0.024887419,long
Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress,"Data from RaDaR natural history study indicates that Alport syndrome patients with autosomal recessive COL4A4 mutations have severest disease, with a more rapid progression to kidney failure","Data from RaDaR natural history study indicates that Alport syndrome patients with autosomal recessive COL4A4 mutations have severest disease, with a more rapid progression to kidney failure",Clinical Study,0.014112938,0.016446048,long
Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study,"Patient treated in trial achieved a remission after eight weeks of treatment, demonstrating a significant reduction in proteinuria","Patient treated in trial achieved a remission after eight weeks of treatment, demonstrating a significant reduction in proteinuria",Clinical Study,-0.034924352,-0.030891454,short
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02,"Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A and patients have significant unmet medical needs, with no disease modifying treatments currently available","Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A and patients have significant unmet medical needs, with no disease modifying treatments currently available",Clinical Study,-0.009852207,-0.007284343,short
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013,Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations,Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations,Clinical Study,0.072243274,0.079212966,long
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria,ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH,ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH,Health,-0.004629625,-6.66E-05,short
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome,All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02,All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02,Clinical Study,0.050526268,0.052657944,long
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update,Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; encouraging initial reduction in proteinuria has been observed in one patient to date,Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; encouraging initial reduction in proteinuria has been observed in one patient to date,Earnings Releases and Operating Results,0,0.001319056,long
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome,Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans,Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans,Clinical Study,0.018707424,0.019429186,long
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update,"Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02","Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02",Earnings Releases and Operating Results,0.050526268,0.052657944,long
Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome,Globally renowned Alport syndrome experts will provide key insights,Globally renowned Alport syndrome experts will provide key insights,Health,-0.119284365,-0.116487224,short
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH),–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin–,–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin–,Company Announcement,0.006306025,0.013008566,long
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split,"NEWTON, Mass., June  01, 2023  (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10.","NEWTON, Mass., June  01, 2023  (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10.",Major shareholder announcements,0.081632671,0.081058326,long
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics,"BOSTON, Aug.  28, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics. Ms. Filoon will oversee all company legal affairs including corporate governance and compliance functions. Dr. Kheoh will provide biostatistical leadership and strategic guidance into the development of the Company’s product candidate portfolio including the ongoing AMPLIFY-201 and AMPLIFY-7P trials of the lead asset, ELI-002.","BOSTON, Aug.  28, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics. Ms. Filoon will oversee all company legal affairs including corporate governance and compliance functions. Dr. Kheoh will provide biostatistical leadership and strategic guidance into the development of the Company’s product candidate portfolio including the ongoing AMPLIFY-201 and AMPLIFY-7P trials of the lead asset, ELI-002.",Directors and Officers,-0.006217561,-0.011376979,short
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model,"BOSTON, Aug.  09, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics (NASDAQ:ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of preclinical data demonstrating its lymph node-targeting Amphiphile (AMP) adjuvant, AMP-CpG, combined with cell surface-associated viral protein EBV gp350 and EBVpoly protein, elicited a potent and durable immune response to Epstein-Barr virus (EBV) in Human Leukocyte Antigen expressing mice. The data was published in Nature Communications and can be accessed here.","BOSTON, Aug.  09, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics (NASDAQ:ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of preclinical data demonstrating its lymph node-targeting Amphiphile (AMP) adjuvant, AMP-CpG, combined with cell surface-associated viral protein EBV gp350 and EBVpoly protein, elicited a potent and durable immune response to Epstein-Barr virus (EBV) in Human Leukocyte Antigen expressing mice. The data was published in Nature Communications and can be accessed here.",Clinical Study,-0.005000019,-0.005623972,short
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting,"BOSTON, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will present updated preliminary data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, targeting mutated KRAS in patients with high relapse risk pancreatic and colorectal cancers, and preclinical data on ELI-007 and ELI-008. ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, are being evaluated in studies funded by a grant from the Gastro-Intestinal (GI) Research Foundation with the aim of developing multivalent cancer vaccines targeting several mutations.","BOSTON, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will present updated preliminary data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, targeting mutated KRAS in patients with high relapse risk pancreatic and colorectal cancers, and preclinical data on ELI-007 and ELI-008. ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, are being evaluated in studies funded by a grant from the Gastro-Intestinal (GI) Research Foundation with the aim of developing multivalent cancer vaccines targeting several mutations.",Research Analysis and Reports,0,-0.002531427,short
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines,"BOSTON, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has been awarded a $2.6 million grant from the GI Research Foundation in Chicago to fund research for two therapeutic cancer vaccines, ELI-007 and ELI-008. This $2.6 million grant is an addition to the $2.8 million that it awarded Elicio in September 2022. Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations. Both vaccines have been designed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) platform that “educates” T cells on how to target particular antigens, such as mutated proteins in cancer.","BOSTON, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has been awarded a $2.6 million grant from the GI Research Foundation in Chicago to fund research for two therapeutic cancer vaccines, ELI-007 and ELI-008. This $2.6 million grant is an addition to the $2.8 million that it awarded Elicio in September 2022. Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations. Both vaccines have been designed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) platform that “educates” T cells on how to target particular antigens, such as mutated proteins in cancer.",Product / Services Announcement,0.029481134,0.036450825,long
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates,"BOSTON, Aug.  11, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical updates.","BOSTON, Aug.  11, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical updates.",Earnings Releases and Operating Results,-0.022000027,-0.017649368,short
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference,"BOSTON, Sept.  06, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 at 9:30 a.m. ET.","BOSTON, Sept.  06, 2023  (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 at 9:30 a.m. ET.",Calendar of Events,0.068965509,0.070835326,long
"Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors","JERUSALEM, June  07, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has appointed Haya Taitel, Head of Sanofi’s Global Transplant Franchise as an independent director to the Company’s Board of Directors.","JERUSALEM, June  07, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has appointed Haya Taitel, Head of Sanofi’s Global Transplant Franchise as an independent director to the Company’s Board of Directors.",Directors and Officers,0.025957933,0.025000047,long
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes,"JERUSALEM, Sept.  12, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK, “OPKO”) have entered into a Research Collaboration Agreement. Under the terms of the Agreement, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin (OXM) analogs for the development of oral tablet formulations using Entera’s proprietary oral delivery technology.","JERUSALEM, Sept.  12, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK, “OPKO”) have entered into a Research Collaboration Agreement. Under the terms of the Agreement, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin (OXM) analogs for the development of oral tablet formulations using Entera’s proprietary oral delivery technology.",Partnerships,0.046337754,0.049682608,long
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis,- Total Hip BMD Established as Primary Endpoint - - Total Hip BMD Established as Primary Endpoint -,- Total Hip BMD Established as Primary Endpoint - - Total Hip BMD Established as Primary Endpoint -,Clinical Study,0.076190521,0.080088797,long
"Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis","JERUSALEM, Feb.  15, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that a Type D meeting protocol review has been accepted by the U.S. Food and Drug Administration (FDA) to provide responses by March 30th, 2023. The pivotal, Phase 3 study protocol is entitled “A 24-Month Phase 3, Randomized, Double-Blind, Global Multicenter Study Comparing the Effects of Oral hPTH(1-34) (EBP05[EB613]) Daily Tablets vs. Placebo on Bone Mineral Density (BMD) in Postmenopausal Women with Osteoporosis.” EB613 is the first oral, once daily mini tablet presentation of hPTH (1-34), (teriparatide). EB613 has a well-established mechanism of action, PK and safety profile and met primary (PD/biomarker) and secondary endpoints (BMD) in a placebo controlled, dose ranging Phase 2 study in 161 postmenopausal women with low bone mass and osteoporosis.","JERUSALEM, Feb.  15, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that a Type D meeting protocol review has been accepted by the U.S. Food and Drug Administration (FDA) to provide responses by March 30th, 2023. The pivotal, Phase 3 study protocol is entitled “A 24-Month Phase 3, Randomized, Double-Blind, Global Multicenter Study Comparing the Effects of Oral hPTH(1-34) (EBP05[EB613]) Daily Tablets vs. Placebo on Bone Mineral Density (BMD) in Postmenopausal Women with Osteoporosis.” EB613 is the first oral, once daily mini tablet presentation of hPTH (1-34), (teriparatide). EB613 has a well-established mechanism of action, PK and safety profile and met primary (PD/biomarker) and secondary endpoints (BMD) in a placebo controlled, dose ranging Phase 2 study in 161 postmenopausal women with low bone mass and osteoporosis.",Product / Services Announcement,0.085057472,0.076211353,long
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons,Company Announcement,Company Announcement,European Regulatory News,0,-0.00892155,short
"Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET","JERUSALEM, Sept.  21, 2022  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it will host a key opinion leader (KOL) webinar on the company’s lead asset EB613, and its potential impact on the osteoporosis market on Wednesday, September 28, 2022 at 10:00am ET.","JERUSALEM, Sept.  21, 2022  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it will host a key opinion leader (KOL) webinar on the company’s lead asset EB613, and its potential impact on the osteoporosis market on Wednesday, September 28, 2022 at 10:00am ET.",Calendar of Events,0,-0.005259155,short
Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program,"JERUSALEM, April  03, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced feedback from its Type D Meeting with the U.S. Food and Drug Administration (FDA) related to EB613’s [daily oral hPTH(1-34), teriparatide, tablets] proposed registrational program for the treatment of postmenopausal women with osteoporosis. Entera submitted a draft phase 3 study protocol and requested the FDA’s written responses to two questions.","JERUSALEM, April  03, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced feedback from its Type D Meeting with the U.S. Food and Drug Administration (FDA) related to EB613’s [daily oral hPTH(1-34), teriparatide, tablets] proposed registrational program for the treatment of postmenopausal women with osteoporosis. Entera submitted a draft phase 3 study protocol and requested the FDA’s written responses to two questions.",Health,0.034482829,0.035801886,long
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis,"JERUSALEM, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reports today that the American Society for Bone and Mineral Research (ASBMR) has announced that the SABRE (Strategy to Advance BMD as a Regulatory Endpoint) project team has submitted to the U.S. Food and Drug Administration (FDA) its full qualification plan to use the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs.","JERUSALEM, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reports today that the American Society for Bone and Mineral Research (ASBMR) has announced that the SABRE (Strategy to Advance BMD as a Regulatory Endpoint) project team has submitted to the U.S. Food and Drug Administration (FDA) its full qualification plan to use the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs.",Clinical Study,0.106060591,0.116529757,long
"Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development","JERUSALEM, Nov.  14, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today reported corporate updates and financial results for the third quarter ended September 30th, 2023.","JERUSALEM, Nov.  14, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today reported corporate updates and financial results for the third quarter ended September 30th, 2023.",Earnings Releases and Operating Results,0,-0.013925816,short
Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting,"JERUSALEM, Oct.  16, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, presented 2 posters at the Annual Society of Bone and Mineral Research (ASBMR) 2023 Annual Meeting held on October 13-16, 2023 in Vancouver, BC, Canada. Both posters will be available on the Company’s website, www.enterabio.com.","JERUSALEM, Oct.  16, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, presented 2 posters at the Annual Society of Bone and Mineral Research (ASBMR) 2023 Annual Meeting held on October 13-16, 2023 in Vancouver, BC, Canada. Both posters will be available on the Company’s website, www.enterabio.com.",Health,0.026027388,0.020650778,long
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons,Company Announcement,Company Announcement,European Regulatory News,-0.004837032,-0.000315175,short
Entera Bio to Participate in the SVB Securities Global Biopharma Conference,"JERUSALEM, Feb.  13, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader in the development of orally delivered peptides and therapeutic proteins, today announced that the Company will participate in the SVB Securities Global Biopharma Conference, which is taking place virtually on February 13 – 16, 2023.","JERUSALEM, Feb.  13, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader in the development of orally delivered peptides and therapeutic proteins, today announced that the Company will participate in the SVB Securities Global Biopharma Conference, which is taking place virtually on February 13 – 16, 2023.",Calendar of Events,-0.021978066,-0.023644551,short
"Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting","JERUSALEM, Aug.  16, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has been selected to present data for its investigational agent EB613 at the ASBMR 2023 Annual Meeting on October 13-16, 2023 in Vancouver, BC, Canada.","JERUSALEM, Aug.  16, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has been selected to present data for its investigational agent EB613 at the ASBMR 2023 Annual Meeting on October 13-16, 2023 in Vancouver, BC, Canada.",Health,0.118333295,0.119304243,long
"Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics","JERUSALEM, May  03, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that its pre-clinical manuscript entitled “Oral Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like-Peptide-2 Analog (GLP-2), Teduglutide - A Novel Approach for Injection-Free Treatment of Short Bowel Syndrome” has been accepted for publication by the International Journal of Peptide Research and Therapeutics.","JERUSALEM, May  03, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that its pre-clinical manuscript entitled “Oral Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like-Peptide-2 Analog (GLP-2), Teduglutide - A Novel Approach for Injection-Free Treatment of Short Bowel Syndrome” has been accepted for publication by the International Journal of Peptide Research and Therapeutics.",Clinical Study,0.035294083,0.043413483,long
"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board","JERUSALEM, April  26, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Steven R. Goldstein, MD, Professor of Obstetrics and Gynecology at New York University School of Medicine and former President of The International Menopause Society, the North American Menopause Society and recipient of the Clarkson Award from NAMS for lifetime achievement in menopause research will be joining its Clinical and Scientific Advisory Board (CSAB).","JERUSALEM, April  26, 2023  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Steven R. Goldstein, MD, Professor of Obstetrics and Gynecology at New York University School of Medicine and former President of The International Menopause Society, the North American Menopause Society and recipient of the Clarkson Award from NAMS for lifetime achievement in menopause research will be joining its Clinical and Scientific Advisory Board (CSAB).",Health,0.014285701,0.012709621,long
89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023,"SAN FRANCISCO, June  07, 2023  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that pegozafermin data in nonalcoholic steatohepatitis (NASH) will be featured in a late-breaker oral presentation during the European Association for the Study of the Liver (EASL) Congress 2023 to be held June 21-24, 2023 in Vienna, Austria. The presentation was selected for inclusion in the Best of EASL Congress summary slide deck that highlights the most noteworthy contributions to the scientific program at EASL.","SAN FRANCISCO, June  07, 2023  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that pegozafermin data in nonalcoholic steatohepatitis (NASH) will be featured in a late-breaker oral presentation during the European Association for the Study of the Liver (EASL) Congress 2023 to be held June 21-24, 2023 in Vienna, Austria. The presentation was selected for inclusion in the Best of EASL Congress summary slide deck that highlights the most noteworthy contributions to the scientific program at EASL.",Health,0.002933959,0.001976074,long
"89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock","SAN FRANCISCO, March  24, 2023  (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25. In addition, 89bio has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 2,538,461 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $275 million. The offering is expected to close on or about March 28, 2023, subject to the satisfaction of customary closing conditions.","SAN FRANCISCO, March  24, 2023  (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25. In addition, 89bio has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 2,538,461 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $275 million. The offering is expected to close on or about March 28, 2023, subject to the satisfaction of customary closing conditions.",Stock Market News,0.021251399,0.024634203,long
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG),First FGF21 analog to enter Phase 3 development First FGF21 analog to enter Phase 3 development,First FGF21 analog to enter Phase 3 development First FGF21 analog to enter Phase 3 development,Clinical Study,0.007505835,0.01158908,long
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update,– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 –,– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 –,Earnings Releases and Operating Results,0.01332289,0.014778624,long
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks,- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) -,- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) -,Health,0.344922177,0.345373389,long
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights,– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation,– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation,Earnings Releases and Operating Results,-0.015904652,-0.013772975,short
89bio to Participate in Upcoming Investor Conferences,"SAN FRANCISCO, May  02, 2023  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Management will participate in the following upcoming conferences in May:","SAN FRANCISCO, May  02, 2023  (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Management will participate in the following upcoming conferences in May:",Trade Show,0.000601337,0.002382331,long
De nouvelles données cliniques passionnantes sur les vaccins anticancéreux individualisés d'Evaxion et basés sur l'AI-Immunology™ seront bientôt présentées,"COPENHAGUE, Danemark,  27 oct. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie clinique spécialisée dans le développement de vaccins basés sur l'AI-Immunology™, est fière d'annoncer qu'elle présentera les lectures cliniques de ses deux essais de vaccins anticancéreux individualisés lors de la 38e réunion annuelle de la SITC, qui se tiendra à San Diego, en Californie, du 1er au 5 novembre 2023.","COPENHAGUE, Danemark,  27 oct. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie clinique spécialisée dans le développement de vaccins basés sur l'AI-Immunology™, est fière d'annoncer qu'elle présentera les lectures cliniques de ses deux essais de vaccins anticancéreux individualisés lors de la 38e réunion annuelle de la SITC, qui se tiendra à San Diego, en Californie, du 1er au 5 novembre 2023.",Calendar of Events,0.01219511,0.008219799,long
Evaxion Announces Business Update and Second Quarter 2023 Financial Results,*Subject to additional funding in the range of $5-10 million secured before initiation,*Subject to additional funding in the range of $5-10 million secured before initiation,Earnings Releases and Operating Results,-0.041666628,-0.048889105,short
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01,"COPENHAGEN, Denmark, Oct.  31, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is pleased to announce initial results from the EVX-01 Phase 2 clinical trial, confirming previous successful Phase 1 findings. A comprehensive clinical update will be presented at the Society for Immunotherapy of Cancer (SITC) 38th annual meeting, taking place in San Diego, California, from November 1-5, 2023.","COPENHAGEN, Denmark, Oct.  31, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is pleased to announce initial results from the EVX-01 Phase 2 clinical trial, confirming previous successful Phase 1 findings. A comprehensive clinical update will be presented at the Society for Immunotherapy of Cancer (SITC) 38th annual meeting, taking place in San Diego, California, from November 1-5, 2023.",Clinical Study,0.142857125,0.138003409,long
Evaxion announces Executive Management Changes to strengthen the AI-strategy,"COPENHAGEN, Denmark, Aug.  29, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced:","COPENHAGEN, Denmark, Aug.  29, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced:",Management Changes,0.022727251,0.022975729,long
Evaxion announces financing commitments totaling up to USD 20 million with Negma Group,"Copenhagen, DENMARK, Aug.  01, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that it has entered into a binding agreement for a financing of up to USD 20 million with Negma Group Investment Ltd, a Paris-based leading financial institution focused on supporting growth and capturing value through a multi-strategy approach.","Copenhagen, DENMARK, Aug.  01, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that it has entered into a binding agreement for a financing of up to USD 20 million with Negma Group Investment Ltd, a Paris-based leading financial institution focused on supporting growth and capturing value through a multi-strategy approach.",Financing Agreements,-0.008064508,-0.004744166,short
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis,#NAME?,#NAME?,Clinical Study,-0.608247439,-0.600839837,short
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company,"COPENHAGEN, Denmark, Sept.  18, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be a collaboration between Evaxion and an undisclosed leading pharmaceutical company, leveraging unique assets and know-how from both organizations.","COPENHAGEN, Denmark, Sept.  18, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be a collaboration between Evaxion and an undisclosed leading pharmaceutical company, leveraging unique assets and know-how from both organizations.",Partnerships,-0.029255261,-0.028533499,short
Evaxion geht Partnerschaft mit dem Pharmaunternehmen Afrigen Biologics zur Entwicklung eines neuartigen mRNA-Impfstoffs gegen Gonorrhoe ein,"KOPENHAGEN, Dänemark, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges Biotechnologieunternehmen, das sich auf die Entwicklung von KI-gestützten Immuntherapien spezialisiert hat, hat heute eine Zusammenarbeit mit Afrigen Biologics (Afrigen) bekanntgegeben. Ziel der Zusammenarbeit ist die Entwicklung eines prophylaktischen Impfstoffs, der auf den mittels der EDEN™-Plattform von Evaxion entdeckten Gonorrhoe-Ziele basiert.","KOPENHAGEN, Dänemark, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges Biotechnologieunternehmen, das sich auf die Entwicklung von KI-gestützten Immuntherapien spezialisiert hat, hat heute eine Zusammenarbeit mit Afrigen Biologics (Afrigen) bekanntgegeben. Ziel der Zusammenarbeit ist die Entwicklung eines prophylaktischen Impfstoffs, der auf den mittels der EDEN™-Plattform von Evaxion entdeckten Gonorrhoe-Ziele basiert.",Partnerships,0.152083303,0.149146803,long
Evaxion gibt ermutigende erste klinische Daten der Phase II zu seinem personalisierten Krebsimpfstoff EVX-01 bekannt,"KOPENHAGEN, Dänemark, Nov.  01, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges TechBio-Unternehmen, das sich auf die Entwicklung von Impfstoffen auf Basis von AI-Immunology™ spezialisiert hat, freut sich, erste Ergebnisse der klinischen Phase-II-Studie mit EVX-01 bekanntzugeben, die frühere erfolgreiche Phase-I-Ergebnisse bestätigen. Ein umfassendes klinisches Update wird auf der 38. Jahrestagung der Society for Immunotherapy of Cancer (SITC) vorgestellt, die vom 1. bis 5. November 2023 in San Diego, Kalifornien, stattfindet.","KOPENHAGEN, Dänemark, Nov.  01, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges TechBio-Unternehmen, das sich auf die Entwicklung von Impfstoffen auf Basis von AI-Immunology™ spezialisiert hat, freut sich, erste Ergebnisse der klinischen Phase-II-Studie mit EVX-01 bekanntzugeben, die frühere erfolgreiche Phase-I-Ergebnisse bestätigen. Ein umfassendes klinisches Update wird auf der 38. Jahrestagung der Society for Immunotherapy of Cancer (SITC) vorgestellt, die vom 1. bis 5. November 2023 in San Diego, Kalifornien, stattfindet.",Clinical Study,-0.092436982,-0.100690779,short
Evaxion lève le voile sur les premiers résultats encourageants de l'essai clinique de phase II de son vaccin contre le cancer personnalisé EVX-01,"COPENHAGUE, Danemark,  01 nov. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX), ci-après « Evaxion » ou « la Société », une société de biotechnologie axée sur la recherche clinique spécialisée dans le développement de vaccins basés sur sa plateforme d'immunologie par l'IA, AI-Immunology™ est fière d'annoncer les premiers résultats de l'essai clinique de phase II portant sur son vaccin EVX-01, en ligne avec les conclusions positives de la phase I. La Société présentera un rapport clinique complet lors de la 38e réunion annuelle de la Society for Immunotherapy of Cancer (ci-après « SITC »), qui se tiendra à San Diego, en Californie, du 1er au 5 novembre 2023.","COPENHAGUE, Danemark,  01 nov. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX), ci-après « Evaxion » ou « la Société », une société de biotechnologie axée sur la recherche clinique spécialisée dans le développement de vaccins basés sur sa plateforme d'immunologie par l'IA, AI-Immunology™ est fière d'annoncer les premiers résultats de l'essai clinique de phase II portant sur son vaccin EVX-01, en ligne avec les conclusions positives de la phase I. La Société présentera un rapport clinique complet lors de la 38e réunion annuelle de la Society for Immunotherapy of Cancer (ci-après « SITC »), qui se tiendra à San Diego, en Californie, du 1er au 5 novembre 2023.",Clinical Study,-0.092436982,-0.100690779,short
"Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus","COPENHAGEN, Denmark, July  31, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA.","COPENHAGEN, Denmark, July  31, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA.",Clinical Study,-0.023622025,-0.024694401,short
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea,"COPENHAGEN, Denmark, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced a collaboration with Afrigen Biologics (Afrigen). The collaboration aims at developing a prophylactic vaccine based on Evaxion’s EDEN™-discovered gonorrhea targets.","COPENHAGEN, Denmark, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced a collaboration with Afrigen Biologics (Afrigen). The collaboration aims at developing a prophylactic vaccine based on Evaxion’s EDEN™-discovered gonorrhea targets.",Partnerships,0.152083303,0.149146803,long
Evaxion präsentiert neueste klinische Daten der Phase II von EVX-01 in einem Webinar mit dem Key Opinion Leader Adnan Khattak,"KOPENHAGEN, Dänemark, Nov.  07, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges Biotechnologieunternehmen, das sich auf die Entwicklung von AI-Immunology™-gestützten Impfstoffen spezialisiert hat, veranstaltet ein Online-Webinar mit dem Key Opinion Leader (KOL) und Leiter der klinischen Prüfung (LKP), Professor Adnan Khattak. Das Webinar findet am 8. November um 11:30 Uhr statt.","KOPENHAGEN, Dänemark, Nov.  07, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges Biotechnologieunternehmen, das sich auf die Entwicklung von AI-Immunology™-gestützten Impfstoffen spezialisiert hat, veranstaltet ein Online-Webinar mit dem Key Opinion Leader (KOL) und Leiter der klinischen Prüfung (LKP), Professor Adnan Khattak. Das Webinar findet am 8. November um 11:30 Uhr statt.",Calendar of Events,-0.025000075,-0.027846112,short
Evaxion präsentiert Proof-of-Principle für sein einzigartiges KI-Modell zur Vorhersage des Ansprechens auf Krebsimmuntherapie,"KOPENHAGEN, Dänemark, Nov.  16, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges TechBio-Unternehmen, das sich auf die Entwicklung von Impfstoffen auf Basis von AI-Immunology™ spezialisiert hat, stellt auf der Biomarkers & Precision Oncology Europe Konferenz in Berlin zum ersten Mal sein KI-Modell vor, das das Ansprechen von Patienten auf eine Krebsimmuntherapie vorhersagen kann.","KOPENHAGEN, Dänemark, Nov.  16, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges TechBio-Unternehmen, das sich auf die Entwicklung von Impfstoffen auf Basis von AI-Immunology™ spezialisiert hat, stellt auf der Biomarkers & Precision Oncology Europe Konferenz in Berlin zum ersten Mal sein KI-Modell vor, das das Ansprechen von Patienten auf eine Krebsimmuntherapie vorhersagen kann.",Health,-0.029530221,-0.02850729,short
Evaxion présente la preuve de concept de son modèle unique d’IA prédisant les réponses à l’immunothérapie du cancer,"COPENHAGUE, Danemark,  16 nov. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie au stade clinique spécialisée dans le développement de vaccins optimisés par AI-Immunology™, présente pour la première fois son modèle d’IA conçu pour prédire les réponses des patients à l’immunothérapie anticancéreuse lors de la conférence Biomarkers & Precision Oncology Europe qui se tient à Berlin, en Allemagne.","COPENHAGUE, Danemark,  16 nov. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie au stade clinique spécialisée dans le développement de vaccins optimisés par AI-Immunology™, présente pour la première fois son modèle d’IA conçu pour prédire les réponses des patients à l’immunothérapie anticancéreuse lors de la conférence Biomarkers & Precision Oncology Europe qui se tient à Berlin, en Allemagne.",Health,-0.029530221,-0.02850729,short
Evaxion présente les dernières données cliniques de la phase II d’EVX-01 à l’occasion d’un webinaire organisé en présence du leader d’opinion Adnan Khattak,"COPENHAGUE, Danemark,  07 nov. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX), ci-après « Evaxion » ou la « Société », une société de biotechnologie axée sur la recherche clinique spécialisée dans le développement de vaccins basés sur sa plateforme d’immunologie par l’IA, AI-Immunology™ organise un webinaire en ligne avec le concours du leader d’opinion et investigateur principal (IP), le Professeur Adnan Khattak, le 8 novembre à 11 h 30, heure de l’Est.","COPENHAGUE, Danemark,  07 nov. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX), ci-après « Evaxion » ou la « Société », une société de biotechnologie axée sur la recherche clinique spécialisée dans le développement de vaccins basés sur sa plateforme d’immunologie par l’IA, AI-Immunology™ organise un webinaire en ligne avec le concours du leader d’opinion et investigateur principal (IP), le Professeur Adnan Khattak, le 8 novembre à 11 h 30, heure de l’Est.",Calendar of Events,-0.025000075,-0.027846112,short
Evelo Biosciences Announces Reverse Stock Split Effective,"– EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 –","– EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 –",Changes in company's own shares,-0.250980391,-0.249994981,short
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy,"COPENHAGEN, Denmark, Nov.  15, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, presents for the first time its AI model designed to predict patient responses to cancer immunotherapy at the Biomarkers & Precision Oncology Europe conference in Berlin, Germany.","COPENHAGEN, Denmark, Nov.  15, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, presents for the first time its AI model designed to predict patient responses to cancer immunotherapy at the Biomarkers & Precision Oncology Europe conference in Berlin, Germany.",Health,0.050420188,0.047344899,long
Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency,nasdaq,nasdaq,Major shareholder announcements,-0.034090877,-0.033384386,short
Evaxion s'associe à la société pharmaceutique Afrigen Biologics pour développer un nouveau vaccin à ARN messager contre la gonorrhée,"COPENHAGUE, Danemark,  05 oct. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX), ci-après « Evaxion » ou la « Société », une société de biotechnologie axée sur la recherche clinique et spécialisée dans le développement d'immunothérapies reposant sur l'IA, a annoncé ce jour une collaboration avec Afrigen Biologics, ci-après « Afrigen ». Cette collaboration vise à développer un vaccin prophylactique basé sur les cibles de la gonorrhée découvertes par la plateforme EDEN™ d'Evaxion.","COPENHAGUE, Danemark,  05 oct. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX), ci-après « Evaxion » ou la « Société », une société de biotechnologie axée sur la recherche clinique et spécialisée dans le développement d'immunothérapies reposant sur l'IA, a annoncé ce jour une collaboration avec Afrigen Biologics, ci-après « Afrigen ». Cette collaboration vise à développer un vaccin prophylactique basé sur les cibles de la gonorrhée découvertes par la plateforme EDEN™ d'Evaxion.",Partnerships,0.152083303,0.149146803,long
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak,"COPENHAGEN, Denmark, Nov.  06, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is hosting an online webinar featuring Key Opinion Leader (KOL) and study’s Principal Investigator (PI), Professor Adnan Khattak. The webinar will take place on November 8 at 11:30 a.m. EST.","COPENHAGEN, Denmark, Nov.  06, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is hosting an online webinar featuring Key Opinion Leader (KOL) and study’s Principal Investigator (PI), Professor Adnan Khattak. The webinar will take place on November 8 at 11:30 a.m. EST.",Calendar of Events,-0.075000025,-0.075505229,short
Neue und aufregende klinische Daten zu AI-Immunology™-basierten personalisierten Krebsimpfstoffen von Evaxion werden präsentiert,"KOPENHAGEN, Dänemark, Oct.  27, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges TechBio-Unternehmen, das sich auf die Entwicklung von KI-Immunologie™-gestützten Impfstoffen spezialisiert hat, freut sich bekanntzugeben, dass es auf der 38. Jahrestagung der SITC, die vom 1. bis 5. November 2023 in San Diego, Kalifornien, stattfindet, klinische Ergebnisse zu seinen beiden personalisierten Krebsimpfstoffstudien vorstellen wird.","KOPENHAGEN, Dänemark, Oct.  27, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges TechBio-Unternehmen, das sich auf die Entwicklung von KI-Immunologie™-gestützten Impfstoffen spezialisiert hat, freut sich bekanntzugeben, dass es auf der 38. Jahrestagung der SITC, die vom 1. bis 5. November 2023 in San Diego, Kalifornien, stattfindet, klinische Ergebnisse zu seinen beiden personalisierten Krebsimpfstoffstudien vorstellen wird.",Calendar of Events,0.01219511,0.008219799,long
New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented,"COPENHAGEN, Denmark, Oct.  26, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™-powered vaccines, is proud to announce that it will be presenting clinical readouts on its two personalized cancer vaccine trials at SITC’s 38th annual meeting, taking place in San Diego, California from November 1-5, 2023. ","COPENHAGEN, Denmark, Oct.  26, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™-powered vaccines, is proud to announce that it will be presenting clinical readouts on its two personalized cancer vaccine trials at SITC’s 38th annual meeting, taking place in San Diego, California from November 1-5, 2023. ",Calendar of Events,0.102941165,0.105575522,long
Revolution in der Entdeckung von Impfstoffen: Neue Daten validieren die KI-Plattform von Evaxion und versprechen Senkung der Risiken und Kosten bei der Entwicklung von Impfstoffen gegen Infektionskrankheiten,"KOPENHAGEN, Dänemark, Sept.  12, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges Biotechnologieunternehmen, das sich auf die Entwicklung von KI-gestützten Immuntherapien spezialisiert hat, hat mit der Validierung seiner KI-gestützten Impfstoffentdeckungsplattform EDENTM einen bahnbrechenden Meilenstein in der Impfstoffforschung erreicht. Die Daten werden auf der Konferenz Vaccines Europe in Berlin vorgestellt, die vom 14. bis 15. September stattfindet.","KOPENHAGEN, Dänemark, Sept.  12, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges Biotechnologieunternehmen, das sich auf die Entwicklung von KI-gestützten Immuntherapien spezialisiert hat, hat mit der Validierung seiner KI-gestützten Impfstoffentdeckungsplattform EDENTM einen bahnbrechenden Meilenstein in der Impfstoffforschung erreicht. Die Daten werden auf der Konferenz Vaccines Europe in Berlin vorgestellt, die vom 14. bis 15. September stattfindet.",Research Analysis and Reports,0.024327776,0.027672631,long
"Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development","COPENHAGEN, Denmark, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (""Evaxion"" or the ""Company""), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDENTM. Data will be shared at the Vaccines Europe conference in Berlin, Germany, taking place from September 14th to 15th.","COPENHAGEN, Denmark, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (""Evaxion"" or the ""Company""), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDENTM. Data will be shared at the Vaccines Europe conference in Berlin, Germany, taking place from September 14th to 15th.",Research Analysis and Reports,0.026392972,0.020287744,long
"Révolutionner la découverte de vaccins : De nouvelles données valident la plateforme d'intelligence artificielle d'Evaxion, promettant de réduire les risques et les coûts dans le développement de vaccins contre les maladies infectieuses","COPENHAGUE, Danemark,  12 sept. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie clinique spécialisée dans le développement d'immunothérapies reposant sur l'Intelligence Artificielle, a franchi une étape décisive dans la découverte de vaccins avec la validation d'EDENTM, sa plateforme de découverte de vaccins reposant sur l'Intelligence Artificielle. Les données seront communiquées lors de la conférence Vaccines Europe qui se tiendra à Berlin, en Allemagne, les 14 et 15 septembre.","COPENHAGUE, Danemark,  12 sept. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie clinique spécialisée dans le développement d'immunothérapies reposant sur l'Intelligence Artificielle, a franchi une étape décisive dans la découverte de vaccins avec la validation d'EDENTM, sa plateforme de découverte de vaccins reposant sur l'Intelligence Artificielle. Les données seront communiquées lors de la conférence Vaccines Europe qui se tiendra à Berlin, en Allemagne, les 14 et 15 septembre.",Research Analysis and Reports,0.024327776,0.027672631,long
Evelo Biosciences Announces $25.5 Million Private Placement,"CAMBRIDGE, Mass., July  10, 2023  (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of its common stock (the “Shares”) at a purchase price of $2.31 per share, which would result in gross proceeds of approximately $25.5 million. The offering is being led by Evelo’s founder, Flagship Pioneering, with participation from other new and existing investors. Evelo intends to use the net proceeds from the private placement to fund the readout of its Phase 2a trial of EDP2939 in moderate psoriasis, to pay down approximately $5.0 million of its existing debt and for general corporate purposes.","CAMBRIDGE, Mass., July  10, 2023  (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of its common stock (the “Shares”) at a purchase price of $2.31 per share, which would result in gross proceeds of approximately $25.5 million. The offering is being led by Evelo’s founder, Flagship Pioneering, with participation from other new and existing investors. Evelo intends to use the net proceeds from the private placement to fund the readout of its Phase 2a trial of EDP2939 in moderate psoriasis, to pay down approximately $5.0 million of its existing debt and for general corporate purposes.",Stock Market News,0.082251109,0.083094787,long
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights,"CAMBRIDGE, Mass., March  16, 2023  (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights for the fourth quarter and full year 2022.","CAMBRIDGE, Mass., March  16, 2023  (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights for the fourth quarter and full year 2022.",Earnings Releases and Operating Results,0.015873,0.022192337,long
Evelo Biosciences Provides Clinical and Business Updates,"– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed –– Clear path to registration trials for EDP1815 in psoriasis based on recently completed interactions with FDA, EMA and MHRA –– Dosing commenced in clinical study with first extracellular vesicle (EV) product candidate EDP2939 in January; Phase 2 data in psoriasis anticipated in 2H 2023 –– Optimizing operations and reducing workforce to focus resources on strategic priorities –– CEO Simba Gill, Ph.D., will continue to lead the organization, halting search for successor –– Management to host conference call today at 8:30 a.m. ET –","– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed –– Clear path to registration trials for EDP1815 in psoriasis based on recently completed interactions with FDA, EMA and MHRA –– Dosing commenced in clinical study with first extracellular vesicle (EV) product candidate EDP2939 in January; Phase 2 data in psoriasis anticipated in 2H 2023 –– Optimizing operations and reducing workforce to focus resources on strategic priorities –– CEO Simba Gill, Ph.D., will continue to lead the organization, halting search for successor –– Management to host conference call today at 8:30 a.m. ET –",Annual report,-0.234615353,-0.23149092,short
Evelo Biosciences Provides Clinical Updates,"– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles (EVs) –– First EV candidate, EDP2939, in Phase 2 moderate psoriasis study fully enrolled; data anticipated in early Q4 2023 –– Management to host conference call today at 8:30 a.m. ET –","– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles (EVs) –– First EV candidate, EDP2939, in Phase 2 moderate psoriasis study fully enrolled; data anticipated in early Q4 2023 –– Management to host conference call today at 8:30 a.m. ET –",Health,-0.093959721,-0.095535802,short
Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes,"NEW YORK, June  26, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the company was added to the small cap Russell 2000® and broad market Russell 3000® Indexes effective today.","NEW YORK, June  26, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the company was added to the small cap Russell 2000® and broad market Russell 3000® Indexes effective today.",Trading information,0.004219506,0.005581424,long
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals,Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs. Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs.,Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs. Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs.,Health,0.101851797,0.093005678,long
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production,Anticipates having product available to ship in January 2024 Anticipates having product available to ship in January 2024,Anticipates having product available to ship in January 2024 Anticipates having product available to ship in January 2024,Product / Services Announcement,0.035461044,0.026186491,long
"Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform",Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis,Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis,Product / Services Announcement,0.02173911,0.020915136,long
Eyenovia Announces First Commercial Sale of Mydcombi™,Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation,Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation,Product / Services Announcement,0,0.004643095,long
Eyenovia Announces Poster Presentation at ARVO 2023,"NEW YORK, April  24, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meeting, which is being held April 23-27 in New Orleans.","NEW YORK, April  24, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meeting, which is being held April 23-27 in New Orleans.",Product / Services Announcement,-0.006122492,-0.005612977,short
Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023,Presentation to highlight recent FDA approval of Mydcombi™ for mydriasis which leverages Eyenovia’s novel Optejet dispensing device,Presentation to highlight recent FDA approval of Mydcombi™ for mydriasis which leverages Eyenovia’s novel Optejet dispensing device,Calendar of Events,-0.007042247,-0.007616592,short
Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops,Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response,Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response,Product / Services Announcement,0.037234071,0.034326444,long
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference,"NEW YORK, Sept.  21, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that Michael Rowe, CEO, will be participating in a panel discussion at the Cantor Global Healthcare Conference, which is taking place September 26-28, 2023, in New York.","NEW YORK, Sept.  21, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that Michael Rowe, CEO, will be participating in a panel discussion at the Cantor Global Healthcare Conference, which is taking place September 26-28, 2023, in New York.",Calendar of Events,-0.012048182,-0.005345641,short
Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference,"NEW YORK, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will deliver a presentation at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place on September 11-13, 2023 at the Lotte New York Palace Hotel.","NEW YORK, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will deliver a presentation at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place on September 11-13, 2023 at the Lotte New York Palace Hotel.",Calendar of Events,0.005347588,0.01231728,long
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®,"In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions","In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions",Clinical Study,0,0.004563072,long
"Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10",Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT,Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT,Calendar of Events,0.013953474,0.009701121,long
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program,Course to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis,Course to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis,Clinical Study,0.02777775,0.020764979,long
Faron Pharmaceuticals Announces Board Changes,"TURKU, Finland and BOSTON, Sept.  22, 2023  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, is pleased to announce the appointment of Ms. Christine Roth and Dr. Marie-Louise Fjällskog as Non-Executive Directors of the Company with immediate effect following the passing of all resolutions put to shareholders of the Company at the Extraordinary General Meeting held earlier today. ","TURKU, Finland and BOSTON, Sept.  22, 2023  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, is pleased to announce the appointment of Ms. Christine Roth and Dr. Marie-Louise Fjällskog as Non-Executive Directors of the Company with immediate effect following the passing of all resolutions put to shareholders of the Company at the Extraordinary General Meeting held earlier today. ",Directors and Officers,-0.011657989,-0.006963808,short
Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference,"TURKU, Finland and BOSTON, Aug.  02, 2023  (GLOBE NEWSWIRE) --  Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company’s Chief Executive Officer, Dr. Markku Jalkanen, and Chief Medical Officer, Dr. Marie-Louise Fjällskog, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023 at 12:30-12:55 PM Eastern Time at the InterContinental Boston Hotel in Boston, Massachusetts, in Room Abigail Adams C.","TURKU, Finland and BOSTON, Aug.  02, 2023  (GLOBE NEWSWIRE) --  Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company’s Chief Executive Officer, Dr. Markku Jalkanen, and Chief Medical Officer, Dr. Marie-Louise Fjällskog, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023 at 12:30-12:55 PM Eastern Time at the InterContinental Boston Hotel in Boston, Massachusetts, in Room Abigail Adams C.",Calendar of Events,0,0.007075909,long
Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting,"TURKU, Finland and BOSTON, Nov.  02, 2023  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that it will present Phase 1/2 data from its ongoing BEXMAB study of bexmarilimab in combination with standard of care (SoC) in relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients having failed hypomethylating agents (HMAs), at the 65th American Society of Hematology (ASH) Annual Meeting.","TURKU, Finland and BOSTON, Nov.  02, 2023  (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that it will present Phase 1/2 data from its ongoing BEXMAB study of bexmarilimab in combination with standard of care (SoC) in relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients having failed hypomethylating agents (HMAs), at the 65th American Society of Hematology (ASH) Annual Meeting.",Calendar of Events,0,-0.009274554,short
Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients,"Company announcement, Inside Information","Company announcement, Inside Information",Health,0.061518298,0.058986872,long
"Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H","Company is eligible to receive up to ~$140 million in potential late-stage development, regulatory and sales milestone payments plus royalties from 4DMT Company is eligible to receive up to ~$140 million in potential late-stage development, regulatory and sales milestone payments plus royalties from 4DMT","Company is eligible to receive up to ~$140 million in potential late-stage development, regulatory and sales milestone payments plus royalties from 4DMT Company is eligible to receive up to ~$140 million in potential late-stage development, regulatory and sales milestone payments plus royalties from 4DMT",Health,-0.014084472,-0.013574957,short
Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules,"MIAMI, Feb.  10, 2023  (GLOBE NEWSWIRE) --  Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the closing of its previously announced registered direct offering and concurrent private placement. The Company issued 16.6 million shares of its common stock in the registered direct offering priced at-the-market under Nasdaq rules. The purchase price of each share was $0.835.  ","MIAMI, Feb.  10, 2023  (GLOBE NEWSWIRE) --  Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the closing of its previously announced registered direct offering and concurrent private placement. The Company issued 16.6 million shares of its common stock in the registered direct offering priced at-the-market under Nasdaq rules. The purchase price of each share was $0.835.  ",Stock Market News,0.027026957,0.02165559,long
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program,Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk of CMV events in high-risk transplant recipients,Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk of CMV events in high-risk transplant recipients,Clinical Study,0.016128991,0.018073284,long
Fortress Biotech Announces Pricing of $10.0 Million Public Offering,"MIAMI, Nov.  10, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the pricing of its public offering of an aggregate of 5,885,000 units, at a public offering price of $1.70 per unit, consisting of (i) one share of common stock (or one pre-funded warrant in lieu thereof) and (ii) one warrant to purchase one share of common stock, immediately exercisable at a price of $1.70 per share and expiring five years from the date of issuance.","MIAMI, Nov.  10, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the pricing of its public offering of an aggregate of 5,885,000 units, at a public offering price of $1.70 per unit, consisting of (i) one share of common stock (or one pre-funded warrant in lieu thereof) and (ii) one warrant to purchase one share of common stock, immediately exercisable at a price of $1.70 per share and expiring five years from the date of issuance.",Management statements,-0.350961503,-0.355894231,short
Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules,"MIAMI, Feb.  08, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that it has entered into definitive agreements for the issuance and sale of 16.6 million shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. The purchase price of each share is $0.835.","MIAMI, Feb.  08, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that it has entered into definitive agreements for the issuance and sale of 16.6 million shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. The purchase price of each share is $0.835.",Prospectus/Announcement of Prospectus,-0.154761961,-0.149800383,short
Fortress Biotech Announces Reverse Stock Split,"MIAMI, Oct.  09, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. Fortress expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on October 10, 2023.","MIAMI, Oct.  09, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. Fortress expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on October 10, 2023.",Changes in share capital and votes,-0.121212107,-0.132227641,short
"Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock","MIAMI, Oct.  05, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced its board of directors has declared the regular monthly dividend of $0.1953125 per share of the Company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”) for the months of October, November and December 2022. The dividend will be payable on the last day of each month (October 31, November 30, and December 31) to holders of record as of the close of business on the fifteenth of that same month (October 15, November 15, December 15). Dividends will be paid in cash.","MIAMI, Oct.  05, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced its board of directors has declared the regular monthly dividend of $0.1953125 per share of the Company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”) for the months of October, November and December 2022. The dividend will be payable on the last day of each month (October 31, November 30, and December 31) to holders of record as of the close of business on the fifteenth of that same month (October 15, November 15, December 15). Dividends will be paid in cash.",Stock Market News,0,0.012117328,long
"Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors","MIAMI, Dec.  19, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lucy Lu, M.D., has been appointed to its Board of Directors. Dr. Lu is an accomplished executive with over 20 years of experience in a wide range of financial and drug development matters in the biotech and healthcare sectors as an investment banker, equity research analyst and executive at several biotech companies.","MIAMI, Dec.  19, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lucy Lu, M.D., has been appointed to its Board of Directors. Dr. Lu is an accomplished executive with over 20 years of experience in a wide range of financial and drug development matters in the biotech and healthcare sectors as an investment banker, equity research analyst and executive at several biotech companies.",Directors and Officers,0.034482781,0.033960924,long
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1,Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for which has now been accepted by the Food and Drug Administration,Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for which has now been accepted by the Food and Drug Administration,Product / Services Announcement,0.003448272,-0.001928338,short
"Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference","MIAMI, Dec.  06, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Fortress will participate in one-on-one meetings at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference, which is being held on Thursday, December 8, 2022 in Miami, FL.","MIAMI, Dec.  06, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Fortress will participate in one-on-one meetings at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference, which is being held on Thursday, December 8, 2022 in Miami, FL.",Trade Show,-0.014285678,-0.013860285,short
Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference,"MIAMI, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 11:30 a.m. ET. The Company will also attend one-on-one meetings during the conference.","MIAMI, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 11:30 a.m. ET. The Company will also attend one-on-one meetings during the conference.",Calendar of Events,-0.025641042,-0.018671351,short
Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference,"Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.","Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.",Calendar of Events,0,0.000706491,long
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023,"MIAMI, Aug.  03, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference on Tuesday, August 8, 2023 at 12:00 PM ET. The Company will also attend virtual one-on-one meetings during the conference.","MIAMI, Aug.  03, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference on Tuesday, August 8, 2023 at 12:00 PM ET. The Company will also attend virtual one-on-one meetings during the conference.",Calendar of Events,0.017241445,0.02188454,long
"Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR",Results demonstrate the potential benefit of vaccinating donors with Triplex to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transplant ,Results demonstrate the potential benefit of vaccinating donors with Triplex to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transplant ,Clinical Study,0.013513479,0.026050322,long
Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex,Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients,Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients,Clinical Study,0,0.005549652,long
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States,"Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese healthy subjects","Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese healthy subjects",Clinical Study,0,0.00098541,long
Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa,"MIAMI, Dec.  14, 2022  (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia, today announced that the Company has expanded its exclusive license agreement with Fuji Yakuhin Co. Ltd. (“Fuji”) for the development of dotinurad to include the Middle East and North Africa (“MENA”) and Turkey territories. The agreement builds upon the exclusive license agreement between Urica and Fuji previously announced in May of 2021 to develop dotinurad in the United States (“US”), United Kingdom, European Union and Canada.","MIAMI, Dec.  14, 2022  (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia, today announced that the Company has expanded its exclusive license agreement with Fuji Yakuhin Co. Ltd. (“Fuji”) for the development of dotinurad to include the Middle East and North Africa (“MENA”) and Turkey territories. The agreement builds upon the exclusive license agreement between Urica and Fuji previously announced in May of 2021 to develop dotinurad in the United States (“US”), United Kingdom, European Union and Canada.",Partnerships,0,0.000895629,long
"Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases","BOSTON, May  23, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader (MGD) of VAV1. The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases.","BOSTON, May  23, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader (MGD) of VAV1. The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases.",Clinical Study,-0.008237263,-0.004154019,short
"Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors","BOSTON, Nov.  01, 2022  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company has dosed the first patient in its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer. MRT-2359 is a potent, selective and orally bioavailable GSPT1-directed MGD, designed to disrupt protein synthesis in MYC-driven tumors, and lead to anti-tumor activity.","BOSTON, Nov.  01, 2022  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company has dosed the first patient in its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer. MRT-2359 is a potent, selective and orally bioavailable GSPT1-directed MGD, designed to disrupt protein synthesis in MYC-driven tumors, and lead to anti-tumor activity.",Product / Services Announcement,0.014130448,0.003954576,long
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update,"BOSTON, May  11, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended March 31, 2023.","BOSTON, May  11, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended March 31, 2023.",Earnings Releases and Operating Results,0.034542282,0.036722235,long
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update,"BOSTON, March  16, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided corporate updates.","BOSTON, March  16, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided corporate updates.",Earnings Releases and Operating Results,-0.024502346,-0.018183009,short
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update,"BOSTON, Aug.  10, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended June 30, 2023.","BOSTON, Aug.  10, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended June 30, 2023.",Earnings Releases and Operating Results,0.011782021,0.006308095,long
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases,Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases,Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases,Partnerships,0.047999954,0.055407557,long
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update,Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update,Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update,Earnings Releases and Operating Results,-0.005420049,-0.008118717,short
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors,"BOSTON, July  26, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases.","BOSTON, July  26, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases.",Directors and Officers,-0.0014925,0.000637311,long
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors,"BOSTON, March  23, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to the Board.","BOSTON, March  23, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to the Board.",Directors and Officers,0.012857165,0.005257228,long
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023,"BOSTON, Jan.  09, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today outlined anticipated 2023 milestones ahead of its participation at the 41st Annual J.P. Morgan Healthcare Conference. The company’s presentation will focus on strategic priorities for 2023, including its plans to report initial data from the Phase 1 arm of its ongoing Phase 1/2 clinical trial for MRT-2359, a highly selective and orally available GSPT1-directed MGD. Further, the company will present its development plan for its additional MGD candidates for patients with high unmet medical needs in oncology, autoimmune and inflammatory indications.","BOSTON, Jan.  09, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today outlined anticipated 2023 milestones ahead of its participation at the 41st Annual J.P. Morgan Healthcare Conference. The company’s presentation will focus on strategic priorities for 2023, including its plans to report initial data from the Phase 1 arm of its ongoing Phase 1/2 clinical trial for MRT-2359, a highly selective and orally available GSPT1-directed MGD. Further, the company will present its development plan for its additional MGD candidates for patients with high unmet medical needs in oncology, autoimmune and inflammatory indications.",Stock Market News,0.012562862,0.006661995,long
"Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases","Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to","Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to",Clinical Study,0.050295808,0.04744977,long
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates,– Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue Degrader in Solid Tumors; Company on Track to File Investigational New Drug (IND) Application Mid-year –,– Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue Degrader in Solid Tumors; Company on Track to File Investigational New Drug (IND) Application Mid-year –,Earnings Releases and Operating Results,0.015923526,0.018479313,long
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates,"– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors –","– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors –",Earnings Releases and Operating Results,0.083811658,0.07666863,long
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates,"– Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors –","– Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors –",Earnings Releases and Operating Results,0.035526314,-0.001679959,short
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference,Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference,Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference,Calendar of Events,-0.015384601,-0.01300707,short
Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference,"BOSTON, Jan.  04, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2023, at 11:15 a.m. PT.","BOSTON, Jan.  04, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2023, at 11:15 a.m. PT.",Calendar of Events,0.010282766,0.004085651,long
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences,"BOSTON, Feb.  03, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events:","BOSTON, Feb.  03, 2023  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events:",Calendar of Events,0.002805046,0.015257665,long
Capital Increase in Genmab as a Result of Employee Warrant Exercise,Company Announcement,Company Announcement,European Regulatory News,0.004444397,0.005061655,long
Capital Increase in Genmab as a Result of Employee Warrant Exercise,Company Announcement,Company Announcement,European Regulatory News,-0.001878682,0.005695151,long
Capital Increase in Genmab as a Result of Employee Warrant Exercise,Company Announcement,Company Announcement,European Regulatory News,0.000541724,0.002689665,long
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’,"Media ReleaseCOPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for “B-cell Lymphomas” (Version 4.2023) for third-line and subsequent therapy for patients with diffuse large B-cell lymphoma (DLBCL), including patients with disease progression after transplant or chimeric antigen receptor (CAR) T-cell therapy and as a Category 2A, preferred regimen for patients with histologic transformation of indolent lymphomas to DLBCL and no intention to proceed to transplant, including patients with disease progression after transplant or CAR T-cell therapy. This recommendation is based on uniform NCCN consensus that the intervention is appropriate.i Epcoritamab is being co-developed by Genmab and AbbVie (NYSE: ABBV) as part of the companies' oncology collaboration.","Media ReleaseCOPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for “B-cell Lymphomas” (Version 4.2023) for third-line and subsequent therapy for patients with diffuse large B-cell lymphoma (DLBCL), including patients with disease progression after transplant or chimeric antigen receptor (CAR) T-cell therapy and as a Category 2A, preferred regimen for patients with histologic transformation of indolent lymphomas to DLBCL and no intention to proceed to transplant, including patients with disease progression after transplant or CAR T-cell therapy. This recommendation is based on uniform NCCN consensus that the intervention is appropriate.i Epcoritamab is being co-developed by Genmab and AbbVie (NYSE: ABBV) as part of the companies' oncology collaboration.",European Regulatory News,-0.007329911,-0.005053757,short
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL),Company Announcement,Company Announcement,European Regulatory News,-0.001385894,0.001518246,long
Genmab Announces Financial Results for the First Half of 2023,"August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023","August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023",European Regulatory News,0.015249423,0.013463895,long
Genmab Announces Financial Results for the First Nine Months of 2023,"November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023","November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023",European Regulatory News,0.020746901,0.017900863,long
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH),Media Release,Media Release,European Regulatory News,0.001381658,-0.007892895,short
Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference,"Media Release  COPENHAGEN, Denmark; August 28, 2023","Media Release  COPENHAGEN, Denmark; August 28, 2023",European Regulatory News,0.002094837,0.000918961,long
Grant of Restricted Stock Units and Warrants to Employees in Genmab,Company Announcement,Company Announcement,European Regulatory News,-0.012024511,-0.019169331,short
Major Shareholder Announcement,Company Announcement,Company Announcement,European Regulatory News,-0.021773447,-0.021087839,short
Major Shareholder Announcement,Company Announcement,Company Announcement,European Regulatory News,0.025161312,0.022462644,long
GigaGen Announces Publication in the Peer-Reviewed Journal mAbs,Article Details GigaGen’s Affinity Maturation Approach for the Optimization of Monoclonal Antibody Drug Candidates Discovered via its Surge Platform Article Details GigaGen’s Affinity Maturation Approach for the Optimization of Monoclonal Antibody Drug Candidates Discovered via its Surge Platform,Article Details GigaGen’s Affinity Maturation Approach for the Optimization of Monoclonal Antibody Drug Candidates Discovered via its Surge Platform Article Details GigaGen’s Affinity Maturation Approach for the Optimization of Monoclonal Antibody Drug Candidates Discovered via its Surge Platform,Health,0.0051467,0.005379585,long
"GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050","SOUTH SAN FRANCISCO, Calif., Aug.  10, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today a new submission to bioRxiv, titled, “Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs.” In this study, GigaGen presents a novel technology for producing a new class of drug, which it calls ""recombinant hyperimmunes.""","SOUTH SAN FRANCISCO, Calif., Aug.  10, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today a new submission to bioRxiv, titled, “Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs.” In this study, GigaGen presents a novel technology for producing a new class of drug, which it calls ""recombinant hyperimmunes.""",Company Announcement,-0.046448006,-0.047970151,short
GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens,"SOUTH SAN FRANCISCO, Calif., Sept.  15, 2022  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombinant human polyclonal antibody discovery platform against biological threats of interest to the DOD.","SOUTH SAN FRANCISCO, Calif., Sept.  15, 2022  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombinant human polyclonal antibody discovery platform against biological threats of interest to the DOD.",Health,0.013317149,0.020544339,long
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19,First-in-human study evaluating recombinant hyperimmunes First-in-human study evaluating recombinant hyperimmunes,First-in-human study evaluating recombinant hyperimmunes First-in-human study evaluating recombinant hyperimmunes,Health,-0.005453301,-0.005363155,short
GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins,Modified agreement expands total grant value to $11.8M to advance development activities including manufacturing and investigational new drug (IND)-enabling studies Modified agreement expands total grant value to $11.8M to advance development activities including manufacturing and investigational new drug (IND)-enabling studies,Modified agreement expands total grant value to $11.8M to advance development activities including manufacturing and investigational new drug (IND)-enabling studies Modified agreement expands total grant value to $11.8M to advance development activities including manufacturing and investigational new drug (IND)-enabling studies,Business Contracts,-0.028070148,-0.029790287,short
GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19,"SOUTH SAN FRANCISCO, Calif., March  30, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19.  ","SOUTH SAN FRANCISCO, Calif., March  30, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19.  ",Company Announcement,0.007827781,-0.015441664,short
"ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023","Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ET Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ET","Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ET Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ET",Health,-0.017612554,-0.022069776,short
"GigaGen Initiates Large-Scale Manufacturing of its First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050","SOUTH SAN FRANCISCO, Calif., Sept.  09, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), Waisman Biomanufacturing and Goodwin Biotechnology, Inc.","SOUTH SAN FRANCISCO, Calif., Sept.  09, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), Waisman Biomanufacturing and Goodwin Biotechnology, Inc.",Product / Services Announcement,-0.009118633,-0.015754749,short
GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates,"SOUTH SAN FRANCISCO, Calif., Sept.  30, 2021  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed a license agreement with Dutch biotech ProteoNic B.V. for the use of its premium 2G UnicTM technology platform to enable high-yield production of GigaGen’s mono- and polyclonal antibody drug candidates.","SOUTH SAN FRANCISCO, Calif., Sept.  30, 2021  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed a license agreement with Dutch biotech ProteoNic B.V. for the use of its premium 2G UnicTM technology platform to enable high-yield production of GigaGen’s mono- and polyclonal antibody drug candidates.",Product / Services Announcement,-0.020120737,-0.004341703,short
GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564,Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development,Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development,Health,0.006600601,0.007938418,long
"GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023","Researchers from the National Cancer Institute will conduct the Phase 1 trial, as established in a recently signed Cooperative Research and Development Agreement (CRADA)        ","Researchers from the National Cancer Institute will conduct the Phase 1 trial, as established in a recently signed Cooperative Research and Development Agreement (CRADA)        ",Product / Services Announcement,-0.00537059,-0.007164969,short
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development,"SOUTH SAN FRANCISCO, Calif., May  19, 2022  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs.","SOUTH SAN FRANCISCO, Calif., May  19, 2022  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs.",Research Analysis and Reports,0.013953512,0.011792027,long
"GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564","--Reduced checkpoint inhibitor activity of GIGA-564 versus current anti-CTLA-4 inhibitors results in superior anti-tumor activity and lower toxicity in murine models ----Data supports advancement of GIGA-564 into the clinic for cancer indications-- SOUTH SAN FRANCISCO, Calif., July  14, 2021  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research in bioRxiv entitled, “Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy.” The publication describes the novel mechanism of action of its anti-CTLA-4 drug candidate, GIGA-564, selected due to its reduced checkpoint inhibition, which resulted in superior anti-tumor activity and lower toxicity in murine models compared to commercially available anti-CTLA-4 drugs.","--Reduced checkpoint inhibitor activity of GIGA-564 versus current anti-CTLA-4 inhibitors results in superior anti-tumor activity and lower toxicity in murine models ----Data supports advancement of GIGA-564 into the clinic for cancer indications-- SOUTH SAN FRANCISCO, Calif., July  14, 2021  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research in bioRxiv entitled, “Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy.” The publication describes the novel mechanism of action of its anti-CTLA-4 drug candidate, GIGA-564, selected due to its reduced checkpoint inhibition, which resulted in superior anti-tumor activity and lower toxicity in murine models compared to commercially available anti-CTLA-4 drugs.",Research Analysis and Reports,-0.011228964,-0.008576921,short
GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies,"SOUTH SAN FRANCISCO, May  25, 2021  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Single cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment,” in the peer-reviewed journal BMC Biology. The preclinical data describes potential new avenues to overcome resistance to anti-PD-L1 therapies.","SOUTH SAN FRANCISCO, May  25, 2021  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Single cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment,” in the peer-reviewed journal BMC Biology. The preclinical data describes potential new avenues to overcome resistance to anti-PD-L1 therapies.",Research Analysis and Reports,0.015242176,0.020214451,long
GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology,"Article describes GigaGen’s technology and approach for the production of a new class of drug, recombinant hyperimmunes, including its novel COVID-19 therapy Article describes GigaGen’s technology and approach for the production of a new class of drug, recombinant hyperimmunes, including its novel COVID-19 therapy","Article describes GigaGen’s technology and approach for the production of a new class of drug, recombinant hyperimmunes, including its novel COVID-19 therapy Article describes GigaGen’s technology and approach for the production of a new class of drug, recombinant hyperimmunes, including its novel COVID-19 therapy",Health,0.023529416,0.018381243,long
"GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies","SOUTH SAN FRANCISCO, Calif., July  28, 2022  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “GMP manufacturing and IND-enabling studies of a recombinant hyperimmune globulin targeting SARS-CoV-2,” in the international, peer-reviewed journal Pathogens. This work showcases for the first time the GMP (good manufacturing practice) manufacturing and IND (Investigational New Drug)-enabling studies of its new class of drugs, recombinant polyclonal antibodies, describing the company’s recombinant polyclonal product that targets SARS-CoV-2, GIGA-2050.","SOUTH SAN FRANCISCO, Calif., July  28, 2022  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “GMP manufacturing and IND-enabling studies of a recombinant hyperimmune globulin targeting SARS-CoV-2,” in the international, peer-reviewed journal Pathogens. This work showcases for the first time the GMP (good manufacturing practice) manufacturing and IND (Investigational New Drug)-enabling studies of its new class of drugs, recombinant polyclonal antibodies, describing the company’s recombinant polyclonal product that targets SARS-CoV-2, GIGA-2050.",Company Announcement,-0.100000036,-0.10211954,short
GigaGen to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium,"SOUTH SAN FRANCISCO, Calif., July  29, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, today announced that it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place on August 4-5, 2020.","SOUTH SAN FRANCISCO, Calif., July  29, 2020  (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, today announced that it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place on August 4-5, 2020.",Company Announcement,0.001037906,-0.008275393,short
GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting,"SOUTH SAN FRANCISCO, Calif., March  23, 2021  (GLOBE NEWSWIRE) -- GigaGen, a biotechnology company advancing transformative antibody drugs for immune deficiency, infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it will present an abstract in a poster session at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held on April 10-15 and May 17-21.","SOUTH SAN FRANCISCO, Calif., March  23, 2021  (GLOBE NEWSWIRE) -- GigaGen, a biotechnology company advancing transformative antibody drugs for immune deficiency, infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it will present an abstract in a poster session at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held on April 10-15 and May 17-21.",Calendar of Events,0.016969739,0.023119119,long
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium,G1 to present four posters at the 2023 ASCO Quality Care Symposium,G1 to present four posters at the 2023 ASCO Quality Care Symposium,Product / Services Announcement,0.008771922,0.003395311,long
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO),G1 Therapeutic's COSELA (trilaciclib) included in ASCO's updated SCLC treatment guidelines,G1 Therapeutic's COSELA (trilaciclib) included in ASCO's updated SCLC treatment guidelines,Health,0.02439022,0.028587245,long
G1 Therapeutics to Participate in Two August Investor Conferences,"RESEARCH TRIANGLE PARK, N.C., July  31, 2023  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August investor conferences.","RESEARCH TRIANGLE PARK, N.C., July  31, 2023  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August investor conferences.",Calendar of Events,0.008403353,0.007572578,long
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC),"- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and Thrombocytopenia -","- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and Thrombocytopenia -",Clinical Study,0.012766047,0.011693671,long
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC),"- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea -","- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea -",Company Announcement,0.003389827,-0.003789041,short
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer,Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events,Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events,Health,-0.013698617,-0.010914121,short
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC),Trilaciclib Reduces Hospitalizations and Myelosuppressive Events in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) and May Improve Survival,Trilaciclib Reduces Hospitalizations and Myelosuppressive Events in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) and May Improve Survival,Product / Services Announcement,0.020689635,0.016714323,long
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting,"SOUTH SAN FRANCISCO, Calif., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece.","SOUTH SAN FRANCISCO, Calif., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece.",Calendar of Events,0.030588262,0.032458079,long
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition,"SOUTH SAN FRANCISCO, Calif., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The oral presentation will take place at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego.","SOUTH SAN FRANCISCO, Calif., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The oral presentation will take place at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego.",Calendar of Events,0,-0.009274554,short
Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress,Dr. Todd E. Rasmussen provides HAV™ clinical update and surgical skills workshop at ICMM Dr. Todd E. Rasmussen provides HAV™ clinical update and surgical skills workshop at ICMM,Dr. Todd E. Rasmussen provides HAV™ clinical update and surgical skills workshop at ICMM Dr. Todd E. Rasmussen provides HAV™ clinical update and surgical skills workshop at ICMM,Product / Services Announcement,-0.019354871,-0.025249235,short
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma,"SOUTH SAN FRANCISCO, Calif., June  27, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the safety, tolerability, and pharmacokinetics of HPN217 in patients with relapsed/refractory multiple myeloma. Additional patients currently in screening will also be allowed to enroll.","SOUTH SAN FRANCISCO, Calif., June  27, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the safety, tolerability, and pharmacokinetics of HPN217 in patients with relapsed/refractory multiple myeloma. Additional patients currently in screening will also be allowed to enroll.",Clinical Study,0,-0.002109224,short
Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort,"SOUTH SAN FRANCISCO, Calif., Sept.  15, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer (SCLC) in an ongoing Phase 1/2 trial of HPN328, a DLL3 targeting TriTAC®, in combination with atezolizumab (Tecentriq®). Harpoon previously entered a Master Clinical Supply Agreement with F. Hoffmann-La Roche for the supply of atezolizumab. Under this agreement, Harpoon is the sponsor of the trial and Roche will supply atezolizumab. This announcement is being made in conjunction with Harpoon’s investor event, “DLL3 Market Opportunity and KOL Discussion of HPN328,” held virtually and in person today in New York beginning at 8 a.m. ET.","SOUTH SAN FRANCISCO, Calif., Sept.  15, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer (SCLC) in an ongoing Phase 1/2 trial of HPN328, a DLL3 targeting TriTAC®, in combination with atezolizumab (Tecentriq®). Harpoon previously entered a Master Clinical Supply Agreement with F. Hoffmann-La Roche for the supply of atezolizumab. Under this agreement, Harpoon is the sponsor of the trial and Roche will supply atezolizumab. This announcement is being made in conjunction with Harpoon’s investor event, “DLL3 Market Opportunity and KOL Discussion of HPN328,” held virtually and in person today in New York beginning at 8 a.m. ET.",Clinical Study,0.0037037,0.010853471,long
Harpoon Therapeutics Announces Up to $150 Million Private Placement,"SOUTH SAN FRANCISCO, Calif., Oct.  23, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a securities purchase agreement for a private placement in public equity (“PIPE”) financing that is expected to result in upfront gross proceeds of approximately $100 million, with up to an additional approximately $50 million of gross proceeds upon cash exercise of warrants, before deducting placement agent fees and offering expenses. The PIPE financing was led by a leading biotechnology investor associated with one of the largest alternative asset managers, with participation from new and existing investors including Soleus Capital, Commodore Capital, New Leaf Venture Partners, Cormorant Asset Management, RA Capital Management, Invus, Surveyor Capital (a Citadel company), K2 HealthVentures, Ally Bridge Group, Lion Point Capital, and a large mutual fund.","SOUTH SAN FRANCISCO, Calif., Oct.  23, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a securities purchase agreement for a private placement in public equity (“PIPE”) financing that is expected to result in upfront gross proceeds of approximately $100 million, with up to an additional approximately $50 million of gross proceeds upon cash exercise of warrants, before deducting placement agent fees and offering expenses. The PIPE financing was led by a leading biotechnology investor associated with one of the largest alternative asset managers, with participation from new and existing investors including Soleus Capital, Commodore Capital, New Leaf Venture Partners, Cormorant Asset Management, RA Capital Management, Invus, Surveyor Capital (a Citadel company), K2 HealthVentures, Ally Bridge Group, Lion Point Capital, and a large mutual fund.",Financing Agreements,0.027616287,0.031367604,long
Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development,"SOUTH SAN FRANCISCO, Calif., Aug.  01, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development. Mr. Wang brings 15 years of biopharma business development, finance, and mergers and acquisitions (M&A) transaction experience to Harpoon.","SOUTH SAN FRANCISCO, Calif., Aug.  01, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development. Mr. Wang brings 15 years of biopharma business development, finance, and mergers and acquisitions (M&A) transaction experience to Harpoon.",Management Changes,-0.003831384,-0.000511041,short
Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023,"Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and integrin-beta6 (ITGB6)-expressing solid tumors Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and integrin-beta6 (ITGB6)-expressing solid tumors","Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and integrin-beta6 (ITGB6)-expressing solid tumors Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and integrin-beta6 (ITGB6)-expressing solid tumors",Clinical Study,-0.015647245,-0.019454523,short
"HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023","NEW YORK and VIENNA, Austria, May  04, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023.","NEW YORK and VIENNA, Austria, May  04, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023.",Calendar of Events,0.024999975,0.027671404,long
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023,"SOUTH SAN FRANCISCO, Calif., April  18, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented preclinical data for two of its key clinical programs, HPN328 and HPN217, in three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023. HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells. HPN328 is Harpoon’s half-life extended TriTAC that targets delta-like canonical Notch ligand 3 (DLL3).","SOUTH SAN FRANCISCO, Calif., April  18, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented preclinical data for two of its key clinical programs, HPN328 and HPN217, in three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023. HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells. HPN328 is Harpoon’s half-life extended TriTAC that targets delta-like canonical Notch ligand 3 (DLL3).",Clinical Study,-0.071428571,-0.068131986,short
Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference,"SOUTH SAN FRANCISCO, Calif., Feb.  07, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will present at the virtual SVB Securities Global Biopharma Conference. The corporate presentation will take place on Tuesday, February 14, 2023 at 1:40 p.m. ET (10:40 a.m. PT).","SOUTH SAN FRANCISCO, Calif., Feb.  07, 2023  (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will present at the virtual SVB Securities Global Biopharma Conference. The corporate presentation will take place on Tuesday, February 14, 2023 at 1:40 p.m. ET (10:40 a.m. PT).",Calendar of Events,0,0.002342414,long
HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers,"NEW YORK and VIENNA, Austria, Feb.  13, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it has achieved a $10 million non-dilutive milestone payment under its collaboration agreement with Roche to develop HB-700, a novel arenaviral immunotherapy for KRAS-mutated cancers. The success-based milestone payment reflects the start of the HB-700 manufacturing process to support a Phase 1 clinical trial. HOOKIPA plans to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration in the first half of 2024.","NEW YORK and VIENNA, Austria, Feb.  13, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it has achieved a $10 million non-dilutive milestone payment under its collaboration agreement with Roche to develop HB-700, a novel arenaviral immunotherapy for KRAS-mutated cancers. The success-based milestone payment reflects the start of the HB-700 manufacturing process to support a Phase 1 clinical trial. HOOKIPA plans to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration in the first half of 2024.",Financing Agreements,0.027322378,0.025655892,long
HOOKIPA Announces Executive Leadership Change,"NEW YORK and VIENNA, Sept.  13, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Katia Schlienger, M.D., Ph.D., is stepping down from her position as Chief Medical Officer (CMO) to pursue new opportunities, effective September 30. Malte Peters, M.D., a current member of the Board of Directors of HOOKIPA, will lead HOOKIPA’s clinical activities ad interim as Senior Clinical Advisor until a CMO search is complete. During this time, Dr. Peters will remain a member of the HOOKIPA Board of Directors.","NEW YORK and VIENNA, Sept.  13, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Katia Schlienger, M.D., Ph.D., is stepping down from her position as Chief Medical Officer (CMO) to pursue new opportunities, effective September 30. Malte Peters, M.D., a current member of the Board of Directors of HOOKIPA, will lead HOOKIPA’s clinical activities ad interim as Senior Clinical Advisor until a CMO search is complete. During this time, Dr. Peters will remain a member of the HOOKIPA Board of Directors.",Management Changes,0.093294477,0.092778746,long
Immunocore to present at upcoming investor conferences,Immunocore to present at upcoming investor conferences,Immunocore to present at upcoming investor conferences,Calendar of Events,0.003101006,0.006225439,long
"HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B","NEW YORK and VIENNA, Austria, May  09, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Gilead-led Phase 1 clinical trial of HB-400, an investigational therapeutic vaccine for chronic hepatitis B. HB-400 is one of two novel compounds being developed in collaboration with Gilead.","NEW YORK and VIENNA, Austria, May  09, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Gilead-led Phase 1 clinical trial of HB-400, an investigational therapeutic vaccine for chronic hepatitis B. HB-400 is one of two novel compounds being developed in collaboration with Gilead.",Product / Services Announcement,0,0.003900725,long
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),"NEW YORK and VIENNA, Sept.  12, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to new employees to purchase an aggregate of 100,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan. The award was granted as an inducement material to the employees’s acceptance of employment with HOOKIPA in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $ 1.00 per share. The options have a ten year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in equal quarterly installments for three years thereafter, subject to the employee’s continued service with HOOKIPA on each such vesting date. The options are subject to the terms and conditions of HOOKIPA’s 2023 Inducement Plan approved by the Board of Directors in April 2023 and the terms and conditions of award agreements covering the grants.","NEW YORK and VIENNA, Sept.  12, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to new employees to purchase an aggregate of 100,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan. The award was granted as an inducement material to the employees’s acceptance of employment with HOOKIPA in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $ 1.00 per share. The options have a ten year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in equal quarterly installments for three years thereafter, subject to the employee’s continued service with HOOKIPA on each such vesting date. The options are subject to the terms and conditions of HOOKIPA’s 2023 Inducement Plan approved by the Board of Directors in April 2023 and the terms and conditions of award agreements covering the grants.",Stock Market News,0.03503648,0.038381335,long
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus,"NEW YORK and VIENNA, Austria, Nov.  20, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV. HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial. Gilead has the exclusive right to assume further development of the program thereafter.","NEW YORK and VIENNA, Austria, Nov.  20, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV. HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial. Gilead has the exclusive right to assume further development of the program thereafter.",Clinical Study,0.040462482,0.041039268,long
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences,"NEW YORK and VIENNA, Austria, Oct.  18, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that The Journal of Infectious Diseases has published preclinical data on HB-400, an investigational therapeutic vaccine for chronic hepatitis B developed in collaboration with Gilead Sciences, Inc. (HB-400 is also referenced as GS-2829 and GS-6779.) The published data highlight HB-400 as a potential component in achieving a functional cure for chronic hepatitis B.","NEW YORK and VIENNA, Austria, Oct.  18, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that The Journal of Infectious Diseases has published preclinical data on HB-400, an investigational therapeutic vaccine for chronic hepatitis B developed in collaboration with Gilead Sciences, Inc. (HB-400 is also referenced as GS-2829 and GS-6779.) The published data highlight HB-400 as a potential component in achieving a functional cure for chronic hepatitis B.",Health,0.032504817,0.036701842,long
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors,"NEW YORK and VIENNA, March  13, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023.","NEW YORK and VIENNA, March  13, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023.",Directors and Officers,-0.012345667,-0.001721413,short
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023,"NEW YORK and VIENNA, Austria, Nov.  03, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced updated Phase 1 clinical, biomarker and translational data on HB-200 as a monotherapy in heavily pretreated patients with recurrent/metastatic Human Papillomavirus 16-positive (HPV16+) head and neck cancer. The data show HB-200 monotherapy induced robust, high-quality and durable tumor-specific T cell responses, which showed a trend of clinical benefit measured by a 44 percent disease control rate in a difficult-to-treat patient population. The data were presented in a poster presentation (abstract #679) at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.","NEW YORK and VIENNA, Austria, Nov.  03, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced updated Phase 1 clinical, biomarker and translational data on HB-200 as a monotherapy in heavily pretreated patients with recurrent/metastatic Human Papillomavirus 16-positive (HPV16+) head and neck cancer. The data show HB-200 monotherapy induced robust, high-quality and durable tumor-specific T cell responses, which showed a trend of clinical benefit measured by a 44 percent disease control rate in a difficult-to-treat patient population. The data were presented in a poster presentation (abstract #679) at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.",Clinical Study,0.047727268,0.044148777,long
HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights,"NEW YORK and VIENNA, May  11, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2023.","NEW YORK and VIENNA, May  11, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2023.",Earnings Releases and Operating Results,-0.037634437,-0.035454483,short
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights,"NEW YORK and VIENNA, Austria, Aug.  10, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the second quarter of 2023.","NEW YORK and VIENNA, Austria, Aug.  10, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the second quarter of 2023.",Earnings Releases and Operating Results,-0.023066432,-0.028540358,short
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights,"NEW YORK and VIENNA, Austria, Nov.  09, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the third quarter of 2023.","NEW YORK and VIENNA, Austria, Nov.  09, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the third quarter of 2023.",Earnings Releases and Operating Results,-0.079999983,-0.082698652,short
HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference,"NEW YORK and VIENNA, Austria, April  19, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that the company will participate in investor meetings at the Van Lanschot Kempen Life Sciences Conference being held in Amsterdam, April 25 - 26, 2023.","NEW YORK and VIENNA, Austria, April  19, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that the company will participate in investor meetings at the Van Lanschot Kempen Life Sciences Conference being held in Amsterdam, April 25 - 26, 2023.",Calendar of Events,0.040540501,0.045344804,long
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May,"NEW YORK and VIENNA, Austria, May  04, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in and present at the following upcoming investor conferences:","NEW YORK and VIENNA, Austria, May  04, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in and present at the following upcoming investor conferences:",Calendar of Events,0.024999975,0.027671404,long
HOOKIPA Pharma to participate in upcoming investor conferences in September,"NEW YORK and VIENNA, Austria, Sept.  06, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in and present at the following upcoming investor conferences:","NEW YORK and VIENNA, Austria, Sept.  06, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in and present at the following upcoming investor conferences:",Calendar of Events,-0.020172908,-0.018303092,short
HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook,"NEW YORK and VIENNA, March  15, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter and full year 2022, as well as the outlook for 2023.","NEW YORK and VIENNA, March  15, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter and full year 2022, as well as the outlook for 2023.",Earnings Releases and Operating Results,0.088888922,0.103797139,long
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO,"NEW YORK and VIENNA, Austria, April  26, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a Trial in Progress poster on its ongoing Phase 1/2 clinical study (NCT05553639) of HB-300 in prostate cancer has been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023.","NEW YORK and VIENNA, Austria, April  26, 2023  (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a Trial in Progress poster on its ongoing Phase 1/2 clinical study (NCT05553639) of HB-300 in prostate cancer has been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023.",Product / Services Announcement,0.022267222,0.028069779,long
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update,-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients,-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients,Earnings Releases and Operating Results,0.025890021,0.029272825,long
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma,"-- Single-arm clinical trial was a success and showed the HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks -- -- BLA planned to be filed with FDA in 4th Quarter 2023 --","-- Single-arm clinical trial was a success and showed the HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks -- -- BLA planned to be filed with FDA in 4th Quarter 2023 --",Research Analysis and Reports,0.054054066,0.057398921,long
Humacyte Third Quarter 2022 Financial Results and Business Update,-- Progress Continues in Clinical Development of Human Acellular Vessel™ (HAV™) for Vascular Trauma; BLA Filing Anticipated mid 2023 –,-- Progress Continues in Clinical Development of Human Acellular Vessel™ (HAV™) for Vascular Trauma; BLA Filing Anticipated mid 2023 –,Earnings Releases and Operating Results,0,-0.037206272,short
Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting,"HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuries HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuries","HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuries HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuries",Health,-0.016759761,-0.007032823,short
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma,– Presentations included results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime injuries in Ukraine –,– Presentations included results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime injuries in Ukraine –,Health,0.016393427,0.016371262,long
Humacyte Expands Board of Directors and Leadership Team with New Appointments,"Lt. General Bruce Green, M.D., USAF-ret. Joins Board of Directors","Lt. General Bruce Green, M.D., USAF-ret. Joins Board of Directors",Health,0.032171551,0.041153639,long
Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022,"Ukrainian surgeon collaborators will present at the VI Congress of Vascular Surgeons, Phlebologists, and Angiologists of Ukraine and the 11th Munich Vascular Conference Ukrainian surgeon collaborators will present at the VI Congress of Vascular Surgeons, Phlebologists, and Angiologists of Ukraine and the 11th Munich Vascular Conference","Ukrainian surgeon collaborators will present at the VI Congress of Vascular Surgeons, Phlebologists, and Angiologists of Ukraine and the 11th Munich Vascular Conference Ukrainian surgeon collaborators will present at the VI Congress of Vascular Surgeons, Phlebologists, and Angiologists of Ukraine and the 11th Munich Vascular Conference",Product / Services Announcement,-0.009615376,-0.012289032,short
Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting,"Six-month primate HAV CABG model demonstrates patency, recellularization and remodeling resembling native blood vessels","Six-month primate HAV CABG model demonstrates patency, recellularization and remodeling resembling native blood vessels",Product / Services Announcement,-0.003039511,-0.006653129,short
Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease,#NAME?,#NAME?,Clinical Study,0,0.00436812,long
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model,-Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease- -Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease-,-Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease- -Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease-,Health,0.003875965,-0.001500645,short
Humacyte Second Quarter 2023 Financial Results and Business Update,– Completed Enrollment in Phase 2/3 V005 Trial of HAV™ in Vascular Trauma Repair; Top-Line Results on Track for Q3 2023 –,– Completed Enrollment in Phase 2/3 V005 Trial of HAV™ in Vascular Trauma Repair; Top-Line Results on Track for Q3 2023 –,Earnings Releases and Operating Results,0.073394499,0.075526175,long
Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference,"-Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage- -Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage-","-Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage- -Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage-",Clinical Study,0.01055408,0.004448852,long
"ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022","Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET","Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET",Calendar of Events,0.015602788,0.006756669,long
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV,Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV,Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV,Health,-0.015187703,-0.016265136,short
Immunocore announces upcoming presentation and posters at ESMO 2023,Immunocore announces upcoming presentation and posters at ESMO 2023,Immunocore announces upcoming presentation and posters at ESMO 2023,Clinical Study,-0.009166496,-0.003206546,short
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update, , ,Earnings Releases and Operating Results,0.011873059,0.006399133,long
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update,Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update,Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update,Earnings Releases and Operating Results,0.005836956,0.005836956,long
"Immunocore to report second quarter 2023 financial results and host call on August 10, 2023","Immunocore to report second quarter 2023 financial results and host call on August 10, 2023","Immunocore to report second quarter 2023 financial results and host call on August 10, 2023",Earnings Releases and Operating Results,-0.012105957,-0.007462862,short
"Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma", , ,Advisory,0.038011659,0.040023486,long
"Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)","LOS ANGELES, Aug.  16, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis has been selected for oral presentation at the 20th International Myeloma Society Annual Meeting to be held in Athens, Greece, September 27-30, 2023.","LOS ANGELES, Aug.  16, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis has been selected for oral presentation at the 20th International Myeloma Society Annual Meeting to be held in Athens, Greece, September 27-30, 2023.",Clinical Study,0.010752678,0.011723626,long
Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting,"LOS ANGELES, Oct.  03, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), today announced presentation of additional AL Amyloidosis clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study of novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, at an oral presentation at the 20th International Myeloma Society Annual (IMS) Meeting being held in Athens, Greece on September 27-30 2023. One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update. All patients were DARZALEX ® (daratumumab) combination therapy relapsed/refractory and experienced a median of 6 earlier treatments that failed to stop worsening of disease (lines of therapy) prior to receiving NXC-201.","LOS ANGELES, Oct.  03, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), today announced presentation of additional AL Amyloidosis clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study of novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, at an oral presentation at the 20th International Myeloma Society Annual (IMS) Meeting being held in Athens, Greece on September 27-30 2023. One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update. All patients were DARZALEX ® (daratumumab) combination therapy relapsed/refractory and experienced a median of 6 earlier treatments that failed to stop worsening of disease (lines of therapy) prior to receiving NXC-201.",Advisory,0.057736722,0.06300222,long
"Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board","LOS ANGELES, Aug.  18, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”) (Nasdaq:IMMX), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced that Dr. Heather Landau has joined the Nexcella Scientific Advisory Board.  Dr. Landau brings extensive experience in designing clinical trials in hematology and oncology, novel treatment approaches for AL amyloidosis and multiple myeloma, and thought leadership to Nexcella.","LOS ANGELES, Aug.  18, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”) (Nasdaq:IMMX), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced that Dr. Heather Landau has joined the Nexcella Scientific Advisory Board.  Dr. Landau brings extensive experience in designing clinical trials in hematology and oncology, novel treatment approaches for AL amyloidosis and multiple myeloma, and thought leadership to Nexcella.",Advisory,-0.024539854,-0.017847027,short
"Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board","LOS ANGELES, Sept.  01, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced that effective today, Dr. Suzanne Lentzsch has joined the Nexcella Scientific Advisory Board. Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella. Dr. Lentzsch Co-Chairs the National Cancer Institute Myeloma Steering Committee; is an Associate Editor of Journal of Clinical Oncology; was a key clinical investigator in establishing bendamustine as a new treatment for relapsed amyloidosis, the principal investigator of the CAEL-101 phase 1a/b study in AL Amyloidosis and co-founder of Caelum Biosciences, subsequently acquired by AstraZeneca.","LOS ANGELES, Sept.  01, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced that effective today, Dr. Suzanne Lentzsch has joined the Nexcella Scientific Advisory Board. Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella. Dr. Lentzsch Co-Chairs the National Cancer Institute Myeloma Steering Committee; is an Associate Editor of Journal of Clinical Oncology; was a key clinical investigator in establishing bendamustine as a new treatment for relapsed amyloidosis, the principal investigator of the CAEL-101 phase 1a/b study in AL Amyloidosis and co-founder of Caelum Biosciences, subsequently acquired by AstraZeneca.",Health,-0.009852207,-0.01611402,short
"Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board","LOS ANGELES, Oct.  26, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.  Dr. Liedtke brings decades of experience in hematology/oncology clinical trials, clinical trial design, and thought leadership to Nexcella.","LOS ANGELES, Oct.  26, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.  Dr. Liedtke brings decades of experience in hematology/oncology clinical trials, clinical trial design, and thought leadership to Nexcella.",Advisory,0.002673794,0.005308151,long
"Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing","LOS ANGELES, Nov.  21, 2023  (GLOBE NEWSWIRE) --  Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BCMA CAR-T NXC-201 (formerly HBI0101). With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to the United States. Favorable tolerability enables potential expansion into autoimmune indications.","LOS ANGELES, Nov.  21, 2023  (GLOBE NEWSWIRE) --  Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BCMA CAR-T NXC-201 (formerly HBI0101). With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to the United States. Favorable tolerability enables potential expansion into autoimmune indications.",Health,-0.041189893,-0.041388482,short
"Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing","LOS ANGELES, Nov.  21, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BCMA CAR-T NXC-201 (formerly HBI0101). With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to the United States. Favorable tolerability enables potential expansion into autoimmune indications.","LOS ANGELES, Nov.  21, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BCMA CAR-T NXC-201 (formerly HBI0101). With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to the United States. Favorable tolerability enables potential expansion into autoimmune indications.",Advisory,-0.041189893,-0.041388482,short
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program,Participating institutional investors include Bridgewest Group Participating institutional investors include Bridgewest Group,Participating institutional investors include Bridgewest Group Participating institutional investors include Bridgewest Group,Financing Agreements,-0.044776136,-0.045577689,short
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site,"LOS ANGELES, Oct.  16, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site.","LOS ANGELES, Oct.  16, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site.",Advisory,-0.018425404,-0.023802014,short
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients, , ,Advisory,0.022409009,0.02061463,long
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients, , ,Advisory,0.022409009,0.02061463,long
Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial, , ,Clinical Study,-0.027149295,-0.030956637,short
Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site, , ,Advisory,0.206896512,0.19560428,long
Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting,"Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in Athens September 27-30, 2023 Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in Athens September 27-30, 2023","Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in Athens September 27-30, 2023 Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in Athens September 27-30, 2023",Advisory,-0.01449274,-0.013876274,short
"Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors", , ,Advisory,-0.041198551,-0.047097842,short
"Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors", , ,Advisory,-0.019512177,-0.026195492,short
"Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors", , ,Advisory,0.052631634,0.053248892,long
"Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors", , ,Advisory,-0.075000025,-0.066964276,short
Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site, , ,Clinical Study,-0.030188739,-0.028047288,short
Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site,Supports planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S. Supports planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.,Supports planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S. Supports planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.,Advisory,-0.017167366,-0.020544999,short
Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial,"LOS ANGELES, June  26, 2023  (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies targeting oncology and other diseases, today announced it has completed a Pre-Investigational New Drug (“Pre-IND”) meeting with the FDA. The subject of the Pre-IND meeting was planned NXC-201 US manufacturing and US clinical trials in AL amyloidosis and multiple myeloma. ","LOS ANGELES, June  26, 2023  (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies targeting oncology and other diseases, today announced it has completed a Pre-Investigational New Drug (“Pre-IND”) meeting with the FDA. The subject of the Pre-IND meeting was planned NXC-201 US manufacturing and US clinical trials in AL amyloidosis and multiple myeloma. ",Clinical Study,-0.04705878,-0.04433123,short
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis,"Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET","Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET",Company Announcement,0.01909306,0.015320426,long
"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference","LOS ANGELES, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that Nexcella NXC-201 clinical data will be presented by Ilya Rachman, MD, PhD, and Gabriel Morris at the Healthcare Trailblazers Private Company Conference Thursday, October 26, 2023.  At this institutional event, Ilya Rachman and Gabriel Morris will plan on being available to meet institutional investors and potential strategic pharmaceutical partners.","LOS ANGELES, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that Nexcella NXC-201 clinical data will be presented by Ilya Rachman, MD, PhD, and Gabriel Morris at the Healthcare Trailblazers Private Company Conference Thursday, October 26, 2023.  At this institutional event, Ilya Rachman and Gabriel Morris will plan on being available to meet institutional investors and potential strategic pharmaceutical partners.",Advisory,-0.0079365,-0.000966809,short
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis,FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for:,FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for:,Clinical Study,0.006688957,0.013391497,long
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma,FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for:,FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for:,Clinical Study,0.044444469,0.0419339,long
Immuneering Announces $30 Million Underwritten Offering,"CAMBRIDGE, Mass., April  18, 2023  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX) (“Immuneering”), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced the pricing of its underwritten offering of 2,727,273 shares of its Class A common stock at an offering price of $11.00 per share. The gross proceeds from the offering are expected be $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All shares in the offering will be offered by Immuneering.","CAMBRIDGE, Mass., April  18, 2023  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX) (“Immuneering”), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced the pricing of its underwritten offering of 2,727,273 shares of its Class A common stock at an offering price of $11.00 per share. The gross proceeds from the offering are expected be $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All shares in the offering will be offered by Immuneering.",Initial Public Offerings,-0.061525843,-0.065487731,short
Immuneering Announces Participation in March Investor Conferences,"CAMBRIDGE, Mass., Feb.  28, 2023  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will participate in two March investor conferences to share commentary around the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.","CAMBRIDGE, Mass., Feb.  28, 2023  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will participate in two March investor conferences to share commentary around the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.",Calendar of Events,0.004166663,0.005423797,long
Business update October 2023,"Unless otherwise stated, comments in this announcement refer to performance from continuing operations from 1 January – 31 October 2023. ","Unless otherwise stated, comments in this announcement refer to performance from continuing operations from 1 January – 31 October 2023. ",European Regulatory News,-0.034117698,-0.03343209,short
"Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline","CAMBRIDGE, Mass., April  18, 2023  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced positive initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 trial of IMM-1-104 (NCT05585320), which are being shared today in a poster presentation titled “Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors” (abstract #4265) at the American Association for Cancer Research (AACR) annual meeting.","CAMBRIDGE, Mass., April  18, 2023  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced positive initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 trial of IMM-1-104 (NCT05585320), which are being shared today in a poster presentation titled “Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors” (abstract #4265) at the American Association for Cancer Research (AACR) annual meeting.",Clinical Study,-0.061525843,-0.065487731,short
Immuneering Appoints Harold E. Brakewood as Chief Business Officer,"Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise","Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise",Directors and Officers,0.019743318,0.021559256,long
"Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors",- No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during the Phase 1a dose escalation portion of ongoing clinical study -,- No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during the Phase 1a dose escalation portion of ongoing clinical study -,Clinical Study,0.005714308,0.004873063,long
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights,"Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter ","Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter ",Earnings Releases and Operating Results,0.04971102,0.012504748,long
Immuneering to Present at the Morgan Stanley Healthcare Conference,"CAMBRIDGE, Mass., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Chief Accounting Officer and Treasurer.","CAMBRIDGE, Mass., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Chief Accounting Officer and Treasurer.",Calendar of Events,-0.011454689,-0.009584872,short
"Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023","- Investor call to be held at 9:00 a.m. ET on April 18, 2023 - - Investor call to be held at 9:00 a.m. ET on April 18, 2023 -","- Investor call to be held at 9:00 a.m. ET on April 18, 2023 - - Investor call to be held at 9:00 a.m. ET on April 18, 2023 -",Clinical Study,-0.003627652,-0.001767937,short
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates,"Management to host conference call on Monday, March 6 at 4:30 p.m. ET Management to host conference call on Monday, March 6 at 4:30 p.m. ET  ","Management to host conference call on Monday, March 6 at 4:30 p.m. ET Management to host conference call on Monday, March 6 at 4:30 p.m. ET  ",Calendar of Events,0.002132143,-0.006672514,short
IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting,"NEW YORK, April  26, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from June 2-6, 2023. The oral presentation will highlight new Phase 1 study results evaluating the safety, tolerability and efficacy of INB-200, a potentially promising treatment for newly diagnosed glioblastoma multiforme (GBM).","NEW YORK, April  26, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from June 2-6, 2023. The oral presentation will highlight new Phase 1 study results evaluating the safety, tolerability and efficacy of INB-200, a potentially promising treatment for newly diagnosed glioblastoma multiforme (GBM).",Clinical Study,-0.024999976,-0.019197419,short
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting,"NEW YORK, June  05, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, announced updated data from the ongoing Phase 1 clinical trial of INB-200 in patients with newly diagnosed glioblastoma multiforme (GBM). The data were featured as one-of-four oral presentations and the only Phase 1 study during the immunotherapy section of the Central Nervous System Tumors session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, Illinois.","NEW YORK, June  05, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, announced updated data from the ongoing Phase 1 clinical trial of INB-200 in patients with newly diagnosed glioblastoma multiforme (GBM). The data were featured as one-of-four oral presentations and the only Phase 1 study during the immunotherapy section of the Central Nervous System Tumors session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, Illinois.",Clinical Study,-0.031746076,-0.032587321,short
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023,"NEW YORK, April  17, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced positive preclinical data for its novel non-signaling CAR (nsCAR) platform and the launch of its INB-330 program in AML. The new data included preliminary results for the nsCAR platform targeting CD33, a challenging but potentially impactful target in AML. The data were presented in a poster session (abstract #1777) at the American Association for Cancer Research (AACR) Annual Meeting 2023.","NEW YORK, April  17, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced positive preclinical data for its novel non-signaling CAR (nsCAR) platform and the launch of its INB-330 program in AML. The new data included preliminary results for the nsCAR platform targeting CD33, a challenging but potentially impactful target in AML. The data were presented in a poster session (abstract #1777) at the American Association for Cancer Research (AACR) Annual Meeting 2023.",Health,0.057024796,0.05724299,long
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting,"NEW YORK, Sept.  29, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced two poster presentations reporting positive data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023, in San Diego, CA. The presentations will showcase biological correlative data from the ongoing Phase 1 clinical trial of INB-200, targeting newly diagnosed glioblastoma multiforme (GBM) and pre-clinical insights on IN8bio’s induced pluripotent stem cell (iPSC) gamma-delta T cell platform.","NEW YORK, Sept.  29, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced two poster presentations reporting positive data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023, in San Diego, CA. The presentations will showcase biological correlative data from the ongoing Phase 1 clinical trial of INB-200, targeting newly diagnosed glioblastoma multiforme (GBM) and pre-clinical insights on IN8bio’s induced pluripotent stem cell (iPSC) gamma-delta T cell platform.",Clinical Study,-0.018018001,-0.02536894,short
"IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors","NEW YORK, May  01, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors.","NEW YORK, May  01, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors.",Directors and Officers,-0.013698617,-0.012592682,short
"IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma","NEW YORK, Oct.  12, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the completion of enrollment in the Phase 1 study of INB-100 in leukemia patients and the initiation of patient enrollment in the Phase 2 clinical trial evaluating INB-400 in newly diagnosed glioblastoma multiforme (GBM).","NEW YORK, Oct.  12, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the completion of enrollment in the Phase 1 study of INB-100 in leukemia patients and the initiation of patient enrollment in the Phase 2 clinical trial evaluating INB-400 in newly diagnosed glioblastoma multiforme (GBM).",Clinical Study,0.00999999,0.008556085,long
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility,"NEW YORK, Aug.  08, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced the grand opening of its advanced research and development (R&D) facility in Birmingham, AL. Spanning 10,000 square feet, the state-of-the-art facility will complement IN8bio’s current GMP manufacturing spaces and bolster the Company's preclinical, clinical, and process development capabilities to advance its groundbreaking pipeline of gamma-delta T cell therapies. To celebrate this milestone, IN8bio will host a grand opening event on August 10th, uniting investors, supporters, collaborators, local officials, and biotechnology leaders.","NEW YORK, Aug.  08, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced the grand opening of its advanced research and development (R&D) facility in Birmingham, AL. Spanning 10,000 square feet, the state-of-the-art facility will complement IN8bio’s current GMP manufacturing spaces and bolster the Company's preclinical, clinical, and process development capabilities to advance its groundbreaking pipeline of gamma-delta T cell therapies. To celebrate this milestone, IN8bio will host a grand opening event on August 10th, uniting investors, supporters, collaborators, local officials, and biotechnology leaders.",Product / Services Announcement,0.017094103,0.022929352,long
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting,"NEW YORK, Nov.  06, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed glioblastoma multiforme (GBM) in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.","NEW YORK, Nov.  06, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed glioblastoma multiforme (GBM) in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.",Health,0,-0.001794379,short
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting,"NEW YORK, Nov.  03, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new positive preclinical data from its induced pluripotent stem cell (iPSC) gamma-delta T cell platform at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (Abstract #: 637 in Exhibit Halls A and B1). The data represents a significant advance in the development of the INB-500 iPSC program towards the development of allogeneic gamma-delta T cell therapies.","NEW YORK, Nov.  03, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new positive preclinical data from its induced pluripotent stem cell (iPSC) gamma-delta T cell platform at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (Abstract #: 637 in Exhibit Halls A and B1). The data represents a significant advance in the development of the INB-500 iPSC program towards the development of allogeneic gamma-delta T cell therapies.",Management statements,0,-0.003578491,short
"IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023","NEW YORK, April  24, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new positive data from the Phase 1 investigator-sponsored trial of INB-100 in leukemia patients. The data presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) showed that 100% of evaluable patients (n=7) treated with INB-100 remained alive, progression-free, and in durable complete remission (CR) as of April 21, 2023, indicating the curative potential of INB-100 for high-risk or relapsed AML and other hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT).","NEW YORK, April  24, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new positive data from the Phase 1 investigator-sponsored trial of INB-100 in leukemia patients. The data presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) showed that 100% of evaluable patients (n=7) treated with INB-100 remained alive, progression-free, and in durable complete remission (CR) as of April 21, 2023, indicating the curative potential of INB-100 for high-risk or relapsed AML and other hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT).",Product / Services Announcement,1.409523892,1.410033406,long
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma,"NEW YORK, April  25, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, announces FDA orphan drug designation for INB-400 and INB-410, covering a broad range of malignant glioma treatments, including newly diagnosed GBM. As an industry leader in gamma-delta T cell development, this milestone marks the first genetically modified gamma-delta T cell therapy to receive this designation, which offers potential incentives such as 7-year market exclusivity.","NEW YORK, April  25, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, announces FDA orphan drug designation for INB-400 and INB-410, covering a broad range of malignant glioma treatments, including newly diagnosed GBM. As an industry leader in gamma-delta T cell development, this milestone marks the first genetically modified gamma-delta T cell therapy to receive this designation, which offers potential incentives such as 7-year market exclusivity.",Clinical Study,-0.086666663,-0.081698488,short
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update,"NEW YORK, May  12, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced financial results and operational highlights for the first quarter ended March 31, 2023. In addition, the Company provided an overview of recent corporate developments through May 2023.","NEW YORK, May  12, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced financial results and operational highlights for the first quarter ended March 31, 2023. In addition, the Company provided an overview of recent corporate developments through May 2023.",Earnings Releases and Operating Results,0.027522909,0.024392808,long
IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer,"NEW YORK, May  17, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced positive preclinical data underscoring the potential of its DeltEx Gamma-Delta T cells to target and kill ovarian cancer. The data were featured in a poster presentation at the American Society of Cell & Gene Therapy (ASGCT) 26th Annual Meeting and showed that DeltEx Gamma-Delta T cells were able to target and kill ovarian cancer cells, even in platinum-resistant and treatment-resistant cell lines.","NEW YORK, May  17, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced positive preclinical data underscoring the potential of its DeltEx Gamma-Delta T cells to target and kill ovarian cancer. The data were featured in a poster presentation at the American Society of Cell & Gene Therapy (ASGCT) 26th Annual Meeting and showed that DeltEx Gamma-Delta T cells were able to target and kill ovarian cancer cells, even in platinum-resistant and treatment-resistant cell lines.",Health,0.003745315,-0.00137353,short
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma,All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months,All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months,Clinical Study,0,0.000576787,long
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents,"NEW YORK, Sept.  19, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced significant updates to its foundational IP portfolio. The company was recently granted patents around the world that cover use of the combination of its proprietary DeltEx DRI platform with CAR-T and CPI’s.","NEW YORK, Sept.  19, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced significant updates to its foundational IP portfolio. The company was recently granted patents around the world that cover use of the combination of its proprietary DeltEx DRI platform with CAR-T and CPI’s.",Product / Services Announcement,0.025104654,0.027246106,long
"IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City","NEW YORK, Sept.  26, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is proud to announce its upcoming Research & Development Day on Thursday, October 12, 2023. The event will run from 9:00 a.m. to 12:00 p.m. ET and will be accessible both virtually and in-person in New York, NY. For in-person and virtual attendance, please register here. The webcast will also be available under the “Events and Presentations” section of the Company’s website at https://investors.in8bio.com.","NEW YORK, Sept.  26, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is proud to announce its upcoming Research & Development Day on Thursday, October 12, 2023. The event will run from 9:00 a.m. to 12:00 p.m. ET and will be accessible both virtually and in-person in New York, NY. For in-person and virtual attendance, please register here. The webcast will also be available under the “Events and Presentations” section of the Company’s website at https://investors.in8bio.com.",Research Analysis and Reports,0.033613412,0.040878096,long
IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium,"NEW YORK, Nov.  01, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in 1x1 meetings at the Truist Securities BioPharma Symposium being held Wednesday, November 8 and Thursday, November 9, 2023, in New York, NY.","NEW YORK, Nov.  01, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in 1x1 meetings at the Truist Securities BioPharma Symposium being held Wednesday, November 8 and Thursday, November 9, 2023, in New York, NY.",Health,-0.051020419,-0.05341162,short
IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference,"NEW YORK, Sept.  06, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023 at 2:00 p.m. ET.","NEW YORK, Sept.  06, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023 at 2:00 p.m. ET.",Calendar of Events,-0.009708729,-0.007838912,short
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting,Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200,Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200,Calendar of Events,-0.000990145,-0.005922873,short
IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting,"NEW YORK, April  11, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced that new data from the ongoing Phase 1 trial evaluating INB-100, an allogeneic, gamma-delta T cell therapy, in patients with hematologic malignancies undergoing haploidentical stem cell transplantation (HSCT), will be presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), being held in Paris, France April 23-26.","NEW YORK, April  11, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced that new data from the ongoing Phase 1 trial evaluating INB-100, an allogeneic, gamma-delta T cell therapy, in patients with hematologic malignancies undergoing haploidentical stem cell transplantation (HSCT), will be presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), being held in Paris, France April 23-26.",Clinical Study,0.106557371,0.104970436,long
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting,"NEW YORK, Nov.  02, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an abstract detailing new, positive data from the Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies has been selected for poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2023.","NEW YORK, Nov.  02, 2023  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an abstract detailing new, positive data from the Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies has been selected for poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2023.",Calendar of Events,0.030612215,0.021337661,long
MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting,"NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONOCTOBER 2, 2023, 4:00pm ET / 22:00 CET","NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONOCTOBER 2, 2023, 4:00pm ET / 22:00 CET",European Regulatory News,,,
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe,"The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open soon. The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open soon.","The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open soon. The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open soon.",Regulatory information,0.02481753,0.021742241,long
"INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer","BOCA RATON, Fla., May  08, 2023  (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for INKmune™, a novel natural killer (NK) cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC).  The Company believes this is the first NK immunotherapy trial in men with mCRPC, which affects more than 80,000 men in the U.S.  The trial is expected to enroll the first of 30 patients in the second half of 2023. It will be opened at 4 more clinical study sites, with a goal to determine short and long-term safety of INKmune™, demonstrate the ability of INKmune™ to control prostate cancer tumor burden, and identify a dose of INKmune™ to be used in a future blinded randomized pivotal trial. ","BOCA RATON, Fla., May  08, 2023  (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for INKmune™, a novel natural killer (NK) cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC).  The Company believes this is the first NK immunotherapy trial in men with mCRPC, which affects more than 80,000 men in the U.S.  The trial is expected to enroll the first of 30 patients in the second half of 2023. It will be opened at 4 more clinical study sites, with a goal to determine short and long-term safety of INKmune™, demonstrate the ability of INKmune™ to control prostate cancer tumor burden, and identify a dose of INKmune™ to be used in a future blinded randomized pivotal trial. ",Company Announcement,0.047146295,0.046322322,long
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease," Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM "," Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM ",Company Announcement,0.025369955,0.023573092,long
"INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy","Boca Raton, Florida, Jan.  25, 2023  (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in collaboration with Professor Armando Villalta, Ph.D. of University California, Irvine School of Medicine, has shown targeting soluble TNF (sTNF) using a Dominant-Negative TNF (DN-TNF) biologic significantly decreased muscle damage in a murine mdx model of Duchenne Muscular Dystrophy (DMD) and showed a statistically significant increase in muscle regeneration. Current clinical approaches to limiting muscle damage and inflammation in DMD patients, such as corticosteroids, can be immunosuppressive and promote metabolic problems, leading to significant long-term side effects including muscle atrophy with chronic use. There are currently no approved drugs that promote muscle regeneration in DMD patients.","Boca Raton, Florida, Jan.  25, 2023  (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in collaboration with Professor Armando Villalta, Ph.D. of University California, Irvine School of Medicine, has shown targeting soluble TNF (sTNF) using a Dominant-Negative TNF (DN-TNF) biologic significantly decreased muscle damage in a murine mdx model of Duchenne Muscular Dystrophy (DMD) and showed a statistically significant increase in muscle regeneration. Current clinical approaches to limiting muscle damage and inflammation in DMD patients, such as corticosteroids, can be immunosuppressive and promote metabolic problems, leading to significant long-term side effects including muscle atrophy with chronic use. There are currently no approved drugs that promote muscle regeneration in DMD patients.",Company Announcement,0,0.01061969,long
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority,"INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune™ therapeutic composition. ","INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune™ therapeutic composition. ",Company Announcement,0.008875731,0.007456071,long
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα,SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular phagocytosis (ADCP).,SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular phagocytosis (ADCP).,Clinical Study,-0.011510781,-0.018523552,short
"INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom","BOCA RATON, Fla., Feb.  08, 2023  (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that it has received a combined approximately $6.4 million in research and development refunds from both Australia (~$3.7 million) and the United Kingdom (~$2.7 million). The Company will use the rebates to reinvest in its clinical programs, particularly the ongoing Phase 2 Alzheimer’s Disease (AD) trial in Australia and Canada. ","BOCA RATON, Fla., Feb.  08, 2023  (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that it has received a combined approximately $6.4 million in research and development refunds from both Australia (~$3.7 million) and the United Kingdom (~$2.7 million). The Company will use the rebates to reinvest in its clinical programs, particularly the ongoing Phase 2 Alzheimer’s Disease (AD) trial in Australia and Canada. ",Clinical Study,-0.003243214,0.001718364,long
"INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy","BOCA RATON, Fla., May  24, 2023  (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) announces that Mark Lowdell, Ph.D., INmune Bio’s CSO, will be giving the opening plenary lecture of the Presidential Symposium at the International Society of Cell and Gene Therapy (ISCT) in Paris, France on May 31st.","BOCA RATON, Fla., May  24, 2023  (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) announces that Mark Lowdell, Ph.D., INmune Bio’s CSO, will be giving the opening plenary lecture of the Presidential Symposium at the International Society of Cell and Gene Therapy (ISCT) in Paris, France on May 31st.",Company Announcement,-0.022397902,-0.018365003,short
Kineta Announces Participation at October Investor Conferences,"SEATTLE, Sept.  28, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in October 2023.","SEATTLE, Sept.  28, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in October 2023.",Calendar of Events,0.114285692,0.107140873,long
"INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3",Management to host conference call and webcast at 4:30 pm ET on that day,Management to host conference call and webcast at 4:30 pm ET on that day,Earnings Releases and Operating Results,0.010884344,0.011393858,long
"INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1", Management to host conference call and webcast at 4:30 pm ET on that day , Management to host conference call and webcast at 4:30 pm ET on that day ,Company Announcement,0.033141213,0.027764603,long
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress,"SAN CARLOS, Calif., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the publication of an abstract reporting clinical data for lifileucel which will be presented at the European Society for Medical Oncology ESMO Congress 2023, October 20-24, 2023 in Madrid, Spain.","SAN CARLOS, Calif., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the publication of an abstract reporting clinical data for lifileucel which will be presented at the European Society for Medical Oncology ESMO Congress 2023, October 20-24, 2023 in Madrid, Spain.",Calendar of Events,0.022038546,0.016661936,long
Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma,Global Trial of Iovance TIL Therapy Lifileucel in Combination with Pembrolizumab Global Trial of Iovance TIL Therapy Lifileucel in Combination with Pembrolizumab,Global Trial of Iovance TIL Therapy Lifileucel in Combination with Pembrolizumab Global Trial of Iovance TIL Therapy Lifileucel in Combination with Pembrolizumab,Clinical Study,-0.009227211,-0.007282918,short
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer,Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC),Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC),Clinical Study,0.006906104,0.007749782,long
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference,"SAN CARLOS, Calif., Sept.  07, 2023  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the 2023 Wells Fargo Healthcare Conference:","SAN CARLOS, Calif., Sept.  07, 2023  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the 2023 Wells Fargo Healthcare Conference:",Calendar of Events,-0.015024988,-0.008055296,short
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting,"SAN CARLOS, Calif., Oct.  31, 2023  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the publication of abstracts for poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA, November 1-5, 2023.","SAN CARLOS, Calif., Oct.  31, 2023  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the publication of abstracts for poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA, November 1-5, 2023.",Clinical Study,-0.0135135,-0.01493316,short
Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer,"William Lis to Continue as Chairman, Board of Directors William Lis to Continue as Chairman, Board of Directors","William Lis to Continue as Chairman, Board of Directors William Lis to Continue as Chairman, Board of Directors",Directors and Officers,0.101604245,0.114671066,long
Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy,"REDWOOD CITY, Calif. and CAMBRIDGE, Mass. , Nov.  09, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic stem cell therapeutics, today announced that it has entered into a non-exclusive research collaboration with AVROBIO, Inc. to evaluate the use of JSP191, Jasper's anti-CD117 monoclonal antibody, as a targeted conditioning agent option for patients with Fabry disease and/or Gaucher disease type 1 who are being treated with one of AVROBIO’s investigational ex vivo lentiviral gene therapies.","REDWOOD CITY, Calif. and CAMBRIDGE, Mass. , Nov.  09, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic stem cell therapeutics, today announced that it has entered into a non-exclusive research collaboration with AVROBIO, Inc. to evaluate the use of JSP191, Jasper's anti-CD117 monoclonal antibody, as a targeted conditioning agent option for patients with Fabry disease and/or Gaucher disease type 1 who are being treated with one of AVROBIO’s investigational ex vivo lentiviral gene therapies.",Product / Services Announcement,-0.007592261,-0.008423973,short
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update,"REDWOOD CITY, Calif., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced results for the fiscal quarter ended September 30, 2023, and provided a business update.","REDWOOD CITY, Calif., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced results for the fiscal quarter ended September 30, 2023, and provided a business update.",Earnings Releases and Operating Results,0.014962624,0.012263956,long
Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference,"REDWOOD CITY, Calif., March  10, 2022  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the Company is participating in the 32nd Annual Oppenheimer Healthcare investor conference, to be held virtually from March 15-17, 2022.","REDWOOD CITY, Calif., March  10, 2022  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the Company is participating in the 32nd Annual Oppenheimer Healthcare investor conference, to be held virtually from March 15-17, 2022.",Calendar of Events,0.00294985,0.014390889,long
Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference,"REDWOOD CITY, Calif., Nov.  08, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman, and Chief Executive Officer, will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on Wednesday, November 10, 2021, at 11:40 a.m. Pacific Time.","REDWOOD CITY, Calif., Nov.  08, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman, and Chief Executive Officer, will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on Wednesday, November 10, 2021, at 11:40 a.m. Pacific Time.",Calendar of Events,-0.0118663,-0.014363501,short
Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting,"REDWOOD CITY, Calif., Dec.  08, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data on JSP191 showing long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting.","REDWOOD CITY, Calif., Dec.  08, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data on JSP191 showing long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting.",Health,0.006250024,0.005353096,long
Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors,"The Combination Arm (Part B) of the Phase 1/2 Clinical Trial Builds Upon the Initial Safety, Tolerability and Pharmacokinetic Data of KVA12123 in the Monotherapy Arm (Part A) ","The Combination Arm (Part B) of the Phase 1/2 Clinical Trial Builds Upon the Initial Safety, Tolerability and Pharmacokinetic Data of KVA12123 in the Monotherapy Arm (Part A) ",Clinical Study,-0.024861856,-0.017454253,short
Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023,"SEATTLE, Oct.  12, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that two abstracts have been accepted for poster presentation on Kineta’s immuno-oncology therapies at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego, California and virtually.","SEATTLE, Oct.  12, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that two abstracts have been accepted for poster presentation on Kineta’s immuno-oncology therapies at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego, California and virtually.",Clinical Study,-0.002732238,0.004797247,long
Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression,"SEATTLE, Sept.  18, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today a research agreement with Fred Hutchinson Cancer Center to evaluate VISTA expression as a potential biomarker in cancer patients from Kineta’s ongoing Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, alone and in combination with pembrolizumab.","SEATTLE, Sept.  18, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today a research agreement with Fred Hutchinson Cancer Center to evaluate VISTA expression as a potential biomarker in cancer patients from Kineta’s ongoing Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, alone and in combination with pembrolizumab.",Health,-0.0045045,-0.005813646,short
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial,Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level,Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level,Clinical Study,0.100222786,0.105488284,long
"Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","SEATTLE, Oct.  04, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 890,208 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.37 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 890,208 shares of common stock with an exercise price of $3.25 per share which will be immediately exercisable for a period of five and one-half years following issuance. The closing of the offering is expected to occur on or about October 5, 2023, subject to the satisfaction of customary closing conditions.","SEATTLE, Oct.  04, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 890,208 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.37 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 890,208 shares of common stock with an exercise price of $3.25 per share which will be immediately exercisable for a period of five and one-half years following issuance. The closing of the offering is expected to occur on or about October 5, 2023, subject to the satisfaction of customary closing conditions.",Major shareholder announcements,-0.281012689,-0.282151262,short
"Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","SEATTLE, April  20, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 1,425,179 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.21 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 1,425,179 shares of common stock with an exercise price of $4.08 per share which will be immediately exercisable for a period of five years following issuance. The closing of the offering is expected to occur on or about April 24, 2023, subject to the satisfaction of customary closing conditions.","SEATTLE, April  20, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 1,425,179 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.21 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 1,425,179 shares of common stock with an exercise price of $4.08 per share which will be immediately exercisable for a period of five years following issuance. The closing of the offering is expected to occur on or about April 24, 2023, subject to the satisfaction of customary closing conditions.",Changes in company's own shares,-0.155789425,-0.148714468,short
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy,Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors,Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors,Clinical Study,-0.281012689,-0.282151262,short
Kineta to Participate in Upcoming Investor Conferences,"SEATTLE, Aug.  31, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in September 2023.","SEATTLE, Aug.  31, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in September 2023.",Trade Show,-0.012896837,-0.010018529,short
Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit,"SEATTLE, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the 5th Annual Macrophage-Directed Therapies Summit, to be held on November 13-15, 2023 in Boston, MA. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present preclinical data on KVA12123, the company’s VISTA blocking immunotherapy, as well as an overview of the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.","SEATTLE, Nov.  09, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the 5th Annual Macrophage-Directed Therapies Summit, to be held on November 13-15, 2023 in Boston, MA. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present preclinical data on KVA12123, the company’s VISTA blocking immunotherapy, as well as an overview of the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.",Calendar of Events,-0.020100483,-0.022799151,short
Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy,"SEATTLE, Sept.  25, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, to be held on October 1-4, 2023 in Toronto, ON, Canada. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting new preclinical data on the company’s anti-CD27 agonist antibodies in development for the treatment of advanced solid tumors.","SEATTLE, Sept.  25, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, to be held on October 1-4, 2023 in Toronto, ON, Canada. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting new preclinical data on the company’s anti-CD27 agonist antibodies in development for the treatment of advanced solid tumors.",Health,0.064102607,0.056972571,long
Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023,"SEATTLE, Oct.  09, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the Oxford Global Immuno US 2023, to be held on October 12-13, 2023 in San Diego, CA. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present a preclinical overview of KVA12123, the company’s novel VISTA blocking immunotherapy, currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.","SEATTLE, Oct.  09, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the Oxford Global Immuno US 2023, to be held on October 12-13, 2023 in San Diego, CA. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present a preclinical overview of KVA12123, the company’s novel VISTA blocking immunotherapy, currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.",Product / Services Announcement,0.088524585,0.077509051,long
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting,Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines,Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines,Clinical Study,-0.019138739,-0.020933118,short
Kraig Biocraft Laboratories Adds Two New Positions on Research Team to Accelerate Implementation of its Spider Silk Technology Roadmap,"ANN ARBOR, Mich., Feb.  28, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has created and seeks to fill two new senior-level genetic engineering positions within its U.S. based research and development team. These new roles will expand and strengthen the research team’s capabilities in order to accelerate the pace of development for the next generation of spider silk technologies.","ANN ARBOR, Mich., Feb.  28, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has created and seeks to fill two new senior-level genetic engineering positions within its U.S. based research and development team. These new roles will expand and strengthen the research team’s capabilities in order to accelerate the pace of development for the next generation of spider silk technologies.",Management statements,0,0.001257134,long
"Kraig Biocraft Laboratories Announces Management Changes and Recalibration at Its Vietnam subsidiary, Prodigy Textiles, to Support Production of Spider Silk","ANN ARBOR, Mich., Oct.  02, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, today announced a shakeup of the management of its Vietnamese subsidiary, Prodigy Textiles (""Prodigy""). The changes in management personnel and the implementation of new procedures are intended to refocus and re-energize Prodigy, as the Company's silkworm breeding and egg production/distribution center to support large-scale spider silk manufacturing.","ANN ARBOR, Mich., Oct.  02, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, today announced a shakeup of the management of its Vietnamese subsidiary, Prodigy Textiles (""Prodigy""). The changes in management personnel and the implementation of new procedures are intended to refocus and re-energize Prodigy, as the Company's silkworm breeding and egg production/distribution center to support large-scale spider silk manufacturing.",Management Changes,0,0.002011827,long
Kraig Biocraft Laboratories Apparel Brand SpydaSilk™ Attends Largest International Textile and Garment Expo in Vietnam,"ANN ARBOR, Mich., Aug.  01, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that representatives of its apparel brand SpydaSilkTM attended Vietnam's premiere textile and garment industry exhibition, SaigonTex.","ANN ARBOR, Mich., Aug.  01, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that representatives of its apparel brand SpydaSilkTM attended Vietnam's premiere textile and garment industry exhibition, SaigonTex.",Trade Show,0,0.006893362,long
"Kraig Biocraft Laboratories Completes Closeout of $8 Million Financing, Extinguishing All Convertible Debentures with Yorkville Advisors","ANN ARBOR, Mich., Nov.  21, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has completed the debt-to-equity conversion on $8 million of convertible debentures with Yorkville Advisors. This closeout comes several months ahead of schedule and positions the Company to enter 2023 without any convertible debt obligations to Yorkville Advisors.","ANN ARBOR, Mich., Nov.  21, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has completed the debt-to-equity conversion on $8 million of convertible debentures with Yorkville Advisors. This closeout comes several months ahead of schedule and positions the Company to enter 2023 without any convertible debt obligations to Yorkville Advisors.",Financing Agreements,0,0.003509795,long
Kraig Biocraft Laboratories Creates Synergy by Onboarding Key Elements and Scientists from the University of Notre Dame Spider Silk Research Operations,"ANN ARBOR, Mich., Oct.  12, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, today announced that it hired key scientists from the University of Notre Dame (""UND"") spider silk research lab following the retirement of Dr. Malcolm Fraser, Professor Emeritus. Onboarding their expertise and blending it with the Company's R&D operations has created significant synergies in both molecular biology and sericulture.","ANN ARBOR, Mich., Oct.  12, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, today announced that it hired key scientists from the University of Notre Dame (""UND"") spider silk research lab following the retirement of Dr. Malcolm Fraser, Professor Emeritus. Onboarding their expertise and blending it with the Company's R&D operations has created significant synergies in both molecular biology and sericulture.",Management Changes,0,-0.001443906,short
Kraig Biocraft Laboratories Delivers the First Two Hybrid Dragon Silk™ Silkworm Strains for Commercial Production,"ANN ARBOR, Mich., Jan.  26, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has delivered the first two hybrid-cross Dragon Silk™ strains to its third-party production partner in Vietnam. These strains were developed to address the most significant immediate hurdle to large-scale production, the robustness of our silkworms within the large-scale production environment. These new lines are the first of several planned silkworm strains in our hybridization program, which are explicitly designed to increase robustness and cocoon size.","ANN ARBOR, Mich., Jan.  26, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has delivered the first two hybrid-cross Dragon Silk™ strains to its third-party production partner in Vietnam. These strains were developed to address the most significant immediate hurdle to large-scale production, the robustness of our silkworms within the large-scale production environment. These new lines are the first of several planned silkworm strains in our hybridization program, which are explicitly designed to increase robustness and cocoon size.",Product / Services Announcement,0,-0.006943921,short
Kraig Biocraft Laboratories Engages Textile Expert to Develop New Innovative Yarns and Fabrics applications for Dragon Silk™,"ANN ARBOR, Mich., Sept.  12, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has contracted Jeff Dorton, a top textile expert to assist the Company in developing new and innovative yarns and fabrics utilizing Dragon Silk™.","ANN ARBOR, Mich., Sept.  12, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has contracted Jeff Dorton, a top textile expert to assist the Company in developing new and innovative yarns and fabrics utilizing Dragon Silk™.",Stock Market News,0,-0.005361517,short
Kraig Biocraft Laboratories Enters Biomedical Field with First Sample Shipments of Fibers and Fabrics for Tissue Engineering,"ANN ARBOR, Mich., May  17, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces the first sample shipment of its recombinant spider silk fibers and fabrics for use and evaluation into a range of biomedical applications. This shipment was made in response to the significant increase in the requests for its propriety spider silk technology, over the last two quarters, for tissue engineering applications.","ANN ARBOR, Mich., May  17, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces the first sample shipment of its recombinant spider silk fibers and fabrics for use and evaluation into a range of biomedical applications. This shipment was made in response to the significant increase in the requests for its propriety spider silk technology, over the last two quarters, for tissue engineering applications.",Product / Services Announcement,0.142857112,0.126760728,long
"Kraig Biocraft Laboratories Enters Next Phase of Business Plan, Signs Deal with Contract Manufacturer to Produce Metric Tons of Recombinant Spider Silk","ANN ARBOR, Mich., July  18, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces the signing of its first 3rd party production contract for large scale manufacturing of the Company's recombinant spider silk. The Company expects to immediately begin operations with this contractor to produce hundreds of kilograms of spider silk per month and to achieve production levels reaching multiple metric tons of spider silk per month as early as the first quarter of 2023. The contractor is in possession of the Company’s specialized eggs and anticipates a 90-day ramp-up for the first deliveries under the contract.","ANN ARBOR, Mich., July  18, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces the signing of its first 3rd party production contract for large scale manufacturing of the Company's recombinant spider silk. The Company expects to immediately begin operations with this contractor to produce hundreds of kilograms of spider silk per month and to achieve production levels reaching multiple metric tons of spider silk per month as early as the first quarter of 2023. The contractor is in possession of the Company’s specialized eggs and anticipates a 90-day ramp-up for the first deliveries under the contract.",Product / Services Announcement,0,-0.008438709,short
Kraig Biocraft Laboratories Expands Operational Footprint in Vietnam,"ANN ARBOR, Mich., Aug.  17, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has now been granted a business license to begin operations in Lam Dong Province.","ANN ARBOR, Mich., Aug.  17, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has now been granted a business license to begin operations in Lam Dong Province.",Company Announcement,0,0.008820127,long
"Kraig Biocraft Laboratories Introduces New, Enhanced Line of Dragon Silk™ Silkworms for Commercial Production","ANN ARBOR, Mich., July  06, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has produced several new lines of larger hybrid Dragon SilkTM silkworms for its production operations in Vietnam. These new breeds of silkworms were explicitly created for large-scale production.","ANN ARBOR, Mich., July  06, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has produced several new lines of larger hybrid Dragon SilkTM silkworms for its production operations in Vietnam. These new breeds of silkworms were explicitly created for large-scale production.",Product / Services Announcement,0,-0.000392695,short
Kraig Biocraft Laboratories poised to Close Out Yorkville Convertible Debenture with Strongest Financial Position in Corporate History,"ANN ARBOR, Mich., Nov.  15, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""the Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has nearly closed out its $8 million in convertible debenture with Yorkville Advisors. Over the last 23 months, the Company has converted more than 98% of this debt to equity. Kraig Labs remains in one of the strongest financial positions in the Company's history, with more than $4.5 million in liquid assets and a remaining debt balance to Yorkville of only $150,000.","ANN ARBOR, Mich., Nov.  15, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""the Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has nearly closed out its $8 million in convertible debenture with Yorkville Advisors. Over the last 23 months, the Company has converted more than 98% of this debt to equity. Kraig Labs remains in one of the strongest financial positions in the Company's history, with more than $4.5 million in liquid assets and a remaining debt balance to Yorkville of only $150,000.",Financing Agreements,0,-0.015261184,short
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC,"Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors","Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors",Research Analysis and Reports,-0.151282045,-0.142757444,short
Kraig Biocraft Laboratories Posts Behind the Scenes Look into the Laboratory R&D Processes for Creating Recombinant Spider Silk,"ANN ARBOR, Mich., Aug.  04, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces the release of the second behind the scenes look into its recombinant spider silk production operations. This video brings the viewer inside the laboratories at its R&D facility in the U.S. and its quality control lab at its production facility in Vietnam.","ANN ARBOR, Mich., Aug.  04, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces the release of the second behind the scenes look into its recombinant spider silk production operations. This video brings the viewer inside the laboratories at its R&D facility in the U.S. and its quality control lab at its production facility in Vietnam.",Product / Services Announcement,0,0.000193068,long
Kraig Biocraft Laboratories Releases First Behind the Scenes Look into the Production of Recombinant Spider Silk,"ANN ARBOR, Mich., July  20, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces the release of a behind the scenes look into its silkworm breeding facility in Vietnam. This video is the first in a series designed to bring the viewer inside the Company's recombinant spider silk production operations.","ANN ARBOR, Mich., July  20, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces the release of a behind the scenes look into its silkworm breeding facility in Vietnam. This video is the first in a series designed to bring the viewer inside the Company's recombinant spider silk production operations.",Product / Services Announcement,0,-0.000509884,short
Kraig Biocraft Laboratories Strengthens Q2 Spider Silk Production Expansion with New Vendor Quality Assurance Program,"ANN ARBOR, Mich., May  03, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has strengthened its second-quarter production expansion with a new vendor quality assurance program. This new program will allow the Company to screen numerous mulberry suppliers and grow its database of trusted vendors.","ANN ARBOR, Mich., May  03, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that it has strengthened its second-quarter production expansion with a new vendor quality assurance program. This new program will allow the Company to screen numerous mulberry suppliers and grow its database of trusted vendors.",Management statements,-0.124999977,-0.126278684,short
Kraig Biocraft Laboratories Takes Next Step in Launching Spydasilk™ Apparel Brand,"ANN ARBOR, Mich., June  27, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that, in collaboration with its joint venture partner, Kings Group, the Company has selected a high-quality garment manufacturer to produce Spydasilk'sTM first apparel line.","ANN ARBOR, Mich., June  27, 2022  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces that, in collaboration with its joint venture partner, Kings Group, the Company has selected a high-quality garment manufacturer to produce Spydasilk'sTM first apparel line.",Product / Services Announcement,0,-0.002486673,short
Longeveron Welcomes Three New Prominent Board Members,"Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of Stockholders","Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of Stockholders",Directors and Officers,0.02459014,0.021086176,long
"New Sericulture Experts Join Kraig Biocraft Laboratories, Bringing Extensive Experience Supporting Acceleration of Production Ramp-Up","ANN ARBOR, Mich., July  19, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has filled two key researcher positions. These new hires hit the ground running with nearly 50 years of combined sericulture experience. The new staff members have been integrated into roles at the intersection of R&D and production to strengthen the transition of new technologies from the lab to the field.","ANN ARBOR, Mich., July  19, 2023  (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (""Company"" or ""Kraig Labs""), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has filled two key researcher positions. These new hires hit the ground running with nearly 50 years of combined sericulture experience. The new staff members have been integrated into roles at the intersection of R&D and production to strengthen the transition of new technologies from the lab to the field.",Directors and Officers,0,-0.001805428,short
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development,"SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug.  17, 2023  (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign from his position to pursue a new professional opportunity as the chief executive officer of a private biotechnology company. The Company has initiated a search to identify a suitable replacement for Dr. Al-Wakeel, who will remain with Kronos Bio until September 15, 2023 to ensure business continuity.","SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug.  17, 2023  (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign from his position to pursue a new professional opportunity as the chief executive officer of a private biotechnology company. The Company has initiated a search to identify a suitable replacement for Dr. Al-Wakeel, who will remain with Kronos Bio until September 15, 2023 to ensure business continuity.",Directors and Officers,-0.043478293,-0.046935642,short
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology,Kronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in milestone payments,Kronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in milestone payments,Partnerships,0.267441878,0.261541011,long
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia,"SAN MATEO, Calif., Aug.  22, 2022  (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).","SAN MATEO, Calif., Aug.  22, 2022  (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).",Clinical Study,-0.016431964,-0.00437429,short
"Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance",Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a track record of successfully advancing clinical programs Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a track record of successfully advancing clinical programs,Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a track record of successfully advancing clinical programs Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a track record of successfully advancing clinical programs,Directors and Officers,-0.005882347,-0.004875574,short
MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings,"NEWS RELEASE - REGULATED INFORMATION                25 May 2023, 22:30 CET","NEWS RELEASE - REGULATED INFORMATION                25 May 2023, 22:30 CET",European Regulatory News,,,
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting,"Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studies at leading international sarcoma meeting","Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studies at leading international sarcoma meeting",Clinical Study,-0.04988123,-0.05968015,short
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting,"Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting","Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting",Product / Services Announcement,0.011363626,0.007388314,long
Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,"MIAMI, Oct.  12, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of Class A common stock (“common stock""), or common stock equivalents in lieu thereof, at a purchase price of $1.65 per share, or per common stock equivalent in lieu thereof, in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Longeveron has also agreed to issue and sell unregistered Series A warrants to purchase up to an aggregate of 2,424,243 shares of its common stock and unregistered Series B warrants to purchase up to an aggregate of 2,424,243 shares of its common stock. The offering is expected to close on or about October 13, 2023, subject to the satisfaction of customary closing conditions.","MIAMI, Oct.  12, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of Class A common stock (“common stock""), or common stock equivalents in lieu thereof, at a purchase price of $1.65 per share, or per common stock equivalent in lieu thereof, in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Longeveron has also agreed to issue and sell unregistered Series A warrants to purchase up to an aggregate of 2,424,243 shares of its common stock and unregistered Series B warrants to purchase up to an aggregate of 2,424,243 shares of its common stock. The offering is expected to close on or about October 13, 2023, subject to the satisfaction of customary closing conditions.",Warrants and Certificates,-0.163043514,-0.16448742,short
Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome,Company Activates Additional Study Location to Expedite Enrollment Completion,Company Activates Additional Study Location to Expedite Enrollment Completion,Clinical Study,-0.043076955,-0.038726296,short
Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease,"Company to Hold Conference Call & Webcast Today, October 5 at 8:00am ET","Company to Hold Conference Call & Webcast Today, October 5 at 8:00am ET",Clinical Study,0.059760994,0.060467485,long
Longeveron Announces Pricing for Rights Offering and Expected Calendar,"MIAMI, Aug.  14, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that it has filed an amended registration statement with the Securities and Exchange Commission to conduct a tradable subscription rights offering to holders of its Class A common stock, Class B common stock and warrants to purchase its Class A common stock.","MIAMI, Aug.  14, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that it has filed an amended registration statement with the Securities and Exchange Commission to conduct a tradable subscription rights offering to holders of its Class A common stock, Class B common stock and warrants to purchase its Class A common stock.",Management statements,-0.02752291,-0.025391233,short
Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer,Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs,Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs,Directors and Officers,0.0095238,0.007726938,long
MDxHealth Announces Results of its Extraordinary General Shareholders’ Meeting,"NEWS RELEASE - REGULATED INFORMATION                30 June 2023, 10:00 p.m. CEST","NEWS RELEASE - REGULATED INFORMATION                30 June 2023, 10:00 p.m. CEST",European Regulatory News,,,
Longeveron Appoints Lisa Locklear as Chief Financial Officer,"MIAMI, July  20, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (""Longeveron"" or ""Company""), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Lisa Locklear as Executive Vice President and Chief Financial Officer. Ms. Locklear is an accomplished leader with global business experience, and is a respected finance professional in the biopharmaceutical industry. The appointment is effective as of July 31, 2023.","MIAMI, July  20, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (""Longeveron"" or ""Company""), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Lisa Locklear as Executive Vice President and Chief Financial Officer. Ms. Locklear is an accomplished leader with global business experience, and is a respected finance professional in the biopharmaceutical industry. The appointment is effective as of July 31, 2023.",Directors and Officers,0.002915449,0.005178188,long
Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors,"MIAMI, July  10, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (""Longeveron"" or ""Company""), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that Chairman, Co-founder and Chief Science Officer Joshua Hare, MD, FACC, has been inducted as a fellow of the prestigious National Academy of Inventors (NAI) in recognition of his leading-edge research and development of stem cell therapies for heart disease. Dr. Hare was officially inducted into NAI on June 27, 2023, at the Academy’s annual meeting in Washington, D.C.","MIAMI, July  10, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (""Longeveron"" or ""Company""), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that Chairman, Co-founder and Chief Science Officer Joshua Hare, MD, FACC, has been inducted as a fellow of the prestigious National Academy of Inventors (NAI) in recognition of his leading-edge research and development of stem cell therapies for heart disease. Dr. Hare was officially inducted into NAI on June 27, 2023, at the Academy’s annual meeting in Washington, D.C.",Contests/Awards,0.012903291,0.013746969,long
Longeveron Issues Letter to Stockholders,"MIAMI, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announces that Wa’el Hashad, Chief Executive Officer of Longeveron, has issued a Letter to Stockholders providing a business update. Full text of the letter, which has been posted to the Company’s website, is as follows:","MIAMI, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announces that Wa’el Hashad, Chief Executive Officer of Longeveron, has issued a Letter to Stockholders providing a business update. Full text of the letter, which has been posted to the Company’s website, is as follows:",Management statements,-0.004149373,-0.010254602,short
Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update,ELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-B™ in HLHS,ELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-B™ in HLHS,Earnings Releases and Operating Results,-0.043076955,-0.038726296,short
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update,Top Line Results from CLEAR MIND Alzheimer’s disease Trial Affirm Safety Profile of Lomecel-B™ and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks,Top Line Results from CLEAR MIND Alzheimer’s disease Trial Affirm Safety Profile of Lomecel-B™ and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks,Earnings Releases and Operating Results,0.036269458,0.03133673,long
MDxHealth annonce une proposition de transition vers une cotation unique de ses actions sur le Nasdaq et convoque une assemblée générale extraordinaire des actionnaires,"COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉEINFORMATION PRIVILÉGIÉELE 2 OCTOBRE 2023, 16h00 EDT / 22h00 CET","COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉEINFORMATION PRIVILÉGIÉELE 2 OCTOBRE 2023, 16h00 EDT / 22h00 CET",European Regulatory News,,,
Longeveron Rights Offering Declared Effective and Calendar Finalized,"MIAMI, Aug.  16, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that its registration statement previously filed with the Securities and Exchange Commission to conduct a tradable subscription rights offering has been declared effective, and that it has finalized the rights offering calendar.","MIAMI, Aug.  16, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that its registration statement previously filed with the Securities and Exchange Commission to conduct a tradable subscription rights offering has been declared effective, and that it has finalized the rights offering calendar.",Changes in share capital and votes,0,0.000970948,long
Longeveron Rights Offering Subscription Period Begins,"MIAMI, Aug.  22, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the subscription period for its previously announced rights offering has begun. The subscription price is $3.00 per share. The subscription period for the rights offering ends at 5:00 p.m. Eastern Time on Thursday, September 21, 2023, unless extended at the Company’s sole discretion. Longeveron reserves the right to modify, extend, postpone or cancel the rights offering at any time prior to the termination of the subscription period or any extension thereof.","MIAMI, Aug.  22, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the subscription period for its previously announced rights offering has begun. The subscription price is $3.00 per share. The subscription period for the rights offering ends at 5:00 p.m. Eastern Time on Thursday, September 21, 2023, unless extended at the Company’s sole discretion. Longeveron reserves the right to modify, extend, postpone or cancel the rights offering at any time prior to the termination of the subscription period or any extension thereof.",Management statements,0.023437478,0.019249386,long
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference,"MIAMI, Aug.  29, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the Company’s management will be participating in the 149th Annual Conference of the National Investment Banking Association, to be held in Fort Lauderdale, FL, September 6-7, 2023.","MIAMI, Aug.  29, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the Company’s management will be participating in the 149th Annual Conference of the National Investment Banking Association, to be held in Fort Lauderdale, FL, September 6-7, 2023.",Calendar of Events,-0.008695644,-0.008447167,short
"Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023","MIAMI, Aug.  07, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (""Longeveron"" or ""Company""), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its second quarter 2023 financial results prior to the market open on Friday, August 11, 2023. The Company will host a conference call and webcast that day to discuss the results, provide an update on its clinical programs and corporate activities. A question-and-answer session will follow the prepared remarks.","MIAMI, Aug.  07, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (""Longeveron"" or ""Company""), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its second quarter 2023 financial results prior to the market open on Friday, August 11, 2023. The Company will host a conference call and webcast that day to discuss the results, provide an update on its clinical programs and corporate activities. A question-and-answer session will follow the prepared remarks.",Pre-Release Comments,-0.002976188,-0.007228541,short
MDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate Update on August 23,"NEWS RELEASE10 AUGUST 2023, 4PM ET / 22:00 CET","NEWS RELEASE10 AUGUST 2023, 4PM ET / 22:00 CET",European Regulatory News,,,
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association,"MIAMI, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today an abstract highlighting long-term survival data from the Company’s ELPIS 1 trial of Lomecel-B™ for patients with hypoplastic left heart syndrome (HLHS) has been accepted for presentation as a poster at the upcoming meeting of the American Heart Association (AHA).","MIAMI, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today an abstract highlighting long-term survival data from the Company’s ELPIS 1 trial of Lomecel-B™ for patients with hypoplastic left heart syndrome (HLHS) has been accepted for presentation as a poster at the upcoming meeting of the American Heart Association (AHA).",Calendar of Events,-0.017094001,-0.01012431,short
Artificial Intelligence-Driven Predictive Medical Diagnostics Company Spectral MD Announces Closing of Business Combination,"Company Renamed “Spectral AI, Ltd.” and Will Commence Trading on Nasdaq Global Market Under the Symbol “MDAI” Effective September 12, 2023","Company Renamed “Spectral AI, Ltd.” and Will Commence Trading on Nasdaq Global Market Under the Symbol “MDAI” Effective September 12, 2023",Stock Market News,-0.050861354,-0.051329902,short
Spectral AI Adds Additional Clinical Sites to Multi-Center Diabetic Foot Ulcer (DFU) Study,"DALLAS, Oct.  16, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the addition of seven clinical sites that are currently enrolling to support the development of its diabetic foot ulcer (DFU) application for the DeepView® Wound Imaging System. The proprietary technology combines multi-spectral imaging and AI technology to provide clinicians with an immediate healing assessment of DFU’s for more accurate and timely diagnosis and therapeutic intervention.","DALLAS, Oct.  16, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the addition of seven clinical sites that are currently enrolling to support the development of its diabetic foot ulcer (DFU) application for the DeepView® Wound Imaging System. The proprietary technology combines multi-spectral imaging and AI technology to provide clinicians with an immediate healing assessment of DFU’s for more accurate and timely diagnosis and therapeutic intervention.",Product / Services Announcement,-0.020689717,-0.026066327,short
Spectral AI Adds Healthcare Services Leader and Population Health Expert Deepak Sadagopan to Board of Directors,"DALLAS, Oct.  02, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Deepak Sadagopan, MHCDS, to its board of directors. A high-impact healthcare executive with more than 25 years of senior leadership experience with top Fortune-rated corporations and aggressive startup environments, he brings to the board expertise in healthcare technology and analytics along with a successful track record in product launches. Currently, Mr. Sadagopan is the Chief Operating Officer of Population Health at Providence St. Joseph Health, one of the largest healthcare systems in the U.S., where he leads population health initiatives across the system to transform care.","DALLAS, Oct.  02, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Deepak Sadagopan, MHCDS, to its board of directors. A high-impact healthcare executive with more than 25 years of senior leadership experience with top Fortune-rated corporations and aggressive startup environments, he brings to the board expertise in healthcare technology and analytics along with a successful track record in product launches. Currently, Mr. Sadagopan is the Chief Operating Officer of Population Health at Providence St. Joseph Health, one of the largest healthcare systems in the U.S., where he leads population health initiatives across the system to transform care.",Directors and Officers,0.040124724,0.042136552,long
"Spectral AI CEO, Wensheng Fan, to Participate in AI Healthcare Panel at Accelerate Health Conference","DALLAS, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the participation of Wensheng Fan, CEO of Spectral AI, as a panelist in the upcoming Accelerate Health: Pioneering Solutions for a Healthier Society Conference. The conference, presented by Worth Media and KPMG, will take place on October 11, 2023, at 8:00 am, at KPMG's Boston office, located at Two Financial Center, 60 South St, Boston, MA 02111.","DALLAS, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the participation of Wensheng Fan, CEO of Spectral AI, as a panelist in the upcoming Accelerate Health: Pioneering Solutions for a Healthier Society Conference. The conference, presented by Worth Media and KPMG, will take place on October 11, 2023, at 8:00 am, at KPMG's Boston office, located at Two Financial Center, 60 South St, Boston, MA 02111.",Calendar of Events,-0.025316506,-0.024610016,short
MDxHealth to Present Third Quarter 2023 Financial Results  and Corporate Update on November 8,"NEWS RELEASE25 OCTOBER 2023, 4PM ET / 22:00 CET","NEWS RELEASE25 OCTOBER 2023, 4PM ET / 22:00 CET",European Regulatory News,,,
"Spectral AI names Prof. Paul Chadwick, Former CEO of the Royal College of Podiatry UK, as Senior Executive for UK and EMEA","DALLAS, Oct.  24, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Prof. Paul Chadwick as Executive Vice President of the Company’s United Kingdom subsidiary. Prof. Chadwick is an experienced clinical scientist and wound care key opinion leader (KOL) with an impressive body of work including a substantial and impactful publication record, particularly in the domain of diabetic wound management. He will be responsible for the international market expansion of the Company’s DeepView® wound imaging technology in the United Kingdom, Europe, Middle East and Africa (EMEA), all of which are geographic areas where Prof. Chadwick has extensive clinical networks, significant experience and has enjoyed previous successes.","DALLAS, Oct.  24, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Prof. Paul Chadwick as Executive Vice President of the Company’s United Kingdom subsidiary. Prof. Chadwick is an experienced clinical scientist and wound care key opinion leader (KOL) with an impressive body of work including a substantial and impactful publication record, particularly in the domain of diabetic wound management. He will be responsible for the international market expansion of the Company’s DeepView® wound imaging technology in the United Kingdom, Europe, Middle East and Africa (EMEA), all of which are geographic areas where Prof. Chadwick has extensive clinical networks, significant experience and has enjoyed previous successes.",Management statements,-0.032142827,-0.037351414,short
Spectral AI Provides 2023-2024 Annual Revenue Guidance,Highlights Path Forward and Opportunities Associated with AI-Driven DeepView® Wound Imaging Technology Highlights Path Forward and Opportunities Associated with AI-Driven DeepView® Wound Imaging Technology,Highlights Path Forward and Opportunities Associated with AI-Driven DeepView® Wound Imaging Technology Highlights Path Forward and Opportunities Associated with AI-Driven DeepView® Wound Imaging Technology,Management statements,-0.073015877,-0.06926456,short
Spectral MD Awarded BARDA Project BioShield Contract Valued at $149 Million for AI-Driven DeepView® Burn Wound Imaging Technology,"DALLAS, Sept.  28, 2023  (GLOBE NEWSWIRE) -- Spectral MD, Inc. (“SMD”), a subsidiary of Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has been awarded a new contract valued at up to $149 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. The contract is for the advanced development of the DeepView® System, the Company’s AI-driven burn wound imaging technology, to be used at emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in burn mass casualty incidents (BMCI).","DALLAS, Sept.  28, 2023  (GLOBE NEWSWIRE) -- Spectral MD, Inc. (“SMD”), a subsidiary of Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has been awarded a new contract valued at up to $149 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. The contract is for the advanced development of the DeepView® System, the Company’s AI-driven burn wound imaging technology, to be used at emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in burn mass casualty incidents (BMCI).",Financing Agreements,-0.079411757,-0.086556577,short
"Spectral MD Holdings, Ltd. (“Spectral MD” or the “Company”) ISO 13485 Certification Received for AI-Driven DeepView® Wound Imaging System","LONDON and DALLAS, Aug.  14, 2023  (GLOBE NEWSWIRE) -- Spectral MD Holdings, Ltd. (AIM: SMD), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announces that it has received ISO 13485 certification for the manufacture and distribution of its AI-driven DeepView® Wound Imaging System which is designed to provide immediate, accurate, and binary wound treatment assessments for Burn and Diabetic Foot Ulcer (DFU) indications.","LONDON and DALLAS, Aug.  14, 2023  (GLOBE NEWSWIRE) -- Spectral MD Holdings, Ltd. (AIM: SMD), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announces that it has received ISO 13485 certification for the manufacture and distribution of its AI-driven DeepView® Wound Imaging System which is designed to provide immediate, accurate, and binary wound treatment assessments for Burn and Diabetic Foot Ulcer (DFU) indications.",Stock Market News,0.009425107,0.011556784,long
Nouveau montant du capital et nouveau nombre d'actions de Mdxhealth,            ,            ,European Regulatory News,,,
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library,"Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that it has selected its lead candidate for MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.","Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that it has selected its lead candidate for MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.",Company Announcement,-0.02253519,-0.021813429,short
Medigene AG Expands Patent Portfolio  for its End-to-End Platform,"Planegg/Martinsried, May 22, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today that the Company has been issued a patent by the Japan Patent Office protecting its PD1-41BB switch receptor. Medigene's PD1-41BB costimulatory switch receptor technology was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene.","Planegg/Martinsried, May 22, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today that the Company has been issued a patent by the Japan Patent Office protecting its PD1-41BB switch receptor. Medigene's PD1-41BB costimulatory switch receptor technology was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene.",Patents,0.003236243,0.00318842,long
Medigene AG to participate at BIO International in Boston,"Planegg/Martinsried, May 30, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO International Convention, taking place June 5-8, 2023 in Boston, MA.","Planegg/Martinsried, May 30, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO International Convention, taking place June 5-8, 2023 in Boston, MA.",Company Announcement,-0.030120454,-0.025736865,short
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study,Mainz Biomed Presents Groundbreaking Results of ColoFuture Study,Mainz Biomed Presents Groundbreaking Results of ColoFuture Study,Clinical Study,0.082251109,0.086448134,long
Medigene AG to present at the Baader Investment Conference 2023,"Planegg/Martinsried, September 11, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the Baader Investment Conference 2023 in Munich to be held from September 18-21, 2023.","Planegg/Martinsried, September 11, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the Baader Investment Conference 2023 in Munich to be held from September 18-21, 2023.",Company Announcement,0,-0.000468548,short
"Medigene AG to report Second Quarter and Six Months 2023 Financial Results and Corporate Update  on August 17, 2023"," Planegg/Martinsried, August 10, 2023.   Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial and operational results for the six months ended June 30, 2023 on Thursday, August 17, 2023. "," Planegg/Martinsried, August 10, 2023.   Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial and operational results for the six months ended June 30, 2023 on Thursday, August 17, 2023. ",Company Announcement,0.021680196,0.026767321,long
Medigene amends 2023 financial guidance,"Planegg/Martinsried, November 21, 2023 The Executive Management Board of Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today adjusted financial guidance for fiscal year 2023.","Planegg/Martinsried, November 21, 2023 The Executive Management Board of Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today adjusted financial guidance for fiscal year 2023.",Company Announcement,0.034161458,0.033962869,long
Medigene Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies,"Planegg/Martinsried, 22 June 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents an overview on elevated activity of T cell receptor engineered T cell (TCR-T) therapies when combining Medigene´s PD1-41BB switch receptor with T cell receptors (TCRs) targeting different antigens at the Immuno-Oncology Summit Europe June 20-22, 2023 in London, UK. ","Planegg/Martinsried, 22 June 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents an overview on elevated activity of T cell receptor engineered T cell (TCR-T) therapies when combining Medigene´s PD1-41BB switch receptor with T cell receptors (TCRs) targeting different antigens at the Immuno-Oncology Summit Europe June 20-22, 2023 in London, UK. ",Company Announcement,0.023316102,0.017416811,long
Medigene to participate in the H.C. Wainwright Immune Cell Engager Virtual Conference,"Planegg/Martinsried, August 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright Immune Cell Engager Virtual Conference on August 17, 2023. ","Planegg/Martinsried, August 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright Immune Cell Engager Virtual Conference on August 17, 2023. ",Company Announcement,-0.020833314,-0.014459909,short
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe,"NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients","NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients",Partnerships,0.019138213,0.017719233,long
MediWound Announces an Additional $10 Million Award from BARDA,"Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension","Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension",Financing Agreements,0,0.003900725,long
"MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer","YAVNE, Israel, Nov.  21, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound.","YAVNE, Israel, Nov.  21, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound.",Directors and Officers,-0.005841143,-0.003463613,short
MediWound Announces Commercial Launch of NexoBrid® in Japan,Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement,Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement,Product / Services Announcement,0,0.003320342,long
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma,MW005 shown to be safe and well-tolerated,MW005 shown to be safe and well-tolerated,Clinical Study,-0.006660385,-0.005816707,short
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer,"YAVNE, Israel, March  16, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound’s Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition.","YAVNE, Israel, March  16, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound’s Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition.",Directors and Officers,-0.076164824,-0.069845487,short
MediWound Deploys NexoBrid® for Emergency Supply,"YAVNE, Israel, Oct.  09, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addresses emergency demand for NexoBrid to treat the mass of burn casualties, inflicted by the war in Israel.","YAVNE, Israel, Oct.  09, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addresses emergency demand for NexoBrid to treat the mass of burn casualties, inflicted by the war in Israel.",Product / Services Announcement,-0.019487136,-0.014924064,short
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients,The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all ages The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all ages ,The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all ages The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all ages ,Product / Services Announcement,-0.001558391,0.001573573,long
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design,Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers,Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers,Health,0.011257025,0.01206912,long
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update,2022 total revenues of $26.5 million,2022 total revenues of $26.5 million,Earnings Releases and Operating Results,-0.076164824,-0.069845487,short
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update,NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand,NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand,Earnings Releases and Operating Results,-0.005841143,-0.003463613,short
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army,R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution,R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution,Product / Services Announcement,0.018529243,0.025793928,long
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress,"YAVNE, Israel, Sept.  11, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its successful participation at the recently concluded 20th European Burns Association (EBA) Congress held in Nantes, France on September 6-9, 2023.","YAVNE, Israel, Sept.  11, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its successful participation at the recently concluded 20th European Burns Association (EBA) Congress held in Nantes, France on September 6-9, 2023.",Calendar of Events,0.015738217,0.009632988,long
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023,Data to be highlighted in oral and poster presentations,Data to be highlighted in oral and poster presentations,Health,-0.0160338,-0.01760988,short
MediWound to Report First Quarter 2023 Financial Results,"Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time","Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time",Calendar of Events,0.011560682,0.008430581,long
MediWound to Report Second Quarter 2023 Financial Results,"Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time","Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time",Calendar of Events,0.025527141,0.021274787,long
Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test,"NEWS RELEASE9 AUGUST 2023, 4PM ET / 22:00 CET","NEWS RELEASE9 AUGUST 2023, 4PM ET / 22:00 CET",European Regulatory News,,,
"MDxHealth annonce l'approbation par ses actionnaires de la proposition de transition vers une cotation unique des actions sur le Nasdaq, ainsi que les détails du regroupement d'actions","COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉEINFORMATION PRIVILÉGIÉE6 NOVEMBRE 2023, 1:00 ET / 7:00 CET","COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉEINFORMATION PRIVILÉGIÉE6 NOVEMBRE 2023, 1:00 ET / 7:00 CET",European Regulatory News,,,
"MDxHealth annonce la réalisation de son regroupement d'actions, et la mise à jour des actions et des droits de vote en circulation","COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉEINFORMATION PRIVILÉGIÉE13 NOVEMBRE 2023, 16:00 ET / 22:00 CET","COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉEINFORMATION PRIVILÉGIÉE13 NOVEMBRE 2023, 16:00 ET / 22:00 CET",European Regulatory News,,,
MDxHealth annonce les résultats de ses assemblées générales ordinaire et extraordinaire des actionnaires,COMMUNIQUE DE PRESSE - INFORMATION REGLEMENTEE,COMMUNIQUE DE PRESSE - INFORMATION REGLEMENTEE,European Regulatory News,,,
MDxHealth annonce les résultats de son assemblée générale  extraordinaire des actionnaires,COMMUNIQUE DE PRESSE - INFORMATION REGLEMENTEE,COMMUNIQUE DE PRESSE - INFORMATION REGLEMENTEE,European Regulatory News,,,
MDxHealth annonce son assemblée générale extraordinaire des actionnaires,          ,          ,European Regulatory News,,,
"MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights","           NEWS RELEASE - REGULATED INFORMATIONINSIDE INFORMATIONNOVEMBER 13, 2023, 4:00 PM ET / 22:00 CET","           NEWS RELEASE - REGULATED INFORMATIONINSIDE INFORMATIONNOVEMBER 13, 2023, 4:00 PM ET / 22:00 CET",European Regulatory News,,,
"MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation","NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONNOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET","NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONNOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET",European Regulatory News,,,
MDxHealth communique ses résultats du 1er trimestre (T1) de l’exercice 2023,"COMMUNIQUÉ DE PRESSE – INFORMATIONS RÉGLEMENTÉES15 MAI 2023, 16 h EDT/22 h CET","COMMUNIQUÉ DE PRESSE – INFORMATIONS RÉGLEMENTÉES15 MAI 2023, 16 h EDT/22 h CET",European Regulatory News,,,
MDxHealth communique ses résultats financiers T2 et S1 2023,"COMMUNIQUÉ DE PRESSE – INFORMATIONS RÉGLEMENTÉES23 AOÛT 2023, 16 h 00 EDT, 22 h 00 CET","COMMUNIQUÉ DE PRESSE – INFORMATIONS RÉGLEMENTÉES23 AOÛT 2023, 16 h 00 EDT, 22 h 00 CET",European Regulatory News,,,
MDxHealth communique ses résultats pour le troisième trimestre et la période de neuf mois clôturée le 30 septembre 2023,"COMMUNIQUÉ DE PRESSE — INFORMATIONS RÉGLEMENTÉES8 NOVEMBRE 2023, 16 h 00 EDT/22 h 00 CET","COMMUNIQUÉ DE PRESSE — INFORMATIONS RÉGLEMENTÉES8 NOVEMBRE 2023, 16 h 00 EDT/22 h 00 CET",European Regulatory News,,,
MDxHealth communique ses revenus préliminaires pour le troisième trimestre de 2023,"COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉE ET PRIVILÉGIÉE Le 9 OCTOBRE 2023, 16h00 EDT / 22h00 CET","COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉE ET PRIVILÉGIÉE Le 9 OCTOBRE 2023, 16h00 EDT / 22h00 CET",European Regulatory News,,,
MDxHealth Reports Preliminary Q3-2023 Revenues,"NEWS RELEASE – INSIDE AND REGULATED INFORMATION9 OCTOBER 2023, 4PM ET / 22:00 CET","NEWS RELEASE – INSIDE AND REGULATED INFORMATION9 OCTOBER 2023, 4PM ET / 22:00 CET",European Regulatory News,,,
MDxHealth Reports Q1-2023 Results,"NEWS RELEASE - REGULATED INFORMATION15 MAY 2023, 4:00PM EDT / 22:00 CET","NEWS RELEASE - REGULATED INFORMATION15 MAY 2023, 4:00PM EDT / 22:00 CET",European Regulatory News,,,
MDxHealth Reports Q2 and Half Year 2023 Results,"NEWS RELEASE – REGULATED INFORMATION23 AUGUST 2023, 4:00PM EDT / 22:00 CET","NEWS RELEASE – REGULATED INFORMATION23 AUGUST 2023, 4:00PM EDT / 22:00 CET",European Regulatory News,,,
"MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023","NEWS RELEASE – REGULATED INFORMATION8 NOVEMBER 2023, 4:00PM EDT / 22:00 CET","NEWS RELEASE – REGULATED INFORMATION8 NOVEMBER 2023, 4:00PM EDT / 22:00 CET",European Regulatory News,,,
Mdxhealth signe une collaboration de recherche avec l'Université d'Oxford pour évaluer la corrélation entre le test GPS et la progression du cancer de la prostate après un traitement pour un cancer de la prostate localisé,"COMMUNIQUÉ DE PRESSE 26 septembre 2023, 17h00 EDT / 22h00 CET","COMMUNIQUÉ DE PRESSE 26 septembre 2023, 17h00 EDT / 22h00 CET",European Regulatory News,,,
Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer,"NEWS RELEASE September 26, 2023, 5:00PM EDT / 23:00 CET","NEWS RELEASE September 26, 2023, 5:00PM EDT / 23:00 CET",European Regulatory News,,,
Mdxhealth's New Share Capital Amount and New Number of Shares,"           NEWS RELEASE - REGULATED INFORMATIONOctober 20, 2023, 4:00 PM EDT / 22:00 CET","           NEWS RELEASE - REGULATED INFORMATIONOctober 20, 2023, 4:00 PM EDT / 22:00 CET",European Regulatory News,,,
MDxHealth to Participate in the 35th Annual Piper Sandler Healthcare Conference,       ,       ,European Regulatory News,,,
MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference,      ,      ,European Regulatory News,,,
MDxHealth to Present First Quarter 2023 Financial Results on May 15,"NEWS RELEASE 1 MAY 2023, 4PM ET / 22:00 CET","NEWS RELEASE 1 MAY 2023, 4PM ET / 22:00 CET",European Regulatory News,,,
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa,MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa,MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa,Company Announcement,0.003276,-0.006607149,short
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update,MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update,MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update,Company Announcement,-0.013483169,-0.01661327,short
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update,MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update,MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update,Company Announcement,0.008999232,-0.004926584,short
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa,MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa ,MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa ,Company Announcement,-0.049199963,-0.040593967,short
"MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11","MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11","MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11",Company Announcement,0.00217823,0.004048046,long
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis,MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis ,MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis ,Company Announcement,-0.016415853,-0.012230479,short
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress,Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress,Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress,Company Announcement,0.001382441,0.000243868,long
Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension,– Topline data from the trial are expected in the first half of 2024 –,– Topline data from the trial are expected in the first half of 2024 –,Health,-0.000732081,0.001048913,long
Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting,– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension –,– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension –,Trade Show,-0.001280378,-0.011079298,short
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology,"LA JOLLA, Calif., Aug.  17, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada. The poster will be presented by MediciNova’s collaborator, Dr. Justin Lathia, Vice Chair in the Department of Cardiovascular and Metabolic Sciences and Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute at Cleveland Clinic; Professor, Department of Molecular Medicine at Case Western Reserve University School of Medicine; and Co-Leader, Molecular Oncology Program, Case Comprehensive Cancer Center.","LA JOLLA, Calif., Aug.  17, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada. The poster will be presented by MediciNova’s collaborator, Dr. Justin Lathia, Vice Chair in the Department of Cardiovascular and Metabolic Sciences and Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute at Cleveland Clinic; Professor, Department of Molecular Medicine at Case Western Reserve University School of Medicine; and Co-Leader, Molecular Oncology Program, Case Comprehensive Cancer Center.",Health,,,
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury,"LA JOLLA, Calif., March  09, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). The contract was amended to extend the period of performance until May 31, 2023.","LA JOLLA, Calif., March  09, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). The contract was amended to extend the period of performance until May 31, 2023.",Clinical Study,,,
"MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation","LA JOLLA, Calif., Dec.  06, 2022  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s Chief Medical Officer, Kazuko Matsuda, MD PhD MPH, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 (tipelukast) for the treatment of hypertriglyceridemia at the International Diabetes Federation (IDF) World Diabetes Congress 2022 held online December 5 - 8, 2022.","LA JOLLA, Calif., Dec.  06, 2022  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s Chief Medical Officer, Kazuko Matsuda, MD PhD MPH, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 (tipelukast) for the treatment of hypertriglyceridemia at the International Diabetes Federation (IDF) World Diabetes Congress 2022 held online December 5 - 8, 2022.",Clinical Study,,,
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder,"LA JOLLA, Calif., Jan.  30, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2b clinical trial evaluating MN-166 (ibudilast) for the treatment of alcohol use disorder (AUD) has completed enrollment.","LA JOLLA, Calif., Jan.  30, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2b clinical trial evaluating MN-166 (ibudilast) for the treatment of alcohol use disorder (AUD) has completed enrollment.",Product / Services Announcement,,,
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma,Preliminary results will be presented at the 20th Annual World Congress of the Society for Brain Mapping and Therapeutics Preliminary results will be presented at the 20th Annual World Congress of the Society for Brain Mapping and Therapeutics,Preliminary results will be presented at the 20th Annual World Congress of the Society for Brain Mapping and Therapeutics Preliminary results will be presented at the 20th Annual World Congress of the Society for Brain Mapping and Therapeutics,Clinical Study,,,
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID,"LA JOLLA, Calif., Feb.  08, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Health Canada has completed its review of the clinical trial application and has granted authorization to commence a grant-funded, multi-center, randomized, clinical trial to evaluate MN-166 (ibudilast) and other therapies for the treatment of Long COVID, the lingering symptoms of COVID-19.","LA JOLLA, Calif., Feb.  08, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Health Canada has completed its review of the clinical trial application and has granted authorization to commence a grant-funded, multi-center, randomized, clinical trial to evaluate MN-166 (ibudilast) and other therapies for the treatment of Long COVID, the lingering symptoms of COVID-19.",Product / Services Announcement,,,
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology,"LA JOLLA, Calif., Nov.  19, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Patrick Wen, Director at the Center for Neuro-Oncology at Dana-Farber Cancer Institute, Professor of Neurology, Harvard Medical School, presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) held November 15 - 19, 2023 in Vancouver, Canada. The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.","LA JOLLA, Calif., Nov.  19, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Patrick Wen, Director at the Center for Neuro-Oncology at Dana-Farber Cancer Institute, Professor of Neurology, Harvard Medical School, presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) held November 15 - 19, 2023 in Vancouver, Canada. The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.",Clinical Study,,,
MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics,"LA JOLLA, Calif., Feb.  20, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator, Justin Lathia, PhD, Scientific Director of the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center at Cleveland Clinic and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Professor and Vice Chair in the Department of Cardiovascular & Metabolic Sciences at the Lerner Research Institute, Cleveland Clinic presented new data regarding tumor tissue analysis and clinical outcome from a glioblastoma clinical trial (protocol no. MN-166-GBM-1201; NCT03782415) at the 20th Annual World Congress of SBMT (Society for Brain Mapping and Therapeutics) held on February 16 - 19, 2023, in Los Angeles, CA.","LA JOLLA, Calif., Feb.  20, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator, Justin Lathia, PhD, Scientific Director of the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center at Cleveland Clinic and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Professor and Vice Chair in the Department of Cardiovascular & Metabolic Sciences at the Lerner Research Institute, Cleveland Clinic presented new data regarding tumor tissue analysis and clinical outcome from a glioblastoma clinical trial (protocol no. MN-166-GBM-1201; NCT03782415) at the 20th Annual World Congress of SBMT (Society for Brain Mapping and Therapeutics) held on February 16 - 19, 2023, in Los Angeles, CA.",Product / Services Announcement,,,
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse,"LA JOLLA, Calif., Dec.  05, 2022  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a secondary analysis of a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in The American Journal of Drug and Alcohol Abuse.","LA JOLLA, Calif., Dec.  05, 2022  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a secondary analysis of a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in The American Journal of Drug and Alcohol Abuse.",Clinical Study,,,
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper,Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper,Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper,Product / Services Announcement,-0.024154567,-0.025574227,short
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting,"LA JOLLA, Calif., June  29, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Principal Investigator, Lara Ray, PhD, Professor, Department of Psychology, University of California Los Angeles (UCLA) presented the results of the Phase 2b trial of MN-166 (ibudilast) in alcohol use disorder (AUD) at the 46th Annual Research Society on Alcoholism (RSA) Scientific Meeting held June 24 - 28, 2023, in Bellevue, Washington.","LA JOLLA, Calif., June  29, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Principal Investigator, Lara Ray, PhD, Professor, Department of Psychology, University of California Los Angeles (UCLA) presented the results of the Phase 2b trial of MN-166 (ibudilast) in alcohol use disorder (AUD) at the 46th Annual Research Society on Alcoholism (RSA) Scientific Meeting held June 24 - 28, 2023, in Bellevue, Washington.",Clinical Study,,,
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury,"LA JOLLA, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the results of the nonclinical studies conducted under its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). Two different nonclinical models were used to investigate the potential clinical utility of MN-166 (ibudilast) for the treatment of chlorine-induced lung damage.","LA JOLLA, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the results of the nonclinical studies conducted under its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). Two different nonclinical models were used to investigate the potential clinical utility of MN-166 (ibudilast) for the treatment of chlorine-induced lung damage.",Product / Services Announcement,,,
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe,"LA JOLLA, Calif., Aug.  15, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Decision to Grant from the European Patent Office for a new patent which covers MN-001 (tipelukast) for the treatment of scleroderma and/or systemic sclerosis.","LA JOLLA, Calif., Aug.  15, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Decision to Grant from the European Patent Office for a new patent which covers MN-001 (tipelukast) for the treatment of scleroderma and/or systemic sclerosis.",Patents,,,
"MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil","LA JOLLA, Calif., Jan.  09, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Brazilian Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.","LA JOLLA, Calif., Jan.  09, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Brazilian Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.",Health,,,
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada,"LA JOLLA, Calif., Jan.  10, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of scleroderma and/or systemic sclerosis.","LA JOLLA, Calif., Jan.  10, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of scleroderma and/or systemic sclerosis.",Health,,,
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update,Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update,Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update,Earnings Releases and Operating Results,0.008264455,0.009287385,long
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada,"LA JOLLA, Calif., April  30, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of advanced nonalcoholic steatohepatitis (NASH).","LA JOLLA, Calif., April  30, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of advanced nonalcoholic steatohepatitis (NASH).",Patents,,,
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada,"LA JOLLA, Calif., Oct.  10, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).","LA JOLLA, Calif., Oct.  10, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).",Patents,,,
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe,"LA JOLLA, Calif., Aug.  14, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced nonalcoholic steatohepatitis (NASH).","LA JOLLA, Calif., Aug.  14, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced nonalcoholic steatohepatitis (NASH).",Product / Services Announcement,,,
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe,"LA JOLLA, Calif., May  14, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for patients diagnosed with a microorganism infection.","LA JOLLA, Calif., May  14, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for patients diagnosed with a microorganism infection.",Patents,,,
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe,"LA JOLLA, Calif., Aug.  16, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.","LA JOLLA, Calif., Aug.  16, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.",Product / Services Announcement,,,
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit,Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit,Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit,Calendar of Events,-0.016949136,-0.016242645,short
MediciNova Receives Gene Therapy Milestone Payment,"LA JOLLA, Calif., Oct.  04, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi. The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV (adeno-associated virus) vector technology that is covered under the assignment agreement.","LA JOLLA, Calif., Oct.  04, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi. The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV (adeno-associated virus) vector technology that is covered under the assignment agreement.",Health,,,
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria,"LA JOLLA, Calif., Oct.  26, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU). SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on adeno-associated virus (AAV) vector technology which is covered under MediciNova’s assignment agreement with Genzyme Corporation.","LA JOLLA, Calif., Oct.  26, 2023  (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU). SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on adeno-associated virus (AAV) vector technology which is covered under MediciNova’s assignment agreement with Genzyme Corporation.",Health,,,
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast),MN-166 (ibudilast) parenteral formulation showed a favorable safety and tolerability profile in healthy volunteers MN-166 (ibudilast) parenteral formulation showed a favorable safety and tolerability profile in healthy volunteers,MN-166 (ibudilast) parenteral formulation showed a favorable safety and tolerability profile in healthy volunteers MN-166 (ibudilast) parenteral formulation showed a favorable safety and tolerability profile in healthy volunteers,Clinical Study,,,
Mydecine Announces Debt Settlements,"DENVER, March  06, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce share for debt settlements (the “Debt Settlements”) for debt owed to certain arms-length creditors, service providers and debtors of the Company (collectively, the “Creditors”).","DENVER, March  06, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce share for debt settlements (the “Debt Settlements”) for debt owed to certain arms-length creditors, service providers and debtors of the Company (collectively, the “Creditors”).",Stock Market News,-0.103448283,-0.105575959,short
Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing,"VANCOUVER, British Columbia, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that further to the Company’s news release dated September 15, 2023 and September 19, 2023, the Company has closed its previously announced offering by way of prospectus supplement (the “Offering”). Pursuant to the Offering, the Company issued 18,750,000 common shares of the Company (each a “Share”) at a price of $0.20 per Share for aggregate gross proceeds of $3,750,000. A previous news release incorrectly stated that the Company issued 18,7500,000 Shares for aggregate gross proceeds of $3,7500,000.","VANCOUVER, British Columbia, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that further to the Company’s news release dated September 15, 2023 and September 19, 2023, the Company has closed its previously announced offering by way of prospectus supplement (the “Offering”). Pursuant to the Offering, the Company issued 18,750,000 common shares of the Company (each a “Share”) at a price of $0.20 per Share for aggregate gross proceeds of $3,750,000. A previous news release incorrectly stated that the Company issued 18,7500,000 Shares for aggregate gross proceeds of $3,7500,000.",Changes in company's own shares,-0.05882356,-0.046729249,short
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference,Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference,Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference,Calendar of Events,0.049586728,0.050163515,long
"Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.","DENVER, Dec.  12, 2022  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address addiction and mental health, is pleased to announce that, further to its news release dated September 1, 2022, it has closed the sale of all of the issued and outstanding shares of its wholly-owned subsidiary, Mindleap Health Inc. (“Mindleap”), to PanGenomic Health Inc. (“PanGenomic”), a company listed on the Canadian Stock Exchange (the “CSE”).","DENVER, Dec.  12, 2022  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address addiction and mental health, is pleased to announce that, further to its news release dated September 1, 2022, it has closed the sale of all of the issued and outstanding shares of its wholly-owned subsidiary, Mindleap Health Inc. (“Mindleap”), to PanGenomic Health Inc. (“PanGenomic”), a company listed on the Canadian Stock Exchange (the “CSE”).",Stock Market News,-0.1333334,-0.145614303,short
Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement,"DENVER, Nov.  21, 2022  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the “Subscription Agreement”) with a third-party investor (the “Investor”) dated August 26, 2022, the Company has filed a shelf prospectus supplement (the “Prospectus Supplement”) to the Company’s Final Short Form Base Shelf Prospectus for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the provinces of Canada, dated January 28, 2022 (together, the “Shelf Prospectus”).","DENVER, Nov.  21, 2022  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the “Subscription Agreement”) with a third-party investor (the “Investor”) dated August 26, 2022, the Company has filed a shelf prospectus supplement (the “Prospectus Supplement”) to the Company’s Final Short Form Base Shelf Prospectus for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the provinces of Canada, dated January 28, 2022 (together, the “Shelf Prospectus”).",Changes in company's own shares,0,0.000126744,long
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues,"VANCOUVER, British Columbia, April  24, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (""Mydecine"" or the ""Company"") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is glad to share promising pharmacokinetics and pharmacodynamics (“PKPD”) results from the MYCO-006 family in mouse models. The mice model data indicates considerably shorter half life and accelerated onset while retaining generation-1 MDMA features. The objective of this effort has been to develop medications that mirror the qualities and effects of Gen-1 MDMA with a shorter duration. The Company believes that these enhanced features will significantly improve their usability in existing medical and clinical settings, removing the need for a specialized ""psychedelic clinic"" where clinicians can use the MYCO-006 drugs to improve the efficacy of therapy sessions while eliminating the need for further post-session monitoring of the patent. As compared to Gen-1 MDMA, this provides a huge cost savings in physician hours and allows more patients to be treated in the same amount of time.","VANCOUVER, British Columbia, April  24, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (""Mydecine"" or the ""Company"") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is glad to share promising pharmacokinetics and pharmacodynamics (“PKPD”) results from the MYCO-006 family in mouse models. The mice model data indicates considerably shorter half life and accelerated onset while retaining generation-1 MDMA features. The objective of this effort has been to develop medications that mirror the qualities and effects of Gen-1 MDMA with a shorter duration. The Company believes that these enhanced features will significantly improve their usability in existing medical and clinical settings, removing the need for a specialized ""psychedelic clinic"" where clinicians can use the MYCO-006 drugs to improve the efficacy of therapy sessions while eliminating the need for further post-session monitoring of the patent. As compared to Gen-1 MDMA, this provides a huge cost savings in physician hours and allows more patients to be treated in the same amount of time.",Clinical Study,0,-0.001553471,short
Mydecine Announces Debt Settlements,"DENVER, March  06, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce share for debt settlements (the “Debt Settlements”) for debt owed to certain arms-length creditors, service providers and debtors of the Company (collectively, the “Creditors”).","DENVER, March  06, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce share for debt settlements (the “Debt Settlements”) for debt owed to certain arms-length creditors, service providers and debtors of the Company (collectively, the “Creditors”).",Stock Market News,-0.036363643,-0.038491318,short
Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing,"VANCOUVER, British Columbia, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that further to the Company’s news release dated September 15, 2023 and September 19, 2023, the Company has closed its previously announced offering by way of prospectus supplement (the “Offering”). Pursuant to the Offering, the Company issued 18,750,000 common shares of the Company (each a “Share”) at a price of $0.20 per Share for aggregate gross proceeds of $3,750,000. A previous news release incorrectly stated that the Company issued 18,7500,000 Shares for aggregate gross proceeds of $3,7500,000.","VANCOUVER, British Columbia, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that further to the Company’s news release dated September 15, 2023 and September 19, 2023, the Company has closed its previously announced offering by way of prospectus supplement (the “Offering”). Pursuant to the Offering, the Company issued 18,750,000 common shares of the Company (each a “Share”) at a price of $0.20 per Share for aggregate gross proceeds of $3,750,000. A previous news release incorrectly stated that the Company issued 18,7500,000 Shares for aggregate gross proceeds of $3,7500,000.",Changes in company's own shares,-0.225806432,-0.213712121,short
"Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.","DENVER, Dec.  12, 2022  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address addiction and mental health, is pleased to announce that, further to its news release dated September 1, 2022, it has closed the sale of all of the issued and outstanding shares of its wholly-owned subsidiary, Mindleap Health Inc. (“Mindleap”), to PanGenomic Health Inc. (“PanGenomic”), a company listed on the Canadian Stock Exchange (the “CSE”).","DENVER, Dec.  12, 2022  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address addiction and mental health, is pleased to announce that, further to its news release dated September 1, 2022, it has closed the sale of all of the issued and outstanding shares of its wholly-owned subsidiary, Mindleap Health Inc. (“Mindleap”), to PanGenomic Health Inc. (“PanGenomic”), a company listed on the Canadian Stock Exchange (the “CSE”).",Stock Market News,0.235154338,0.222873434,long
Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement,"DENVER, Nov.  21, 2022  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the “Subscription Agreement”) with a third-party investor (the “Investor”) dated August 26, 2022, the Company has filed a shelf prospectus supplement (the “Prospectus Supplement”) to the Company’s Final Short Form Base Shelf Prospectus for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the provinces of Canada, dated January 28, 2022 (together, the “Shelf Prospectus”).","DENVER, Nov.  21, 2022  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the “Subscription Agreement”) with a third-party investor (the “Investor”) dated August 26, 2022, the Company has filed a shelf prospectus supplement (the “Prospectus Supplement”) to the Company’s Final Short Form Base Shelf Prospectus for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the provinces of Canada, dated January 28, 2022 (together, the “Shelf Prospectus”).",Changes in company's own shares,0.022222268,0.022349012,long
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues,"VANCOUVER, British Columbia, April  24, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (""Mydecine"" or the ""Company"") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is glad to share promising pharmacokinetics and pharmacodynamics (“PKPD”) results from the MYCO-006 family in mouse models. The mice model data indicates considerably shorter half life and accelerated onset while retaining generation-1 MDMA features. The objective of this effort has been to develop medications that mirror the qualities and effects of Gen-1 MDMA with a shorter duration. The Company believes that these enhanced features will significantly improve their usability in existing medical and clinical settings, removing the need for a specialized ""psychedelic clinic"" where clinicians can use the MYCO-006 drugs to improve the efficacy of therapy sessions while eliminating the need for further post-session monitoring of the patent. As compared to Gen-1 MDMA, this provides a huge cost savings in physician hours and allows more patients to be treated in the same amount of time.","VANCOUVER, British Columbia, April  24, 2023  (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (""Mydecine"" or the ""Company"") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is glad to share promising pharmacokinetics and pharmacodynamics (“PKPD”) results from the MYCO-006 family in mouse models. The mice model data indicates considerably shorter half life and accelerated onset while retaining generation-1 MDMA features. The objective of this effort has been to develop medications that mirror the qualities and effects of Gen-1 MDMA with a shorter duration. The Company believes that these enhanced features will significantly improve their usability in existing medical and clinical settings, removing the need for a specialized ""psychedelic clinic"" where clinicians can use the MYCO-006 drugs to improve the efficacy of therapy sessions while eliminating the need for further post-session monitoring of the patent. As compared to Gen-1 MDMA, this provides a huge cost savings in physician hours and allows more patients to be treated in the same amount of time.",Clinical Study,-0.135555536,-0.137109007,short
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering,Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering,Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering,Financing Agreements,0.008196713,0.005121425,long
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania,Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania,Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania,Product / Services Announcement,0.010453035,0.009314462,long
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering,Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering,Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering,Financing Agreements,-0.410714265,-0.407582301,short
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations,Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations,Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations,Health,-0.004830913,-0.002196557,short
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test,Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test,Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test,Partnerships,0,-0.002698668,short
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology,Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology,Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology,Calendar of Events,-0.034920676,-0.037761832,short
"Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA","Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA","Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA",Health,0.036363602,0.036363602,long
"Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark","Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark","Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark",Clinical Study,0.004166663,0.001635236,long
NANOBIOTIX ANNONCE LES MODALITES DEFINITIVES DE L'AUGMENTATION DE CAPITAL POUR UN PRODUIT BRUT TOTAL DE $55 MILLIONS,"PARIS et CAMBRIDGE, Massachusetts,  02 nov. 2023  (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX –  « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe des approches thérapeutiques novatrices basées sur la physique afin de révolutionner les bénéfices des traitements pour des patients atteints de cancer, annonce la fixation des modalités définitives de son offre globale, préalablement annoncée, réservée à des catégories spécifiques d’investisseurs et composée (i) d’une offre de 3.106.907 American Depositary Shares (« ADS »), chacune représentant une action ordinaire de la Société, d’une valeur nominale de 0,03 euros (une « Action Ordinaire »), aux Etats-Unis d’Amérique (l’« Offre ADS »), émises au prix de 5,36$ par ADS et (ii) d'une offre de 2.492.223 Actions Ordinaires, exclusivement à des « investisseurs qualifiés » en Europe (y compris en France) au sens de l’article 2(e) du règlement (UE) 2017/1129, tel que modifié (le « Règlement Prospectus »), et dans certains autres pays (à l’exclusion des Etats-Unis d’Amérique et du Canada) (l’« Offre Européenne »), émises au prix de 5,07€ par Action Ordinaire. L’Offre ADS et l’Offre Européenne sont ci-après désignées ensemble l’« Offre Globale ».","PARIS et CAMBRIDGE, Massachusetts,  02 nov. 2023  (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX –  « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe des approches thérapeutiques novatrices basées sur la physique afin de révolutionner les bénéfices des traitements pour des patients atteints de cancer, annonce la fixation des modalités définitives de son offre globale, préalablement annoncée, réservée à des catégories spécifiques d’investisseurs et composée (i) d’une offre de 3.106.907 American Depositary Shares (« ADS »), chacune représentant une action ordinaire de la Société, d’une valeur nominale de 0,03 euros (une « Action Ordinaire »), aux Etats-Unis d’Amérique (l’« Offre ADS »), émises au prix de 5,36$ par ADS et (ii) d'une offre de 2.492.223 Actions Ordinaires, exclusivement à des « investisseurs qualifiés » en Europe (y compris en France) au sens de l’article 2(e) du règlement (UE) 2017/1129, tel que modifié (le « Règlement Prospectus »), et dans certains autres pays (à l’exclusion des Etats-Unis d’Amérique et du Canada) (l’« Offre Européenne »), émises au prix de 5,07€ par Action Ordinaire. L’Offre ADS et l’Offre Européenne sont ci-après désignées ensemble l’« Offre Globale ».",Stock Market News,-0.041818185,-0.051617105,short
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M,"PARIS and CAMBRIDGE, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its previously announced global follow-on offering reserved to specified categories of investors, consisting of (i) an offering of 3,106,907 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) at an offering price of $5.36 per ADS, and (ii) an offering of 2,492,223 Ordinary Shares, exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”) and certain other countries (excluding the United States and Canada) (the “European Offering”) at an offering price of €5.07 per Ordinary Share. The U.S. Offering and the European Offering are referred to, together, as the “Global Offering.”","PARIS and CAMBRIDGE, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its previously announced global follow-on offering reserved to specified categories of investors, consisting of (i) an offering of 3,106,907 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) at an offering price of $5.36 per ADS, and (ii) an offering of 2,492,223 Ordinary Shares, exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”) and certain other countries (excluding the United States and Canada) (the “European Offering”) at an offering price of €5.07 per Ordinary Share. The U.S. Offering and the European Offering are referred to, together, as the “Global Offering.”",Stock Market News,-0.041818185,-0.051617105,short
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M,"PARIS and CAMBRIDGE, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its previously announced global follow-on offering reserved to specified categories of investors, consisting of (i) an offering of 3,106,907 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) at an offering price of $5.36 per ADS, and (ii) an offering of 2,492,223 Ordinary Shares, exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”) and certain other countries (excluding the United States and Canada) (the “European Offering”) at an offering price of €5.07 per Ordinary Share. The U.S. Offering and the European Offering are referred to, together, as the “Global Offering.”","PARIS and CAMBRIDGE, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its previously announced global follow-on offering reserved to specified categories of investors, consisting of (i) an offering of 3,106,907 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) at an offering price of $5.36 per ADS, and (ii) an offering of 2,492,223 Ordinary Shares, exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”) and certain other countries (excluding the United States and Canada) (the “European Offering”) at an offering price of €5.07 per Ordinary Share. The U.S. Offering and the European Offering are referred to, together, as the “Global Offering.”",Stock Market News,-0.041818185,-0.051617105,short
NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH),The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunological diseases The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunological diseases,The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunological diseases The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunological diseases,Partnerships,-0.007692308,-0.003794031,short
NexImmune Announces 1-for-25 Reverse Stock Split,"GAITHERSBURG, Md., Oct.  18, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that the Board of Directors and stockholders of the Company approved a 1-for-25 reverse stock split of the Company’s common stock at a special meeting of the Company held on October 17, 2023. The reverse stock split will take effect after the close of trading on The Nasdaq Capital Market at 5:00 p.m. Eastern Time, on Wednesday, October 18, 2023. The Company’s common stock will open for trading under a new CUSIP number 65344D 208 on The Nasdaq Capital Market on October 19, 2023, on a split-adjusted basis under the current ticker symbol ""NEXI."" The reverse stock split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.","GAITHERSBURG, Md., Oct.  18, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that the Board of Directors and stockholders of the Company approved a 1-for-25 reverse stock split of the Company’s common stock at a special meeting of the Company held on October 17, 2023. The reverse stock split will take effect after the close of trading on The Nasdaq Capital Market at 5:00 p.m. Eastern Time, on Wednesday, October 18, 2023. The Company’s common stock will open for trading under a new CUSIP number 65344D 208 on The Nasdaq Capital Market on October 19, 2023, on a split-adjusted basis under the current ticker symbol ""NEXI."" The reverse stock split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.",Health,-0.221739147,-0.212572628,short
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors,"GAITHERSBURG, Md., May  10, 2022  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the appointment of Leena Gandhi, M.D., Ph.D., Director for the Center of Therapeutic Innovation at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director.","GAITHERSBURG, Md., May  10, 2022  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the appointment of Leena Gandhi, M.D., Ph.D., Director for the Center of Therapeutic Innovation at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director.",Directors and Officers,-0.022900763,-0.038773322,short
NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR,"GAITHERSBURG, Md., Feb.  16, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that new positive, preclinical data will be presented in an abstract titled “Prior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy” at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida.","GAITHERSBURG, Md., Feb.  16, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that new positive, preclinical data will be presented in an abstract titled “Prior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy” at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida.",Trade Show,0.780487805,0.793024648,long
NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center,"GAITHERSBURG, Md., April  26, 2022  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert Irving Comprehensive Cancer Center (HICCC). The research will focus on the use of NexImmune’s adoptive cell therapy, AIM ACT, in Columbia’s patient-derived organoid (PDO) models of HPV-associated cancers, including head and neck squamous cell carcinoma. Columbia scientists Hiroshi Nakagawa, MD, Associate Professor of Medicine, and Brian Henick, MD, Assistant Professor of Medicine, will lead the research. Dr. Anil Rustgi, Director of HICCC, will join Drs. Nakagawa and Henick in the investigations. HICCC is an NCI designated cancer center that is at the forefront of discovery science, translational medicine, clinical trials, clinical care and community outreach.","GAITHERSBURG, Md., April  26, 2022  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert Irving Comprehensive Cancer Center (HICCC). The research will focus on the use of NexImmune’s adoptive cell therapy, AIM ACT, in Columbia’s patient-derived organoid (PDO) models of HPV-associated cancers, including head and neck squamous cell carcinoma. Columbia scientists Hiroshi Nakagawa, MD, Associate Professor of Medicine, and Brian Henick, MD, Assistant Professor of Medicine, will lead the research. Dr. Anil Rustgi, Director of HICCC, will join Drs. Nakagawa and Henick in the investigations. HICCC is an NCI designated cancer center that is at the forefront of discovery science, translational medicine, clinical trials, clinical care and community outreach.",Clinical Study,-0.007633588,-0.001379304,short
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting,"GAITHERSBURG, Md., Oct.  19, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA , being held November 1-5, 2023.","GAITHERSBURG, Md., Oct.  19, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA , being held November 1-5, 2023.",Calendar of Events,-0.065921806,-0.067641945,short
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting,#NAME?,#NAME?,Clinical Study,0.079999978,0.079158734,long
"NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes","GAITHERSBURG, Md., Oct.  24, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The extension includes an additional $300,000 grant, funded by JDRF to Yale, as a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D).","GAITHERSBURG, Md., Oct.  24, 2023  (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The extension includes an additional $300,000 grant, funded by JDRF to Yale, as a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D).",Partnerships,0.058968,0.053759413,long
NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023,"SANTA ANA, Calif., Oct.  11, 2023  (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced an upcoming poster presentation on an interim report of a Phase I study of SNK01 in patients with Alzheimer’s Disease, at the XXVI World Congress of Neurology (WCN) Annual Meeting to be held in Montreal, QC, Canada and online between October 15–19, 2023.","SANTA ANA, Calif., Oct.  11, 2023  (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced an upcoming poster presentation on an interim report of a Phase I study of SNK01 in patients with Alzheimer’s Disease, at the XXVI World Congress of Neurology (WCN) Annual Meeting to be held in Montreal, QC, Canada and online between October 15–19, 2023.",Calendar of Events,0.015822769,0.013291343,long
NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease,NKGen’s neurodegenerative program continues to advance with dosing in the Phase 1/2a clinical trial anticipated to commence by year-end 2023,NKGen’s neurodegenerative program continues to advance with dosing in the Phase 1/2a clinical trial anticipated to commence by year-end 2023,Health,0.103333314,0.098124727,long
NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference,"SANTA ANA, Calif., Oct.  19, 2023  (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapeutics, today announced an upcoming poster presentation on a final report of a Phase I dose escalation study of SNK01 in subjects with Alzheimer’s Disease, at the 16th Clinical Trials on Alzheimer’s Disease Annual Meeting to be held in Boston, MA, USA from October 24–27, 2023.","SANTA ANA, Calif., Oct.  19, 2023  (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapeutics, today announced an upcoming poster presentation on a final report of a Phase I dose escalation study of SNK01 in subjects with Alzheimer’s Disease, at the 16th Clinical Trials on Alzheimer’s Disease Annual Meeting to be held in Boston, MA, USA from October 24–27, 2023.",Health,0.010309268,0.00858913,long
NKGen Biotech Presented Phase I Clinical Trial Data at the  16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference,90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score (ADCOMS) following 11 weeks,90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score (ADCOMS) following 11 weeks,Clinical Study,0.04571431,0.048348667,long
NKGen Biotech Presents Interim Phase I Trial Data at the  XXVI World Congress of Neurology (WCN) Annual Meeting 2023,"SANTA ANA, Calif., Oct.  17, 2023  (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today presented a poster with interim Phase I trial data on the use of its investigational NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the XXVI World Congress of Neurology (WCN) Annual Meeting in Montreal, QC, Canada and online.","SANTA ANA, Calif., Oct.  17, 2023  (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today presented a poster with interim Phase I trial data on the use of its investigational NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the XXVI World Congress of Neurology (WCN) Annual Meeting in Montreal, QC, Canada and online.",Health,-0.019999981,-0.012592379,short
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma,"SOUTH SAN FRANCISCO, Calif., Dec.  05, 2022  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL).","SOUTH SAN FRANCISCO, Calif., Dec.  05, 2022  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL).",Product / Services Announcement,0.005820744,0.013095059,long
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting,Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models,Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models,Product / Services Announcement,0.005823602,0.002209983,long
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights,"SOUTH SAN FRANCISCO, Calif., Aug.  10, 2023  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2023.","SOUTH SAN FRANCISCO, Calif., Aug.  10, 2023  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2023.",Earnings Releases and Operating Results,0.00999999,0.004526065,long
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial,Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system,Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system,Clinical Study,0.065420495,0.066782413,long
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia,"SOUTH SAN FRANCISCO, Calif., June  27, 2023  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced positive updated data from its Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r) acute myeloid leukemia (AML). NKX101 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target NKG2D ligands on cancer cells.","SOUTH SAN FRANCISCO, Calif., June  27, 2023  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced positive updated data from its Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r) acute myeloid leukemia (AML). NKX101 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target NKG2D ligands on cancer cells.",Clinical Study,-0.033112602,-0.035221826,short
"Inotiv, Inc. Announces Changes to its Board Composition","WEST LAFAYETTE, Ind., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board’s succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board.","WEST LAFAYETTE, Ind., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board’s succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board.",Directors and Officers,0.03414631,0.028769699,long
"Inotiv, Inc. Expands Safety Pharmacology Offering to Include Cardiopulmonary Telemetry","WEST LAFAYETTE, Ind., May  04, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, and research models and related products and services, announced today the expansion of the Company’s safety pharmacology offering with the validation and verification of a cardiopulmonary telemetry study model in cynomolgus macaques. Offered through Inotiv’s Discovery and Safety Assessment business, telemetry allows for the continuous observation of ECG, respiratory rate and volume, blood pressure and other cardiovascular parameters during preclinical safety studies.","WEST LAFAYETTE, Ind., May  04, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, and research models and related products and services, announced today the expansion of the Company’s safety pharmacology offering with the validation and verification of a cardiopulmonary telemetry study model in cynomolgus macaques. Offered through Inotiv’s Discovery and Safety Assessment business, telemetry allows for the continuous observation of ECG, respiratory rate and volume, blood pressure and other cardiovascular parameters during preclinical safety studies.",Product / Services Announcement,0.003533566,0.006204994,long
"Inotiv, Inc. to Participate in May Investor Conferences","WEST LAFAYETTE, Ind., May  19, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today its participation in the following investor conferences:","WEST LAFAYETTE, Ind., May  19, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today its participation in the following investor conferences:",Calendar of Events,0.018604708,0.016362496,long
"Inotiv, Inc. to Participate in Upcoming Investor Conferences","WEST LAFAYETTE, Ind., Nov.  01, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in multiple upcoming investor conferences throughout November 2023.","WEST LAFAYETTE, Ind., Nov.  01, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in multiple upcoming investor conferences throughout November 2023.",Calendar of Events,0,-0.0023912,short
"Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference","WEST LAFAYETTE, Ind., May  25, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will present at the Jefferies Healthcare Conference, being held in New York, NY, from June 7-9, 2023. Management will also be available for one-on-one meetings.","WEST LAFAYETTE, Ind., May  25, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will present at the Jefferies Healthcare Conference, being held in New York, NY, from June 7-9, 2023. Management will also be available for one-on-one meetings.",Calendar of Events,0,-0.00887882,short
Inotiv Ranked Number 127 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™,"Attributes 1156% Revenue Growth to Adding Strategic Capacity, Key Integration Initiatives, Optimization of Infrastructure, and Right-Sizing its Global Footprint Attributes 1156% Revenue Growth to Adding Strategic Capacity, Key Integration Initiatives, Optimization of Infrastructure, and Right-Sizing its Global Footprint","Attributes 1156% Revenue Growth to Adding Strategic Capacity, Key Integration Initiatives, Optimization of Infrastructure, and Right-Sizing its Global Footprint Attributes 1156% Revenue Growth to Adding Strategic Capacity, Key Integration Initiatives, Optimization of Infrastructure, and Right-Sizing its Global Footprint",Feature Article,0.062500008,0.061081028,long
Inotiv Selected as a Winner of the 2023 Top Workplaces USA Award,"WEST LAFAYETTE, Ind., Feb.  01, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that it has earned the 2023 Top Workplaces USA award, issued by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 15-year history of surveying more than 20 million employees and recognizing the top organizations across 60 markets for regional Top Workplaces awards.","WEST LAFAYETTE, Ind., Feb.  01, 2023  (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that it has earned the 2023 Top Workplaces USA award, issued by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 15-year history of surveying more than 20 million employees and recognizing the top organizations across 60 markets for regional Top Workplaces awards.",Contests/Awards,0.059147157,0.045351849,long
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23,"TEL AVIV, Israel, and MIAMI, Aug.  31, 2023  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing upcoming 30-day results from its C-Guardians U.S. IDE clinical trial has been accepted for presentation as a late-breaking clinical trial at the Vascular InterVentional Advances Annual Meeting (VIVA23), which is being held October 30 through November 2 in Las Vegas.","TEL AVIV, Israel, and MIAMI, Aug.  31, 2023  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing upcoming 30-day results from its C-Guardians U.S. IDE clinical trial has been accepted for presentation as a late-breaking clinical trial at the Vascular InterVentional Advances Annual Meeting (VIVA23), which is being held October 30 through November 2 in Las Vegas.",Health,-0.002985072,-0.004404074,short
InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing,Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketing Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketing,Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketing Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketing,Company Announcement,-0.016393427,-0.012541971,short
InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR,"In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure","In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure",Product / Services Announcement,0.040000025,0.027214561,long
InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update,-Conference call and webcast to be held at 8:30 a.m. EDT-,-Conference call and webcast to be held at 8:30 a.m. EDT-,Calendar of Events,0.022556369,0.013226033,long
InspireMD Announces Private Placement of Up to $113.6 Million,"Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members","Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members",Financing Agreements,0.062068904,0.060538243,long
InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer,Mr. Tommasoli formerly served as the Company’s Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St. Jude Medical Mr. Tommasoli formerly served as the Company’s Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St. Jude Medical,Mr. Tommasoli formerly served as the Company’s Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St. Jude Medical Mr. Tommasoli formerly served as the Company’s Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St. Jude Medical,Directors and Officers,0.032786853,0.030709883,long
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives,"Announces hiring of Patrick Verta, MD, as Executive VP of Clinical and Medical Affairs","Announces hiring of Patrick Verta, MD, as Executive VP of Clinical and Medical Affairs",Management Changes,0.009090901,0.014356399,long
"InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform",Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system,Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system,Clinical Study,0,0.001105935,long
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23,Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure,Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure,Clinical Study,0.112094355,0.103840559,long
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"TEL AVIV, Israel and MIAMI, May  18, 2023  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that, in connection with the appointment of Shane Gleason as General Manager of North America and VP of Global Marketing in February 2023, InspireMD granted Mr. Gleason 256,450 shares of restricted stock and stock options to purchase 85,480 shares of InspireMD’s common stock. The grant of restricted stock and stock options was approved by the Compensation Committee of InspireMD’s Board of Directors and was granted outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date of May 17, 2023, as an inducement material to Mr. Gleason entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).","TEL AVIV, Israel and MIAMI, May  18, 2023  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that, in connection with the appointment of Shane Gleason as General Manager of North America and VP of Global Marketing in February 2023, InspireMD granted Mr. Gleason 256,450 shares of restricted stock and stock options to purchase 85,480 shares of InspireMD’s common stock. The grant of restricted stock and stock options was approved by the Compensation Committee of InspireMD’s Board of Directors and was granted outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date of May 17, 2023, as an inducement material to Mr. Gleason entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).",Regulatory information,-0.022727251,-0.02193247,short
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update,"- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront –","- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront –",Earnings Releases and Operating Results,0.009677487,0.015512736,long
InspireMD Reports Third Quarter 2023 Financial Results and Provides  Business Update,- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from procedure through 30 days at the Vascular InterVentional Advances Annual Meeting (VIVA23) –,- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from procedure through 30 days at the Vascular InterVentional Advances Annual Meeting (VIVA23) –,Earnings Releases and Operating Results,-0.063768123,-0.065562503,short
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients,Provides additional treatment options for patients and treating physicians; likely expands CAS addressable market,Provides additional treatment options for patients and treating physicians; likely expands CAS addressable market,Product / Services Announcement,0.057692331,0.056248426,long
InspireMD to Participate in Upcoming November Investor Conferences,"TEL AVIV, Israel and MIAMI, Fla., Nov.  02, 2023  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November:","TEL AVIV, Israel and MIAMI, Fla., Nov.  02, 2023  (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November:",Calendar of Events,-0.127320961,-0.136595514,short
"InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th",-Conference call and webcast to be held at 8:30 a.m. EDT-,-Conference call and webcast to be held at 8:30 a.m. EDT-,Company Announcement,-0.003144651,-0.002528185,short
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting,"CAMBRIDGE, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today presented additional interim results from its ongoing Phase 1 study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis. Results were presented in an oral presentation at the 4th International ATTR Amyloidosis Meeting, held Nov. 2–3 in Madrid, Spain.","CAMBRIDGE, Mass., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today presented additional interim results from its ongoing Phase 1 study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis. Results were presented in an oral presentation at the 4th International ATTR Amyloidosis Meeting, held Nov. 2–3 in Madrid, Spain.",Clinical Study,0.023529427,0.014254873,long
"Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)","NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAE NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAE","NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAE NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAE",Product / Services Announcement,0.076809842,0.082028461,long
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy,"CAMBRIDGE, Mass., Oct.  18, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy. The global Phase 3 study of NTLA-2001, an in vivo CRISPR-based gene editing candidate, is expected to initiate by year-end 2023.","CAMBRIDGE, Mass., Oct.  18, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy. The global Phase 3 study of NTLA-2001, an in vivo CRISPR-based gene editing candidate, is expected to initiate by year-end 2023.",Clinical Study,0.015834802,0.020031827,long
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema,"CAMBRIDGE, Mass., March  21, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to inactivate the target gene, kallikrein B1 (KLKB1), to potentially prevent life-threatening swelling attacks in people with HAE.","CAMBRIDGE, Mass., March  21, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to inactivate the target gene, kallikrein B1 (KLKB1), to potentially prevent life-threatening swelling attacks in people with HAE.",Health,0.013848936,0.004959821,long
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress,"CAMBRIDGE, Mass., May  04, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2023.","CAMBRIDGE, Mass., May  04, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2023.",Earnings Releases and Operating Results,0.004665539,0.007336967,long
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress,"CAMBRIDGE, Mass., Feb.  23, 2023  (GLOBE NEWSWIRE) --  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2022.","CAMBRIDGE, Mass., Feb.  23, 2023  (GLOBE NEWSWIRE) --  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2022.",Earnings Releases and Operating Results,0.046995426,0.039417795,long
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress,"CAMBRIDGE, Mass., Aug.  03, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the second quarter ended June 30, 2023.","CAMBRIDGE, Mass., Aug.  03, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the second quarter ended June 30, 2023.",Earnings Releases and Operating Results,-0.034751883,-0.030108788,short
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress,"CAMBRIDGE, Mass., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the third quarter ended September 30, 2023.","CAMBRIDGE, Mass., Nov.  09, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the third quarter ended September 30, 2023.",Earnings Releases and Operating Results,0.001757442,-0.000941226,short
"Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema","CAMBRIDGE, Mass., Jan.  11, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for NTLA-2002, an in vivo genome editing candidate being developed for the treatment of hereditary angioedema (HAE). The Innovation Passport is the point of entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP), which is designed to accelerate time to market and facilitate patient access to innovative medicines.","CAMBRIDGE, Mass., Jan.  11, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for NTLA-2002, an in vivo genome editing candidate being developed for the treatment of hereditary angioedema (HAE). The Innovation Passport is the point of entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP), which is designed to accelerate time to market and facilitate patient access to innovative medicines.",Product / Services Announcement,0.002380327,-0.001844223,short
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones,"CAMBRIDGE, Mass., Jan.  05, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced its strategic priorities for the upcoming two years as the Company enters its next phase of pipeline execution and platform innovation.","CAMBRIDGE, Mass., Jan.  05, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced its strategic priorities for the upcoming two years as the Company enters its next phase of pipeline execution and platform innovation.",Company Announcement,-0.013033532,-0.007717688,short
"Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema","CAMBRIDGE, Mass., Nov.  14, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative single-dose therapeutics leveraging CRISPR-based technologies, today announced that the European Commission (EC) has granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.","CAMBRIDGE, Mass., Nov.  14, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative single-dose therapeutics leveraging CRISPR-based technologies, today announced that the European Commission (EC) has granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.",Regulatory information,0.064678746,0.050752931,long
"Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema","CAMBRIDGE, Mass., Oct.  13, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.","CAMBRIDGE, Mass., Oct.  13, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.",Clinical Study,0.003459024,-0.000115177,short
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates,"CAMBRIDGE, Mass., April  27, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET.","CAMBRIDGE, Mass., April  27, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET.",Calendar of Events,0.002208165,-0.004320707,short
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates,"CAMBRIDGE, Mass., Feb.  16, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its fourth quarter and full-year 2022 financial results and operational highlights in a conference call on February 23, 2023, at 8 a.m. ET.","CAMBRIDGE, Mass., Feb.  16, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its fourth quarter and full-year 2022 financial results and operational highlights in a conference call on February 23, 2023, at 8 a.m. ET.",Calendar of Events,-0.029679222,-0.017142379,short
Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November,"CAMBRIDGE, Mass., Oct.  26, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced two upcoming events in November.","CAMBRIDGE, Mass., Oct.  26, 2023  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced two upcoming events in November.",Calendar of Events,0.013125579,0.015759936,long
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases,"TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct.  03, 2023  (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases. This builds on the success of the companies’ existing collaboration and continues to combine both companies’ deep biology and technology expertise. The collaboration will leverage Regeneron’s proprietary antibody-targeted adeno-associated virus (AAV) vectors and delivery systems and Intellia’s proprietary Nme2 CRISPR/Cas9 (Nme2Cas9) systems adapted for viral vector delivery and designed to precisely modify a target gene.","TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct.  03, 2023  (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases. This builds on the success of the companies’ existing collaboration and continues to combine both companies’ deep biology and technology expertise. The collaboration will leverage Regeneron’s proprietary antibody-targeted adeno-associated virus (AAV) vectors and delivery systems and Intellia’s proprietary Nme2 CRISPR/Cas9 (Nme2Cas9) systems adapted for viral vector delivery and designed to precisely modify a target gene.",Product / Services Announcement,-0.001020085,0.004245414,long
"A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC",• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore,• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore,Product / Services Announcement,-0.00714285,-0.003797996,short
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting,"BELTSVILLE, Md., Nov.  07, 2022  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology, Chair, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, will present initial clinical data from a Phase 1 clinical trial of NC762 and Eric Christenson, M.D., Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, will present a Trials in Progress poster for a combo study of NC410 at the Society for Immunotherapy of Cancer (SITC) annual meeting in Boston. The initial clinical data come from a Phase 1 study evaluating NC762, a monoclonal antibody that binds specifically to B7-H4, in patients with advanced/metastatic solid tumors.","BELTSVILLE, Md., Nov.  07, 2022  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology, Chair, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, will present initial clinical data from a Phase 1 clinical trial of NC762 and Eric Christenson, M.D., Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, will present a Trials in Progress poster for a combo study of NC410 at the Society for Immunotherapy of Cancer (SITC) annual meeting in Boston. The initial clinical data come from a Phase 1 study evaluating NC762, a monoclonal antibody that binds specifically to B7-H4, in patients with advanced/metastatic solid tumors.",Health,-0.015151501,-0.018765119,short
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer  Annual Meeting,"BELTSVILLE, Md., Oct.  05, 2022  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Boston in November 8-12, 2022. NextCure will share new data from its Phase 1 clinical study of NC762 and a high level overview of its ongoing NC410 combination study during poster sessions.","BELTSVILLE, Md., Oct.  05, 2022  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Boston in November 8-12, 2022. NextCure will share new data from its Phase 1 clinical study of NC762 and a high level overview of its ongoing NC410 combination study during poster sessions.",Calendar of Events,0.033112551,0.04522988,long
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference,"BELTSVILLE, Md., April  11, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th, at 10:15 am ET.","BELTSVILLE, Md., April  11, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th, at 10:15 am ET.",Calendar of Events,-0.038461503,-0.040048438,short
NextCure to Present at SVB Securities Global Biopharma Conference,"BELTSVILLE, Md., Feb.  07, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15th at 1:40 pm ET.","BELTSVILLE, Md., Feb.  07, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15th at 1:40 pm ET.",Calendar of Events,-0.017857126,-0.015514712,short
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference,"BELTSVILLE, Md., Aug.  31, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference in New York City on Monday, September 11th, at 5:00 pm ET.","BELTSVILLE, Md., Aug.  31, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference in New York City on Monday, September 11th, at 5:00 pm ET.",Calendar of Events,0.082758621,0.081339619,long
NextCure to Present at the JMP Securities Life Sciences Conference,"BELTSVILLE, Md., May  09, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET.","BELTSVILLE, Md., May  09, 2023  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET.",Calendar of Events,-0.006172834,-0.002272108,short
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting,"BELTSVILLE, Md., Nov.  03, 2022  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator Nicholas Short, M.D., Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, will present a Trials in Progress poster for NC525, a novel first-in-class immunomedicine, at the American Society of Hematology (ASH) annual meeting in New Orleans. NC525 is a humanized monoclonal antibody that specifically binds to leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) and is being developed for the treatment of advanced myeloid leukemia (AML).","BELTSVILLE, Md., Nov.  03, 2022  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator Nicholas Short, M.D., Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, will present a Trials in Progress poster for NC525, a novel first-in-class immunomedicine, at the American Society of Hematology (ASH) annual meeting in New Orleans. NC525 is a humanized monoclonal antibody that specifically binds to leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) and is being developed for the treatment of advanced myeloid leukemia (AML).",Clinical Study,-0.006072917,0.002996878,long
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI),Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting,Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting,Clinical Study,0.0151515,0.022559102,long
Combination between Novozymes and Chr. Hansen approved by the Novozymes shareholders,Please read the announcement in PDF,Please read the announcement in PDF,European Regulatory News,0.005742176,-0.001084758,short
Novozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner,Please read the announcement in PDF,Please read the announcement in PDF,European Regulatory News,-0.00371107,-0.002745978,short
Resolutions from Novozymes A/S’ Extraordinary Shareholders’ Meeting on 30 March 2023,Please read the announcement in PDF,Please read the announcement in PDF,European Regulatory News,0.005742176,-0.001084758,short
Trading by management and close relations of management,Please read the full announcement in PDF,Please read the full announcement in PDF,European Regulatory News,0,-0.00207697,short
Trading by management and close relations of management,Please read the full announcement in PDF,Please read the full announcement in PDF,European Regulatory News,-0.017494552,-0.009920719,short
Trading by management and close relations of management,Please read the full announcement in PDF,Please read the full announcement in PDF,European Regulatory News,-0.000662073,-0.004759164,short
Trading by management and close relations of management,Please read the full announcement in PDF,Please read the full announcement in PDF,European Regulatory News,-0.001596424,-0.00650502,short
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of  ABCA4-Associated Retinopathies,"U.S. Food & Drug Administration (FDA) grants orphan drug designation to OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt, RP19 and CORD3 U.S. Food & Drug Administration (FDA) grants orphan drug designation to OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt, RP19 and CORD3","U.S. Food & Drug Administration (FDA) grants orphan drug designation to OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt, RP19 and CORD3 U.S. Food & Drug Administration (FDA) grants orphan drug designation to OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt, RP19 and CORD3",Health,0.01111105,0.004582178,long
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly,"MALVERN, Pa., June  30, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s Chairman, CEO and Co-Founder, Shankar Musunuri, PhD, MBA, and Chief Scientific Officer, Head of Research, Development and Medical, Arun Upadhyay, PhD, will present at the American Association of Physicians of Indian Origin (AAPI) Convention and Scientific Assembly, July 6 – 9, 2023 in Philadelphia, PA.","MALVERN, Pa., June  30, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s Chairman, CEO and Co-Founder, Shankar Musunuri, PhD, MBA, and Chief Scientific Officer, Head of Research, Development and Medical, Arun Upadhyay, PhD, will present at the American Association of Physicians of Indian Origin (AAPI) Convention and Scientific Assembly, July 6 – 9, 2023 in Philadelphia, PA.",Calendar of Events,0.009541976,0.001941106,long
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit,"MALVERN, Pa., Nov.  07, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Dry AMD Therapeutic Development Summit, which is being held November 14-16, 2023 in Boston, Mass.","MALVERN, Pa., Nov.  07, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Dry AMD Therapeutic Development Summit, which is being held November 14-16, 2023 in Boston, Mass.",Calendar of Events,0.005291016,0.005291016,long
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference,"MALVERN, Pa., Sept.  29, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held October 3-5, 2023 in Boston, Mass.","MALVERN, Pa., Sept.  29, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held October 3-5, 2023 in Boston, Mass.",Calendar of Events,0.012345667,0.004994728,long
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy,Agreement on Phase 3 Primary Endpoint of 3-step Worsening on Binocular Diabetic Retinopathy Severity Scale (DRSS) Score,Agreement on Phase 3 Primary Endpoint of 3-step Worsening on Binocular Diabetic Retinopathy Severity Scale (DRSS) Score,Product / Services Announcement,0.052264844,0.04299029,long
"Ocugen, Inc. Announces Business Advisory Board","MALVERN, Pa., June  05, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company has established a Business Advisory Board to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company’s differentiated capabilities; and promoting access to the Company’s therapies around the world.","MALVERN, Pa., June  05, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company has established a Business Advisory Board to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company’s differentiated capabilities; and promoting access to the Company’s therapies around the world.",Management Changes,0.004237297,0.003396052,long
"Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board","MALVERN, Pa., Sept.  21, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Connie Collingsworth, former Chief Operating Officer of the Bill and Melinda Gates Foundation, will join the Company’s Business Advisory Board (BAB). The BAB was established in June 2023 to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company’s differentiated capabilities; and promoting access to the Company’s therapies around the world.","MALVERN, Pa., Sept.  21, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Connie Collingsworth, former Chief Operating Officer of the Bill and Melinda Gates Foundation, will join the Company’s Business Advisory Board (BAB). The BAB was established in June 2023 to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company’s differentiated capabilities; and promoting access to the Company’s therapies around the world.",Management Changes,-0.012626251,-0.00592371,short
"Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease","MALVERN, Pa., Nov.  10, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease, a rare genetically inherited disease that directly affects the retina, often resulting in slow progressive vision loss in children and adults.","MALVERN, Pa., Nov.  10, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease, a rare genetically inherited disease that directly affects the retina, often resulting in slow progressive vision loss in children and adults.",Clinical Study,0,-0.004932728,short
"Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock","MALVERN, Pa., May  24, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the pricing of its underwritten public offering of 30,000,000 shares of its common stock for gross proceeds of $16.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about May 26, 2023, subject to customary closing conditions. In addition, Ocugen has granted to the underwriter a 30-day option to purchase up to 4,500,000 additional shares of its common stock.","MALVERN, Pa., May  24, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the pricing of its underwritten public offering of 30,000,000 shares of its common stock for gross proceeds of $16.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about May 26, 2023, subject to customary closing conditions. In addition, Ocugen has granted to the underwriter a 30-day option to purchase up to 4,500,000 additional shares of its common stock.",Major shareholder announcements,-0.232267037,-0.228234139,short
Ocugen Provides Business Update with First Quarter 2023 Financial Results,Conference Call and Webcast Today at 8:30 a.m. ET,Conference Call and Webcast Today at 8:30 a.m. ET,Earnings Releases and Operating Results,0.046043173,0.036712838,long
"Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results","MALVERN, Pa., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2023 financial results and provide a business update at 8:30 a.m. ET on Thursday, November 9, 2023.","MALVERN, Pa., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2023 financial results and provide a business update at 8:30 a.m. ET on Thursday, November 9, 2023.",Calendar of Events,0.01955307,0.010278516,long
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023,"MALVERN, Pa., Sept.  20, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a panel at the annual Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in NYC.","MALVERN, Pa., Sept.  20, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a panel at the annual Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in NYC.",Trade Show,0.00248753,-0.000448971,short
Ocugen to Present at BIO International Convention 2023,"MALVERN, Pa., May  23, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present at the 2023 BIO International Convention taking place in Boston, Mass. from June 5-8, 2023.","MALVERN, Pa., May  23, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present at the 2023 BIO International Convention taking place in Boston, Mass. from June 5-8, 2023.",Calendar of Events,0.00418413,0.008267374,long
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa,"MALVERN, Pa., Oct.  04, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the 2023 Cell & Gene Meeting on the Mesa being held October 10-12, 2023 in Carlsbad, CA at the Park Hyatt Aviara Resort.","MALVERN, Pa., Oct.  04, 2023  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the 2023 Cell & Gene Meeting on the Mesa being held October 10-12, 2023 in Carlsbad, CA at the Park Hyatt Aviara Resort.",Trade Show,0,-0.001138573,short
Oculis to Present at Upcoming November Investor Conferences,"ZUG, Switzerland, and BOSTON, Nov.  08, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer will be attending and presenting at the following upcoming investor conferences:","ZUG, Switzerland, and BOSTON, Nov.  08, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer will be attending and presenting at the following upcoming investor conferences:",Calendar of Events,,,
"OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery","ZUG, Switzerland, and BOSTON, Aug.  08, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced today positive top line results from its Phase 3 OPTIMIZE trial with OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical OPTIREACH® formulation of dexamethasone for the treatment of inflammation and pain following ocular surgery.","ZUG, Switzerland, and BOSTON, Aug.  08, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced today positive top line results from its Phase 3 OPTIMIZE trial with OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical OPTIREACH® formulation of dexamethasone for the treatment of inflammation and pain following ocular surgery.",Product / Services Announcement,,,
"Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase","ZUG, Switzerland and BOSTON, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of global commercial executive with extensive ophthalmology experience, Rebecca Weil, to the role of Chief Commercial Officer. In this key role, Ms. Weil will lead the organization to commercial readiness from designing launch strategies for U.S. and globally, and building the required commercial infrastructure to bring all of Oculis’ groundbreaking ophthalmic product candidates to markets worldwide.","ZUG, Switzerland and BOSTON, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of global commercial executive with extensive ophthalmology experience, Rebecca Weil, to the role of Chief Commercial Officer. In this key role, Ms. Weil will lead the organization to commercial readiness from designing launch strategies for U.S. and globally, and building the required commercial infrastructure to bring all of Oculis’ groundbreaking ophthalmic product candidates to markets worldwide.",Directors and Officers,,,
Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update,"ZUG, Switzerland, and BOSTON, Aug.  29, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced second quarter and first half 2023 financial results for the period ended June 30, 2023, and an overview of the Company’s progress.","ZUG, Switzerland, and BOSTON, Aug.  29, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced second quarter and first half 2023 financial results for the period ended June 30, 2023, and an overview of the Company’s progress.",Earnings Releases and Operating Results,,,
Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema,"ZUG, Switzerland, and BOSTON, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that the positive readout from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME) will be presented as a late-breaking abstract at the 23rd EURETINA Congress, taking place Thursday, October 5, 2023 through Sunday, October 8, 2023 in Amsterdam, the Netherlands.","ZUG, Switzerland, and BOSTON, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that the positive readout from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME) will be presented as a late-breaking abstract at the 23rd EURETINA Congress, taking place Thursday, October 5, 2023 through Sunday, October 8, 2023 in Amsterdam, the Netherlands.",Clinical Study,,,
Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema,"ZUG, Switzerland and BOSTON, Nov.  01, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that the positive results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME), will be presented as a late-breaking abstract at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting, taking place Friday, November 3, 2023 through Monday, November 6, 2023 in San Francisco, California.","ZUG, Switzerland and BOSTON, Nov.  01, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that the positive results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME), will be presented as a late-breaking abstract at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting, taking place Friday, November 3, 2023 through Monday, November 6, 2023 in San Francisco, California.",Calendar of Events,,,
Oculis to Present at Upcoming September Investor Conferences,"ZUG, Switzerland, and BOSTON, Aug.  30, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer will be attending and presenting at the following upcoming investor conferences:","ZUG, Switzerland, and BOSTON, Aug.  30, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer will be attending and presenting at the following upcoming investor conferences:",Calendar of Events,,,
Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress,"ZUG, Switzerland and BOSTON, Oct.  10, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Professor Ramin Tadayoni, M.D., Ph.D., presented the positive results from Stage 1 of the Phase 3 DIAMOND trial of OCS-01 in patients with DME at the 23rd EURETINA congress, which took place October 5-8, 2023 in Amsterdam, the Netherlands.","ZUG, Switzerland and BOSTON, Oct.  10, 2023  (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Professor Ramin Tadayoni, M.D., Ph.D., presented the positive results from Stage 1 of the Phase 3 DIAMOND trial of OCS-01 in patients with DME at the 23rd EURETINA congress, which took place October 5-8, 2023 in Amsterdam, the Netherlands.",Product / Services Announcement,,,
Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium,ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an award distinction ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an award distinction,ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an award distinction ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an award distinction,Clinical Study,0.005089054,-7.04E-05,short
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting,Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients,Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients,Clinical Study,-0.002785513,-0.010385449,short
Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings,"Topline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11th at 20th Angiogenesis, Exudation, and Degeneration 2023 Meeting","Topline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11th at 20th Angiogenesis, Exudation, and Degeneration 2023 Meeting",Calendar of Events,0.01305488,0.025591723,long
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences,"FARMINGTON HILLS, Mich., Sept.  11, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that company management will be participating in one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City on September 11-13, 2023. Additionally, Ronil Patel, MS, Ocuphire’s SVP of Operations & Business Development, will be participating in panel presentations at both the Cantor Annual Global Healthcare Conference being held in New York City on September 26-28, 2023 and the Inaugural Jones Trading 2023 Healthcare Summit being held in Miami Beach on October 9-11, 2023.","FARMINGTON HILLS, Mich., Sept.  11, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that company management will be participating in one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City on September 11-13, 2023. Additionally, Ronil Patel, MS, Ocuphire’s SVP of Operations & Business Development, will be participating in panel presentations at both the Cantor Annual Global Healthcare Conference being held in New York City on September 26-28, 2023 and the Inaugural Jones Trading 2023 Healthcare Summit being held in Miami Beach on October 9-11, 2023.",Calendar of Events,0.009975052,0.009506504,long
Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference,"FARMINGTON HILLS, Mich., June  21, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that Victor H. Gonzalez, MD will present a late breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy at the 83rd Scientific Sessions of the American Diabetes Association (ADA), in San Diego, CA, June 23-26.","FARMINGTON HILLS, Mich., June  21, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that Victor H. Gonzalez, MD will present a late breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy at the 83rd Scientific Sessions of the American Diabetes Association (ADA), in San Diego, CA, June 23-26.",Health,0.002518889,0.004851999,long
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer,Seasoned operating executive with successful track record at late-stage biopharmaceutical companies Seasoned operating executive with successful track record at late-stage biopharmaceutical companies,Seasoned operating executive with successful track record at late-stage biopharmaceutical companies Seasoned operating executive with successful track record at late-stage biopharmaceutical companies,Directors and Officers,-0.08279217,-0.08354481,short
"Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents",RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024,RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024,Product / Services Announcement,0.007462739,0.004621583,long
"Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director","Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development","Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Development",Directors and Officers,-0.003508769,-0.005899969,short
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update,End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR),End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR),Earnings Releases and Operating Results,0.009950239,0.008419578,long
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update,Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025,Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025,Earnings Releases and Operating Results,0.008333392,0.001506457,long
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update,End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR),End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR),Earnings Releases and Operating Results,0.038647423,0.042998082,long
Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase,"FARMINGTON HILLS, Mich., Oct.  26, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced presentations featuring APX3330 and phentolamine ophthalmic solution at the American Academy of Ophthalmology Annual Meeting (AAO 2023) to take place in San Francisco, California on November 3-6, 2023. In addition, Jay Pepose, M.D. Ph.D., Chief Medical Advisor at Ocuphire, will provide a corporate overview at the Eyecelerator AAO 2023 Retina Showcase in San Francisco, California on November 2, 2023.","FARMINGTON HILLS, Mich., Oct.  26, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced presentations featuring APX3330 and phentolamine ophthalmic solution at the American Academy of Ophthalmology Annual Meeting (AAO 2023) to take place in San Francisco, California on November 3-6, 2023. In addition, Jay Pepose, M.D. Ph.D., Chief Medical Advisor at Ocuphire, will provide a corporate overview at the Eyecelerator AAO 2023 Retina Showcase in San Francisco, California on November 2, 2023.",Health,0,0.002634357,long
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September,"ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasis ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasis","ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasis ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasis",Calendar of Events,0.020942451,0.027912143,long
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August,"FARMINGTON HILLS, Mich., Aug.  08, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that Ronil Patel, MS, SVP of Operations and Business Development and Charlie Hoffmann, MBA, SVP of Corporate Development, will participate in a Fireside Chat at the Canaccord 43rd Annual Growth Conference being held August 7-10, 2023 in Boston, MA and will present a company overview and participate in a panel at the H.C. Wainwright Ophthalmology Conference being held virtually on August 16, 2023.","FARMINGTON HILLS, Mich., Aug.  08, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that Ronil Patel, MS, SVP of Operations and Business Development and Charlie Hoffmann, MBA, SVP of Corporate Development, will participate in a Fireside Chat at the Canaccord 43rd Annual Growth Conference being held August 7-10, 2023 in Boston, MA and will present a company overview and participate in a panel at the H.C. Wainwright Ophthalmology Conference being held virtually on August 16, 2023.",Calendar of Events,-0.011904694,-0.006069446,short
Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference,"FARMINGTON HILLS, Mich., June  27, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that a late-breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy was presented by retina specialist and ZETA-1 clinical trial investigator, Victor H. Gonzalez, M.D. at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA on Saturday, June 24, 2023.","FARMINGTON HILLS, Mich., June  27, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that a late-breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy was presented by retina specialist and ZETA-1 clinical trial investigator, Victor H. Gonzalez, M.D. at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA on Saturday, June 24, 2023.",Clinical Study,0.010335969,0.008226745,long
Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023,"FARMINGTON HILLS, Mich., June  12, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that a presentation titled, Safety and Efficacy of an Oral Therapeutic APX3330 from ZETA-1 Phase 2 Trial in Patients with Diabetic Retinopathy, was delivered by David Lally, M.D. F.A.S.R.S. at the Clinical Trials at the Summit (CTS) 2023 meeting in Park City, Utah on Saturday, June 10. Dr. Lally is a member of Ocuphire’s Medical Advisory Board. APX3330 was evaluated in patients with mild to moderate non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR).","FARMINGTON HILLS, Mich., June  12, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that a presentation titled, Safety and Efficacy of an Oral Therapeutic APX3330 from ZETA-1 Phase 2 Trial in Patients with Diabetic Retinopathy, was delivered by David Lally, M.D. F.A.S.R.S. at the Clinical Trials at the Summit (CTS) 2023 meeting in Park City, Utah on Saturday, June 10. Dr. Lally is a member of Ocuphire’s Medical Advisory Board. APX3330 was evaluated in patients with mild to moderate non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR).",Clinical Study,0.007978716,0.005606026,long
Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs,"PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million Milestone Linked to Approval","PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million Milestone Linked to Approval",Health,-0.013084055,-0.00811588,short
Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit,ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy,ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy,Health,0.015075362,0.017205174,long
"Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board","SAN DIEGO, Oct.  25, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB). Dr. Smith, along with the other Prostate Cancer SAB members, will help guide Oncternal’s next steps in the clinical development of its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-534, which is currently under investigation in an ongoing Phase 1/2 clinical study, ONCT-534-101.","SAN DIEGO, Oct.  25, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB). Dr. Smith, along with the other Prostate Cancer SAB members, will help guide Oncternal’s next steps in the clinical development of its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-534, which is currently under investigation in an ongoing Phase 1/2 clinical study, ONCT-534-101.",Directors and Officers,-0.031249971,-0.027142636,short
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer,"SAN DIEGO, Oct.  26, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer (mCRPC) resistant to approved androgen receptor pathway inhibitors (ARPIs).","SAN DIEGO, Oct.  26, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer (mCRPC) resistant to approved androgen receptor pathway inhibitors (ARPIs).",Health,0.12903223,0.131666587,long
Change in management,"The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.","The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.",European Regulatory News,0.194690292,0.199073881,long
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board,"SAN DIEGO, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Prostate Cancer Scientific Advisory Board (SAB). The Prostate Cancer SAB is comprised of distinguished academic and industry leaders in the prostate cancer field, which will advise Oncternal as it develops its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-534.","SAN DIEGO, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Prostate Cancer Scientific Advisory Board (SAB). The Prostate Cancer SAB is comprised of distinguished academic and industry leaders in the prostate cancer field, which will advise Oncternal as it develops its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-534.",Directors and Officers,0.034482829,0.041452521,long
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4),"SAN DIEGO, March  27, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined Oncternal as Head of IT.","SAN DIEGO, March  27, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined Oncternal as Head of IT.",Stock Market News,0.011494242,0.005505625,long
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update,"ROCKVILLE, Md., March  30, 2023  (GLOBE NEWSWIRE) -- In a release published March 29, 2023 under the same headline by OpGen, Inc. (Nasdaq: OPGN), the financial tables were incorrect. The corrected release follows:","ROCKVILLE, Md., March  30, 2023  (GLOBE NEWSWIRE) -- In a release published March 29, 2023 under the same headline by OpGen, Inc. (Nasdaq: OPGN), the financial tables were incorrect. The corrected release follows:",Earnings Releases and Operating Results,-0.032786951,-0.031821859,short
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds,"ROCKVILLE, Md., Oct.  12, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to purchase up to a maximum of 10,892,728 common shares at an exercise price of $0.7785 per share. As part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per share, resulting in gross proceeds of up to approximately $11.2 million, assuming full exercise of the existing warrants and before deducting offering fees and expenses.","ROCKVILLE, Md., Oct.  12, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to purchase up to a maximum of 10,892,728 common shares at an exercise price of $0.7785 per share. As part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per share, resulting in gross proceeds of up to approximately $11.2 million, assuming full exercise of the existing warrants and before deducting offering fees and expenses.",Stock Market News,-0.442424224,-0.434894739,short
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering,"ROCKVILLE, Md., Aug.  07, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today a major feature upgrade for the AREScloud platform that has been implemented with our healthcare clients to enhance genomic surveillance.","ROCKVILLE, Md., Aug.  07, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today a major feature upgrade for the AREScloud platform that has been implemented with our healthcare clients to enhance genomic surveillance.",Product / Services Announcement,0.022146527,0.017894174,long
OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement,"ROCKVILLE, Md., Aug.  03, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has signed an extended and continued research and development (“R&D”) collaboration agreement with FIND. Following the successful completion of the feasibility phase of the collaboration and having met all milestones on time and within budgets, the parties now plan to collaborate on first phases of product development of an antimicrobial resistance (AMR) cartridge from blood culture that is tailored to the needs of low- and middle-income countries (LMICs) in terms of panel design and coverage of specific genetic variants of bacterial strains and their AMR markers in such countries, as well as ensuring attractive cost profile and pricing models that allow for access to such rapid testing in LMICs.","ROCKVILLE, Md., Aug.  03, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has signed an extended and continued research and development (“R&D”) collaboration agreement with FIND. Following the successful completion of the feasibility phase of the collaboration and having met all milestones on time and within budgets, the parties now plan to collaborate on first phases of product development of an antimicrobial resistance (AMR) cartridge from blood culture that is tailored to the needs of low- and middle-income countries (LMICs) in terms of panel design and coverage of specific genetic variants of bacterial strains and their AMR markers in such countries, as well as ensuring attractive cost profile and pricing models that allow for access to such rapid testing in LMICs.",Partnerships,0.033898375,0.03854147,long
Major shareholder announcement,Company announcement        ,Company announcement        ,European Regulatory News,0.069518779,0.062534409,long
OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics,"ROCKVILLE, Md., April  03, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that it has completed two interim milestones as part of its collaboration project with InfectoGnostics under the PREPLEX grant. The InfectoGnostics Research Campus Jena is a public-private partnership breaking new ground in the diagnosis of infections. More than 30 partners from science, medicine and industry are jointly developing novel solutions for fast and cost-effective diagnostics of infectious diseases.","ROCKVILLE, Md., April  03, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that it has completed two interim milestones as part of its collaboration project with InfectoGnostics under the PREPLEX grant. The InfectoGnostics Research Campus Jena is a public-private partnership breaking new ground in the diagnosis of infections. More than 30 partners from science, medicine and industry are jointly developing novel solutions for fast and cost-effective diagnostics of infectious diseases.",Management statements,0.00751879,0.008837846,long
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND,"ROCKVILLE, Md., July  19, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has met all milestones under its extended and expanded research and development (“R&D”) collaboration agreement with FIND. Following the delivery of a comprehensive milestone report at the end of the second quarter of 2023, FIND recently confirmed that all requirements have been met successfully.","ROCKVILLE, Md., July  19, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has met all milestones under its extended and expanded research and development (“R&D”) collaboration agreement with FIND. Following the delivery of a comprehensive milestone report at the end of the second quarter of 2023, FIND recently confirmed that all requirements have been met successfully.",Product / Services Announcement,0.001538533,-0.000266894,short
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments,"ROCKVILLE, Md., June  22, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany. The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats.","ROCKVILLE, Md., June  22, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany. The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats.",Product / Services Announcement,-0.015873001,-0.013596847,short
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND,"ROCKVILLE, Md., April  05, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that it signed an amendment to its research and development (“R&D”) collaboration agreement with FIND, to expand the collaboration which was originally started in fall of 2022.","ROCKVILLE, Md., April  05, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that it signed an amendment to its research and development (“R&D”) collaboration agreement with FIND, to expand the collaboration which was originally started in fall of 2022.",Product / Services Announcement,-0.00757584,-0.005716125,short
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov.  02, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation on the initial Phase 1b clinical data for ORIC-533 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023, in San Diego, CA.","SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov.  02, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation on the initial Phase 1b clinical data for ORIC-533 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023, in San Diego, CA.",Clinical Study,0.010654443,0.00137989,long
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel,"ROCKVILLE, Md., April  18, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that it has submitted a De Novo classification request to the U.S. Food and Drug Administration (FDA) seeking marketing authorization for its Unyvero UTI Urinary Tract Infection (UTI) panel, following successful completion of its clinical trial. OpGen’s Unyvero UTI Panel tests for a broad range of bacterial and fungal pathogens as well as antimicrobial resistance markers directly from urine specimens. The test aims at quantitative detection of microorganisms.","ROCKVILLE, Md., April  18, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that it has submitted a De Novo classification request to the U.S. Food and Drug Administration (FDA) seeking marketing authorization for its Unyvero UTI Urinary Tract Infection (UTI) panel, following successful completion of its clinical trial. OpGen’s Unyvero UTI Panel tests for a broad range of bacterial and fungal pathogens as well as antimicrobial resistance markers directly from urine specimens. The test aims at quantitative detection of microorganisms.",Clinical Study,0.035625503,0.031663615,long
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe,"ROCKVILLE, Md., June  26, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today that one of its key patents under opposition has been successfully maintained.","ROCKVILLE, Md., June  26, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today that one of its key patents under opposition has been successfully maintained.",Patents,0,0.001361918,long
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time,"ROCKVILLE, Md., Aug.  03, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.","ROCKVILLE, Md., Aug.  03, 2023  (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.",Calendar of Events,0.033898375,0.03854147,long
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing,"Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital","Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital",Changes in company's own shares,0.123266598,0.124628515,long
Major shareholder announcement,Company announcement                                                                                         Orphazyme A/SNo. 06/2023                                                                                                             Ole Maaløes Vej 3                                                                                                                DK-2200 Copenhagen N                                                                                                                                                       www.orphazyme.comCompany Registration No. 32266355,Company announcement                                                                                         Orphazyme A/SNo. 06/2023                                                                                                             Ole Maaløes Vej 3                                                                                                                DK-2200 Copenhagen N                                                                                                                                                       www.orphazyme.comCompany Registration No. 32266355,European Regulatory News,-0.031666754,-0.027240222,short
New CEO appointed,"As mentioned in announcement 11/2023 the Company and CEO/CFO Anders Fink Vadsholt entered into a severance agreement at May 30th 2023, where Mr. Vadsholt would step down as CEO/CFO of the Company no later than October 1st 2023, or when a replacement had been found.","As mentioned in announcement 11/2023 the Company and CEO/CFO Anders Fink Vadsholt entered into a severance agreement at May 30th 2023, where Mr. Vadsholt would step down as CEO/CFO of the Company no later than October 1st 2023, or when a replacement had been found.",European Regulatory News,0.020952453,0.033046764,long
Notice of Extraordinary General Meeting in Orphazyme A/S,"The board of directors hereby convenes for an extraordinary general meeting in Orphazyme A/S at the company’s address at Lyskjær 8A, 2730 Herlev on Thursday 30 November 2023 at 10.00 AM (CET). ","The board of directors hereby convenes for an extraordinary general meeting in Orphazyme A/S at the company’s address at Lyskjær 8A, 2730 Herlev on Thursday 30 November 2023 at 10.00 AM (CET). ",European Regulatory News,-0.034117698,-0.03343209,short
Orphazyme reports financial results in Interim Report First Half 2022,Company announcementOrphazyme A/SNo. 36/2022             www.orphazyme.comCompany Registration No. 32266355,Company announcementOrphazyme A/SNo. 36/2022             www.orphazyme.comCompany Registration No. 32266355,European Regulatory News,-0.043414287,-0.037682986,short
Updated financial calendar for 2022,Company announcement Orphazyme A/SNo. 34/2022 www.orphazyme.comCompany Registration No. 32266355,Company announcement Orphazyme A/SNo. 34/2022 www.orphazyme.comCompany Registration No. 32266355,European Regulatory News,0.066393417,0.049938706,long
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting,"NEW YORK, April  27, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) reports that Takeda Pharmaceuticals presented interim data at the 2023 annual meeting of the American Academy of Neurology (AAN) from ENDYMION 1, a long-term, open label extension study evaluating the effects of soticlestat on patients with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The findings reaffirm soticlestat was generally safe and well tolerated. Soticlestat additionally showed an encouraging median seizure reduction in both conditions.","NEW YORK, April  27, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) reports that Takeda Pharmaceuticals presented interim data at the 2023 annual meeting of the American Academy of Neurology (AAN) from ENDYMION 1, a long-term, open label extension study evaluating the effects of soticlestat on patients with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The findings reaffirm soticlestat was generally safe and well tolerated. Soticlestat additionally showed an encouraging median seizure reduction in both conditions.",Clinical Study,0.07761194,0.064319547,long
Ovid Therapeutics Added to Russell 3000® Index,"NEW YORK, June  26, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that the company was added to the Russell 3000® Index, effective after the U.S. market opens on June 26, 2023, as part of the 2023 Russell indexes annual reconstitution.","NEW YORK, June  26, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that the company was added to the Russell 3000® Index, effective after the U.S. market opens on June 26, 2023, as part of the 2023 Russell indexes annual reconstitution.",Stock Market News,-0.03753354,-0.036171622,short
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026,"NEW YORK and SAN DIEGO, Oct.  18, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of soticlestat. In return, Ovid will receive a $30 million payment, less certain reimbursable expenses.","NEW YORK and SAN DIEGO, Oct.  18, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of soticlestat. In return, Ovid will receive a $30 million payment, less certain reimbursable expenses.",Partnerships,-0.020188374,-0.01599135,short
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial,"A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options","A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options",Clinical Study,-0.010526306,-0.005210461,short
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments,"NEW YORK, Feb.  08, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, is expanding its medical and development team with the respective appointments of industry veterans, Manoj Malhotra, M.D., as its Chief Medical Officer and Toshiya Nishi, D.V.M., as its Head of Epilepsy Research.","NEW YORK, Feb.  08, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, is expanding its medical and development team with the respective appointments of industry veterans, Manoj Malhotra, M.D., as its Chief Medical Officer and Toshiya Nishi, D.V.M., as its Head of Epilepsy Research.",Management Changes,-0.011857696,-0.006896118,short
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer,"NEW YORK, June  28, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic development programs. The Company also announced changes to its administrative functions intended to enhance efficiency and reduce costs.","NEW YORK, June  28, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic development programs. The Company also announced changes to its administrative functions intended to enhance efficiency and reduce costs.",Management statements,-0.014880939,-0.012313074,short
"Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results","NEW YORK, March  13, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.","NEW YORK, March  13, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.",Earnings Releases and Operating Results,-0.040000021,-0.029375767,short
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates,"NEW YORK, May  05, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the first quarter ended March 31, 2023.","NEW YORK, May  05, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the first quarter ended March 31, 2023.",Earnings Releases and Operating Results,-0.038356192,-0.047686527,short
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates,"NEW YORK, Aug.  04, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.","NEW YORK, Aug.  04, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.",Earnings Releases and Operating Results,0.009036136,0.00484755,long
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights,"NEW YORK, Nov.  08, 2022  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the third quarter ended September 30, 2022.","NEW YORK, Nov.  08, 2022  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the third quarter ended September 30, 2022.",Earnings Releases and Operating Results,0,-0.003052963,short
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates,"NEW YORK, Nov.  03, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the third quarter ended September 30, 2023.","NEW YORK, Nov.  03, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the third quarter ended September 30, 2023.",Earnings Releases and Operating Results,0.016997151,0.011472021,long
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference,"NEW YORK, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York.","NEW YORK, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York.",Calendar of Events,0.0025974,-0.000339101,short
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023,"NEW YORK, Aug.  01, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 7, 2023, at 9:30 a.m. ET.","NEW YORK, Aug.  01, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 7, 2023, at 9:30 a.m. ET.",Calendar of Events,0.002785513,0.006105855,long
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022),"NEW YORK, Dec.  02, 2022  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant seizures will be presented at the 2022 American Epilepsy Society (AES) Annual Meeting, taking place December 2-6 in Nashville, Tennessee.","NEW YORK, Dec.  02, 2022  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant seizures will be presented at the 2022 American Epilepsy Society (AES) Annual Meeting, taking place December 2-6 in Nashville, Tennessee.",Calendar of Events,0.022099493,0.010514649,long
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures,"NEW YORK, March  08, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced the publication of multiple preclinical studies of OV350 in Cell Reports Medicine. The preclinical studies indicate that OV350 directly activates the potassium chloride cotransporter isoform 2 target, known as KCC2, and suggest that OV350 confers therapeutic efficacy in resistant epilepsy models and may offer a neuroprotective benefit.","NEW YORK, March  08, 2023  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced the publication of multiple preclinical studies of OV350 in Cell Reports Medicine. The preclinical studies indicate that OV350 directly activates the potassium chloride cotransporter isoform 2 target, known as KCC2, and suggest that OV350 confers therapeutic efficacy in resistant epilepsy models and may offer a neuroprotective benefit.",Clinical Study,-0.008163257,-0.008464625,short
PCI Biotech: Employee share option scheme,"Oslo, 25 November 2022 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees.        ","Oslo, 25 November 2022 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees.        ",European Regulatory News,-0.059360781,-0.060605089,short
PCI Biotech: Invitation to first half interim 2023 results presentation,"Oslo, Norway, 25 August 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2023 interim report on Thursday 31 August 2023, 08:30am – 09:30am CEST (local time).","Oslo, Norway, 25 August 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2023 interim report on Thursday 31 August 2023, 08:30am – 09:30am CEST (local time).",European Regulatory News,0.011976108,0.007879017,long
PCI Biotech: Invitation to Q1 2023 results presentation,"Oslo, Norway, 9 May 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's Q1 2023 interim report on Friday 12 May 2023, 08:30am – 09:30am CEST (local time).","Oslo, Norway, 9 May 2023 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's Q1 2023 interim report on Friday 12 May 2023, 08:30am – 09:30am CEST (local time).",European Regulatory News,0.145945869,0.146432363,long
PCI Biotech: Invitation to Q3 2022 results presentation,"Oslo, Norway, 17 November 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q3 2022 interim report on Wednesday 23 November 2022, 08:30am – 09:30am CET (local time).","Oslo, Norway, 17 November 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q3 2022 interim report on Wednesday 23 November 2022, 08:30am – 09:30am CET (local time).",European Regulatory News,-0.05454543,-0.064226316,short
PCI Biotech: Invitation to Q4 2022 results presentation,"Oslo, Norway, 13 February 2023 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q4 2022 interim report on Friday 17 February 2023, 08:30am – 09:30am CET (local time).","Oslo, Norway, 13 February 2023 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q4 2022 interim report on Friday 17 February 2023, 08:30am – 09:30am CET (local time).",European Regulatory News,-0.086172314,-0.096228062,short
"American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care","SCHAUMBURG, Ill. and TAMPA, Fla., Oct.  02, 2023  (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) and Pacira BioSciences, Inc. (Nasdaq: PCRX), today announced a new grant of $2.5 million, by Pacira to the ASA Charitable Foundation,  to advance the medical specialty of anesthesiology and pain medicine; facilitate best-in-class clinician education; and improve patient care.","SCHAUMBURG, Ill. and TAMPA, Fla., Oct.  02, 2023  (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) and Pacira BioSciences, Inc. (Nasdaq: PCRX), today announced a new grant of $2.5 million, by Pacira to the ASA Charitable Foundation,  to advance the medical specialty of anesthesiology and pain medicine; facilitate best-in-class clinician education; and improve patient care.",Partnerships,0.002281607,0.004293434,long
Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures,"TAMPA, Fla., March  29, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL label to include both single-dose sciatic nerve block in the popliteal fossa as well as femoral nerve block in the adductor canal. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is November 13, 2023.","TAMPA, Fla., March  29, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL label to include both single-dose sciatic nerve block in the popliteal fossa as well as femoral nerve block in the adductor canal. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is November 13, 2023.",Health,0.010022589,-0.000922776,short
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications,—  EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — ,—  EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — ,Health,0.010903956,0.005971228,long
Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference,"TAMPA, Fla., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced its participation in an analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference.  The pre-recorded audio of the virtual event can be accessed beginning Monday, September 11th at 7:00AM ET by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks. ","TAMPA, Fla., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced its participation in an analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference.  The pre-recorded audio of the virtual event can be accessed beginning Monday, September 11th at 7:00AM ET by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks. ",Calendar of Events,0.005466123,0.00733594,long
Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources,– Term Loan A Carries Significantly Lower Interest Rate –,– Term Loan A Carries Significantly Lower Interest Rate –,Financing Agreements,-0.002205345,-0.000886289,short
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors,"TAMPA, Fla., March  22, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that after serving as an independent director for nine years, Yvonne Greenstreet, MBChB, is retiring from the company’s Board of Directors effective March 31, 2023. Dr. Greenstreet is currently serving as Chief Executive Officer of Alnylam Pharmaceuticals, Inc. Pacira is initiating a process to identify an independent Board member to replace Dr. Greenstreet.","TAMPA, Fla., March  22, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that after serving as an independent director for nine years, Yvonne Greenstreet, MBChB, is retiring from the company’s Board of Directors effective March 31, 2023. Dr. Greenstreet is currently serving as Chief Executive Officer of Alnylam Pharmaceuticals, Inc. Pacira is initiating a process to identify an independent Board member to replace Dr. Greenstreet.",Directors and Officers,-0.000248221,0.000202991,long
Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors,"-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct.  10, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors effective immediately.","-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct.  10, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors effective immediately.",Directors and Officers,0.003635182,0.002131576,long
"Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer","TAMPA, Fla., April  19, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointment of Christopher Young to the position of Chief Manufacturing Officer. Mr. Young will be responsible for oversight of all manufacturing activities across the Pacira product portfolio including supply chain design, product life cycle management, demand and requirements planning, capacity, and product launches across all global manufacturing locations.","TAMPA, Fla., April  19, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointment of Christopher Young to the position of Chief Manufacturing Officer. Mr. Young will be responsible for oversight of all manufacturing activities across the Pacira product portfolio including supply chain design, product life cycle management, demand and requirements planning, capacity, and product launches across all global manufacturing locations.",Directors and Officers,-0.003680696,0.001123607,long
Pacira BioSciences Partners with The Invited Celebrity Classic – a PGA TOUR Champions Event – to Make iovera° The Official Non-Opioid Pain Management Partner,"PGA TOUR Champions Golfer, Paul Goydos, Promotes Further Awareness of Non-Opioids with 2023 Partnership PGA TOUR Champions Golfer, Paul Goydos, Promotes Further Awareness of Non-Opioids with 2023 Partnership","PGA TOUR Champions Golfer, Paul Goydos, Promotes Further Awareness of Non-Opioids with 2023 Partnership PGA TOUR Champions Golfer, Paul Goydos, Promotes Further Awareness of Non-Opioids with 2023 Partnership",Product / Services Announcement,-0.004625614,0.002449344,long
Pacira BioSciences Reports First Quarter 2023 Financial Results,-- EXPAREL continues to outperform elective surgery market with average daily volumes up 6 percent over prior year -- -- Conference call today at 8:30 a.m. ET --,-- EXPAREL continues to outperform elective surgery market with average daily volumes up 6 percent over prior year -- -- Conference call today at 8:30 a.m. ET --,Earnings Releases and Operating Results,-0.04456404,-0.045829713,short
Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results,— Record revenues of $667 million in 2022 —,— Record revenues of $667 million in 2022 —,Earnings Releases and Operating Results,0.01660157,0.017858705,long
Pacira BioSciences Reports Second Quarter 2023 Financial Results,"-- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Aug.  02, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2023.","-- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Aug.  02, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2023.",Earnings Releases and Operating Results,-0.034722222,-0.027646313,short
Pacira BioSciences Reports Third Quarter 2023 Financial Results,"-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 -- ","-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 -- ",Earnings Releases and Operating Results,-0.00035324,-0.009627794,short
Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference,"TAMPA, Fla., March  08, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 9:00 AM ET on Wednesday, March 15, 2023 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.","TAMPA, Fla., March  08, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 9:00 AM ET on Wednesday, March 15, 2023 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.",Calendar of Events,0.005196711,0.004895343,long
Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference,"TAMPA, Fla., May  09, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference at 3:05 PM ET on Tuesday, May 16, 2023 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.","TAMPA, Fla., May  09, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference at 3:05 PM ET on Tuesday, May 16, 2023 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.",Calendar of Events,-0.004732536,-0.00083181,short
Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference,"TAMPA, Fla., April  12, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 22nd Annual Needham Virtual Healthcare Conference at 10:15 AM ET on Wednesday, April 19, 2023. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.","TAMPA, Fla., April  12, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 22nd Annual Needham Virtual Healthcare Conference at 10:15 AM ET on Wednesday, April 19, 2023. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.",Calendar of Events,0.00816131,0.002913838,long
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November,"TAMPA, Fla., Nov.  07, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:","TAMPA, Fla., Nov.  07, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:",Calendar of Events,-0.004554307,-0.004554307,short
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments,- Continuing to open CONNECT1-EDO51 trial sites in Canada -,- Continuing to open CONNECT1-EDO51 trial sites in Canada -,Earnings Releases and Operating Results,-0.039999962,-0.041418942,short
"Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023","TAMPA, Fla., April  26, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Wednesday, May 3, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.","TAMPA, Fla., April  26, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Wednesday, May 3, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.",Calendar of Events,-0.007212074,-0.008788154,short
"Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023","TAMPA, Fla., July  26, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 2, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.","TAMPA, Fla., July  26, 2023  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 2, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.",Calendar of Events,0,0.002129811,long
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants,-- Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of Stage 1 Safety and Tolerability Data -- -- The Stage 2 Portion of VAX-24 Infant Study Will Include Prevnar 20® (PCV20) as Study Comparator -- ,-- Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of Stage 1 Safety and Tolerability Data -- -- The Stage 2 Portion of VAX-24 Infant Study Will Include Prevnar 20® (PCV20) as Study Comparator -- ,Clinical Study,-0.027725261,-0.029522123,short
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs),"-- New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations -- -- Expanded Collaboration Builds on Vaxcyte’s Current Strategy to Conduct Initial Commercial Launch of VAX-24 in Adults from Existing Lonza Facilities in Visp (CH) --","-- New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations -- -- Expanded Collaboration Builds on Vaxcyte’s Current Strategy to Conduct Initial Commercial Launch of VAX-24 in Adults from Existing Lonza Facilities in Visp (CH) --",Business Contracts,0.008043455,0.002666845,long
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults,"-- Company Expects to Initiate VAX-31 Phase 1/2 Study in Healthy Adults This Quarter-- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-31 Phase 1/2 Study Expected in the Second Half of 2024 --","-- Company Expects to Initiate VAX-31 Phase 1/2 Study in Healthy Adults This Quarter-- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-31 Phase 1/2 Study Expected in the Second Half of 2024 --",Clinical Study,0.002389759,0.000669621,long
TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference,"Fireside chat scheduled for Tuesday, May 9, 2023, at 3:00 PM PT Fireside chat scheduled for Tuesday, May 9, 2023, at 3:00 PM PT","Fireside chat scheduled for Tuesday, May 9, 2023, at 3:00 PM PT Fireside chat scheduled for Tuesday, May 9, 2023, at 3:00 PM PT",Calendar of Events,-0.000573572,0.002097857,long
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults,"-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and Immunogenicity Data Expected in Second Half of 2024 --","-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and Immunogenicity Data Expected in Second Half of 2024 --",Clinical Study,0.005928914,0.003230246,long
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants,"-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by 2025 -- -- The Nine Incremental Serotypes in VAX-24 Cover an Additional 20-25 Percent of Strains Causing Invasive Pneumococcal Disease Over the Current Standard-of-Care PCV in Infants --","-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by 2025 -- -- The Nine Incremental Serotypes in VAX-24 Cover an Additional 20-25 Percent of Strains Causing Invasive Pneumococcal Disease Over the Current Standard-of-Care PCV in Infants --",Clinical Study,-0.005156001,-0.011982936,short
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults,"-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults Aged 18-64 That Suggest Potential Best-in-Class Profile -- -- Topline Safety, Tolerability and Immunogenicity Data from VAX-24 Phase 2 Study in Adults 65 and Older Expected in Q2 2023 --","-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults Aged 18-64 That Suggest Potential Best-in-Class Profile -- -- Topline Safety, Tolerability and Immunogenicity Data from VAX-24 Phase 2 Study in Adults 65 and Older Expected in Q2 2023 --",Product / Services Announcement,-0.001280439,0.004035405,long
"PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors","BOSTON, Nov.  15, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Howard Mayer, M.D. to the PepGen Board of Directors, effective November 15, 2023.","BOSTON, Nov.  15, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Howard Mayer, M.D. to the PepGen Board of Directors, effective November 15, 2023.",Directors and Officers,-0.032558218,-0.035633507,short
"PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy","- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with mutations amenable to skipping exon 51 -","- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with mutations amenable to skipping exon 51 -",Clinical Study,0.000688655,0.001483437,long
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies,- PGN-EDODM1 was well-tolerated in acute GLP studies in rodents and non-human primates (NHPs) at clinically relevant doses-,- PGN-EDODM1 was well-tolerated in acute GLP studies in rodents and non-human primates (NHPs) at clinically relevant doses-,Clinical Study,-0.004325845,-0.002066027,short
"Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis",Follows positive data from INTEGRIS-IPF Phase 2a trial Follows positive data from INTEGRIS-IPF Phase 2a trial,Follows positive data from INTEGRIS-IPF Phase 2a trial Follows positive data from INTEGRIS-IPF Phase 2a trial,Clinical Study,-0.006604339,-0.007228292,short
PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting,"BOSTON, April  17, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will present at the 2023 American Academy of Neurology (AAN) Annual Meeting, taking place on April 22-27, 2023 in Boston, Massachusetts.","BOSTON, April  17, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will present at the 2023 American Academy of Neurology (AAN) Annual Meeting, taking place on April 22-27, 2023 in Boston, Massachusetts.",Health,0.031930907,0.032149102,long
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference,"BOSTON, March  13, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference, taking place on March 19-22, 2023 in Dallas, Texas.","BOSTON, March  13, 2023  (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference, taking place on March 19-22, 2023 in Dallas, Texas.",Calendar of Events,-0.02018093,-0.009556675,short
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1),"– Lifting of FDA hold allows FREEDOM-DM1 study to launch in the U.S. with target dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg –","– Lifting of FDA hold allows FREEDOM-DM1 study to launch in the U.S. with target dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg –",Product / Services Announcement,-0.005703462,-0.007147367,short
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences,- EDO platform observed to drive 25-fold higher level of oligonucleotide delivery to myotube nuclei compared to “naked” oligonucleotide -,- EDO platform observed to drive 25-fold higher level of oligonucleotide delivery to myotube nuclei compared to “naked” oligonucleotide -,Clinical Study,0.008561595,0.010431411,long
PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference,"- In NHP, four monthly doses of 20 mg/kg of PGN-EDO51 resulted in 34.9% exon skipped transcripts in biceps; a 14-fold increase over the 2.5% exon 51 skipped transcripts observed after a single dose –","- In NHP, four monthly doses of 20 mg/kg of PGN-EDO51 resulted in 34.9% exon skipped transcripts in biceps; a 14-fold increase over the 2.5% exon 51 skipped transcripts observed after a single dose –",Health,0.072352914,0.072804125,long
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments,– Phase 2 open-label CONNECT1-EDO51 study open in Canada –,– Phase 2 open-label CONNECT1-EDO51 study open in Canada –,Earnings Releases and Operating Results,-0.002000046,0.003835203,long
BiomX Announces the Appointment of Edward L. Williams to its Board of Directors,"CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct.  18, 2023  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors.","CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct.  18, 2023  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors.",Directors and Officers,0,0.004197024,long
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors,"CAMBRIDGE, Mass. and NESS ZIONA, Israel, May  12, 2023  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointments of Jason M. Marks and Michael E. Dambach to its Board of Directors.","CAMBRIDGE, Mass. and NESS ZIONA, Israel, May  12, 2023  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointments of Jason M. Marks and Michael E. Dambach to its Board of Directors.",Directors and Officers,0.181102371,0.17797227,long
BiomX Presenting at Two Upcoming Conferences in November,"Jefferies London Healthcare Conference on November 18 - 19, 2021","Jefferies London Healthcare Conference on November 18 - 19, 2021",Calendar of Events,-0.013698617,-0.013101961,short
BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage,"NESS ZIONA, Israel, Nov.  29, 2022  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022.","NESS ZIONA, Israel, Nov.  29, 2022  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022.",Calendar of Events,0.035714252,0.035360676,long
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference,"CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct.  27, 2023  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in people with cystic fibrosis (“CF”) at the 37th Annual North American Cystic Fibrosis Conference, which is being held November 2-4, 2023, in Phoenix, Arizona. The abstract was selected for an oral presentation at the conference.","CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct.  27, 2023  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in people with cystic fibrosis (“CF”) at the 37th Annual North American Cystic Fibrosis Conference, which is being held November 2-4, 2023, in Phoenix, Arizona. The abstract was selected for an oral presentation at the conference.",Calendar of Events,0.111111111,0.1071358,long
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023,"CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept.  07, 2023  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in patients with cystic fibrosis (“CF”) at European Respiratory Society (ERS) International Congress 2023, which is being held September 9-13, 2023, in Milan, Italy. The abstract was submitted as a Late-Breaking Abstract and selected for oral presentation at the conference.","CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept.  07, 2023  (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in patients with cystic fibrosis (“CF”) at European Respiratory Society (ERS) International Congress 2023, which is being held September 9-13, 2023, in Milan, Italy. The abstract was submitted as a Late-Breaking Abstract and selected for oral presentation at the conference.",Clinical Study,-0.010256355,-0.003286663,short
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma,Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective for patients with locally advanced fully resectable melanoma,Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective for patients with locally advanced fully resectable melanoma,Product / Services Announcement,0.018970106,0.013593496,long
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis,Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose,Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose,Clinical Study,-0.016440282,-0.005816028,short
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis,Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events,Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events,Clinical Study,0.078875146,0.08613983,long
Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference,"Posters include data across biomarker, translation and clinical studies supportingdevelopment of bexotegrast (PLN-74809), a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF","Posters include data across biomarker, translation and clinical studies supportingdevelopment of bexotegrast (PLN-74809), a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF",Trade Show,0.003906265,-0.002082352,short
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023,"SOUTH SAN FRANCISCO, Calif., Sept.  11, 2023  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced presentations made at the European Respiratory Society (ERS) International Congress 2023 taking place from September 9, 2023 to September 13, 2023.","SOUTH SAN FRANCISCO, Calif., Sept.  11, 2023  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced presentations made at the European Respiratory Society (ERS) International Congress 2023 taking place from September 9, 2023 to September 13, 2023.",Calendar of Events,0.006686851,0.000581623,long
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer,"SOUTH SAN FRANCISCO, Calif., Sept.  15, 2023  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer. Ms. Kuo will oversee all aspects of the Company’s nonclinical and clinical development activities.","SOUTH SAN FRANCISCO, Calif., Sept.  15, 2023  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer. Ms. Kuo will oversee all aspects of the Company’s nonclinical and clinical development activities.",Directors and Officers,0.001854065,0.009003836,long
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023,"Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13 Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13","Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13 Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13",Clinical Study,-0.002952027,-0.004672165,short
"Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1","SOUTH SAN FRANCISCO, Calif., Nov.  06, 2023  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, presented three posters highlighting PLN-101095, a novel inhibitor of integrins αvβ8 and αvβ1. These posters were presented as part of the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held November 1 - 5, 2023.","SOUTH SAN FRANCISCO, Calif., Nov.  06, 2023  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, presented three posters highlighting PLN-101095, a novel inhibitor of integrins αvβ8 and αvβ1. These posters were presented as part of the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held November 1 - 5, 2023.",Calendar of Events,-0.001241493,-0.003035873,short
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™,Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitis Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitis ,Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitis Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitis ,Product / Services Announcement,-0.013627862,-0.005426407,short
Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference,"SOUTH SAN FRANCISCO, Calif., April  12, 2023  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a fireside chat as part of the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023, at 3:45 p.m. Eastern Time.","SOUTH SAN FRANCISCO, Calif., April  12, 2023  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a fireside chat as part of the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023, at 3:45 p.m. Eastern Time.",Health,0.008722015,0.003474544,long
Pliant Therapeutics to Participate in Upcoming Investor Conferences,"SOUTH SAN FRANCISCO, Calif., Aug.  30, 2023  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following September investor conferences.","SOUTH SAN FRANCISCO, Calif., Aug.  30, 2023  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following September investor conferences.",Calendar of Events,0.012055501,0.011276255,long
"PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds","PETACH TIKVA, Israel, March  31, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the closing of an underwritten public offering (the “Public Offering”) of ordinary shares, no par value, (“Ordinary Shares”) with gross proceeds of approximately $7.1 million, which includes the full exercise of the underwriter's option to purchase additional Ordinary Shares. The Company also announced the closing of a concurrent private placement of pre-funded warrants with certain of its existing shareholders with gross proceeds of $4.35 million.","PETACH TIKVA, Israel, March  31, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the closing of an underwritten public offering (the “Public Offering”) of ordinary shares, no par value, (“Ordinary Shares”) with gross proceeds of approximately $7.1 million, which includes the full exercise of the underwriter's option to purchase additional Ordinary Shares. The Company also announced the closing of a concurrent private placement of pre-funded warrants with certain of its existing shareholders with gross proceeds of $4.35 million.",Financing Agreements,0.057471264,0.045782411,long
PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections,Recruitment to Resume Imminently,Recruitment to Resume Imminently,Business Contracts,0.052631614,0.052583791,long
PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections,"Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide Range of Bacteria Tested, including Resistant Strains ","Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide Range of Bacteria Tested, including Resistant Strains ",Health,0.02493079,0.025916201,long
PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023,"PETACH TIKVA, Israel, Oct.  09, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA.","PETACH TIKVA, Israel, Oct.  09, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA.",Calendar of Events,0.051443596,0.056006668,long
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants,"PETACH TIKVA, Israel, March  29, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the pricing of an underwritten public offering of 14,660,000 ordinary shares, no par value (the “Ordinary Shares”) at a public offering price of $0.42 per share (the “Public Offering”). The gross proceeds to PolyPid from the Public Offering, before deducting underwriting commissions and other estimated offering expenses payable by PolyPid, are expected to be approximately $6.2 million. In addition, PolyPid has granted the underwriter a 30-day option to purchase up to an additional 2,199,000 Ordinary Shares at the public offering price, less underwriting discounts and commissions, to cover over-allotments in connection with the Public Offering. All of the Ordinary Shares in the Public Offering were offered by PolyPid. The Public Offering is expected to close on or about March 31, 2023, subject to the satisfaction of customary closing conditions.","PETACH TIKVA, Israel, March  29, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the pricing of an underwritten public offering of 14,660,000 ordinary shares, no par value (the “Ordinary Shares”) at a public offering price of $0.42 per share (the “Public Offering”). The gross proceeds to PolyPid from the Public Offering, before deducting underwriting commissions and other estimated offering expenses payable by PolyPid, are expected to be approximately $6.2 million. In addition, PolyPid has granted the underwriter a 30-day option to purchase up to an additional 2,199,000 Ordinary Shares at the public offering price, less underwriting discounts and commissions, to cover over-allotments in connection with the Public Offering. All of the Ordinary Shares in the Public Offering were offered by PolyPid. The Public Offering is expected to close on or about March 31, 2023, subject to the satisfaction of customary closing conditions.",Initial Public Offerings,-0.157894737,-0.168840102,short
PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform,Safety Profile of D-PLEX100 and PLEX Platform Shown in Juvenile Animals for the First Time,Safety Profile of D-PLEX100 and PLEX Platform Shown in Juvenile Animals for the First Time,Clinical Study,-0.018735345,-0.019873918,short
PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections,Company Recently Reached Agreement with FDA on Design of Trial,Company Recently Reached Agreement with FDA on Design of Trial,Clinical Study,0.08401087,0.086287024,long
PolyPid Announces Reverse Share Split,"PETACH TIKVA, Israel, Sept.  20, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announces a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, no par value (“Ordinary Shares”), at the ratio of 1-for-30, such that each thirty (30) Ordinary Shares, shall be consolidated into one (1) Ordinary Share.","PETACH TIKVA, Israel, Sept.  20, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announces a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, no par value (“Ordinary Shares”), at the ratio of 1-for-30, such that each thirty (30) Ordinary Shares, shall be consolidated into one (1) Ordinary Share.",Stock Market News,0.243781051,0.24084455,long
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health,Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ Globally Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ Globally,Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ Globally Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ Globally,Product / Services Announcement,-0.002721086,0.003981455,long
PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀,Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale,Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale,Product / Services Announcement,0.233183846,0.235325298,long
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors,"Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal","Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal",Directors and Officers,0.008905813,0.008905813,long
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results,Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections,Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections,Earnings Releases and Operating Results,-0.089622617,-0.091041598,short
PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule,"PETACH TIKVA, Israel, Oct.  11, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notice from The Nasdaq Stock Market LLC (""Nasdaq"") that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities, including the Company's ordinary shares, to maintain a minimum bid price of $1.00 per share.","PETACH TIKVA, Israel, Oct.  11, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notice from The Nasdaq Stock Market LLC (""Nasdaq"") that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities, including the Company's ordinary shares, to maintain a minimum bid price of $1.00 per share.",Changes in company's own shares,-0.023136285,-0.025667712,short
PolyPid to Participate in Upcoming Investor Conferences,"PETACH TIKVA, Israel, April  24, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that members of management will participate in the following upcoming investor conferences:","PETACH TIKVA, Israel, April  24, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that members of management will participate in the following upcoming investor conferences:",Calendar of Events,0.013953512,0.014463027,long
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference,"PETACH TIKVA, Israel, Sept.  22, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company’s management will present at the Cantor Global Healthcare Conference taking place on September 26-28, 2023, in New York City, New York.","PETACH TIKVA, Israel, Sept.  22, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company’s management will present at the Cantor Global Healthcare Conference taking place on September 26-28, 2023, in New York City, New York.",Calendar of Events,0.060092505,0.057635337,long
Les spécialistes du rein en Tunisie recommandent l'utilisation des solutions QuantiFERON de QIAGEN,"TUNIS, Tunisie,  28 sept. 2023  (GLOBE NEWSWIRE) -- QIAGEN annonce que l'utilisation de ses tests de la gamme QuantiFERON a été recommandée par les cliniciens de la Société Tunisienne de Néphrologie pour la prise en charge des patients greffés, dialysés et atteints de maladies rénales, marquant ainsi la première recommandation de ce type au niveau mondial émise par un organisme professionnel spécialisé dans la médecine rénale.","TUNIS, Tunisie,  28 sept. 2023  (GLOBE NEWSWIRE) -- QIAGEN annonce que l'utilisation de ses tests de la gamme QuantiFERON a été recommandée par les cliniciens de la Société Tunisienne de Néphrologie pour la prise en charge des patients greffés, dialysés et atteints de maladies rénales, marquant ainsi la première recommandation de ce type au niveau mondial émise par un organisme professionnel spécialisé dans la médecine rénale.",Health,0.001773491,0.003111308,long
Partnerschaft zwischen QIAGEN und Element Biosciences ermöglicht vollständige NGS-Workflows für das AVITI-System,"Partnerschaft unterstützt Nutzer des AVITI-Systems von Element bei der Genomanalyse mit QIAseq Panels, CLC LightSpeed und QCI Interpret von QIAGEN // Zusammenarbeit beschleunigt wissenschaftliche Entdeckungen bei Genomanwendungen, macht sie kosteneffizienter und verkürzt Durchlaufzeiten // QIAGEN präsentiert beim Jahrestreffen der American Society of Human Genetics 2023 in Washington D.C. Leistungsdaten für universelle QIAseq-Panels zur Bibliotheksvorbereitung auf anderen Sequenzierungsplattformen","Partnerschaft unterstützt Nutzer des AVITI-Systems von Element bei der Genomanalyse mit QIAseq Panels, CLC LightSpeed und QCI Interpret von QIAGEN // Zusammenarbeit beschleunigt wissenschaftliche Entdeckungen bei Genomanwendungen, macht sie kosteneffizienter und verkürzt Durchlaufzeiten // QIAGEN präsentiert beim Jahrestreffen der American Society of Human Genetics 2023 in Washington D.C. Leistungsdaten für universelle QIAseq-Panels zur Bibliotheksvorbereitung auf anderen Sequenzierungsplattformen",Business Contracts,0.007921818,-0.001352736,short
QIAGEN and Element Biosciences partner to offer complete next-generation sequencing workflows for the AVITI System,"Partnership combines QIAGEN’s QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element’s AVITI System users in genomic analysis // Collaboration to accelerate discovery, enhance cost efficiencies, and improve turnaround times for genomic applications in the scientific community // QIAGEN to present performance data for universal QIAseq library preparation panels running on other sequencing platforms at ASHG Annual Meeting 2023 in Washington, DC Partnership combines QIAGEN’s QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element’s AVITI System users in genomic analysis // Collaboration to accelerate discovery, enhance cost efficiencies, and improve turnaround times for genomic applications in the scientific community // QIAGEN to present performance data for universal QIAseq library preparation panels running on other sequencing platforms at ASHG Annual Meeting 2023 in Washington, DC","Partnership combines QIAGEN’s QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element’s AVITI System users in genomic analysis // Collaboration to accelerate discovery, enhance cost efficiencies, and improve turnaround times for genomic applications in the scientific community // QIAGEN to present performance data for universal QIAseq library preparation panels running on other sequencing platforms at ASHG Annual Meeting 2023 in Washington, DC Partnership combines QIAGEN’s QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element’s AVITI System users in genomic analysis // Collaboration to accelerate discovery, enhance cost efficiencies, and improve turnaround times for genomic applications in the scientific community // QIAGEN to present performance data for universal QIAseq library preparation panels running on other sequencing platforms at ASHG Annual Meeting 2023 in Washington, DC",Company Announcement,0.007921818,-0.001352736,short
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer,"Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests // Combined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion diagnostic solutions based on PCR, digital PCR (using the QIAcuity system), and NGS // Future projects may include advanced analysis and accessibility of measurable residual disease (MRD) and homologous recombination deficiency (HRD) assays to potentially improve cancer treatment decision-making Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests // Combined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion diagnostic solutions based on PCR, digital PCR (using the QIAcuity system), and NGS // Future projects may include advanced analysis and accessibility of measurable residual disease (MRD) and homologous recombination deficiency (HRD) assays to potentially improve cancer treatment decision-making","Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests // Combined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion diagnostic solutions based on PCR, digital PCR (using the QIAcuity system), and NGS // Future projects may include advanced analysis and accessibility of measurable residual disease (MRD) and homologous recombination deficiency (HRD) assays to potentially improve cancer treatment decision-making Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests // Combined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion diagnostic solutions based on PCR, digital PCR (using the QIAcuity system), and NGS // Future projects may include advanced analysis and accessibility of measurable residual disease (MRD) and homologous recombination deficiency (HRD) assays to potentially improve cancer treatment decision-making",Company Announcement,-0.000813637,0.00182072,long
QIAGEN N.V. to release results for Q2 2023 and hold webcast,"Venlo, The Netherlands, July  24, 2023  (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter 2023.","Venlo, The Netherlands, July  24, 2023  (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter 2023.",Company Announcement,-0.003431264,-0.006062965,short
QIAGEN N.V. to release results for Q3 2023 and hold webcast,"Venlo, the Netherlands, Oct.  09, 2023  (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. ","Venlo, the Netherlands, Oct.  09, 2023  (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. ",Company Announcement,-0.007964154,-0.018979688,short
QIAGEN’s QuantiFERON solutions recommended for use by kidney specialists in Tunisia,"TUNIS, Tunisia, Sept.  28, 2023  (GLOBE NEWSWIRE) -- QIAGEN today announced that the comprehensive QuantiFERON immune response blood tests have been recommended for use by clinicians in Tunisia to help kidney disease, transplant and dialysis patients – the world’s first-ever guidance of this type by a professional body in kidney medicine.","TUNIS, Tunisia, Sept.  28, 2023  (GLOBE NEWSWIRE) -- QIAGEN today announced that the comprehensive QuantiFERON immune response blood tests have been recommended for use by clinicians in Tunisia to help kidney disease, transplant and dialysis patients – the world’s first-ever guidance of this type by a professional body in kidney medicine.",Health,0.001773491,0.003111308,long
QIAGEN und Myriad Genetics schließen Partnerschaft und treiben Entwicklung von Begleitdiagnostika für Krebs voran,"Partnerschaft umfasst die Entwicklung von im Labor entwickelten (LDT) und vertriebsfähigen diagnostischen Begleittests auf Kit-Basis // Vereinte Stärken in den Bereichen Assay-Entwicklung, klinische Tests und regulatorische Zulassungen bieten Pharmapartnern umfassende globale Lösungen für die Begleitdiagnostik auf Basis von PCR, digitaler PCR (QIAcuity-System) und NGS // Künftige Projekte könnten erweiterte Analyse und Zugänglichkeit von Tests für messbare Resterkrankungen (MRD) und homologe Rekombinationsdefizienz (HRD) umfassen, um Entscheidungsfindung bei Krebsbehandlung zu verbessern","Partnerschaft umfasst die Entwicklung von im Labor entwickelten (LDT) und vertriebsfähigen diagnostischen Begleittests auf Kit-Basis // Vereinte Stärken in den Bereichen Assay-Entwicklung, klinische Tests und regulatorische Zulassungen bieten Pharmapartnern umfassende globale Lösungen für die Begleitdiagnostik auf Basis von PCR, digitaler PCR (QIAcuity-System) und NGS // Künftige Projekte könnten erweiterte Analyse und Zugänglichkeit von Tests für messbare Resterkrankungen (MRD) und homologe Rekombinationsdefizienz (HRD) umfassen, um Entscheidungsfindung bei Krebsbehandlung zu verbessern",Partnerships,-0.000813637,0.00182072,long
Dr Ken Herrmann Appointed to RAD Scientific Advisory Board,"SYDNEY, Australia, March  03, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Dr Ken Herrmann to the Company’s Scientific Advisory Board (SAB).","SYDNEY, Australia, March  03, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Dr Ken Herrmann to the Company’s Scientific Advisory Board (SAB).",Directors and Officers,0,-0.004776134,short
Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope,"Agreement will supply Tb-161 for RAD 602, a potential first in class radiopharmaceutical for treatment of brain cancers Agreement will supply Tb-161 for RAD 602, a potential first in class radiopharmaceutical for treatment of brain cancers","Agreement will supply Tb-161 for RAD 602, a potential first in class radiopharmaceutical for treatment of brain cancers Agreement will supply Tb-161 for RAD 602, a potential first in class radiopharmaceutical for treatment of brain cancers",Product / Services Announcement,0,0.000218194,long
Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer,"Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancer Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancer","Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancer Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancer",Business Contracts,0.056818213,0.05307128,long
Radiopharm Theranostics Initiates Process for Nasdaq Listing,Proposed listing on NASDAQ with RADX ticker symbolForm 20-F registration filed with Securities and Exchange CommissionTrading expected to commence late March 2023,Proposed listing on NASDAQ with RADX ticker symbolForm 20-F registration filed with Securities and Exchange CommissionTrading expected to commence late March 2023,Exchange announcement,0.038461618,0.042313073,long
Radiopharm Theranostics Invited to Participate in Jefferies Radiopharma Innovation Summit,"SYDNEY, Australia, March  28, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that the Company will participate in Jefferies Inaugural Radiopharma Innovation Summit being held in New York City on April 3rd, 2023. Riccardo Canevari, Chief Executive Officer and Managing Director of Radiopharm Theranostics, and Vittorio Puppo, Chief Operating Officer will be available for 1x1 meetings.","SYDNEY, Australia, March  28, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that the Company will participate in Jefferies Inaugural Radiopharma Innovation Summit being held in New York City on April 3rd, 2023. Riccardo Canevari, Chief Executive Officer and Managing Director of Radiopharm Theranostics, and Vittorio Puppo, Chief Operating Officer will be available for 1x1 meetings.",Calendar of Events,-0.028571402,-0.026755464,short
Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2),"- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients -","- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients -",Clinical Study,0.008576362,-0.007568728,short
Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals,"SYDNEY, Australia, March  03, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that through its wholly owned subsidiary, Radiopharm Theranostics (USA) Inc., it has entered into a binding agreement to acquire Pharma15 Corporation (Pharma15), a private US-based venture which is developing next-generation therapeutic radiopharmaceuticals for Prostate Cancer. Pharma15 was founded by leading radiopharmaceutical scientist Professor David Ulmert and CEO Suzanne Dance.","SYDNEY, Australia, March  03, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that through its wholly owned subsidiary, Radiopharm Theranostics (USA) Inc., it has entered into a binding agreement to acquire Pharma15 Corporation (Pharma15), a private US-based venture which is developing next-generation therapeutic radiopharmaceuticals for Prostate Cancer. Pharma15 was founded by leading radiopharmaceutical scientist Professor David Ulmert and CEO Suzanne Dance.",Mergers and Acquisitions,0,-0.004776134,short
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer,"SYDNEY, Australia, May  09, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Ga68-Trivehexin (RAD 301) radiopharmaceutical technology for imaging of patients with pancreatic ductal adenocarcinoma (PDAC).","SYDNEY, Australia, May  09, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Ga68-Trivehexin (RAD 301) radiopharmaceutical technology for imaging of patients with pancreatic ductal adenocarcinoma (PDAC).",Health,0.05882356,0.062724286,long
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer,"SYDNEY, Australia, Oct.  09, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to commence its First-In-Human Phase I study in Australia for the Company’s therapy for patients with PDL1-positive non-small cell lung cancer (NSCLC).","SYDNEY, Australia, Oct.  09, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to commence its First-In-Human Phase I study in Australia for the Company’s therapy for patients with PDL1-positive non-small cell lung cancer (NSCLC).",Clinical Study,0,0.004563072,long
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences,"NEWARK, Calif., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain’s programs.","NEWARK, Calif., Oct.  16, 2023  (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain’s programs.",Management statements,0.111111124,0.105734514,long
RAPT Therapeutics Reports Third Quarter 2023 Financial Results,Company maintains strong cash position of $184.8 million Company maintains strong cash position of $184.8 million,Company maintains strong cash position of $184.8 million Company maintains strong cash position of $184.8 million,Earnings Releases and Operating Results,0.000852534,0.003984498,long
Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting,"NEWARK, Calif., Nov.  17, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place on November 16-19, 2022 in Vancouver, BC, Canada.","NEWARK, Calif., Nov.  17, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place on November 16-19, 2022 in Vancouver, BC, Canada.",Calendar of Events,0.019077883,0.009396997,long
Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium,"NEWARK, Calif., Nov.  23, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.","NEWARK, Calif., Nov.  23, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.",Calendar of Events,0.002358545,0.003233779,long
Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium,"NEWARK, Calif., Oct.  26, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the 34th EORTC/AACR/NCI Symposium taking place on October 26-28, 2022 in Barcelona, Spain.","NEWARK, Calif., Oct.  26, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the 34th EORTC/AACR/NCI Symposium taking place on October 26-28, 2022 in Barcelona, Spain.",Trade Show,0.070208707,0.06916056,long
Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma,– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance –,– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance –,Clinical Study,0.014792885,0.014985953,long
Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2),"The interventional, multicenter, open-label Phase 2 basket trial will evaluate the safety and efficacy of milademetan in patients with MDM2-amplified advanced solid tumors The interventional, multicenter, open-label Phase 2 basket trial will evaluate the safety and efficacy of milademetan in patients with MDM2-amplified advanced solid tumors","The interventional, multicenter, open-label Phase 2 basket trial will evaluate the safety and efficacy of milademetan in patients with MDM2-amplified advanced solid tumors The interventional, multicenter, open-label Phase 2 basket trial will evaluate the safety and efficacy of milademetan in patients with MDM2-amplified advanced solid tumors",Health,0,0.00025552,long
Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference,"NEWARK, Calif., Aug.  31, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in Citi’s 17th Annual BioPharma Conference on September 7-8, 2022 taking place at the Four Seasons Hotel in Boston, MA.","NEWARK, Calif., Aug.  31, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in Citi’s 17th Annual BioPharma Conference on September 7-8, 2022 taking place at the Four Seasons Hotel in Boston, MA.",Calendar of Events,0.024000015,0.019680683,long
Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference,"NEWARK, Calif., Nov.  14, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwright’s 3rd Annual Precision Oncology Conference on November 14, 2022.","NEWARK, Calif., Nov.  14, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwright’s 3rd Annual Precision Oncology Conference on November 14, 2022.",Calendar of Events,0.009463713,0.014106021,long
"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022","NEWARK, Calif., Oct.  27, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.","NEWARK, Calif., Oct.  27, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.",Calendar of Events,0.05496453,0.052215935,long
UPDATE -- Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma,– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance –,– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance –,Clinical Study,0.034985389,0.035468005,long
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires,"SOUTH SAN FRANCISCO, Calif., Sept.  28, 2022  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Jennifer Nicholson as Senior Vice President of Regulatory Affairs and Quality Assurance and Adnan Rahman as Vice President of Commercial.","SOUTH SAN FRANCISCO, Calif., Sept.  28, 2022  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Jennifer Nicholson as Senior Vice President of Regulatory Affairs and Quality Assurance and Adnan Rahman as Vice President of Commercial.",Directors and Officers,0.020050106,0.017298166,long
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma,"SOUTH SAN FRANCISCO, Calif., March  29, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that it has initiated its global 14-week randomized, double-blind, placebo-controlled Phase 2a clinical trial to evaluate the efficacy and safety of RPT193 as an oral, once-daily monotherapy in patients with moderate-to-severe asthma.","SOUTH SAN FRANCISCO, Calif., March  29, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that it has initiated its global 14-week randomized, double-blind, placebo-controlled Phase 2a clinical trial to evaluate the efficacy and safety of RPT193 as an oral, once-daily monotherapy in patients with moderate-to-severe asthma.",Health,0.016228259,0.005282894,long
"RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC",- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI),- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI),Product / Services Announcement,0.069703261,0.066124769,long
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel,"SOUTH SAN FRANCISCO, Calif., May  03, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Michael Listgarten as General Counsel.","SOUTH SAN FRANCISCO, Calif., May  03, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Michael Listgarten as General Counsel.",Directors and Officers,0.017643681,0.016378008,long
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting,"SOUTH SAN FRANCISCO, Calif., Oct.  18, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present two posters on FLX475, its oncology drug candidate, at the Society for Immunotherapy of Cancer 2023 Annual Meeting taking place November 3-5, 2023 in San Diego, CA.","SOUTH SAN FRANCISCO, Calif., Oct.  18, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present two posters on FLX475, its oncology drug candidate, at the Society for Immunotherapy of Cancer 2023 Annual Meeting taking place November 3-5, 2023 in San Diego, CA.",Calendar of Events,-0.009811929,-0.005614904,short
RAPT Therapeutics Reports First Quarter 2023 Financial Results,Company maintains strong cash position of $231.6 million Company maintains strong cash position of $231.6 million,Company maintains strong cash position of $231.6 million Company maintains strong cash position of $231.6 million,Earnings Releases and Operating Results,-0.008138344,-0.005958391,short
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results,Company maintains strong cash position of $249.1 million Company maintains strong cash position of $249.1 million,Company maintains strong cash position of $249.1 million Company maintains strong cash position of $249.1 million,Earnings Releases and Operating Results,-0.077414556,-0.090752771,short
RAPT Therapeutics Reports Second Quarter 2023 Financial Results,Company maintains strong cash position of $205 million Company maintains strong cash position of $205 million,Company maintains strong cash position of $205 million Company maintains strong cash position of $205 million,Earnings Releases and Operating Results,-0.038118432,-0.033767773,short
RAPT Therapeutics Reports Third Quarter 2022 Financial Results,Company maintains strong cash position of $195.4 million Company maintains strong cash position of $195.4 million,Company maintains strong cash position of $195.4 million Company maintains strong cash position of $195.4 million,Earnings Releases and Operating Results,0.001148132,-0.036058141,short
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences,"SOUTH SAN FRANCISCO, Calif., Nov.  09, 2022  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in November.","SOUTH SAN FRANCISCO, Calif., Nov.  09, 2022  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in November.",Calendar of Events,-0.005414103,4.76E-06,long
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September,"SOUTH SAN FRANCISCO, Calif., Aug.  31, 2022  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in September:","SOUTH SAN FRANCISCO, Calif., Aug.  31, 2022  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in September:",Calendar of Events,0.010959975,0.006640642,long
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference,"SOUTH SAN FRANCISCO, Calif., June  07, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 12, 2023 at 1:20 p.m. PT.","SOUTH SAN FRANCISCO, Calif., June  07, 2023  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 12, 2023 at 1:20 p.m. PT.",Calendar of Events,0.001913004,0.000955119,long
"AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer","LOS ANGELES, Aug.  09, 2023  (GLOBE NEWSWIRE) -- Renovaro BioSciences Inc. (NASDAQ:RENB) (formerly NASDAQ: ENOB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has executed a binding, exclusive letter of intent to merge a subsidiary with the cutting-edge health AI company GEDi Cube Intl Ltd. The combined company would aim to accelerate diagnosis, enhance treatment effectiveness, discover new therapies, and expand access to life-saving technologies for cancer and other diseases.","LOS ANGELES, Aug.  09, 2023  (GLOBE NEWSWIRE) -- Renovaro BioSciences Inc. (NASDAQ:RENB) (formerly NASDAQ: ENOB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has executed a binding, exclusive letter of intent to merge a subsidiary with the cutting-edge health AI company GEDi Cube Intl Ltd. The combined company would aim to accelerate diagnosis, enhance treatment effectiveness, discover new therapies, and expand access to life-saving technologies for cancer and other diseases.",Mergers and Acquisitions,1.18823525,1.187611297,long
TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference,"Fireside chat scheduled for Monday, September 11, 2023, at 10:30 AM ET Fireside chat scheduled for Monday, September 11, 2023, at 10:30 AM ET","Fireside chat scheduled for Monday, September 11, 2023, at 10:30 AM ET Fireside chat scheduled for Monday, September 11, 2023, at 10:30 AM ET",Calendar of Events,-0.011764716,-0.004795024,short
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements,"LOS ANGELES, March  13, 2023  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms 10-Q for the quarters ending September 30, 2022 and December 31, 2022 on March 7th and March 9th, 2023, respectively. ","LOS ANGELES, March  13, 2023  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms 10-Q for the quarters ending September 30, 2022 and December 31, 2022 on March 7th and March 9th, 2023, respectively. ",Stock Market News,-0.018691681,-0.008067427,short
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher,"LOS ANGELES, March  29, 2023  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (UCLA). The experiments demonstrated highly significant reductions in the weight and volume of pancreatic tumors following therapy with the Company’s proprietary technology combining cell-, gene- and immunotherapy. Those results correlated with strong immune responses, indicating proof-of-concept of the way the technology was intended to act.","LOS ANGELES, March  29, 2023  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (UCLA). The experiments demonstrated highly significant reductions in the weight and volume of pancreatic tumors following therapy with the Company’s proprietary technology combining cell-, gene- and immunotherapy. Those results correlated with strong immune responses, indicating proof-of-concept of the way the technology was intended to act.",Product / Services Announcement,0,-0.010945365,short
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review,"LOS ANGELES, June  08, 2023  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB).  Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company’s Pre-IND submission. If successful, that would allow clinical trials to begin by the first half of 2024.","LOS ANGELES, June  08, 2023  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB).  Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company’s Pre-IND submission. If successful, that would allow clinical trials to begin by the first half of 2024.",Research Analysis and Reports,-0.018963319,-0.019127444,short
Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor,"LOS ANGELES, July  25, 2022  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Company’s Senior Scientific Advisor. A Distinguished Professor of Pediatrics at UAB, Dr. Whitley brings decades of virology research experience to the Company, including clinical research experience to develop antiviral therapies.","LOS ANGELES, July  25, 2022  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Company’s Senior Scientific Advisor. A Distinguished Professor of Pediatrics at UAB, Dr. Whitley brings decades of virology research experience to the Company, including clinical research experience to develop antiviral therapies.",Health,-0.105042012,-0.104587198,short
Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform,"Initial, Pre-Clinical Animal Study Results Show Potential To Effectively Treat Pancreatic Cancer Initial, Pre-Clinical Animal Study Results Show Potential To Effectively Treat Pancreatic Cancer","Initial, Pre-Clinical Animal Study Results Show Potential To Effectively Treat Pancreatic Cancer Initial, Pre-Clinical Animal Study Results Show Potential To Effectively Treat Pancreatic Cancer",Patents,0.03211006,0.01427038,long
Enochian BioSciences’ CEO Letter to Shareholders,Turning the Page; A Promising Future Turning the Page; A Promising Future,Turning the Page; A Promising Future Turning the Page; A Promising Future,Management statements,-0.029508207,-0.028189151,short
TransCode Therapeutics Announces 1-for-20 Reverse Stock Split,"BOSTON, May  22, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors approved a 1-for-20 reverse stock split, to be effective 4:05 p.m. Eastern Time today, May 22, 2023. TransCode common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Tuesday, May 23, 2023, under the current trading symbol, “RNAZ.” The reverse stock split was approved by TransCode’s stockholders on May 10, 2023, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.","BOSTON, May  22, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors approved a 1-for-20 reverse stock split, to be effective 4:05 p.m. Eastern Time today, May 22, 2023. TransCode common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Tuesday, May 23, 2023, under the current trading symbol, “RNAZ.” The reverse stock split was approved by TransCode’s stockholders on May 10, 2023, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.",Stock Market News,-0.186619714,-0.186667537,short
"Enochian BioSciences Forges Ahead With Focused Approach, Promising Future","LOS ANGELES, Oct.  24, 2022  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the world’s deadliest diseases. Last week, the Company announced its oncology platform was awarded a U.S. patent and has produced promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. The Company also awaits potentially positive results from studies on its HIV platform, which are being conducted by scientists at the Fred Hutchinson Cancer Center.","LOS ANGELES, Oct.  24, 2022  (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the world’s deadliest diseases. Last week, the Company announced its oncology platform was awarded a U.S. patent and has produced promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. The Company also awaits potentially positive results from studies on its HIV platform, which are being conducted by scientists at the Fred Hutchinson Cancer Center.",Law & Legal Issues,-0.028435993,-0.03271077,short
"Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD",AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine,AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine,Major shareholder announcements,0.035242257,0.033624887,long
Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine,"The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments, and drug discovery","The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments, and drug discovery",Mergers and Acquisitions,-0.046683059,-0.054033998,short
Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors,"LOS ANGELES, Oct.  10, 2023  (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy, is pleased to announce the appointment of Leni Boeren and Ruud Hendriks as Independent Directors.","LOS ANGELES, Oct.  10, 2023  (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy, is pleased to announce the appointment of Leni Boeren and Ruud Hendriks as Independent Directors.",Directors and Officers,-0.057471266,-0.058974872,short
Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer,"LOS ANGELES, Aug.  21, 2023  (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDi Cube on its appointment of Dr. Lester Russell as Chief Medical Officer. For more information: (https://gedicube.com/news).","LOS ANGELES, Aug.  21, 2023  (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDi Cube on its appointment of Dr. Lester Russell as Chief Medical Officer. For more information: (https://gedicube.com/news).",Mergers and Acquisitions,0.017964127,0.015558656,long
Renovaro BioSciences Welcomes GEDiCube Announcement of New Joint Effort,"LOS ANGELES, Aug.  30, 2023  (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDiCube on their joint effort to work to accelerate early diagnosis of cancer in clinical trials.","LOS ANGELES, Aug.  30, 2023  (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDiCube on their joint effort to work to accelerate early diagnosis of cancer in clinical trials.",Clinical Study,0.026923144,0.026143898,long
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions,"BOSTON, Oct.  27, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced The Nasdaq Hearings Panel (“Panel”) granted the Company’s request to continue its listing on The Nasdaq Stock Market (“Nasdaq” or the “Exchange”.) Based on information the Company presented to the Panel, the Panel granted the Company’s request for an exception until January 22, 2024, subject to the conditions outlined below.","BOSTON, Oct.  27, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced The Nasdaq Hearings Panel (“Panel”) granted the Company’s request to continue its listing on The Nasdaq Stock Market (“Nasdaq” or the “Exchange”.) Based on information the Company presented to the Panel, the Panel granted the Company’s request for an exception until January 22, 2024, subject to the conditions outlined below.",Exchange Members,-0.30288465,-0.306859961,short
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock,"BOSTON, April  03, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement with Triton Funds, LP for the sale of 60 shares of the Company’s Series A Convertible Preferred Stock (“Series A Preferred Stock”), each with a stated value of $10,000 per share (the “Stated Value”), for an aggregate purchase price of $500,000 in a registered direct offering.","BOSTON, April  03, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement with Triton Funds, LP for the sale of 60 shares of the Company’s Series A Convertible Preferred Stock (“Series A Preferred Stock”), each with a stated value of $10,000 per share (the “Stated Value”), for an aggregate purchase price of $500,000 in a registered direct offering.",Stock Market News,-0.032448416,-0.031129359,short
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas,"BOSTON, April  14, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a Common Stock Purchase Agreement (the “Agreement”) with White Lion Capital, LLC (“White Lion Capital”) an investor in the glioblastomas / oncology sector. The Agreement provides the Company with the right to sell White Lion Capital up to approximately $1.08 million of its common stock until May 31, 2023, subject to certain limitations and conditions. The Company intends to use the net proceeds from the transaction for working capital and general corporate purposes.","BOSTON, April  14, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a Common Stock Purchase Agreement (the “Agreement”) with White Lion Capital, LLC (“White Lion Capital”) an investor in the glioblastomas / oncology sector. The Agreement provides the Company with the right to sell White Lion Capital up to approximately $1.08 million of its common stock until May 31, 2023, subject to certain limitations and conditions. The Company intends to use the net proceeds from the transaction for working capital and general corporate purposes.",Prospectus/Announcement of Prospectus,-0.065162905,-0.063566649,short
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial,Designed to demonstrate delivery of TTX-MC138 to metastatic lesions Designed to demonstrate delivery of TTX-MC138 to metastatic lesions,Designed to demonstrate delivery of TTX-MC138 to metastatic lesions Designed to demonstrate delivery of TTX-MC138 to metastatic lesions,Health,0.035928182,0.033417612,long
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial,"BOSTON, April  27, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat cancer, announced today that it has received written approval from the Dana Farber Cancer Institute Institutional Review Board (IRB) to proceed with its First-in-Human (FIH) Phase 0 clinical trial. The planned clinical trial is to evaluate delivery of TransCode’s lead therapeutic candidate, TTX-MC138, to metastatic lesions in up to 12 cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode believes that TTX-MC138 could become a treatment for many of these cancers.","BOSTON, April  27, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat cancer, announced today that it has received written approval from the Dana Farber Cancer Institute Institutional Review Board (IRB) to proceed with its First-in-Human (FIH) Phase 0 clinical trial. The planned clinical trial is to evaluate delivery of TransCode’s lead therapeutic candidate, TTX-MC138, to metastatic lesions in up to 12 cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode believes that TTX-MC138 could become a treatment for many of these cancers.",Clinical Study,0.162162199,0.155633327,long
"TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138",Further Supports TTX-MC138 Application in Brain Cancer Further Supports TTX-MC138 Application in Brain Cancer,Further Supports TTX-MC138 Application in Brain Cancer Further Supports TTX-MC138 Application in Brain Cancer,Research Analysis and Reports,0.972891555,0.975795695,long
"TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138",Further Supporting TTX-MC138 Application in Metastatic Cancer Further Supporting TTX-MC138 Application in Metastatic Cancer,Further Supporting TTX-MC138 Application in Metastatic Cancer Further Supporting TTX-MC138 Application in Metastatic Cancer,Clinical Study,0.021551704,0.020479328,long
"TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138",Evidence of Drug Accumulation in Metastatic Lesions Evidence of Drug Accumulation in Metastatic Lesions,Evidence of Drug Accumulation in Metastatic Lesions Evidence of Drug Accumulation in Metastatic Lesions,Research Analysis and Reports,0.192810511,0.187601924,long
"TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138",Suggests potential to improve survival outcomes in patients with GBM Suggests potential to improve survival outcomes in patients with GBM,Suggests potential to improve survival outcomes in patients with GBM Suggests potential to improve survival outcomes in patients with GBM,Clinical Study,0.212938,0.215572356,long
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer,"BOSTON, June  22, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today publication of new data relevant to its lead therapeutic candidate, TTX-MC138, in the Journal of Clinical Oncology. The abstract, published in the June 1 supplemental issue of the journal, was presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO).","BOSTON, June  22, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today publication of new data relevant to its lead therapeutic candidate, TTX-MC138, in the Journal of Clinical Oncology. The abstract, published in the June 1 supplemental issue of the journal, was presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO).",Research Analysis and Reports,0.051660467,0.05393662,long
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio,Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.” Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.”,Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.” Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.”,Product / Services Announcement,-0.010929016,-0.012505096,short
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138,"BOSTON, April  05, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded the third year of a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support the clinical evaluation of TTX-MC138, TransCode’s lead therapeutic candidate for the treatment of advanced solid tumors. The award totals nearly $871,000.","BOSTON, April  05, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded the third year of a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support the clinical evaluation of TTX-MC138, TransCode’s lead therapeutic candidate for the treatment of advanced solid tumors. The award totals nearly $871,000.",Contests/Awards,0.217522743,0.219382458,long
"TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA",Study showed a 70% Inhibition of Recurrent Tumor Growth Study showed a 70% Inhibition of Recurrent Tumor Growth,Study showed a 70% Inhibition of Recurrent Tumor Growth Study showed a 70% Inhibition of Recurrent Tumor Growth,Clinical Study,0.141203676,0.135827066,long
TransCode Therapeutics to present at AACR Annual Meeting 2023,"BOSTON, April  06, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it will present new results and a clinical study overview at the Phase I and First-in-Human Clinical Trials in Progress Session at the 2023 American Association of Cancer Research (AACR) Annual Meeting to be held April 14-19. Studies to be highlighted as part of the Meeting’s Poster Sessions include:","BOSTON, April  06, 2023  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it will present new results and a clinical study overview at the Phase I and First-in-Human Clinical Trials in Progress Session at the 2023 American Association of Cancer Research (AACR) Annual Meeting to be held April 14-19. Studies to be highlighted as part of the Meeting’s Poster Sessions include:",Calendar of Events,-0.057471266,-0.055434914,short
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech,Purchased MDMA supply from PharmAla Biotech for upcoming IND-enabling studies,Purchased MDMA supply from PharmAla Biotech for upcoming IND-enabling studies,Research Analysis and Reports,0,0.001319056,long
Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents,"TORONTO, July  28, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has filed a provisional patent application titled “Compositions, methods and uses of Bucillamine in the treatment of a victim exposed to a chemical warfare agent.”","TORONTO, July  28, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has filed a provisional patent application titled “Compositions, methods and uses of Bucillamine in the treatment of a victim exposed to a chemical warfare agent.”",Patents,-0.185185211,-0.192677122,short
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants,"TORONTO, Jan.  09, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces an independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto, which evaluated the potential disruption of the SARS-CoV-2 virus spike protein by various FDA-approved mild anti-oxidants has shown that Bucillamine had the most potent effect on COVID-19 Omicron variants when compared to these anti-oxidants being explored as a potential treatment for COVID-19. Disruption of the spike protein to prevent viral entry into the host cells with a molecule that is already approved and deemed safe for human use could accelerate the development of a new treatment option for COVID patients. A copy of the publication can be found at https://www.biorxiv.org/content/10.1101/2023.01.06.522977v1.full#F7.","TORONTO, Jan.  09, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces an independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto, which evaluated the potential disruption of the SARS-CoV-2 virus spike protein by various FDA-approved mild anti-oxidants has shown that Bucillamine had the most potent effect on COVID-19 Omicron variants when compared to these anti-oxidants being explored as a potential treatment for COVID-19. Disruption of the spike protein to prevent viral entry into the host cells with a molecule that is already approved and deemed safe for human use could accelerate the development of a new treatment option for COVID patients. A copy of the publication can be found at https://www.biorxiv.org/content/10.1101/2023.01.06.522977v1.full#F7.",Health,0.287356399,0.293786221,long
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure,"TORONTO, Oct.  17, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has entered into an agreement with Defence R&D Canada - Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure. The DRDC will fund the research project, which is expected to begin in early Q1-2024.","TORONTO, Oct.  17, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has entered into an agreement with Defence R&D Canada - Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure. The DRDC will fund the research project, which is expected to begin in early Q1-2024.",Partnerships,0,0.007407602,long
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test,Potential world-first patented biomarker for long COVID,Potential world-first patented biomarker for long COVID,Health,0,-0.001794379,short
"Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden Sitzung des Typs C vor, die von der FDA für die geänderte Prüfplanvereinbarung der klinischen Phase-III-Studie für Bucillamin zur Behandlung von COVID-19 genehmigt wurde","TORONTO (Kanada), Jan.  13, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. („Revive“ oder das „Unternehmen“) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), ein spezialisiertes Biowissenschaftsunternehmen, das sich auf die Erforschung und Entwicklung von Therapeutika für medizinische Bedürfnisse und seltene Erkrankungen konzentriert, gibt bekannt, dass es ein aktualisiertes Informationspaket bei der US-amerikanischen Food & Drug Administration („FDA“) einreichen wird, das zusätzliche unterstützende Informationen und die Daten der unabhängigen veröffentlichten Studie mit dem Titel „Omicron Spike Protein Is Vulnerable to Reduction“ (Omicron-Spike-Protein ist anfällig für eine Reduktion) von der Universität Toronto enthält. Die Studie untersuchte die potenzielle Störung des Spike-Proteins des SARS-CoV-2-Virus durch verschiedene von der FDA zugelassene milde Antioxidantien. Dabei zeigte sich, dass Bucillamin im Vergleich zu diesen Antioxidantien, die als potenzielle Behandlung für COVID-19 untersucht werden, die stärkste Wirkung auf COVID-19 Omicron-Varianten hat.","TORONTO (Kanada), Jan.  13, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. („Revive“ oder das „Unternehmen“) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), ein spezialisiertes Biowissenschaftsunternehmen, das sich auf die Erforschung und Entwicklung von Therapeutika für medizinische Bedürfnisse und seltene Erkrankungen konzentriert, gibt bekannt, dass es ein aktualisiertes Informationspaket bei der US-amerikanischen Food & Drug Administration („FDA“) einreichen wird, das zusätzliche unterstützende Informationen und die Daten der unabhängigen veröffentlichten Studie mit dem Titel „Omicron Spike Protein Is Vulnerable to Reduction“ (Omicron-Spike-Protein ist anfällig für eine Reduktion) von der Universität Toronto enthält. Die Studie untersuchte die potenzielle Störung des Spike-Proteins des SARS-CoV-2-Virus durch verschiedene von der FDA zugelassene milde Antioxidantien. Dabei zeigte sich, dass Bucillamin im Vergleich zu diesen Antioxidantien, die als potenzielle Behandlung für COVID-19 untersucht werden, die stärkste Wirkung auf COVID-19 Omicron-Varianten hat.",Product / Services Announcement,0.048076876,0.03567912,long
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19,FDA recommends additional revised primary symptom-based endpoints,FDA recommends additional revised primary symptom-based endpoints,Clinical Study,-0.00990101,-0.010202377,short
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development,"TORONTO, Nov.  21, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.","TORONTO, Nov.  21, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.",Company Announcement,-0.125000019,-0.122622489,short
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development,"TORONTO, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.","TORONTO, Oct.  11, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.",Product / Services Announcement,0,-0.002531427,short
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19,"TORONTO, March  20, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties in patients with mild to moderate COVID-19.","TORONTO, March  20, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties in patients with mild to moderate COVID-19.",Clinical Study,-0.376811557,-0.378888528,short
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19,"TORONTO, May  12, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.","TORONTO, May  12, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.",Health,-0.339622631,-0.342752732,short
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder,First subject enrolled and initial top-line results expected in Q3-2023 First subject enrolled and initial top-line results expected in Q3-2023,First subject enrolled and initial top-line results expected in Q3-2023 First subject enrolled and initial top-line results expected in Q3-2023,Clinical Study,0,0.001815938,long
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development,"TORONTO, Feb.  06, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a supply agreement with PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) to obtain PharmAla’s LaNeo, GMP source of 3,4-Methylenedioxy​methamphetamine (“MDMA”), for the development of Revive’s microneedle patch delivery system. Recently, Revive Therapeutics announced it entered into a research collaboration agreement with PharmaTher Holdings (CSE: PHRM) (OTCQB: PHRRF) to evaluate their microneedle patch technology with MDMA.","TORONTO, Feb.  06, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a supply agreement with PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) to obtain PharmAla’s LaNeo, GMP source of 3,4-Methylenedioxy​methamphetamine (“MDMA”), for the development of Revive’s microneedle patch delivery system. Recently, Revive Therapeutics announced it entered into a research collaboration agreement with PharmaTher Holdings (CSE: PHRM) (OTCQB: PHRRF) to evaluate their microneedle patch technology with MDMA.",Health,0.099999978,0.10620829,long
Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program,"Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services","Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services",Management statements,0,-0.0023912,short
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19,"TORONTO, Jan.  12, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces it will submit an updated briefing package to the U.S. Food & Drug Administration (“FDA”) to include additional supporting information and the data from the independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto. The study evaluated the potential disruption of the SARS-CoV-2 virus spike protein by various FDA-approved mild anti-oxidants, which has shown that Bucillamine had the most potent effect on COVID-19 Omicron variants when compared to these anti-oxidants being explored as a potential treatment for COVID-19.","TORONTO, Jan.  12, 2023  (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces it will submit an updated briefing package to the U.S. Food & Drug Administration (“FDA”) to include additional supporting information and the data from the independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto. The study evaluated the potential disruption of the SARS-CoV-2 virus spike protein by various FDA-approved mild anti-oxidants, which has shown that Bucillamine had the most potent effect on COVID-19 Omicron variants when compared to these anti-oxidants being explored as a potential treatment for COVID-19.",Product / Services Announcement,-0.086956567,-0.087687598,short
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism,"REDWOOD CITY, Calif., Oct.  11, 2023  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced results following administration of RZ358 to a patient with refractory hypoglycemia due to tumor-mediated hyperinsulinism (tmHI) on a compassionate-use basis, under its expanded access program (EAP). ","REDWOOD CITY, Calif., Oct.  11, 2023  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced results following administration of RZ358 to a patient with refractory hypoglycemia due to tumor-mediated hyperinsulinism (tmHI) on a compassionate-use basis, under its expanded access program (EAP). ",Clinical Study,-0.00999999,-0.012531417,short
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema,RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye,RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye,Company Announcement,0.006578941,0.01934811,long
Rezolute Announces Presentation at the 60th Annual ESPE Meeting,Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation,Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation,Calendar of Events,0.013157882,0.014002434,long
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting,"REDWOOD CITY, Calif., Oct.  20, 2022  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced it will present clinical data from its Phase 1b multiple-ascending dose (MAD) study of RZ402 in Diabetic Macular Edema (DME) in a podium presentation at The Retina Society 55th Annual Scientific Meeting being held November 2-5, 2022 in Pasadena, CA.","REDWOOD CITY, Calif., Oct.  20, 2022  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced it will present clinical data from its Phase 1b multiple-ascending dose (MAD) study of RZ402 in Diabetic Macular Edema (DME) in a podium presentation at The Retina Society 55th Annual Scientific Meeting being held November 2-5, 2022 in Pasadena, CA.",Health,-0.027523018,-0.026247574,short
"Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer","REDWOOD CITY, Calif., June  01, 2022  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Brian Roberts, M.D., previously Senior Vice President and Head of Clinical Development, has been promoted to Chief Medical Officer. Dr. Roberts joined Rezolute in 2017 as Vice President of Clinical Development and a member of the founding management team, with responsibilities that included oversight of preclinical, regulatory, and clinical operations functions.","REDWOOD CITY, Calif., June  01, 2022  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Brian Roberts, M.D., previously Senior Vice President and Head of Clinical Development, has been promoted to Chief Medical Officer. Dr. Roberts joined Rezolute in 2017 as Vice President of Clinical Development and a member of the founding management team, with responsibilities that included oversight of preclinical, regulatory, and clinical operations functions.",Health,0.07142859,0.066003891,long
"Rezolute, Inc. Announces Closing of Registered Direct Offering","REDWOOD CITY, Calif., May  04, 2022  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the closing of its previously announced underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 12,921,055 shares of common stock at an offering price of $3.799 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Certain of the pre-funded warrants offered to investors are only exercisable upon receipt of stockholder approval of an increase in the authorized shares of Rezolute’s common stock which Rezolute will first seek to obtain at an annual meeting of stockholders to be held by June 30, 2022, and the shares of common stock underlying such pre-funded warrants are not being registered under the Securities Act of 1933, as amended (the “Securities Act”). Concurrent with the underwritten registered direct offering, certain existing investors agreed to purchase pre-funded warrants to purchase up to 3,263,157 shares of common stock in a private placement at the same offering price as the offering price of the pre-funded warrants offered in the underwritten registered direct offering. The concurrent private placement is expected to close subject to satisfaction of the closing conditions.","REDWOOD CITY, Calif., May  04, 2022  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the closing of its previously announced underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 12,921,055 shares of common stock at an offering price of $3.799 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Certain of the pre-funded warrants offered to investors are only exercisable upon receipt of stockholder approval of an increase in the authorized shares of Rezolute’s common stock which Rezolute will first seek to obtain at an annual meeting of stockholders to be held by June 30, 2022, and the shares of common stock underlying such pre-funded warrants are not being registered under the Securities Act of 1933, as amended (the “Securities Act”). Concurrent with the underwritten registered direct offering, certain existing investors agreed to purchase pre-funded warrants to purchase up to 3,263,157 shares of common stock in a private placement at the same offering price as the offering price of the pre-funded warrants offered in the underwritten registered direct offering. The concurrent private placement is expected to close subject to satisfaction of the closing conditions.",Warrants and Certificates,0.025850348,-0.002873185,short
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism,PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism,PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism,Product / Services Announcement,0.054347838,0.06175544,long
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day,"REDWOOD CITY, Calif., Nov.  17, 2023  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the management team will participate in BTIG’s 3rd Annual Ophthalmology Day, taking place virtually on November 27th.","REDWOOD CITY, Calif., Nov.  17, 2023  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the management team will participate in BTIG’s 3rd Annual Ophthalmology Day, taking place virtually on November 27th.",Calendar of Events,-0.009888771,-0.009910936,short
Rezolute to Participate in Upcoming Investor Conferences in September,"REDWOOD CITY, Calif., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder, will participate in two upcoming investor conferences.","REDWOOD CITY, Calif., Sept.  06, 2023  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder, will participate in two upcoming investor conferences.",Calendar of Events,-0.006993001,-0.005123184,short
Rezolute to Present at the Jefferies London Healthcare Conference,"REDWOOD CITY, Calif., Nov.  01, 2022  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder, will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 17, 2022, at 11:25 a.m. EST/4:25 p.m. GMT.","REDWOOD CITY, Calif., Nov.  01, 2022  (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder, will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 17, 2022, at 11:25 a.m. EST/4:25 p.m. GMT.",Calendar of Events,0.071005847,0.060829976,long
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results,"Third quarter 2023 total net revenue of $165.8 million, including quarterly BRIUMVI® net sales of $25.1 million in the United States, and license revenue of $140.0 million from the upfront payment received from Neuraxpharm","Third quarter 2023 total net revenue of $165.8 million, including quarterly BRIUMVI® net sales of $25.1 million in the United States, and license revenue of $140.0 million from the upfront payment received from Neuraxpharm",Earnings Releases and Operating Results,0.318240563,0.315849363,long
Scilex Holding Company Added to the Preliminary List of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 2023 Russell Indexes Annual Reconstitution in June 2023,"PALO ALTO, Calif., May  22, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced today that it has been added to the preliminary list of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 35th Russell indexes annual reconstitution. Preliminary membership lists (reflecting any updates) will be posted to the FTSE Russell website from May 26 – June 16, 2023. The annual reconstitution will be final after the close of market on Friday, June 23, 2023 and will become effective Monday, June 26th 2023 at the open of the equity markets. This rebalancing process is designed to capture market shifts from the previous year to ensure the Russell U.S. Indexes continue to accurately reflect the US equity market.","PALO ALTO, Calif., May  22, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced today that it has been added to the preliminary list of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 35th Russell indexes annual reconstitution. Preliminary membership lists (reflecting any updates) will be posted to the FTSE Russell website from May 26 – June 16, 2023. The annual reconstitution will be final after the close of market on Friday, June 23, 2023 and will become effective Monday, June 26th 2023 at the open of the equity markets. This rebalancing process is designed to capture market shifts from the previous year to ensure the Russell U.S. Indexes continue to accurately reflect the US equity market.",Health,0.008403353,0.008355531,long
"Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain","PALO ALTO, Calif., May  04, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced complete enrollment in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% triple strength formulation for ZTlido®, in subjects with acute LBP.","PALO ALTO, Calif., May  04, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced complete enrollment in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% triple strength formulation for ZTlido®, in subjects with acute LBP.",Clinical Study,0,0.002671429,long
Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch,"PALO ALTO, Calif., Nov.  17, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Patent and Trademark Office has issued a second new patent, No. 11,786,455 (the ”Patent”), further strengthening the Company’s intellectual property position and coverage for its lead commercial product, ZTlido® (lidocaine topical system) 1.8%, which will expire in 2031. The Patent, titled “Non-aqueous Patch,” covers a non-aqueous lidocaine patch with certain specifications, as well as a method of relieving pain through the application of a non-aqueous lidocaine-containing patch.","PALO ALTO, Calif., Nov.  17, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Patent and Trademark Office has issued a second new patent, No. 11,786,455 (the ”Patent”), further strengthening the Company’s intellectual property position and coverage for its lead commercial product, ZTlido® (lidocaine topical system) 1.8%, which will expire in 2031. The Patent, titled “Non-aqueous Patch,” covers a non-aqueous lidocaine patch with certain specifications, as well as a method of relieving pain through the application of a non-aqueous lidocaine-containing patch.",Patents,0.05607471,0.056052545,long
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update,"Conference call to be held Tuesday, August 1, 2023, at 8:30 AM ET Conference call to be held Tuesday, August 1, 2023, at 8:30 AM ET","Conference call to be held Tuesday, August 1, 2023, at 8:30 AM ET Conference call to be held Tuesday, August 1, 2023, at 8:30 AM ET",Calendar of Events,0.012182729,0.011110353,long
Scilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch,"PALO ALTO, Calif., Nov.  15, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,793,766 (the “Patent”), further strengthening the Company’s intellectual property position and coverage for its lead commercial product, ZTlido® (lidocaine topical system) 1.8%. The Patent, titled “Non-aqueous Patch for the Relief of Pain,” covers a method of relieving pain through the application of a lidocaine-containing patch.","PALO ALTO, Calif., Nov.  15, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,793,766 (the “Patent”), further strengthening the Company’s intellectual property position and coverage for its lead commercial product, ZTlido® (lidocaine topical system) 1.8%. The Patent, titled “Non-aqueous Patch for the Relief of Pain,” covers a method of relieving pain through the application of a lidocaine-containing patch.",Patents,0.032520294,0.029445005,long
"Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy","PALO ALTO, Calif., Nov.  22, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the key product attributes of ELYXYB® meet the high unmet needs of clinicians treating patients with acute migraine, with and without aura, in adults, based on the results from a recent market research study.","PALO ALTO, Calif., Nov.  22, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the key product attributes of ELYXYB® meet the high unmet needs of clinicians treating patients with acute migraine, with and without aura, in adults, based on the results from a recent market research study.",Product / Services Announcement,0.025316444,0.021543809,long
"Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders","PALO ALTO, Calif., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced a peer-review publication which contains results of skin penetration studies conducted at the Institute for Biomedical Research and Technologies, Graz, Austria. A set of studies assessed drug delivery from SP-103, ZTlido and control (Pennsaid®, 2% diclofenac) using open flow microperfusion. Interstitial fluid from the dermis, subcutaneous adipose tissue, and muscle was continuously sampled to assess drug penetration in all tissue layers. Ex vivo and in vivo experiments showed a higher diffusive transport of lidocaine compared to diclofenac. The data showed a clear contribution of diffusive transport to lidocaine concentration, with SP-103 resulting in a significantly higher lidocaine concentration in muscle tissue than commercially available ZTlido (p = 0.008). The Company believes that these results indicate that SP-103 is highly effective in delivering lidocaine into muscle tissue in areas of localized pain for the treatment of musculoskeletal pain disorders.","PALO ALTO, Calif., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced a peer-review publication which contains results of skin penetration studies conducted at the Institute for Biomedical Research and Technologies, Graz, Austria. A set of studies assessed drug delivery from SP-103, ZTlido and control (Pennsaid®, 2% diclofenac) using open flow microperfusion. Interstitial fluid from the dermis, subcutaneous adipose tissue, and muscle was continuously sampled to assess drug penetration in all tissue layers. Ex vivo and in vivo experiments showed a higher diffusive transport of lidocaine compared to diclofenac. The data showed a clear contribution of diffusive transport to lidocaine concentration, with SP-103 resulting in a significantly higher lidocaine concentration in muscle tissue than commercially available ZTlido (p = 0.008). The Company believes that these results indicate that SP-103 is highly effective in delivering lidocaine into muscle tissue in areas of localized pain for the treatment of musculoskeletal pain disorders.",Research Analysis and Reports,0.02762435,0.018349796,long
Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica),"PALO ALTO, Calif., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). The Company has reached agreement with the FDA on the path forward to advance the clinical development of SP-102 and on the requirements to file a New Drug Application (“NDA”).","PALO ALTO, Calif., Nov.  02, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). The Company has reached agreement with the FDA on the path forward to advance the clinical development of SP-102 and on the requirements to file a New Drug Application (“NDA”).",Regulatory information,0.02762435,0.018349796,long
"Scilex Holding Company Announces Production Increase, Product Availability, and The Brand Marketed and Distributed Under Scilex Pharmaceuticals, Inc. for ELYXYB®","PALO ALTO, Calif., Nov.  21, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the increase of ELYXYB® (celecoxib oral solution) manufacturing to meet its rising demand for ELYXYB® and increased stocking needs in its distribution center. Scilex has met another significant corporate objective and produced our first commercial batch with Scilex labeled ELYXYB which will enable the Company to meet the growing demands of future customers seeking a rapid onset pain management regimen for the acute treatment of migraine.","PALO ALTO, Calif., Nov.  21, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the increase of ELYXYB® (celecoxib oral solution) manufacturing to meet its rising demand for ELYXYB® and increased stocking needs in its distribution center. Scilex has met another significant corporate objective and produced our first commercial batch with Scilex labeled ELYXYB which will enable the Company to meet the growing demands of future customers seeking a rapid onset pain management regimen for the acute treatment of migraine.",Company Announcement,-0.0181818,-0.01580427,short
Scilex Holding Company Announces Results From Independent Market Research Study Conducted with Pain Specialists and HCPs Treating Post-Herpetic Neuralgia (PHN) Pain on ZTlido®,"PALO ALTO, Calif., July  13, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the results from a primary market research study with 80 pain specialists conducted on behalf of the Company by Syneos. The study was a primary market research analysis in which 80 US-based pain specialists and HCPs were presented with various product attributes, including efficacy, safety and tolerability, to determine comparative prescribing preferences for currently available lidocaine patches, neuropathic pain agents and ZTlido® for the treatment of PHN shingles-related pain. Respondents stated that the greatest unmet need in the treatment of PHN pain with current agents is greater efficacy, followed by better tolerability and fewer side effects.","PALO ALTO, Calif., July  13, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the results from a primary market research study with 80 pain specialists conducted on behalf of the Company by Syneos. The study was a primary market research analysis in which 80 US-based pain specialists and HCPs were presented with various product attributes, including efficacy, safety and tolerability, to determine comparative prescribing preferences for currently available lidocaine patches, neuropathic pain agents and ZTlido® for the treatment of PHN shingles-related pain. Respondents stated that the greatest unmet need in the treatment of PHN pain with current agents is greater efficacy, followed by better tolerability and fewer side effects.",Product / Services Announcement,0.042750932,0.038535863,long
"Scilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock","PALO ALTO, Calif., June  15, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that, in connection with Sorrento Therapeutics, Inc.’s ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) has entered a temporary restraining order suspending short-sales of common stock of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) that Sorrento distributed to its stockholders on or around January 19, 2023 (the “Dividended Scilex Stock”).","PALO ALTO, Calif., June  15, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that, in connection with Sorrento Therapeutics, Inc.’s ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) has entered a temporary restraining order suspending short-sales of common stock of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) that Sorrento distributed to its stockholders on or around January 19, 2023 (the “Dividended Scilex Stock”).",Changes in company's own shares,0.073825531,0.075769824,long
"Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)","PALO ALTO, Calif., Sept.  14, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the completion of its SP-103 Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy in subjects with acute LBP. Objectives of the trial were to assess safety and tolerability of SP-103 and to provide treatment effect estimates in patient population that can be used to power future studies. The trial enrolled 75 subjects, 38 received SP-103, and 37 received placebo. Topical systems were applied to the area of most tenderness in the lower back in 12-hours ON/ 12-hours OFF regimen.","PALO ALTO, Calif., Sept.  14, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the completion of its SP-103 Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy in subjects with acute LBP. Objectives of the trial were to assess safety and tolerability of SP-103 and to provide treatment effect estimates in patient population that can be used to power future studies. The trial enrolled 75 subjects, 38 received SP-103, and 37 received placebo. Topical systems were applied to the area of most tenderness in the lower back in 12-hours ON/ 12-hours OFF regimen.",Clinical Study,0.008968601,0.003235253,long
"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023","PALO ALTO, Calif., Sept.  25, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List (“PDL”) effective October 1, 2023.","PALO ALTO, Calif., Sept.  25, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List (“PDL”) effective October 1, 2023.",Product / Services Announcement,-0.012658291,-0.009754151,short
"Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder","PALO ALTO, Calif., Sept.  13, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, “Oramed”) and Sorrento executed non-binding term sheets relating to, among other things, the Securities Transfer (as defined below) (the “Securities Transfer Term Sheet”) (which the official committee of unsecured creditors and the official committee of equity security holders in Sorrento’s bankruptcy cases have each signed as “Consenting Parties” thereto) and the Note (as defined below) (the “Note Term Sheet” and together with the Securities Transfer Term Sheet, the “Scilex Term Sheets”). After a hearing before the Bankruptcy Court in Sorrento’s bankruptcy cases on September 12, 2023, such court entered a final order approving the Scilex Term Sheets. The Scilex Term Sheets are subject to entry into definitive documentation relating thereto. The transactions contemplated by the Scilex Term Sheets are expected to close on or about September 19, 2023.  ","PALO ALTO, Calif., Sept.  13, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, “Oramed”) and Sorrento executed non-binding term sheets relating to, among other things, the Securities Transfer (as defined below) (the “Securities Transfer Term Sheet”) (which the official committee of unsecured creditors and the official committee of equity security holders in Sorrento’s bankruptcy cases have each signed as “Consenting Parties” thereto) and the Note (as defined below) (the “Note Term Sheet” and together with the Securities Transfer Term Sheet, the “Scilex Term Sheets”). After a hearing before the Bankruptcy Court in Sorrento’s bankruptcy cases on September 12, 2023, such court entered a final order approving the Scilex Term Sheets. The Scilex Term Sheets are subject to entry into definitive documentation relating thereto. The transactions contemplated by the Scilex Term Sheets are expected to close on or about September 19, 2023.  ",Major shareholder announcements,0.01229507,0.011779339,long
"Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia","PALO ALTO, Calif., May  31, 2023  (GLOBE NEWSWIRE) --  Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced a master distributor agreement with Farouk, Maamoun Tamer & Co. for the distribution of ZTlido® in Kingdom of Saudi Arabia.","PALO ALTO, Calif., May  31, 2023  (GLOBE NEWSWIRE) --  Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced a master distributor agreement with Farouk, Maamoun Tamer & Co. for the distribution of ZTlido® in Kingdom of Saudi Arabia.",Product / Services Announcement,-0.019769417,-0.018741415,short
"Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure","PALO ALTO, Calif., Oct.  27, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today filed an emergency motion (the “Motion”) for entry of an order compelling the production of books and records from certain brokers, dealers, banks and other nominees pursuant to Rule 2004 of the federal rules of bankruptcy procedure in the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”).   Attached to this press release is the court motion filed by Scilex on October 27, 2023.","PALO ALTO, Calif., Oct.  27, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today filed an emergency motion (the “Motion”) for entry of an order compelling the production of books and records from certain brokers, dealers, banks and other nominees pursuant to Rule 2004 of the federal rules of bankruptcy procedure in the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”).   Attached to this press release is the court motion filed by Scilex on October 27, 2023.",Law & Legal Issues,-0.051546403,-0.043072007,short
"Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Information","PALO ALTO, Calif., Sept.  11, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announces record revenue for the month of August 2023 and is providing certain preliminary unaudited financial results for the month ended August 31, 2023, and year-to-date as of August 31, 2023, based on currently available information.","PALO ALTO, Calif., Sept.  11, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announces record revenue for the month of August 2023 and is providing certain preliminary unaudited financial results for the month ended August 31, 2023, and year-to-date as of August 31, 2023, based on currently available information.",Pre-Release Comments,0.023622025,0.017516797,long
Seer Announces Publication of Seminal Study Demonstrating the Power of Engineered Nano-Bio Interactions to Enable Deep Access to the Proteome,"Published results highlight how the combination of proteomic methods, nanoengineering and machine learning enables the capture of thousands of proteins Published results highlight how the combination of proteomic methods, nanoengineering and machine learning enables the capture of thousands of proteins","Published results highlight how the combination of proteomic methods, nanoengineering and machine learning enables the capture of thousands of proteins Published results highlight how the combination of proteomic methods, nanoengineering and machine learning enables the capture of thousands of proteins",Product / Services Announcement,0.002000046,0.003088741,long
"Scilex Holding Company Generates Record Monthly Revenue In October 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended October 2023, And Year-To-Date Through October 31, 2023, Based On Currently Available Information","PALO ALTO, Calif., Nov.  01, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced record monthly revenue in October 2023 for ZTlido and provided certain preliminary unaudited financial results for gross and net sales for the one month ended October 2023 and year-to-date through October 31, 2023.","PALO ALTO, Calif., Nov.  01, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced record monthly revenue in October 2023 for ZTlido and provided certain preliminary unaudited financial results for gross and net sales for the one month ended October 2023 and year-to-date through October 31, 2023.",Interim information,-0.016042765,-0.018433966,short
"Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV","PALO ALTO, Calif., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual Brain Week Conference on the benefits of Elyxyb (celecoxib oral solution). The conference was held from September 6-8, 2023 in Las Vegas, NV.","PALO ALTO, Calif., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual Brain Week Conference on the benefits of Elyxyb (celecoxib oral solution). The conference was held from September 6-8, 2023 in Las Vegas, NV.",Calendar of Events,0.024896241,0.028241095,long
"Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV","PALO ALTO, Calif., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual PAINWeek Conference on the benefits of ZTlido (lidocaine topical system). The conference was held from September 5-8, 2023 in Las Vegas, NV.","PALO ALTO, Calif., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual PAINWeek Conference on the benefits of ZTlido (lidocaine topical system). The conference was held from September 5-8, 2023 in Las Vegas, NV.",Research Analysis and Reports,0.024896241,0.028241095,long
"Scilex Holding Company provides certain preliminary unaudited financial results for gross and net Sales for the one month ended May 2023, and year-to-date May 2023, based on currently available information","PALO ALTO, Calif., June  01, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, is providing certain preliminary unaudited financial results for the month ended May 31, 2023, and year-to-date as of May 31, 2023, based on currently available information.","PALO ALTO, Calif., June  01, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, is providing certain preliminary unaudited financial results for the month ended May 31, 2023, and year-to-date as of May 31, 2023, based on currently available information.",Pre-Release Comments,-0.015024988,-0.023946539,short
Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company,"PALO ALTO, Calif., Oct.  04, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides notice to all lenders of short positions of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) to Sorrento equity holders of record as of January 9, 2023.","PALO ALTO, Calif., Oct.  04, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides notice to all lenders of short positions of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) to Sorrento equity holders of record as of January 9, 2023.",Dividend Reports and Estimates,0.137096739,0.130960324,long
Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company,"PALO ALTO, Calif., Oct.  03, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides notice to all record holders and beneficial owners of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) to Sorrento equity holders of record as of January 9, 2023.","PALO ALTO, Calif., Oct.  03, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides notice to all record holders and beneficial owners of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) to Sorrento equity holders of record as of January 9, 2023.",Changes in share capital and votes,-0.00751879,-0.002253291,short
Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401),"PALO ALTO, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, submitted a request to the Securities and Exchange Commission (the “SEC”) to withdraw its Registration Statement on Form S-1 (File No. 333-271401) (the “Registration Statement”), as amended, initially filed with the SEC on April 21, 2023. The Company anticipates that, in accordance with SEC rules and regulations, such request will be deemed granted as of the date of such request, unless the SEC notifies the Company within 15 days that such request will not be granted. The Registration Statement had not been declared effective by the SEC, and no securities had been sold pursuant to the Registration Statement.","PALO ALTO, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, submitted a request to the Securities and Exchange Commission (the “SEC”) to withdraw its Registration Statement on Form S-1 (File No. 333-271401) (the “Registration Statement”), as amended, initially filed with the SEC on April 21, 2023. The Company anticipates that, in accordance with SEC rules and regulations, such request will be deemed granted as of the date of such request, unless the SEC notifies the Company within 15 days that such request will not be granted. The Registration Statement had not been declared effective by the SEC, and no securities had been sold pursuant to the Registration Statement.",Regulatory information,-0.019230752,-0.022071907,short
"Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023","PALO ALTO, Calif., April  28, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that Henry Ji, Ph.D., Executive Chairman of Scilex, and Jaisim Shah, Chief Executive Officer and President of Scilex will participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq:","PALO ALTO, Calif., April  28, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that Henry Ji, Ph.D., Executive Chairman of Scilex, and Jaisim Shah, Chief Executive Officer and President of Scilex will participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq:",Calendar of Events,-0.043927608,-0.041696786,short
"Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center",Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific community to dig deeper into the proteome Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific community to dig deeper into the proteome,Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific community to dig deeper into the proteome Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific community to dig deeper into the proteome,Partnerships,0.010288007,0.009330121,long
"Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX.","PALO ALTO, Calif., June  16, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it will be presenting data on ELYXYB™ (celecoxib oral solution) for acute treatment of migraine with or without aura in adults at the 65th Annual Scientific Meeting of American Headache Society (AHS) to be held on June 14-18, 2023 in Austin, Texas.","PALO ALTO, Calif., June  16, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it will be presenting data on ELYXYB™ (celecoxib oral solution) for acute treatment of migraine with or without aura in adults at the 65th Annual Scientific Meeting of American Headache Society (AHS) to be held on June 14-18, 2023 in Austin, Texas.",Calendar of Events,0.017994841,0.017045941,long
"UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure","PALO ALTO, Calif., Oct.  27, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today filed an emergency motion (the “Motion”) for entry of an order compelling the production of books and records from certain brokers, dealers, banks and other nominees pursuant to Rule 2004 of the federal rules of bankruptcy procedure in the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). Attached to this press release is the court motion filed by Scilex on October 27, 2023:","PALO ALTO, Calif., Oct.  27, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today filed an emergency motion (the “Motion”) for entry of an order compelling the production of books and records from certain brokers, dealers, banks and other nominees pursuant to Rule 2004 of the federal rules of bankruptcy procedure in the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). Attached to this press release is the court motion filed by Scilex on October 27, 2023:",Law & Legal Issues,-0.051546403,-0.043072007,short
scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives,Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients,Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients,Product / Services Announcement,0,0.002141452,long
scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion,Company also announces issuance of key patents covering development of alternate formulations of furosemide Company also announces issuance of key patents covering development of alternate formulations of furosemide,Company also announces issuance of key patents covering development of alternate formulations of furosemide Company also announces issuance of key patents covering development of alternate formulations of furosemide,Health,0,0.003320342,long
scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes,"BURLINGTON, Mass., June  23, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it expects to be added to the small cap Russell 2000® and broad market Russell 3000® Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective when the US market opens on June 26, 2023, according to a preliminary list of additions posted on May 19, 2023.","BURLINGTON, Mass., June  23, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it expects to be added to the small cap Russell 2000® and broad market Russell 3000® Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective when the US market opens on June 26, 2023, according to a preliminary list of additions posted on May 19, 2023.",Stock Market News,0.000964342,0.009165797,long
scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer,Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role,Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role,Directors and Officers,0.004702152,0.004180295,long
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"BURLINGTON, Mass., Feb.  06, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on February 1, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 142,500 shares of its common stock to 38 new employees.","BURLINGTON, Mass., Feb.  06, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on February 1, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 142,500 shares of its common stock to 38 new employees.",Stock Market News,0.004981315,0.011189628,long
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"BURLINGTON, Mass., July  19, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on July 3, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 26,250 shares of its common stock to seven new employees.","BURLINGTON, Mass., July  19, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on July 3, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 26,250 shares of its common stock to seven new employees.",Major shareholder announcements,-0.004645756,-0.006451184,short
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"BURLINGTON, Mass., Oct.  05, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on October 2, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 52,500 shares of its common stock to 14 new employees comprised of sales representatives.","BURLINGTON, Mass., Oct.  05, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on October 2, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 52,500 shares of its common stock to 14 new employees comprised of sales representatives.",Health,-0.004739294,-0.004032804,short
scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update,"Commercial launch planned for February 20, 2023 Commercial launch planned for February 20, 2023","Commercial launch planned for February 20, 2023 Commercial launch planned for February 20, 2023",Product / Services Announcement,0.010544805,0.017644009,long
"scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22",Management to host conference call and webcast at 4:30 p.m. ET,Management to host conference call and webcast at 4:30 p.m. ET,Earnings Releases and Operating Results,-0.021306832,-0.006398614,short
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates,On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024,On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024,Earnings Releases and Operating Results,0.079303644,0.082435608,long
scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event,"BURLINGTON, Mass., Dec.  14, 2022  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in the 12th Annual LifeSci Partners Corporate Access Event, on Monday, January 9 and Tuesday, January 10, 2023, in San Francisco. Learn more about the event and schedule an in-person meeting with the scPharmaceuticals management here.","BURLINGTON, Mass., Dec.  14, 2022  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in the 12th Annual LifeSci Partners Corporate Access Event, on Monday, January 9 and Tuesday, January 10, 2023, in San Francisco. Learn more about the event and schedule an in-person meeting with the scPharmaceuticals management here.",Calendar of Events,0,0.000895629,long
scPharmaceuticals to Present at the Jefferies Healthcare Conference,"BURLINGTON, Mass., May  31, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference, which is being held June 7-9 in New York.","BURLINGTON, Mass., May  31, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference, which is being held June 7-9 in New York.",Health,-0.003917724,0.000604133,long
Shockwave Medical Launches New Coronary IVL Catheter Internationally and Enrolls First Patient in All-Female Empower Study,Shockwave C2+ Catheter Expands Utility of IVL in Calcified Coronary Arteries,Shockwave C2+ Catheter Expands Utility of IVL in Calcified Coronary Arteries,Health,0.002464485,0.000933824,long
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies,Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale,Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale,Product / Services Announcement,0,-0.000574345,short
Seer’s Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression,"Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers","Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers",Health,0.002688169,-0.000862486,short
Seer’s Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist,"Annual award from The Scientist celebrates transformative products like Seer’s Proteograph™ Product Suite, which make unbiased, at-scale proteomics accessible Annual award from The Scientist celebrates transformative products like Seer’s Proteograph™ Product Suite, which make unbiased, at-scale proteomics accessible","Annual award from The Scientist celebrates transformative products like Seer’s Proteograph™ Product Suite, which make unbiased, at-scale proteomics accessible Annual award from The Scientist celebrates transformative products like Seer’s Proteograph™ Product Suite, which make unbiased, at-scale proteomics accessible",Contests/Awards,0.037891271,0.025610367,long
"Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum","REDWOOD CITY, Calif., Nov.  10, 2023  (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.","REDWOOD CITY, Calif., Nov.  10, 2023  (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.",Calendar of Events,-0.009287917,-0.014220645,short
Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500,Seer technology receives recognition for excellence in the field of proteomics Seer technology receives recognition for excellence in the field of proteomics,Seer technology receives recognition for excellence in the field of proteomics Seer technology receives recognition for excellence in the field of proteomics,Contests/Awards,-0.040697704,-0.042116685,short
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023,"SAN MATEO, Calif., Oct.  24, 2023  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announces the acceptance of two abstracts, one of which is a late-breaking poster, at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, to be held November 10-14, 2023 in Boston, MA.","SAN MATEO, Calif., Oct.  24, 2023  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announces the acceptance of two abstracts, one of which is a late-breaking poster, at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, to be held November 10-14, 2023 in Boston, MA.",Health,-0.024719025,-0.027037754,short
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023,"Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver fibrosis, while semaglutide alone did not significantly improve fibrosis","Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver fibrosis, while semaglutide alone did not significantly improve fibrosis",Clinical Study,0.050000038,0.04506731,long
"Science 37 Adds New Head of Quality, Irena Lambridis",New role supports the Company’s objective to be the DCT industry’s “undisputed leader” in quality New role supports the Company’s objective to be the DCT industry’s “undisputed leader” in quality,New role supports the Company’s objective to be the DCT industry’s “undisputed leader” in quality New role supports the Company’s objective to be the DCT industry’s “undisputed leader” in quality,Directors and Officers,0.013157882,0.009195994,long
"Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity","New role supports the Company’s objective to lead the industry with faster, more inclusive clinical research New role supports the Company’s objective to lead the industry with faster, more inclusive clinical research","New role supports the Company’s objective to lead the industry with faster, more inclusive clinical research New role supports the Company’s objective to lead the industry with faster, more inclusive clinical research",Management Changes,-0.005847965,-0.000879789,short
"Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List","RESEARCH TRIANGLE PARK, N.C., Sept.  20, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, today announced that its Chief Delivery Officer, Darcy Forman, has been honored with a coveted spot on the prestigious PharmaVoice 100 list. This recognition not only underscores Darcy's leadership, it highlights the industry-wide impact of Science 37 and its positive contributions to patients, community providers, CROs, and clinical trial sponsors.","RESEARCH TRIANGLE PARK, N.C., Sept.  20, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, today announced that its Chief Delivery Officer, Darcy Forman, has been honored with a coveted spot on the prestigious PharmaVoice 100 list. This recognition not only underscores Darcy's leadership, it highlights the industry-wide impact of Science 37 and its positive contributions to patients, community providers, CROs, and clinical trial sponsors.",Contests/Awards,0.017441809,0.014505308,long
"Science 37 Collaborates with AWS to Enable Faster, Patient-Friendly, Clinical Research","RESEARCH TRIANGLE PARK, N.C., April  20, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, today announced a multi-year relationship with Amazon Web Services (AWS) to scale and accelerate adoption of the Science 37 Metasite, which provides clinical trial sponsors the ability to securely engage with patients beyond traditional clinical trial sites.","RESEARCH TRIANGLE PARK, N.C., April  20, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, today announced a multi-year relationship with Amazon Web Services (AWS) to scale and accelerate adoption of the Science 37 Metasite, which provides clinical trial sponsors the ability to securely engage with patients beyond traditional clinical trial sites.",Partnerships,0.107784474,0.114859432,long
Science 37 Joins Partnership in Support of White House CancerX and Cancer Moonshot,Strategic partnership will leverage Science 37’s leadership in remote and hybrid clinical research to enable expansive clinical trial access for oncology patients Strategic partnership will leverage Science 37’s leadership in remote and hybrid clinical research to enable expansive clinical trial access for oncology patients,Strategic partnership will leverage Science 37’s leadership in remote and hybrid clinical research to enable expansive clinical trial access for oncology patients Strategic partnership will leverage Science 37’s leadership in remote and hybrid clinical research to enable expansive clinical trial access for oncology patients,Partnerships,-0.014084535,-0.012303541,short
Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards,"RESEARCH TRIANGLE PARK, N.C., Aug.  15, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ is proud to announce its nomination for the prestigious 2023 Prix Galien USA Awards in the category of ""Best Digital Health Solution.” The Prix Galien Awards, organized by The Galien Foundation, recognize and celebrate groundbreaking innovations in the life sciences industry that significantly advance human health and well-being.","RESEARCH TRIANGLE PARK, N.C., Aug.  15, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ is proud to announce its nomination for the prestigious 2023 Prix Galien USA Awards in the category of ""Best Digital Health Solution.” The Prix Galien Awards, organized by The Galien Foundation, recognize and celebrate groundbreaking innovations in the life sciences industry that significantly advance human health and well-being.",Contests/Awards,-0.038997211,-0.034891084,short
"Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023","RESEARCH TRIANGLE PARK, N.C., Sept.  13, 2023  (GLOBE NEWSWIRE) -- Science 37 announced today that it has been recognized in the Gartner Hype Cycle for Life Science Clinical Development, 2023. As stated by Gartner, “This Hype Cycle explores innovative technologies that are specifically relevant to life science clinical development programs in the pharmaceutical, biotechnology, diagnostics, medical device, research institutions, and contract research sectors.”","RESEARCH TRIANGLE PARK, N.C., Sept.  13, 2023  (GLOBE NEWSWIRE) -- Science 37 announced today that it has been recognized in the Gartner Hype Cycle for Life Science Clinical Development, 2023. As stated by Gartner, “This Hype Cycle explores innovative technologies that are specifically relevant to life science clinical development programs in the pharmaceutical, biotechnology, diagnostics, medical device, research institutions, and contract research sectors.”",Contests/Awards,0.011111078,0.010595347,long
"Science 37 to Report First Quarter 2023 Financial Results on May 15, 2023","RESEARCH TRIANGLE PARK, N.C., May  01, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will report first quarter 2023 financial results prior to the market open on Monday, May 15, 2023.","RESEARCH TRIANGLE PARK, N.C., May  01, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will report first quarter 2023 financial results prior to the market open on Monday, May 15, 2023.",Calendar of Events,0.045774582,0.046880517,long
"Science 37 Wins 2023 MedTech Breakthrough Award for ""Best Overall Clinical Trial Platform""",Science 37's unified platform that powers the Metasite receives award for outstanding digital health and technology innovation Science 37's unified platform that powers the Metasite receives award for outstanding digital health and technology innovation,Science 37's unified platform that powers the Metasite receives award for outstanding digital health and technology innovation Science 37's unified platform that powers the Metasite receives award for outstanding digital health and technology innovation,Contests/Awards,0.029411713,0.030206495,long
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU),Science 37's Metasite to Facilitate Phase 3 Study Enrollment by Expanding Access and Maximizing Convenience for Patients Science 37's Metasite to Facilitate Phase 3 Study Enrollment by Expanding Access and Maximizing Convenience for Patients,Science 37's Metasite to Facilitate Phase 3 Study Enrollment by Expanding Access and Maximizing Convenience for Patients Science 37's Metasite to Facilitate Phase 3 Study Enrollment by Expanding Access and Maximizing Convenience for Patients,Partnerships,0.027027014,0.025230152,long
ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis,"SAN DIEGO, May  09, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA) posted briefing documents for the Pulmonology, Allergy-Drugs Advisory Committee (PADAC) meeting to review the new drug application (NDA) for neffy®. neffy has the potential to be the first, non-injectable epinephrine nasal spray medicine for the treatment of patients with allergic reactions (type 1), including anaphylaxis.","SAN DIEGO, May  09, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA) posted briefing documents for the Pulmonology, Allergy-Drugs Advisory Committee (PADAC) meeting to review the new drug application (NDA) for neffy®. neffy has the potential to be the first, non-injectable epinephrine nasal spray medicine for the treatment of patients with allergic reactions (type 1), including anaphylaxis.",Product / Services Announcement,-0.016638998,-0.012738273,short
"ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis","SAN DIEGO, March  28, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Division of Pulmonology, Allergy and Critical Care Advisory Committee meeting on May 11, 2023 to review the new drug application (NDA) for neffy®. neffy has the potential to be the first, non-injectable epinephrine nasal spray medicine for the treatment of patients with allergic reactions (type 1), including anaphylaxis.","SAN DIEGO, March  28, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Division of Pulmonology, Allergy and Critical Care Advisory Committee meeting on May 11, 2023 to review the new drug application (NDA) for neffy®. neffy has the potential to be the first, non-injectable epinephrine nasal spray medicine for the treatment of patients with allergic reactions (type 1), including anaphylaxis.",Product / Services Announcement,-0.00970143,-0.009271931,short
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis,"Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting","Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting",Trade Show,0.059405963,0.022199691,long
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis,"Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting","Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting",Clinical Study,-0.047222178,-0.036753013,short
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray),"SAN DIEGO, Oct.  06, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that the United States (U.S.) Food and Drug Administration (FDA) has scheduled a Type A meeting to discuss the contents of a Complete Response Letter (CRL) previously issued regarding its new drug application (NDA) for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (Type I), including anaphylaxis.","SAN DIEGO, Oct.  06, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that the United States (U.S.) Food and Drug Administration (FDA) has scheduled a Type A meeting to discuss the contents of a Complete Response Letter (CRL) previously issued regarding its new drug application (NDA) for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (Type I), including anaphylaxis.",Clinical Study,-0.00751879,-0.00155884,short
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results,"FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment of Allergic Reactions (Type I), Including Anaphylaxis","FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment of Allergic Reactions (Type I), Including Anaphylaxis",Earnings Releases and Operating Results,0.00870643,0.007175768,long
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology,"SAN DIEGO, Oct.  03, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today the publication of its full pharmacokinetic and pharmacodynamic results from one of its four primary registration studies of neffy (epinephrine nasal spray) in the Journal of Allergy and Clinical Immunology (JACI). JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology. The clinical study evaluated single and repeat doses of neffy compared to single and repeat doses of approved injection products in healthy subjects.","SAN DIEGO, Oct.  03, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today the publication of its full pharmacokinetic and pharmacodynamic results from one of its four primary registration studies of neffy (epinephrine nasal spray) in the Journal of Allergy and Clinical Immunology (JACI). JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology. The clinical study evaluated single and repeat doses of neffy compared to single and repeat doses of approved injection products in healthy subjects.",Clinical Study,0.046875018,0.052140517,long
Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer,"SOUTH SAN FRANCISCO, Calif., Feb.  28, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Anne Borgman, M.D., as Chief Medical Officer, effective February 28, 2023. Dr. Borgman brings over 20 years of oncology and hematology drug development experience to Sutro, including extensive regulatory experience in both the U.S. and Europe, leading to nine regulatory approvals.","SOUTH SAN FRANCISCO, Calif., Feb.  28, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Anne Borgman, M.D., as Chief Medical Officer, effective February 28, 2023. Dr. Borgman brings over 20 years of oncology and hematology drug development experience to Sutro, including extensive regulatory experience in both the U.S. and Europe, leading to nine regulatory approvals.",Directors and Officers,0,0.001257134,long
Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer,"SOUTH SAN FRANCISCO, Calif., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs, targeted oncology, and novel biotherapeutic platforms.","SOUTH SAN FRANCISCO, Calif., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs, targeted oncology, and novel biotherapeutic platforms.",Directors and Officers,-0.01061007,-0.008468618,short
Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023,"ORLANDO, Fla., April  18, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced expanded preclinical data for STRO-003, its ROR1 targeting ADC, presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held in Orlando, Florida from April 14-19, 2023.","ORLANDO, Fla., April  18, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced expanded preclinical data for STRO-003, its ROR1 targeting ADC, presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held in Orlando, Florida from April 14-19, 2023.",Product / Services Announcement,-0.038379494,-0.035082908,short
"Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones","- Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as an oral presentation at ASCO 2023 -","- Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as an oral presentation at ASCO 2023 -",Earnings Releases and Operating Results,-0.005319102,-0.006849763,short
Sutro Biopharma to Participate in the Jefferies Healthcare Conference,"SOUTH SAN FRANCISCO, Calif., May  31, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 4:30 p.m. ET/1:30 p.m. PT in New York City.","SOUTH SAN FRANCISCO, Calif., May  31, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 4:30 p.m. ET/1:30 p.m. PT in New York City.",Calendar of Events,0.002169144,0.006691001,long
Sutro Biopharma to Participate in Upcoming Investor Conferences,"SOUTH SAN FRANCISCO, Calif., Aug.  30, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.","SOUTH SAN FRANCISCO, Calif., Aug.  30, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.",Calendar of Events,0,-0.000779246,short
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference,"SOUTH SAN FRANCISCO, Calif., Jan.  04, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.","SOUTH SAN FRANCISCO, Calif., Jan.  04, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.",Calendar of Events,0.013715667,0.007518552,long
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference,"SOUTH SAN FRANCISCO, Calif., May  08, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15th, 2023, at 2:00 p.m. ET / 11:00 a.m. PT in New York City.","SOUTH SAN FRANCISCO, Calif., May  08, 2023  (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15th, 2023, at 2:00 p.m. ET / 11:00 a.m. PT in New York City.",Calendar of Events,-0.001824859,-0.002648833,short
Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer,"- Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET -","- Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET -",Health,0.047904219,0.040782782,long
Shattuck Labs Announces Participation in Upcoming November Conferences,"AUSTIN, TX and DURHAM, NC, Nov.  03, 2022  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in three investor conferences in November 2022.  ","AUSTIN, TX and DURHAM, NC, Nov.  03, 2022  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in three investor conferences in November 2022.  ",Calendar of Events,0.003952565,0.01302236,long
Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting,"– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease –","– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease –",Product / Services Announcement,-0.021428551,-0.015109214,short
Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting,"- Data from two distinct GADLEN product candidates, one targeting CD20 and another targeting B7-H3, enhanced γδT cell killing of tumor cells, demonstrating preclinical proof-of-concept in the treatment of cancer -","- Data from two distinct GADLEN product candidates, one targeting CD20 and another targeting B7-H3, enhanced γδT cell killing of tumor cells, demonstrating preclinical proof-of-concept in the treatment of cancer -",Health,-0.002016175,-0.005629794,short
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results,"Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET","Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET",Earnings Releases and Operating Results,-0.071563109,-0.070305974,short
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023,"AUSTIN, TX & DURHAM, NC, Jan.  09, 2023  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2023.","AUSTIN, TX & DURHAM, NC, Jan.  09, 2023  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2023.",Management statements,0.003448272,-0.002452595,short
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting,– SL-172154 as monotherapy and in combination with azacitidine demonstrates anti-leukemic activity and an acceptable safety and tolerability profile –,– SL-172154 as monotherapy and in combination with azacitidine demonstrates anti-leukemic activity and an acceptable safety and tolerability profile –,Calendar of Events,0.006249994,-0.00302456,short
"Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023","AUSTIN, TX & DURHAM, NC, Feb.  16, 2023  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its fourth quarter and full year 2022 financial results and provide a general business overview on Thursday, February 23, 2023.","AUSTIN, TX & DURHAM, NC, Feb.  16, 2023  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its fourth quarter and full year 2022 financial results and provide a general business overview on Thursday, February 23, 2023.",Calendar of Events,-0.045005473,-0.03246863,short
Centers For Medicare & Medicaid Services Creates New Hospital Inpatient Payment for Coronary Intravascular Lithotripsy,"Three New IVL-Specific Diagnostic Related Groups (DRGs) with Increased Payments Go Into Effect October 1, 2023 Three New IVL-Specific Diagnostic Related Groups (DRGs) with Increased Payments Go Into Effect October 1, 2023","Three New IVL-Specific Diagnostic Related Groups (DRGs) with Increased Payments Go Into Effect October 1, 2023 Three New IVL-Specific Diagnostic Related Groups (DRGs) with Increased Payments Go Into Effect October 1, 2023",Product / Services Announcement,-0.014937459,-0.00786155,short
Centers for Medicare & Medicaid Services Establishes New Category I CPT® Add-On Code for Coronary IVL,"New Add-On Code Goes Into Effect January 1, 2024 New Add-On Code Goes Into Effect January 1, 2024","New Add-On Code Goes Into Effect January 1, 2024 New Add-On Code Goes Into Effect January 1, 2024",Product / Services Announcement,0.001535249,-0.00398988,short
New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies,Clinical Research Validates Utility of IVL in Complex Nodular and Eccentric Calcium Clinical Research Validates Utility of IVL in Complex Nodular and Eccentric Calcium,Clinical Research Validates Utility of IVL in Complex Nodular and Eccentric Calcium Clinical Research Validates Utility of IVL in Complex Nodular and Eccentric Calcium,Product / Services Announcement,-0.000483749,-0.002203887,short
New Shockwave Coronary IVL Publication Shows Similar Outcomes in Women And Men,"One-Year Outcomes Published in JSCAI Confirm Excellent, Consistent IVL Safety and Effectiveness Across Sexes One-Year Outcomes Published in JSCAI Confirm Excellent, Consistent IVL Safety and Effectiveness Across Sexes","One-Year Outcomes Published in JSCAI Confirm Excellent, Consistent IVL Safety and Effectiveness Across Sexes One-Year Outcomes Published in JSCAI Confirm Excellent, Consistent IVL Safety and Effectiveness Across Sexes",Clinical Study,0.005578373,0.002879705,long
Shockwave Appoints Kevin Ballinger to Board of Directors,"SANTA CLARA, Calif., May  17, 2023  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Kevin Ballinger has joined its Board of Directors and will serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board.","SANTA CLARA, Calif., May  17, 2023  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Kevin Ballinger has joined its Board of Directors and will serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board.",Management Changes,-0.005208564,-0.010327409,short
Shockwave Medical Announces Proposed Private Offering of $500.0 Million of Convertible Senior Notes,"SANTA CLARA, Calif., Aug.  10, 2023  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave Medical”) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Shockwave Medical also intends to grant the initial purchaser of the notes an option to purchase, within a 13-day period from, and including, the date on which the notes are first issued, up to an additional $75.0 million aggregate principal amount of notes.","SANTA CLARA, Calif., Aug.  10, 2023  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave Medical”) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Shockwave Medical also intends to grant the initial purchaser of the notes an option to purchase, within a 13-day period from, and including, the date on which the notes are first issued, up to an additional $75.0 million aggregate principal amount of notes.",Changes in company's own shares,-0.063217886,-0.068691812,short
Shockwave Medical Announces U.S. Launch of New Peripheral IVL Catheter,Shockwave L⁶ Provides Physicians with Larger-Diameter Catheters to Expand Potential Treatment of Peripheral Vessels Shockwave L⁶ Provides Physicians with Larger-Diameter Catheters to Expand Potential Treatment of Peripheral Vessels,Shockwave L⁶ Provides Physicians with Larger-Diameter Catheters to Expand Potential Treatment of Peripheral Vessels Shockwave L⁶ Provides Physicians with Larger-Diameter Catheters to Expand Potential Treatment of Peripheral Vessels,Product / Services Announcement,0.024140854,0.010802638,long
Shockwave Medical Appoints Nick West as Associate Chief Medical Officer,"Nick West, MD, joins Shockwave from Abbott Vascular Nick West, MD, joins Shockwave from Abbott Vascular","Nick West, MD, joins Shockwave from Abbott Vascular Nick West, MD, joins Shockwave from Abbott Vascular",Directors and Officers,-0.013461491,-0.010116637,short
Shockwave Medical Completes Acquisition of Neovasc,"SANTA CLARA, Calif., April  11, 2023  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (“IVL”) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”).","SANTA CLARA, Calif., April  11, 2023  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (“IVL”) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”).",Mergers and Acquisitions,0.044513029,0.042926094,long
Shockwave Medical Introduces Enhanced Coronary IVL Catheter in the United States,Shockwave C2+ Debut Joins Packed Shockwave Agenda at Transcatheter Cardiovascular Therapeutics Conference in San Francisco,Shockwave C2+ Debut Joins Packed Shockwave Agenda at Transcatheter Cardiovascular Therapeutics Conference in San Francisco,Product / Services Announcement,-0.001770263,-0.000715033,short
Shockwave Medical to Participate in the Piper Sandler 35th Annual Healthcare Conference,"SANTA CLARA, Calif., Nov.  15, 2023  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the Piper Sandler 35th Annual Healthcare Conference, which is being held from Tuesday, November 28 to Thursday, November 30, 2023 in New York, NY.","SANTA CLARA, Calif., Nov.  15, 2023  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the Piper Sandler 35th Annual Healthcare Conference, which is being held from Tuesday, November 28 to Thursday, November 30, 2023 in New York, NY.",Health,0.003676256,0.000600967,long
Shockwave Medical to Participate in Upcoming Investor Conferences,"SANTA CLARA, Calif., Aug.  22, 2023  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in two upcoming investor conferences:","SANTA CLARA, Calif., Aug.  22, 2023  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in two upcoming investor conferences:",Calendar of Events,0.005551769,0.001363677,long
Updated SCAI Guidance Includes Coronary IVL as a Treatment Option in All U.S. Catheterization Labs Regardless of Surgical Backup Status,Guidance Expands Number of Hospitals that Can Access IVL to Include Sites Where Calcium Modification Tools Were Previously Not Recommended Guidance Expands Number of Hospitals that Can Access IVL to Include Sites Where Calcium Modification Tools Were Previously Not Recommended,Guidance Expands Number of Hospitals that Can Access IVL to Include Sites Where Calcium Modification Tools Were Previously Not Recommended Guidance Expands Number of Hospitals that Can Access IVL to Include Sites Where Calcium Modification Tools Were Previously Not Recommended,Health,0.005370167,0.004022134,long
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement,"Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD)","Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD)",Mergers and Acquisitions,0.231818172,0.234094326,long
Talaris Therapeutics Announces Changes to Board of Directors,"BOSTON and LOUISVILLE, Ky., May  17, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company’s Board of Directors.","BOSTON and LOUISVILLE, Ky., May  17, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company’s Board of Directors.",Directors and Officers,0.041284401,0.025188016,long
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results,"Second quarter 2023 BRIUMVI® net sales of $16 million in the United States, representing 100% quarter over quarter growth; total net revenue of approximately $24 million since launch","Second quarter 2023 BRIUMVI® net sales of $16 million in the United States, representing 100% quarter over quarter growth; total net revenue of approximately $24 million since launch",Earnings Releases and Operating Results,-0.425809579,-0.422489237,short
Talaris Therapeutics Announces Leadership Transition,"BOSTON and LOUISVILLE, Ky., May  26, 2023  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris’s Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company.","BOSTON and LOUISVILLE, Ky., May  26, 2023  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris’s Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company.",Directors and Officers,-0.022471977,-0.024111897,short
Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan,"BOSTON and LOUISVILLE, Ky., Feb.  16, 2023  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based on this review, Talaris has decided to discontinue its FREEDOM-1 and FREEDOM-2 clinical trials evaluating FCR001’s ability to induce durable tolerance in living donor kidney transplant recipients. This decision was primarily attributable to the pace of enrollment and the associated timeline to critical milestones. The company will continue to enroll its FREEDOM-3 Phase 2 clinical trial evaluating FCR001’s ability to induce tolerance in scleroderma.","BOSTON and LOUISVILLE, Ky., Feb.  16, 2023  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based on this review, Talaris has decided to discontinue its FREEDOM-1 and FREEDOM-2 clinical trials evaluating FCR001’s ability to induce durable tolerance in living donor kidney transplant recipients. This decision was primarily attributable to the pace of enrollment and the associated timeline to critical milestones. The company will continue to enroll its FREEDOM-3 Phase 2 clinical trial evaluating FCR001’s ability to induce tolerance in scleroderma.",Major shareholder announcements,0.088607583,0.101144427,long
Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update,"All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection drugs","All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection drugs",Earnings Releases and Operating Results,-0.070103027,-0.064647591,short
Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update,Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients,Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients,Earnings Releases and Operating Results,0.027972086,-0.009234187,short
Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting,"BOSTON and LOUISVILLE, Ky., Oct.  17, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced upcoming data presentations at the American Society of Nephrology (ASN) Annual Meeting, taking place November 3-6, 2022 in Orlando, Fla.","BOSTON and LOUISVILLE, Ky., Oct.  17, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced upcoming data presentations at the American Society of Nephrology (ASN) Annual Meeting, taking place November 3-6, 2022 in Orlando, Fla.",Health,0.026086932,0.008247252,long
Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance,"BOSTON and LOUISVILLE, Ky., Nov.  07, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented new data characterizing the mechanisms of FCR001-induced immune tolerance in two oral presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting.","BOSTON and LOUISVILLE, Ky., Nov.  07, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented new data characterizing the mechanisms of FCR001-induced immune tolerance in two oral presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting.",Health,0,-0.003613619,short
Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update,"BOSTON and LOUISVILLE, Ky., June  30, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today provided a clinical update on its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.","BOSTON and LOUISVILLE, Ky., June  30, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today provided a clinical update on its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.",Health,-0.008415139,0.002364706,long
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial,"BOSTON and LOUISVILLE, Ky., Oct.  20, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced a status update on its Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.","BOSTON and LOUISVILLE, Ky., Oct.  20, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced a status update on its Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.",Clinical Study,-0.0909091,-0.089633656,short
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa,"BOSTON and LOUISVILLE, Ky., Oct.  04, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California and livestreamed globally. In addition, members from the management team will also be in attendance.","BOSTON and LOUISVILLE, Ky., Oct.  04, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California and livestreamed globally. In addition, members from the management team will also be in attendance.",Calendar of Events,0.0074074,-0.008385974,short
TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy),"Total deal size of approximately ~$650M, including over $150M in upfront and near-term milestones","Total deal size of approximately ~$650M, including over $150M in upfront and near-term milestones",Clinical Study,-0.425809579,-0.422489237,short
TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting,"NEW YORK, May  31, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), to be presented at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 31 - June 4, 2023, in Aurora, Colorado. The abstract is now available online and can be accessed on the International Journal of MS Care (IJMSC) website at www.ijmsc.org, or by following this direct link: https://doi.org/10.7224/1537-2073-25.s1.1. Details of the presentation are included below.","NEW YORK, May  31, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), to be presented at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 31 - June 4, 2023, in Aurora, Colorado. The abstract is now available online and can be accessed on the International Journal of MS Care (IJMSC) website at www.ijmsc.org, or by following this direct link: https://doi.org/10.7224/1537-2073-25.s1.1. Details of the presentation are included below.",Product / Services Announcement,-0.002746163,0.001775694,long
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting,"NEW YORK, March  03, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Massachusetts. Abstracts are now available online and can be accessed within the AAN annual meeting program at www.aan.com/msa/public/events/index/45. Details of the presentations are outlined below.","NEW YORK, March  03, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Massachusetts. Abstracts are now available online and can be accessed within the AAN annual meeting program at www.aan.com/msa/public/events/index/45. Details of the presentations are outlined below.",Clinical Study,0.009451832,0.004675698,long
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults,"NEW YORK, June  01, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the European Commission (EC) has granted approval of BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.","NEW YORK, June  01, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the European Commission (EC) has granted approval of BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.",Product / Services Announcement,0.004506228,0.003931882,long
TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services,"NEW YORK, April  27, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). Under the Healthcare Common Procedure Coding System (HCPCS), the BRIUMVI J-Code (J2329) will become effective July 1, 2023.","NEW YORK, April  27, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). Under the Healthcare Common Procedure Coding System (HCPCS), the BRIUMVI J-Code (J2329) will become effective July 1, 2023.",Health,0.009049722,0.00252085,long
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults,"NEW YORK, March  31, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of BRIUMVI™ (ublituximab-xiiy) for the treatment of adult patients relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.","NEW YORK, March  31, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of BRIUMVI™ (ublituximab-xiiy) for the treatment of adult patients relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.",Health,0.024606948,0.022228966,long
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting,"NEW YORK, Oct.  11, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy. A link to each presentation is included below.","NEW YORK, Oct.  11, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy. A link to each presentation is included below.",Product / Services Announcement,-0.044560963,-0.046121868,short
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting,"NEW YORK, Oct.  12, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy. A link to the presentation is included below.","NEW YORK, Oct.  12, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy. A link to the presentation is included below.",Clinical Study,-0.032078106,-0.024548621,short
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting,"NEW YORK, June  02, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. A link to the oral presentation is included below.","NEW YORK, June  02, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. A link to the oral presentation is included below.",Clinical Study,0.006748111,0.000394707,long
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting,"NEW YORK, April  25, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) annual meeting. Links to each of the presentations are below.Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are pleased to present additional analyses from the ULTIMATE I & II Phase 3 trials and further in-vitro characterization of BRIUMVI at the AAN conference this week. We look forward to continuing to share additional exploratory analyses throughout the year.”","NEW YORK, April  25, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) annual meeting. Links to each of the presentations are below.Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are pleased to present additional analyses from the ULTIMATE I & II Phase 3 trials and further in-vitro characterization of BRIUMVI at the AAN conference this week. We look forward to continuing to share additional exploratory analyses throughout the year.”",Clinical Study,0.000883803,0.005851978,long
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting,"NEW YORK, Oct.  02, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 11 – 13, 2023, in Milan, Italy. Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: https://apps.congrex.com/ectrims2023/en-GB/pag. The late breaking abstract will be available on October 11, 2023. Details of the presentations are outlined below.","NEW YORK, Oct.  02, 2023  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 11 – 13, 2023, in Milan, Italy. Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: https://apps.congrex.com/ectrims2023/en-GB/pag. The late breaking abstract will be available on October 11, 2023. Details of the presentations are outlined below.",Clinical Study,0.010765569,0.012777396,long
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results,First quarter 2023 BRIUMVI net sales of $7.8 million,First quarter 2023 BRIUMVI net sales of $7.8 million,Earnings Releases and Operating Results,0.026983491,0.028089426,long
"Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance","NEW YORK, Sept.  06, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”, in the preeminent1 journal, Proceedings of the National Academy of Sciences (PNAS), that supports foralumab’s mechanism as a potential treatment for Alzheimer’s disease (AD), a difficult-to-treat neuroinflammatory disease.2   This is the second publication pertaining to intranasal administration of anti-CD3 monoclonal antibody this year to be published in PNAS.3","NEW YORK, Sept.  06, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”, in the preeminent1 journal, Proceedings of the National Academy of Sciences (PNAS), that supports foralumab’s mechanism as a potential treatment for Alzheimer’s disease (AD), a difficult-to-treat neuroinflammatory disease.2   This is the second publication pertaining to intranasal administration of anti-CD3 monoclonal antibody this year to be published in PNAS.3",Clinical Study,0.013157882,0.015027699,long
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS),"NEW YORK, Oct.  13, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab in its Expanded Access Program (EAP). Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis, or ALS.","NEW YORK, Oct.  13, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab in its Expanded Access Program (EAP). Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis, or ALS.",Clinical Study,0.067567583,0.063993382,long
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress,"Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes","Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes",Calendar of Events,-0.041095932,-0.043627358,short
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment,"NEW YORK, Oct.  18, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce a significant milestone in the treatment of multiple sclerosis. The U.S. Food and Drug Administration (FDA) has allowed multiple sclerosis patients to take home and self-administer Intranasal Foralumab, a groundbreaking treatment developed by Tiziana Life Sciences. Delivery Device Training materials have been developed and refined in collaboration with the FDA, and patients will be trained in the use of the nasal device in accordance with these materials.","NEW YORK, Oct.  18, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce a significant milestone in the treatment of multiple sclerosis. The U.S. Food and Drug Administration (FDA) has allowed multiple sclerosis patients to take home and self-administer Intranasal Foralumab, a groundbreaking treatment developed by Tiziana Life Sciences. Delivery Device Training materials have been developed and refined in collaboration with the FDA, and patients will be trained in the use of the nasal device in accordance with these materials.",Product / Services Announcement,0.123287632,0.127484657,long
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer,"NEW YORK, Aug.  23, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective September 1, 2023. In this role, Dr. Clementi will be responsible for overseeing the company's development strategies and advancing its portfolio of groundbreaking therapeutic candidates.","NEW YORK, Aug.  23, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective September 1, 2023. In this role, Dr. Clementi will be responsible for overseeing the company's development strategies and advancing its portfolio of groundbreaking therapeutic candidates.",Directors and Officers,0.07812502,0.069519445,long
"Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate",No Vaccine Related Serious Adverse Events (SAEs) reported to date,No Vaccine Related Serious Adverse Events (SAEs) reported to date,Clinical Study,0.039370136,0.040376908,long
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17,"NEW YORK, May  17, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Medical Officer is presenting at the Hanson Wade Novel Nasal Formulation and Delivery Summit on May 17 in San Diego.","NEW YORK, May  17, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Medical Officer is presenting at the Hanson Wade Novel Nasal Formulation and Delivery Summit on May 17 in San Diego.",Calendar of Events,-0.012658291,-0.017777136,short
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease,"NEW YORK, Aug.  15, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease. Foralumab could be a potentially groundbreaking treatment for Alzheimer’s disease, given it targets the disease’s underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.","NEW YORK, Aug.  15, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease. Foralumab could be a potentially groundbreaking treatment for Alzheimer’s disease, given it targets the disease’s underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.",Regulatory information,0.51666665,0.520772777,long
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology,"NEW YORK, Aug.  23, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced an oral presentation of “Nasal anti-CD3 mAb induces Tregs that dampen microglial activation and treat neuroinflammatory diseases including MS, AD and ALS” at the 16th International Society of Neuroimmunology (ISNI) Congress in Quebec City, Canada, being held August 21-24, 2023. Dr. Weiner’s live presentation is scheduled for 11:42 a.m. ET on August 24, 2023.","NEW YORK, Aug.  23, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced an oral presentation of “Nasal anti-CD3 mAb induces Tregs that dampen microglial activation and treat neuroinflammatory diseases including MS, AD and ALS” at the 16th International Society of Neuroimmunology (ISNI) Congress in Quebec City, Canada, being held August 21-24, 2023. Dr. Weiner’s live presentation is scheduled for 11:42 a.m. ET on August 24, 2023.",Calendar of Events,-0.044776165,-0.047286734,short
"Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023","NEW YORK, Nov.  01, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at BIO-Europe, Munich, Germany, November 6-8, 2023. The presentation will be primarily focused on the recent clinical updates of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s. Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.","NEW YORK, Nov.  01, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at BIO-Europe, Munich, Germany, November 6-8, 2023. The presentation will be primarily focused on the recent clinical updates of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s. Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.",Calendar of Events,-0.046153804,-0.048545004,short
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease,"NEW YORK, Aug.  17, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Howard L. Weiner, a thought leader in the field of neurology and immunology, was featured in an exclusive live interview on Bloomberg to discuss the Company’s latest announcement on its advancement of the novel foralumab program in Alzheimer's disease following recent U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.","NEW YORK, Aug.  17, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Howard L. Weiner, a thought leader in the field of neurology and immunology, was featured in an exclusive live interview on Bloomberg to discuss the Company’s latest announcement on its advancement of the novel foralumab program in Alzheimer's disease following recent U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.",Management statements,0,-0.003457349,short
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform,"NEW YORK, May  23, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that they are now participating on the new Webull Corporate Communication services platform. The Tiziana portal on the Webull platform will help provide the Company with a direct line of communication with its shareholders while providing Tiziana's followers with instant notifications regarding corporate content like company news, earnings reports, investor presentations, and more.","NEW YORK, May  23, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that they are now participating on the new Webull Corporate Communication services platform. The Tiziana portal on the Webull platform will help provide the Company with a direct line of communication with its shareholders while providing Tiziana's followers with instant notifications regarding corporate content like company news, earnings reports, investor presentations, and more.",Calendar of Events,0.013157882,0.017241127,long
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab,"NEW YORK, Oct.  16, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program.   This follows on from previously announced positive six-month PET scan data which was presented at ECTRIMS 2023.","NEW YORK, Oct.  16, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program.   This follows on from previously announced positive six-month PET scan data which was presented at ECTRIMS 2023.",Clinical Study,0.08749999,0.08212338,long
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis,"NEW YORK, June  05, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a reduction in microglial activation as seen in 3-month Positron Emission Tomography (PET) scans that has now been seen in a total of 5 of the 6 patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab in its Expanded Access program. Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory diseases including multiple sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).   ","NEW YORK, June  05, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a reduction in microglial activation as seen in 3-month Positron Emission Tomography (PET) scans that has now been seen in a total of 5 of the 6 patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab in its Expanded Access program. Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory diseases including multiple sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).   ",Clinical Study,-0.252032518,-0.249277329,short
"Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery",-Appointment expected to aid advancement of Theriva’s discovery program and strengthen collaboration with the Institut Catala d’Oncologia (ICO) and the Biomedical Research Institute of Bellvitge (IDIBELL)-,-Appointment expected to aid advancement of Theriva’s discovery program and strengthen collaboration with the Institut Catala d’Oncologia (ICO) and the Biomedical Research Institute of Bellvitge (IDIBELL)-,Directors and Officers,-0.044117692,-0.040034448,short
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis,"NEW YORK, Sept.  26, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held an Investigator’s Meeting with principal investigators at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, to begin site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. In total, six to ten new clinical trial sites will be recruited.","NEW YORK, Sept.  26, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held an Investigator’s Meeting with principal investigators at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, to begin site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. In total, six to ten new clinical trial sites will be recruited.",Clinical Study,0.030303,0.037567685,long
Tiziana Life Sciences meldet Verringerung der mikroglialen Aktivierung bei insgesamt 5 von 6 an nicht-aktiver sekundär progredienter Multipler Sklerose erkrankten Patienten mit erweitertem Zugang zu intranasalem Foralumab,"NEW YORK, June  06, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) („Tiziana“ oder das „Unternehmen“), ein Biotechnologieunternehmen, das bahnbrechende Immunmodulationstherapien über neuartige Verabreichungswege entwickelt, hat eine Verringerung der mikroglialen Aktivierung bekanntgegeben, die in 3-Monats-Positronen-Emissions-Tomographie-Scans (PET) bei insgesamt 5 von 6 Patienten mit nicht-aktiver sekundär progredienter Multipler Sklerose (na-SPMS) beobachtet wurde, die im Rahmen des Programms für erweiterten Zugang mit intranasalem Foralumab behandelt wurden. Es wird angenommen, dass aktivierte Mikroglia eine wichtige Rolle in der Pathogenese neuroinflammatorischer Krankheiten wie Multiple Sklerose, Alzheimer und amyotrophe Lateralsklerose (ALS) spielen. ","NEW YORK, June  06, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) („Tiziana“ oder das „Unternehmen“), ein Biotechnologieunternehmen, das bahnbrechende Immunmodulationstherapien über neuartige Verabreichungswege entwickelt, hat eine Verringerung der mikroglialen Aktivierung bekanntgegeben, die in 3-Monats-Positronen-Emissions-Tomographie-Scans (PET) bei insgesamt 5 von 6 Patienten mit nicht-aktiver sekundär progredienter Multipler Sklerose (na-SPMS) beobachtet wurde, die im Rahmen des Programms für erweiterten Zugang mit intranasalem Foralumab behandelt wurden. Es wird angenommen, dass aktivierte Mikroglia eine wichtige Rolle in der Pathogenese neuroinflammatorischer Krankheiten wie Multiple Sklerose, Alzheimer und amyotrophe Lateralsklerose (ALS) spielen. ",Clinical Study,-0.054347838,-0.053341065,short
"Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer","NEW YORK, June  13, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD, RPh as its new Chief Operating Officer (COO). Dr. Davis, who also serves as the Chief Medical Officer (CMO), will now take on this additional role to further drive the company's growth and strategic initiatives and will report to Gabriele Cerrone, Executive Chairman, Founder, and interim Chief Executive Officer of Tiziana.","NEW YORK, June  13, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD, RPh as its new Chief Operating Officer (COO). Dr. Davis, who also serves as the Chief Medical Officer (CMO), will now take on this additional role to further drive the company's growth and strategic initiatives and will report to Gabriele Cerrone, Executive Chairman, Founder, and interim Chief Executive Officer of Tiziana.",Directors and Officers,0,-0.003503964,short
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS),"Webinar to take place on Monday, June 5, 2023 at 12:30 PM ET Webinar to take place on Monday, June 5, 2023 at 12:30 PM ET","Webinar to take place on Monday, June 5, 2023 at 12:30 PM ET Webinar to take place on Monday, June 5, 2023 at 12:30 PM ET",Calendar of Events,0,-0.00887882,short
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference,"NEW YORK, Sept.  08, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present and host one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.","NEW YORK, Sept.  08, 2023  (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present and host one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.",Calendar of Events,-0.027397315,-0.027509685,short
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress,In vitro data demonstrated the miRARE control element downregulates MECP2 transgene and protein expression in response to cellular levels of MeCP2 in cell culture models,In vitro data demonstrated the miRARE control element downregulates MECP2 transgene and protein expression in response to cellular levels of MeCP2 in cell culture models,Clinical Study,0.009174303,0.003965716,long
Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients,- Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) - - Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) -,- Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) - - Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) -,Health,0,-0.002769281,short
Theriva Biologics anuncia el nombramiento del Dr. Ramón Alemany en el cargo de vicepresidente sénior de descubrimiento de fármacos,-Con este nombramiento se espera contribuir al avance del programa de descubrimiento de Theriva y al fortalecimiento de la colaboración con el Institut Català d'Oncologia (ICO) y el Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)-,-Con este nombramiento se espera contribuir al avance del programa de descubrimiento de Theriva y al fortalecimiento de la colaboración con el Institut Català d'Oncologia (ICO) y el Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)-,Directors and Officers,0.061538497,0.068707362,long
Theriva Biologics anuncia la designación de fármaco huérfano concedida por la FDA estadounidense al VCN-01 para el tratamiento del cáncer de páncreas,"ROCKVILLE, Maryland, June  28, 2023  (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), («Theriva» o la «Empresa»), una empresa de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que la Administración de Alimentos y Medicamentos (FDA) de EE. UU. ha concedido la designación de fármaco huérfano al principal candidato clínico VCN-01, el adenovirus oncolítico sistémico, selectivo y degradador del estroma de Theriva para el tratamiento del cáncer de páncreas. En VIRAGE, el estudio clínico multinacional de fase 2b en curso, se está evaluando el VCN-01 intravenoso en combinación con quimioterapia de tratamiento estándar (gemcitabina/nab-paclitaxel) como tratamiento de primera línea para pacientes con adenocarcinoma pancreático ductal (PDAC). Anteriormente, la FDA concedió la designación de fármaco huérfano al VCN-01 para el tratamiento del retinoblastoma.","ROCKVILLE, Maryland, June  28, 2023  (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), («Theriva» o la «Empresa»), una empresa de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que la Administración de Alimentos y Medicamentos (FDA) de EE. UU. ha concedido la designación de fármaco huérfano al principal candidato clínico VCN-01, el adenovirus oncolítico sistémico, selectivo y degradador del estroma de Theriva para el tratamiento del cáncer de páncreas. En VIRAGE, el estudio clínico multinacional de fase 2b en curso, se está evaluando el VCN-01 intravenoso en combinación con quimioterapia de tratamiento estándar (gemcitabina/nab-paclitaxel) como tratamiento de primera línea para pacientes con adenocarcinoma pancreático ductal (PDAC). Anteriormente, la FDA concedió la designación de fármaco huérfano al VCN-01 para el tratamiento del retinoblastoma.",Health,-0.173913037,-0.176993204,short
Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results,"– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma –","– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma –",Earnings Releases and Operating Results,-0.014084494,-0.01190454,short
Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer,- Theriva signs exclusive option to license intellectual property from Sant Joan de Déu-Barcelona Children’s Hospital (SJD) to explore the therapeutic potential of VCN-01 in combination with topoisomerase I inhibitors -,- Theriva signs exclusive option to license intellectual property from Sant Joan de Déu-Barcelona Children’s Hospital (SJD) to explore the therapeutic potential of VCN-01 in combination with topoisomerase I inhibitors -,Partnerships,0,-0.009274554,short
"Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma",– Initiated dosing at U.S. sites for VIRAGE –– Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated –– VIRAGE remains on track to complete enrollment in the first quarter of 2024 –,– Initiated dosing at U.S. sites for VIRAGE –– Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated –– VIRAGE remains on track to complete enrollment in the first quarter of 2024 –,Clinical Study,0.015384693,0.022460602,long
Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,"-Results from investigator-sponsored study in collaboration with the Institut Catala d’Oncologia (ICO) show enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1-","-Results from investigator-sponsored study in collaboration with the Institut Catala d’Oncologia (ICO) show enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1-",Trade Show,0,-0.00537661,short
"Theriva™ Biologics anuncia avances clave en VIRAGE, un ensayo multinacional de fase 2b en curso de VCN-01 en combinación con quimioterapia en adenocarcinoma ductal pancreático","– Inicio de la dosificación en centros de EE. UU. para VIRAGE –– Administración de la segunda dosis de VCN-01 intravenoso a pacientes en España, que fue bien tolerada –– VIRAGE sigue avanzando para completar la inscripción en el primer trimestre de 2024 –","– Inicio de la dosificación en centros de EE. UU. para VIRAGE –– Administración de la segunda dosis de VCN-01 intravenoso a pacientes en España, que fue bien tolerada –– VIRAGE sigue avanzando para completar la inscripción en el primer trimestre de 2024 –",Clinical Study,0.0454545,0.052338108,long
Theriva™ Biologics anuncia la presentación en el Congreso ESMO 2023 de los resultados de supervivencia del estudio de fase 1 que evalúa el VCN-01 en combinación con durvalumab en pacientes con carcinoma de células escamosas de cabeza y cuello metastásico o recurrente,"- Los resultados del estudio patrocinado por investigadores en colaboración con el Instituto Catalán de Oncología (ICO) muestran una mayor supervivencia de los pacientes, correlacionada con la regulación al alza inducida por el VCN-01 de PD(L)-1 -","- Los resultados del estudio patrocinado por investigadores en colaboración con el Instituto Catalán de Oncología (ICO) muestran una mayor supervivencia de los pacientes, correlacionada con la regulación al alza inducida por el VCN-01 de PD(L)-1 -",Trade Show,0,-0.00537661,short
Theriva™ Biologics participará en la conferencia BIO-Europe,"ROCKVILLE, Maryland, Nov.  03, 2023  (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), empresa diversificada de fase clínica que investiga tratamientos antineoplásicos y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que la dirección de la empresa ofrecerá una actualización corporativa y participará en reuniones individuales durante la Conferencia BIO-Europe, que se celebrará en Múnich del 6 al 8 de noviembre de 2023.","ROCKVILLE, Maryland, Nov.  03, 2023  (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), empresa diversificada de fase clínica que investiga tratamientos antineoplásicos y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que la dirección de la empresa ofrecerá una actualización corporativa y participará en reuniones individuales durante la Conferencia BIO-Europe, que se celebrará en Múnich del 6 al 8 de noviembre de 2023.",Calendar of Events,0,-0.003578491,short
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2023,"– Inicio de la dosificación en centros de EE. UU. de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia en el adenocarcinoma ductal pancreático –","– Inicio de la dosificación en centros de EE. UU. de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia en el adenocarcinoma ductal pancreático –",Earnings Releases and Operating Results,0,0.007304632,long
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2023,"- VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma ductal de páncreas metastásico, sigue el curso previsto para completar la inscripción en el primer semestre de 2024; muchos pacientes han recibido la segunda dosis de VCN-01, que sigue siendo bien tolerado y mantiene un perfil de seguridad coherente con ensayos clínicos anteriores -","- VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma ductal de páncreas metastásico, sigue el curso previsto para completar la inscripción en el primer semestre de 2024; muchos pacientes han recibido la segunda dosis de VCN-01, que sigue siendo bien tolerado y mantiene un perfil de seguridad coherente con ensayos clínicos anteriores -",Earnings Releases and Operating Results,-0.06382979,-0.060697826,short
Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023,"-Results show enhanced patient survival, correlating with VCN-01 mediated increases in the CPS score, a key determinant of outcomes with anti-PD-(L)1 checkpoint inhibitor therapies-","-Results show enhanced patient survival, correlating with VCN-01 mediated increases in the CPS score, a key determinant of outcomes with anti-PD-(L)1 checkpoint inhibitor therapies-",Clinical Study,-0.022222202,-0.018470885,short
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results,"- Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma","- Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma",Earnings Releases and Operating Results,0.015624985,0.021460234,long
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results,"- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of VCN-01, which continues to be well tolerated with a safety profile consistent with prior clinical trials -","- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of VCN-01, which continues to be well tolerated with a safety profile consistent with prior clinical trials -",Earnings Releases and Operating Results,-0.06382979,-0.060697826,short
Theriva™ Biologics y el Hospital Infantil Sant Joan de Déu Barcelona avanzan en su colaboración estratégica para estudiar la combinación del VCN-01 con inhibidores de la topoisomerasa para tratar el cáncer,- Theriva firma la opción de licencia exclusiva de propiedad intelectual del Hospital Infantil Sant Joan de Déu Barcelona (SJD) para explorar el potencial terapéutico del VCN-01 en combinación con inhibidores de la topoisomerasa I -,- Theriva firma la opción de licencia exclusiva de propiedad intelectual del Hospital Infantil Sant Joan de Déu Barcelona (SJD) para explorar el potencial terapéutico del VCN-01 en combinación con inhibidores de la topoisomerasa I -,Partnerships,0,-0.009274554,short
Taysha Gene Therapies Announces $150 Million Private Placement Financing,Financing led by RA Capital Management with participation from new and existing investors,Financing led by RA Capital Management with participation from new and existing investors,Financing Agreements,1.056833471,1.058965147,long
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome,Fast Track Designation (FTD) is designed to accelerate the development and expedite the review of therapies with potential to address unmet medical needs for a serious or life-threatening condition,Fast Track Designation (FTD) is designed to accelerate the development and expedite the review of therapies with potential to address unmet medical needs for a serious or life-threatening condition,Clinical Study,0.180180113,0.176433181,long
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome,"The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 in adults with Rett syndrome","The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 in adults with Rett syndrome",Clinical Study,0.002531613,0.001690368,long
Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome,Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on encouraging initial clinical data from the first adult with Rett syndrome dosed with investigational gene therapy TSHA-102,Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on encouraging initial clinical data from the first adult with Rett syndrome dosed with investigational gene therapy TSHA-102,Research Analysis and Reports,0.017699152,0.016626775,long
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome,Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly earnings call following Independent Data Monitoring Committee (IDMC) review,Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed during upcoming quarterly earnings call following Independent Data Monitoring Committee (IDMC) review,Clinical Study,-0.050675707,-0.043411023,short
Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress,"DALLAS, Oct.  10, 2023  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will present data on its TSHA-102 program in evaluation for Rett syndrome during two poster presentations at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress, taking place in Brussels, Belgium from October 24-27, 2023.","DALLAS, Oct.  10, 2023  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will present data on its TSHA-102 program in evaluation for Rett syndrome during two poster presentations at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress, taking place in Brussels, Belgium from October 24-27, 2023.",Calendar of Events,-0.018656698,-0.020160304,short
"Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV","– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine –","– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine –",Clinical Study,-0.003045755,-0.005982256,short
Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting,"New preclinical data after neonatal administration in wild-type mice showed no detectable impact on survival, neurobehavioral functions and overall health, suggesting TSHA-102, engineered with novel miRARE technology, avoided toxic overexpression of MeCP2 within cells already expressing MeCP2","New preclinical data after neonatal administration in wild-type mice showed no detectable impact on survival, neurobehavioral functions and overall health, suggesting TSHA-102, engineered with novel miRARE technology, avoided toxic overexpression of MeCP2 within cells already expressing MeCP2",Trade Show,0.090000035,0.087757823,long
Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day,Company views that results of comprehensive data analysis of TSHA-120 and development of disease progression model (DPM) address U.S. Food and Drug Administration (FDA) feedback regarding the effort-dependent nature of MFM32 as primary endpoint in an unblinded study and heterogeneity of GAN; Taysha plans to review potential regulatory pathway for TSHA-120 at a formal meeting with the FDA expected in Q3 2023 ,Company views that results of comprehensive data analysis of TSHA-120 and development of disease progression model (DPM) address U.S. Food and Drug Administration (FDA) feedback regarding the effort-dependent nature of MFM32 as primary endpoint in an unblinded study and heterogeneity of GAN; Taysha plans to review potential regulatory pathway for TSHA-120 at a formal meeting with the FDA expected in Q3 2023 ,Calendar of Events,-0.032258034,-0.029690169,short
Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results,"Data from first adult patient dosed in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated with no treatment-emergent serious adverse events (SAEs) as of six-week assessment and improvement in key efficacy measures, including Clinical Global Impression – Improvement (CGI-I), Clinical Global Impression – Severity (CGI-S) and Rett Syndrome Behavior Questionnaire (RSBQ), four weeks post-treatment","Data from first adult patient dosed in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated with no treatment-emergent serious adverse events (SAEs) as of six-week assessment and improvement in key efficacy measures, including Clinical Global Impression – Improvement (CGI-I), Clinical Global Impression – Severity (CGI-S) and Rett Syndrome Behavior Questionnaire (RSBQ), four weeks post-treatment",Earnings Releases and Operating Results,1.056833471,1.058965147,long
Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update,$50 million strategic investment from Astellas Pharma to support development of TSHA-120 in giant axonal neuropathy (GAN) and TSHA-102 in Rett syndrome,$50 million strategic investment from Astellas Pharma to support development of TSHA-120 in giant axonal neuropathy (GAN) and TSHA-102 in Rett syndrome,Earnings Releases and Operating Results,0.00999999,0.006947028,long
Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11,"DALLAS, May  04, 2023  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2023, and host a corporate update conference call and webcast on Thursday, May 11, 2023, at 4:30 PM Eastern Time.","DALLAS, May  04, 2023  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2023, and host a corporate update conference call and webcast on Thursday, May 11, 2023, at 4:30 PM Eastern Time.",Calendar of Events,-0.0074074,-0.004735971,short
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention,"– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector –","– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector –",Health,-0.005961829,-0.004180835,short
T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement,"LEXINGTON, Mass., Oct.  23, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”).","LEXINGTON, Mass., Oct.  23, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”).",Financing Agreements,-0.007339443,-0.003588126,short
T2 Biosystems Announces Clinical Collaboration with Vanderbilt University Medical Center to Implement and Evaluate the T2Bacteria Panel for Clinical Use,"LEXINGTON, Mass., June  09, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced a collaborative relationship with Vanderbilt University Medical Center’s (VUMC) Learning Healthcare System (LHS) Platform, which unites clinical research and clinical operations to evaluate and implement new approaches to care that can improve the health of patients and the community. Through this collaboration, VUMC will implement and evaluate the FDA-cleared T2Bacteria® Panel in a clinical setting and conduct a prospective study to assess the impact of the direct-from-blood T2Bacteria Panel to improve antibiotic usage and clinical interventions for patients with a bloodstream infection.","LEXINGTON, Mass., June  09, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced a collaborative relationship with Vanderbilt University Medical Center’s (VUMC) Learning Healthcare System (LHS) Platform, which unites clinical research and clinical operations to evaluate and implement new approaches to care that can improve the health of patients and the community. Through this collaboration, VUMC will implement and evaluate the FDA-cleared T2Bacteria® Panel in a clinical setting and conduct a prospective study to assess the impact of the direct-from-blood T2Bacteria Panel to improve antibiotic usage and clinical interventions for patients with a bloodstream infection.",Clinical Study,0.024096362,0.022162247,long
T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity,"LEXINGTON, Mass., July  06, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the conversion of approximately 20% of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems common stock and Series B convertible preferred stock.","LEXINGTON, Mass., July  06, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the conversion of approximately 20% of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems common stock and Series B convertible preferred stock.",Prospectus/Announcement of Prospectus,0.0135135,0.021885742,long
T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results,Received record quarterly sepsis test panel orders and strengthened balance sheet Received record quarterly sepsis test panel orders and strengthened balance sheet,Received record quarterly sepsis test panel orders and strengthened balance sheet Received record quarterly sepsis test panel orders and strengthened balance sheet,Pre-Release Comments,-0.146666654,-0.155548865,short
T2 Biosystems Announces Reverse Stock Split Effective Today,"TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2023 TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2023","TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2023 TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2023",Changes in company's own shares,-0.403225806,-0.404669712,short
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test,Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel,Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel,Company Announcement,0.362745086,0.361903842,long
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements,"LEXINGTON, Mass., July  31, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension through November 20, 2023, to evidence compliance with Nasdaq's minimum bid price and market value of listed securities (“MVLS”) requirements, as set forth in Nasdaq Listing Rules 5550(a)(2) and (b)(2) (the “Rules”).","LEXINGTON, Mass., July  31, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension through November 20, 2023, to evidence compliance with Nasdaq's minimum bid price and market value of listed securities (“MVLS”) requirements, as set forth in Nasdaq Listing Rules 5550(a)(2) and (b)(2) (the “Rules”).",Stock Market News,0.068965449,0.067893073,long
T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel,The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company,The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company,Product / Services Announcement,-0.128540334,-0.126398882,short
T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test,"LEXINGTON, Mass., July  20, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s Candida auris (C. auris) direct-from-blood molecular diagnostic test.","LEXINGTON, Mass., July  20, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s Candida auris (C. auris) direct-from-blood molecular diagnostic test.",Product / Services Announcement,0.372549045,0.374811784,long
T2 Biosystems Regains Compliance with Nasdaq Listing Requirements,"LEXINGTON, Mass., Nov.  01, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that on October 31, 2023 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.","LEXINGTON, Mass., Nov.  01, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that on October 31, 2023 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.",Company Regulatory Filings,0.006768183,0.004376983,long
T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement,"LEXINGTON, Mass., Aug.  09, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) on August 8, 2023 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the NASDAQ Capital Market.","LEXINGTON, Mass., Aug.  09, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) on August 8, 2023 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the NASDAQ Capital Market.",Major shareholder announcements,-0.08387098,-0.084494933,short
T2 Biosystems to Attend Upcoming Investor Conferences,"LEXINGTON, Mass., July  28, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2023:","LEXINGTON, Mass., July  28, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2023:",Calendar of Events,0.008547041,0.00105513,long
"T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum","LEXINGTON, Mass., Nov.  03, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NY.","LEXINGTON, Mass., Nov.  03, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NY.",Health,-0.006802714,-0.012327844,short
Valneva dépose une demande d’autorisation auprès de l’EMA pour son candidat vaccin contre le chikungunya et annonce une revue accélérée par le CHMP,"Saint-Herblain (France), 25 octobre 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd’hui avoir déposé une demande d’autorisation de mise sur le marché auprès de l’Agence européenne des médicaments (EMA) pour son candidat vaccin à injection unique contre le chikungunya, VLA1553. Valneva s’est également vu accorder une revue accélérée1 de cette demande par le Comité des médicaments à usage humain (CHMP) de l’EMA compte tenu « de l’intérêt majeur pour la santé publique et l’innovation thérapeutique » que représente ce candidat vaccin.","Saint-Herblain (France), 25 octobre 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd’hui avoir déposé une demande d’autorisation de mise sur le marché auprès de l’Agence européenne des médicaments (EMA) pour son candidat vaccin à injection unique contre le chikungunya, VLA1553. Valneva s’est également vu accorder une revue accélérée1 de cette demande par le Comité des médicaments à usage humain (CHMP) de l’EMA compte tenu « de l’intérêt majeur pour la santé publique et l’innovation thérapeutique » que représente ce candidat vaccin.",European Regulatory News,0.077065914,0.087353018,long
Valneva effectuera des présentations sur le chikungunya lors de différentes conférences scientifiques de premier plan,"Saint-Herblain (France), 11 octobre 2023 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd'hui qu'elle fera des présentations sur le chikungunya, une maladie transmise par les moustiques, durant différentes conférences scientifiques de premier plan organisées au cours du quatrième trimestre 2023.","Saint-Herblain (France), 11 octobre 2023 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd'hui qu'elle fera des présentations sur le chikungunya, une maladie transmise par les moustiques, durant différentes conférences scientifiques de premier plan organisées au cours du quatrième trimestre 2023.",European Regulatory News,0.031705217,0.030144312,long
Valneva participera à différentes conférences investisseurs aux Etats-Unis et en Europe en septembre 2023,"Saint-Herblain (France), 31 août 2023 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante participeront à des rendez-vous avec des investisseurs institutionnels dans le courant du mois de septembre lors des conférences mentionnées ci-dessous.","Saint-Herblain (France), 31 août 2023 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante participeront à des rendez-vous avec des investisseurs institutionnels dans le courant du mois de septembre lors des conférences mentionnées ci-dessous.",European Regulatory News,-0.001428604,0.001449704,long
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment,"Saint-Herblain (France), October 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the submission of a marketing application with the European Medicines Agency (EMA) for approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553. Valneva was also granted accelerated assessment1 for the application by EMA’s Committee for Medicinal Products for Human Use (CHMP) based on the vaccine candidate’s “major interest for public health and therapeutic innovation”.","Saint-Herblain (France), October 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the submission of a marketing application with the European Medicines Agency (EMA) for approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553. Valneva was also granted accelerated assessment1 for the application by EMA’s Committee for Medicinal Products for Human Use (CHMP) based on the vaccine candidate’s “major interest for public health and therapeutic innovation”.",European Regulatory News,0.077065914,0.087353018,long
Valneva to Participate in Investor Conferences in the United States and Europe in September 2023,"Saint-Herblain (France), August 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its senior leadership team are scheduled to participate in 1-on-1 meetings with institutional investors at the following investor conferences in September 2023.","Saint-Herblain (France), August 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its senior leadership team are scheduled to participate in 1-on-1 meetings with institutional investors at the following investor conferences in September 2023.",European Regulatory News,-0.001428604,0.001449704,long
Valneva to Present on Chikungunya at Several Leading Scientific Conferences,"Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023.","Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023.",European Regulatory News,0.031705217,0.030144312,long
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash,"MODIIN, Israel and NEW YORK, March  09, 2023  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company. VBL intends to include the proceeds in the Agreement and Plan of Merger entered into with Notable Labs Inc., announced on February 23, 2023.","MODIIN, Israel and NEW YORK, March  09, 2023  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company. VBL intends to include the proceeds in the Agreement and Plan of Merger entered into with Notable Labs Inc., announced on February 23, 2023.",Company Announcement,0.019003862,0.016948371,long
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting,Approved Merger with Notable Labs and All Other Proposals,Approved Merger with Notable Labs and All Other Proposals,Mergers and Acquisitions,0.066666578,0.065222673,long
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC,"Merger with Notable expected to close in mid-October, subject to shareholder approval","Merger with Notable expected to close in mid-October, subject to shareholder approval",Mergers and Acquisitions,0.04691945,0.048789266,long
VBL Therapeutics Announces Workforce Reduction,"TEL AVIV, Israel and NEW YORK, Aug.  02, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced an organizational streamlining designed to reduce operating expenses and preserve capital. As a result, VBL will reduce its workforce by approximately 35%. As part of the cost cutting initiatives, Dr. Ron Cohen, Dr. Bennett Shapiro and Ms. Alison Finger resigned from the board of directors, effective August 1, 2022.","TEL AVIV, Israel and NEW YORK, Aug.  02, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced an organizational streamlining designed to reduce operating expenses and preserve capital. As a result, VBL will reduce its workforce by approximately 35%. As part of the cost cutting initiatives, Dr. Ron Cohen, Dr. Bennett Shapiro and Ms. Alison Finger resigned from the board of directors, effective August 1, 2022.",Restructuring / Recapitalization,-0.027923228,-0.023906396,short
VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer,"TEL AVIV, Israel and NEW YORK, April  26, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ofra-vec (ofranergene obadenovec or VB-111) in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer.","TEL AVIV, Israel and NEW YORK, April  26, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ofra-vec (ofranergene obadenovec or VB-111) in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer.",Product / Services Announcement,-0.013793172,-0.007538888,short
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting,"Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023 Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023","Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023 Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023",Annual Meetings & Shareholder Rights,-0.027237351,-0.028375924,short
VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update,"OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023","OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023",Calendar of Events,-0.034246623,-0.050343008,short
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update,"MODIIN, Israel and NEW YORK, March  14, 2023  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate update.","MODIIN, Israel and NEW YORK, March  14, 2023  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate update.",Earnings Releases and Operating Results,0.083106255,0.069768039,long
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update,"Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval","Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval",Earnings Releases and Operating Results,-0.03389836,-0.031766683,short
VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May,"TEL AVIV, Israel and NEW YORK, May  03, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the company will present new data on its novel Monocyte Targeting Technology and lead candidate VB-601 at IMMUNOLOGY2022TM being held in Portland, OR on May 6 – 10, 2022. In addition, Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will discuss the VB-601 program at the LifeSci Immunology & Inflammation Symposium being held virtually on May 11, 2022. Prof. Harats will also provide a keynote presentation at the Biomed Israel 2022 Conference on May 12, 2022, and a corporate overview at the H.C. Wainwright Global Investment Conference taking place May 23 – May 26, 2022.","TEL AVIV, Israel and NEW YORK, May  03, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the company will present new data on its novel Monocyte Targeting Technology and lead candidate VB-601 at IMMUNOLOGY2022TM being held in Portland, OR on May 6 – 10, 2022. In addition, Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will discuss the VB-601 program at the LifeSci Immunology & Inflammation Symposium being held virtually on May 11, 2022. Prof. Harats will also provide a keynote presentation at the Biomed Israel 2022 Conference on May 12, 2022, and a corporate overview at the H.C. Wainwright Global Investment Conference taking place May 23 – May 26, 2022.",Calendar of Events,0.023529389,0.022250681,long
VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17,"TEL AVIV, Israel and NEW YORK, May  10, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release first quarter financial results for the period ended March 31, 2022 on Tuesday, May 17 before market open. Professor Dror Harats, M.D, Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update.","TEL AVIV, Israel and NEW YORK, May  10, 2022  (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release first quarter financial results for the period ended March 31, 2022 on Tuesday, May 17 before market open. Professor Dror Harats, M.D, Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update.",Calendar of Events,0,-0.015872558,short
"Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI",– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – ,– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – ,Product / Services Announcement,-0.007364988,-0.005185034,short
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023,Eight abstracts highlighting new data from Vir's chronic hepatitis B and chronic hepatitis delta programs have been accepted for presentation at AASLD.,Eight abstracts highlighting new data from Vir's chronic hepatitis B and chronic hepatitis delta programs have been accepted for presentation at AASLD.,Calendar of Events,-0.009009,-0.011540427,short
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness,"SAN FRANCISCO, July  20, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed. Participants who received the highest dose showed an approximately 57% reduction in symptomatic influenza A illness, when defined according to CDC influenza-like-illness criteria, which was one of two secondary endpoints. VIR-2482 was generally well tolerated and no safety signals were identified.","SAN FRANCISCO, July  20, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed. Participants who received the highest dose showed an approximately 57% reduction in symptomatic influenza A illness, when defined according to CDC influenza-like-illness criteria, which was one of two secondary endpoints. VIR-2482 was generally well tolerated and no safety signals were identified.",Clinical Study,-0.405639902,-0.403377163,short
"Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer","SAN FRANCISCO, May  15, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for leading the Company’s business development efforts, optimizing existing alliances and establishing new strategic industry and public-private partnerships. He reports to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and joins Vir’s executive management team.","SAN FRANCISCO, May  15, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for leading the Company’s business development efforts, optimizing existing alliances and establishing new strategic industry and public-private partnerships. He reports to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and joins Vir’s executive management team.",Directors and Officers,0.00202508,0.000494419,long
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer,"SAN FRANCISCO, June  29, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company’s strategic approach to corporate communications, government affairs, investor relations and patient advocacy, as well as for establishing Vir’s corporate social responsibility and environmental, social and governance efforts. She will report to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company’s Executive Management Team.","SAN FRANCISCO, June  29, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company’s strategic approach to corporate communications, government affairs, investor relations and patient advocacy, as well as for establishing Vir’s corporate social responsibility and environmental, social and governance efforts. She will report to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company’s Executive Management Team.",Management Changes,-0.003617293,-0.002631883,short
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats,Vir Biotechnology Awarded approximately $50 million in BARDA Funding to Support Development of Antibody Platform Technologies for COVID-19,Vir Biotechnology Awarded approximately $50 million in BARDA Funding to Support Development of Antibody Platform Technologies for COVID-19,Contests/Awards,0,0.005265498,long
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate,Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity,Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity,Clinical Study,0,0.008372242,long
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers,Trial evaluating the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants,Trial evaluating the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants,Clinical Study,-0.030769203,-0.040043756,short
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate,Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults,Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults,Clinical Study,0.021978,0.025829456,long
"Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock","SOUTH SAN FRANCISCO, Calif., June  07, 2023  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock, for gross proceeds of approximately $15,000,000, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Vaxart. The offering is expected to close on or about June 9, 2023, subject to customary closing conditions. In addition, Vaxart has granted to the underwriter a 30-day option to purchase up to 2.4 million additional shares of its common stock.","SOUTH SAN FRANCISCO, Calif., June  07, 2023  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock, for gross proceeds of approximately $15,000,000, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Vaxart. The offering is expected to close on or about June 9, 2023, subject to customary closing conditions. In addition, Vaxart has granted to the underwriter a 30-day option to purchase up to 2.4 million additional shares of its common stock.",Changes in company's own shares,-0.266129017,-0.267086902,short
"Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET","SOUTH SAN FRANCISCO, Calif., May  31, 2023  (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it is launching an investor communication program that will give investors the ability to ask questions of Company management. The first event will be a fireside chat with Vaxart executives on Thursday, June 15 at 11 a.m. ET.","SOUTH SAN FRANCISCO, Calif., May  31, 2023  (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it is launching an investor communication program that will give investors the ability to ask questions of Company management. The first event will be a fireside chat with Vaxart executives on Thursday, June 15 at 11 a.m. ET.",Product / Services Announcement,0.008130073,0.012651931,long
Vaxart Names Phillip Lee as Chief Financial Officer,"Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions","Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions",Directors and Officers,-0.028301861,-0.028823719,short
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus,Company to provide a detailed overview of its norovirus clinical program,Company to provide a detailed overview of its norovirus clinical program,Clinical Study,0,0.007295913,long
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19,"SOUTH SAN FRANCISCO, Calif., Oct.  11, 2023  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on Wednesday, October 18 and Thursday, October 19, 2023.","SOUTH SAN FRANCISCO, Calif., Oct.  11, 2023  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on Wednesday, October 18 and Thursday, October 19, 2023.",Calendar of Events,0,-0.002531427,short
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6,"SOUTH SAN FRANCISCO, Calif., March  29, 2023  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will make presentations at the World Vaccine Congress Washington 2023 in Washington, D.C. on Wednesday, April 5 and Thursday, April 6, 2023.","SOUTH SAN FRANCISCO, Calif., March  29, 2023  (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will make presentations at the World Vaccine Congress Washington 2023 in Washington, D.C. on Wednesday, April 5 and Thursday, April 6, 2023.",Calendar of Events,0.039999962,0.029054597,long
Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators  by the US Patent and Trademark Office,Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients,Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients,Patents,0.101694924,0.099184354,long
Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference,"WARRINGTON, Pa., Feb.  27, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is targeting cardiogenic shock as a potential indication for its drug candidate, istaroxime.   ","WARRINGTON, Pa., Feb.  27, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is targeting cardiogenic shock as a potential indication for its drug candidate, istaroxime.   ",Calendar of Events,0.002898548,-0.00590611,short
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism,This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure,This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure,Patents,0.016949137,0.014576446,long
Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure,"Additionally, the USPTO Has Published the Patent Application for One Group of Windtree’s SERCA2a Activators Additionally, the USPTO Has Published the Patent Application for One Group of Windtree’s SERCA2a Activators","Additionally, the USPTO Has Published the Patent Application for One Group of Windtree’s SERCA2a Activators Additionally, the USPTO Has Published the Patent Application for One Group of Windtree’s SERCA2a Activators",Product / Services Announcement,-0.081210225,-0.079953091,short
Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime,US Hospital Claims Data Reveals Cardiogenic Shock Patients Have an Average Hospital Length of Stay of 19.6 Days Making Its Intensive Patient Care Cost Very High,US Hospital Claims Data Reveals Cardiogenic Shock Patients Have an Average Hospital Length of Stay of 19.6 Days Making Its Intensive Patient Care Cost Very High,Health,-0.05348459,-0.055612266,short
22nd Century Group (XXII) Highlights Recent TCORS Symposium Findings,FDA Authorized VLN® Products from 22nd Century Group Provide Key Support to Menthol Ban and Reduced Nicotine Content Policies Currently Advancing in the U.S.,FDA Authorized VLN® Products from 22nd Century Group Provide Key Support to Menthol Ban and Reduced Nicotine Content Policies Currently Advancing in the U.S.,Product / Services Announcement,0,-0.00887882,short
Windtree Regains Compliance with Nasdaq,"WARRINGTON, Pa., March  13, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC (""Nasdaq"") informing Windtree that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.","WARRINGTON, Pa., March  13, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC (""Nasdaq"") informing Windtree that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.",Changes in company's own shares,-0.036796554,-0.0261723,short
Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent,Compounds that activate SERCA2a may lead to novel therapies for heart failure Compounds that activate SERCA2a may lead to novel therapies for heart failure,Compounds that activate SERCA2a may lead to novel therapies for heart failure Compounds that activate SERCA2a may lead to novel therapies for heart failure,Product / Services Announcement,0.084474858,0.084693052,long
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office,New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039 New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039,New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039 New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039,Patents,0.034999967,0.048078363,long
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent,This class of SERCA2a Activators selectively activates SERCA2a and may lead to novel therapies for heart failure beyond the Company’s current lead program This class of SERCA2a Activators selectively activates SERCA2a and may lead to novel therapies for heart failure beyond the Company’s current lead program,This class of SERCA2a Activators selectively activates SERCA2a and may lead to novel therapies for heart failure beyond the Company’s current lead program This class of SERCA2a Activators selectively activates SERCA2a and may lead to novel therapies for heart failure beyond the Company’s current lead program,Product / Services Announcement,0.032608664,0.033631595,long
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering,"WARRINGTON, Pa., April  20, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the pricing of its underwritten public offering of 3,686,006 shares of common stock and warrants to purchase up to 3,686,006 shares of common stock (the “Offering”). Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined public offering price of $2.93 per share of common stock and accompanying warrant, less the underwriting discounts and commissions. The warrants have an exercise price of $2.93 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The warrants are fixed priced and do not contain any price based anti-dilution or variable pricing features. The Offering is expected to close on or about April 24, 2023, subject to the satisfaction of customary closing conditions.","WARRINGTON, Pa., April  20, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the pricing of its underwritten public offering of 3,686,006 shares of common stock and warrants to purchase up to 3,686,006 shares of common stock (the “Offering”). Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined public offering price of $2.93 per share of common stock and accompanying warrant, less the underwriting discounts and commissions. The warrants have an exercise price of $2.93 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The warrants are fixed priced and do not contain any price based anti-dilution or variable pricing features. The Offering is expected to close on or about April 24, 2023, subject to the satisfaction of customary closing conditions.",Stock Market News,-0.571428547,-0.564353589,short
Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime,"WARRINGTON, Pa., April  27, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders of acute heart failure and a lead program studying istaroxime in cardiogenic shock. Cardiogenic shock is caused by a failing heart resulting in diminished cardiac output to the body and is characterized by very low blood pressure and hypoperfusion to end-organs. It is a treatment emergency with high morbidity and mortality.","WARRINGTON, Pa., April  27, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders of acute heart failure and a lead program studying istaroxime in cardiogenic shock. Cardiogenic shock is caused by a failing heart resulting in diminished cardiac output to the body and is characterized by very low blood pressure and hypoperfusion to end-organs. It is a treatment emergency with high morbidity and mortality.",Clinical Study,0.034090944,0.027562072,long
"22nd Century Group (XXII) Launching VLN® at #1 U.S. C-Store Chain in Texas, California and Florida","Largest U.S. C-Store Chain Will Add VLN® to More Than 1,450 Corporate Stores in Three Largest State Markets, Incentivizes Additional 3,100 Franchise Stores to Join the Launch","Largest U.S. C-Store Chain Will Add VLN® to More Than 1,450 Corporate Stores in Three Largest State Markets, Incentivizes Additional 3,100 Franchise Stores to Join the Launch",Product / Services Announcement,0.030456905,0.031463678,long
Windtree Therapeutics Announces Reverse Stock Split,"WARRINGTON, Pa., Feb.  23, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the Company’s Board of Directors has approved a 1-for-50 reverse stock split of its issued and outstanding common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on February 24, 2023 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a split-adjusted basis under the symbol “WINT”. At such time, the Company’s common stock will also commence trading under a new CUSIP number, 97382D 402.","WARRINGTON, Pa., Feb.  23, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the Company’s Board of Directors has approved a 1-for-50 reverse stock split of its issued and outstanding common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on February 24, 2023 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a split-adjusted basis under the symbol “WINT”. At such time, the Company’s common stock will also commence trading under a new CUSIP number, 97382D 402.",Product / Services Announcement,-0.36,-0.357758756,short
"Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors","WARRINGTON, Pa., June  27, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck, Ph.D. to its Board of Directors.","WARRINGTON, Pa., June  27, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck, Ph.D. to its Board of Directors.",Directors and Officers,0.015624985,0.013515761,long
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates,"WARRINGTON, Pa., April  03, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided key business updates.","WARRINGTON, Pa., April  03, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided key business updates.",Earnings Releases and Operating Results,-0.030060045,-0.028740989,short
"Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones","Virtual event to take place on June 14, 2023 at 1:00 pm ET","Virtual event to take place on June 14, 2023 at 1:00 pm ET",Health,0.007194238,0.006352993,long
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th,"WARRINGTON, Pa., Oct.  03, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming Dawson James Small Cap Growth Conference on October 12, 2023 in Jupiter, FL.  ","WARRINGTON, Pa., Oct.  03, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming Dawson James Small Cap Growth Conference on October 12, 2023 in Jupiter, FL.  ",Calendar of Events,-0.029411737,-0.024146239,short
Windtree to Present at the Sidoti Micro Cap Conference on November 16th,"WARRINGTON, Pa., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate update at the Sidoti Micro Cap Conference on Thursday, November 16, 2023 at 1:45pm ET. Windtree management will also be participating in virtual 1x1 meetings with investors at the event on November 15 and 16.","WARRINGTON, Pa., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate update at the Sidoti Micro Cap Conference on Thursday, November 16, 2023 at 1:45pm ET. Windtree management will also be participating in virtual 1x1 meetings with investors at the event on November 15 and 16.",Calendar of Events,0.028571516,0.027152536,long
Windtree to Present at the ThinkEquity Conference on October 19th in New York City,"WARRINGTON, Pa., Oct.  12, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming ThinkEquity Conference on Thursday, October 19, 2023 at 4:30pm ET. Windtree management will also be hosting 1x1 meetings with investors at the event.","WARRINGTON, Pa., Oct.  12, 2023  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming ThinkEquity Conference on Thursday, October 19, 2023 at 4:30pm ET. Windtree management will also be hosting 1x1 meetings with investors at the event.",Calendar of Events,0.043859712,0.042415807,long
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis,(Phase II Multicenter Study is Proceeding Well with High Anticipation) (Phase II Multicenter Study is Proceeding Well with High Anticipation),(Phase II Multicenter Study is Proceeding Well with High Anticipation) (Phase II Multicenter Study is Proceeding Well with High Anticipation),Clinical Study,0.010178107,-0.003747709,short
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients,XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment,XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment,Product / Services Announcement,-0.0040404,-0.004088223,short
XBiotech annonce la première administration du nouveau traitement Natrunix à un patient lors d'un essai clinique de phase II sur l'arthrite rhumatoïde (AR),"AUSTIN, Texas,  09 août 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a débuté aujourd'hui le traitement du premier patient dans le cadre d'une étude clinique randomisée de phase II en double aveugle et contrôlée par placebo visant à évaluer Natrunix en tant que nouveau traitement pour l'arthrite. Natrunix bloque une cause clé de l'inflammation impliquée dans la douleur et la destruction articulaire de l'arthrite rhumatoïde (AR).","AUSTIN, Texas,  09 août 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a débuté aujourd'hui le traitement du premier patient dans le cadre d'une étude clinique randomisée de phase II en double aveugle et contrôlée par placebo visant à évaluer Natrunix en tant que nouveau traitement pour l'arthrite. Natrunix bloque une cause clé de l'inflammation impliquée dans la douleur et la destruction articulaire de l'arthrite rhumatoïde (AR).",Clinical Study,-0.039999962,-0.03269533,short
XBiotech annonce le recrutement du premier patient à l'étude clinique de phase I/II/III sur Natrunix™ pour le traitement du cancer colorectal parrainée par l'Institut national du cancer (INCa) français,"Lancement de l'étude de phase I/II/III sur Natrunix en combinaison avec la trifluridine/le tipiracil (étude TASKIN), financée par l'INCa, dans 20 centres médicaux de premier plan en France Lancement de l'étude de phase I/II/III sur Natrunix en combinaison avec la trifluridine/le tipiracil (étude TASKIN), financée par l'INCa, dans 20 centres médicaux de premier plan en France","Lancement de l'étude de phase I/II/III sur Natrunix en combinaison avec la trifluridine/le tipiracil (étude TASKIN), financée par l'INCa, dans 20 centres médicaux de premier plan en France Lancement de l'étude de phase I/II/III sur Natrunix en combinaison avec la trifluridine/le tipiracil (étude TASKIN), financée par l'INCa, dans 20 centres médicaux de premier plan en France",Health,-0.018766738,0.010862846,long
22nd Century Group (XXII) Reduces Debt by $8.1 Million,37% Reduction Through the Transfer of Non-Core and Previously Restricted Assets 37% Reduction Through the Transfer of Non-Core and Previously Restricted Assets,37% Reduction Through the Transfer of Non-Core and Previously Restricted Assets 37% Reduction Through the Transfer of Non-Core and Previously Restricted Assets,Financing Agreements,0,0.004107335,long
"XBiotech annonce le recrutement du premier sujet dans son essai clinique de phase I pour Hutrukin, un nouveau traitement candidat pour l'AVC","Hutrukin, un traitement découvert et fabriqué chez XBiotech, vise à réduire l'endommagement cérébral suite à un AVC Hutrukin, un traitement découvert et fabriqué chez XBiotech, vise à réduire l'endommagement cérébral suite à un AVC","Hutrukin, un traitement découvert et fabriqué chez XBiotech, vise à réduire l'endommagement cérébral suite à un AVC Hutrukin, un traitement découvert et fabriqué chez XBiotech, vise à réduire l'endommagement cérébral suite à un AVC",Product / Services Announcement,-0.010752678,-0.014559956,short
"XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke","AUSTIN, Texas, Sept.  26, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical study has been enrolled. XBiotech discovered, manufactures, and is conducting this clinical study of Hutrukin.","AUSTIN, Texas, Sept.  26, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical study has been enrolled. XBiotech discovered, manufactures, and is conducting this clinical study of Hutrukin.",Clinical Study,-0.00717697,8.77E-05,long
"XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer","AUSTIN, Texas, Aug.  30, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer.","AUSTIN, Texas, Aug.  30, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer.",Clinical Study,-0.003883491,-0.004662737,short
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial,"AUSTIN, Texas, Aug.  08, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (RA).","AUSTIN, Texas, Aug.  08, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (RA).",Clinical Study,0.008064508,0.00656921,long
"XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke","Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke","Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke",Product / Services Announcement,0.044943845,0.045162039,long
"XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares","AUSTIN, Texas, May  17, 2023  (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in value of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not greater than $4.00 nor less than $3.80 per common share, to the seller in cash, less any applicable withholding taxes and without interest (the “Offer”). The Offer is made upon the terms and subject to the conditions described in an offer to purchase dated May 17, 2023, the related letter of transmittal and the website established for purposes of effectuating the Offer. The closing price of XBiotech’s common shares on the NASDAQ Global Select Market on May 17, 2023, the last trading day before the commencement of the Offer, was $3.48 per share. The Offer is scheduled to expire at 5:00 p.m., Eastern Time, on June 15, 2023, unless the Offer is extended.","AUSTIN, Texas, May  17, 2023  (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in value of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not greater than $4.00 nor less than $3.80 per common share, to the seller in cash, less any applicable withholding taxes and without interest (the “Offer”). The Offer is made upon the terms and subject to the conditions described in an offer to purchase dated May 17, 2023, the related letter of transmittal and the website established for purposes of effectuating the Offer. The closing price of XBiotech’s common shares on the NASDAQ Global Select Market on May 17, 2023, the last trading day before the commencement of the Offer, was $3.48 per share. The Offer is scheduled to expire at 5:00 p.m., Eastern Time, on June 15, 2023, unless the Offer is extended.",Changes in company's own shares,0.1408046,0.135685755,long
USDA-APHIS Determines that Yield10 Bioscience’s Glufosinate Tolerant Camelina May Be Planted and Bred in the United States,-Yield10 Achieves a Significant Milestone in the Development of Camelina as a Commercial Crop for Producing Biofuels and Omega-3 Oils,-Yield10 Achieves a Significant Milestone in the Development of Camelina as a Commercial Crop for Producing Biofuels and Omega-3 Oils,Product / Services Announcement,-0.064516163,-0.067591452,short
XBiotech gibt ersten mit der neuartigen Natrunix-Therapie behandelten Patienten in einer klinischen Phase-II-Studie zu rheumatoider Arthritis (RA) bekannt,"AUSTIN, Texas, Aug.  09, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc.(NASDAQ: XBIT) hat heute mit der Behandlung des ersten Patienten in einer doppelblinden, placebokontrollierten, randomisierten klinischen Studie der Phase II begonnen, um Natrunix als neue Behandlung für Arthritis zu untersuchen. Natrunix blockiert eine der Hauptursachen für Entzündungen, die zu Schmerzen und Gelenkzerstörung bei rheumatoider Arthritis (RA) führen.","AUSTIN, Texas, Aug.  09, 2023  (GLOBE NEWSWIRE) -- XBiotech Inc.(NASDAQ: XBIT) hat heute mit der Behandlung des ersten Patienten in einer doppelblinden, placebokontrollierten, randomisierten klinischen Studie der Phase II begonnen, um Natrunix als neue Behandlung für Arthritis zu untersuchen. Natrunix blockiert eine der Hauptursachen für Entzündungen, die zu Schmerzen und Gelenkzerstörung bei rheumatoider Arthritis (RA) führen.",Clinical Study,-0.039999962,-0.03269533,short
"XBiotech meldet Rekrutierung des ersten Teilnehmers in klinischer Phase-I-Studie zu Hutrukin, einem neuartigen Therapiekandidaten bei Schlaganfällen","Hutrukin, eine bei XBiotech entdeckte und hergestellte Therapie, soll Hirnschäden nach einem Schlaganfall verringern Hutrukin, eine bei XBiotech entdeckte und hergestellte Therapie, soll Hirnschäden nach einem Schlaganfall verringern","Hutrukin, eine bei XBiotech entdeckte und hergestellte Therapie, soll Hirnschäden nach einem Schlaganfall verringern Hutrukin, eine bei XBiotech entdeckte und hergestellte Therapie, soll Hirnschäden nach einem Schlaganfall verringern",Product / Services Announcement,-0.010752678,-0.014559956,short
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market,X4 WHIM Phase 3 clinical data webinar to be held today at 4 pm ET X4 WHIM Phase 3 clinical data webinar to be held today at 4 pm ET,X4 WHIM Phase 3 clinical data webinar to be held today at 4 pm ET X4 WHIM Phase 3 clinical data webinar to be held today at 4 pm ET,Management statements,0.177631569,0.180416064,long
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors,"BOSTON, Oct.  18, 2023  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of R. Keith Woods as an independent director to the company’s Board of Directors.","BOSTON, Oct.  18, 2023  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of R. Keith Woods as an independent director to the company’s Board of Directors.",Directors and Officers,0.003344438,0.007541463,long
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome,"FDA sets a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024","FDA sets a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024",Product / Services Announcement,0.105047782,0.103628122,long
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital,"BOSTON, Aug.  03, 2023  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The company also announced that it drew down $22.5 million upon the transaction’s closing.","BOSTON, Aug.  03, 2023  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The company also announced that it drew down $22.5 million upon the transaction’s closing.",Mergers and Acquisitions,-0.005747121,-0.001104026,short
X4 Pharmaceuticals Expected to Join Russell 3000® Index,"BOSTON, June  13, 2023  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced that it expects to be added to the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023, according to a preliminary list of additions posted on June 9, 2023.","BOSTON, June  13, 2023  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced that it expects to be added to the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023, according to a preliminary list of additions posted on June 9, 2023.",Product / Services Announcement,0.035242257,0.031738293,long
X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference,"BOSTON, Sept.  19, 2023  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City, from September 26-28, 2023.","BOSTON, Sept.  19, 2023  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City, from September 26-28, 2023.",Calendar of Events,0.009174303,0.011315755,long
22nd Century Announces Executive Leadership Changes,Expands Board with New Highly Accomplished Independent Director,Expands Board with New Highly Accomplished Independent Director,Directors and Officers,-0.402061824,-0.404693525,short
22nd Century Announces Pricing of $5.25 Million Public Offering,"BUFFALO, N.Y., Oct.  17, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced the pricing of its previously announced public offering of 10,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 20,000,000 shares of common stock, at a combined public offering price of $0.525 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The warrants have an exercise price of $0.525 per share, are immediately exercisable and will expire five years following the date of issuance. The offering is expected to close on or about October 19, 2023, subject to the satisfaction of customary closing conditions.","BUFFALO, N.Y., Oct.  17, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced the pricing of its previously announced public offering of 10,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 20,000,000 shares of common stock, at a combined public offering price of $0.525 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The warrants have an exercise price of $0.525 per share, are immediately exercisable and will expire five years following the date of issuance. The offering is expected to close on or about October 19, 2023, subject to the satisfaction of customary closing conditions.",Stock Market News,-0.090909111,-0.083501508,short
"22nd Century Group Continues VLN® Expansion, Now Retailing in More Than 5,100 Stores",Adds another 500+ stores Adds another 500+ stores,Adds another 500+ stores Adds another 500+ stores,Management statements,-0.088372132,-0.087686524,short
"22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2023 Results on August 14, 2023","BUFFALO, N.Y., Aug.  07, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, will host a live webcast on Monday, August 14, 2023, at 10:00 AM ET to discuss its 2023 first quarter results, which are to be reported in a press release at 6:00 AM ET the same day.","BUFFALO, N.Y., Aug.  07, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, will host a live webcast on Monday, August 14, 2023, at 10:00 AM ET to discuss its 2023 first quarter results, which are to be reported in a press release at 6:00 AM ET the same day.",Calendar of Events,-0.009493662,-0.013746015,short
"22nd Century Group (XXII) Adds 1,200 Drug Store Locations Selling VLN® in Five States","First Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023 First Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023","First Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023 First Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023",Product / Services Announcement,0.015999985,0.019344839,long
"22nd Century Group (XXII) Announces New Agreement with Hub, Inc. to Expand Midwest Distribution","Enhances Reach for Regional, Specialty and Tribal Retail Channels Enhances Reach for Regional, Specialty and Tribal Retail Channels","Enhances Reach for Regional, Specialty and Tribal Retail Channels Enhances Reach for Regional, Specialty and Tribal Retail Channels",Financing Agreements,0.041840962,0.032958751,long
22nd Century Group (XXII) Announces Participation in the LD Micro Invitational XIII,"BUFFALO, N.Y., June  02, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced it will participate in the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, Los Angeles, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private one-on-one meetings.","BUFFALO, N.Y., June  02, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced it will participate in the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, Los Angeles, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private one-on-one meetings.",Calendar of Events,0.004958686,-0.001394717,short
22nd Century Group (XXII) Announces Production of VLN® Homogenized Tobacco Leaf Sheet,HTL Is Commonly Used in Heat-Not-Burn and Cigar Binder and Wrapper Applications,HTL Is Commonly Used in Heat-Not-Burn and Cigar Binder and Wrapper Applications,Product / Services Announcement,-0.02158277,-0.013381315,short
22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License,Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding Capabilities Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding Capabilities,Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding Capabilities Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding Capabilities,Company Announcement,0.031111109,0.031111109,long
22nd Century Group (XXII) Regains Compliance with Nasdaq Listing Standards,"BUFFALO, N.Y., July  20, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today announced notification that it has regained compliance with Nasdaq listing requirements.","BUFFALO, N.Y., July  20, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today announced notification that it has regained compliance with Nasdaq listing requirements.",Changes in company's own shares,0.003649632,0.00591237,long
22nd Century Group (XXII) Reports Third Quarter 2023 Financial Results,"BUFFALO, N.Y., Nov.  06, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today reported results for the third quarter ended September 30, 2023, and provided an update on recent business highlights.","BUFFALO, N.Y., Nov.  06, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today reported results for the third quarter ended September 30, 2023, and provided an update on recent business highlights.",Earnings Releases and Operating Results,-0.009900981,-0.01169536,short
"22nd Century Group (XXII) Supports FDA Policy Advancements, Proposed Menthol Ban Now at OMB","BUFFALO, N.Y., Oct.  26, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, announced that it supports the recent move by the US Food and Drug Administration to send final rules aimed at banning menthol in cigarettes and banning flavored cigars to the White House Office of Management and Budget for review, a key regulatory step toward the rules becoming federal policy.","BUFFALO, N.Y., Oct.  26, 2023  (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, announced that it supports the recent move by the US Food and Drug Administration to send final rules aimed at banning menthol in cigarettes and banning flavored cigars to the White House Office of Management and Budget for review, a key regulatory step toward the rules becoming federal policy.",Management statements,0.027026989,0.029661345,long
22nd Century Group (XXII) VLN® Products Now Selling in Montana C-Stores,"Town Pump, #1 Chain in Montana, Selling VLN® Products in More Than 80 Stores Across the State","Town Pump, #1 Chain in Montana, Selling VLN® Products in More Than 80 Stores Across the State",Product / Services Announcement,0.031111081,0.026896013,long
"A Cigarette to Help Californians Smoke Less: 22nd Century Group, Inc. Launches Reduced Nicotine VLN® King Cigarettes in California, VLN Will Be Sold at #1 U.S. Convenience Store Chain and Other Responsible Retail Locations","With 95% less nicotine than a traditional cigarette, VLN® cigarettes help existing adult smokers reduce their nicotine consumption and dependence With 95% less nicotine than a traditional cigarette, VLN® cigarettes help existing adult smokers reduce their nicotine consumption and dependence","With 95% less nicotine than a traditional cigarette, VLN® cigarettes help existing adult smokers reduce their nicotine consumption and dependence With 95% less nicotine than a traditional cigarette, VLN® cigarettes help existing adult smokers reduce their nicotine consumption and dependence",Product / Services Announcement,0.012931023,0.013264876,long
VLN® Products Launch in Nevada to Help Smokers Smoke Less,Terrible Herbst and Speedee Mart Selling VLN® Reduced Nicotine Products in Approximately 200 Las Vegas Area Stores,Terrible Herbst and Speedee Mart Selling VLN® Reduced Nicotine Products in Approximately 200 Las Vegas Area Stores,Product / Services Announcement,0.022222236,0.024555346,long
USDA-APHIS Determines that Yield10 Bioscience’s Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States,-Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America -Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America,-Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America -Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America,Regulatory information,-0.064516163,-0.067591452,short
Yield10 Bioscience and American Airlines Sign MOU to Form a Collaboration to Develop the Value Chain for Camelina as a Feedstock Oil for Sustainable Aviation Fuel,"WOBURN, Mass., March  02, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that it signed a Memorandum of Understanding (“MOU”) with American Airlines, Inc. (NASDAQ: AAL) on February 27, 2023 to collaborate in developing the value chain for Camelina as a low-carbon feedstock oil for sustainable aviation fuel (“SAF”). American is committed to helping to scale SAF production as a cornerstone of its climate strategy this decade.","WOBURN, Mass., March  02, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that it signed a Memorandum of Understanding (“MOU”) with American Airlines, Inc. (NASDAQ: AAL) on February 27, 2023 to collaborate in developing the value chain for Camelina as a low-carbon feedstock oil for sustainable aviation fuel (“SAF”). American is committed to helping to scale SAF production as a cornerstone of its climate strategy this decade.",Partnerships,0.078358221,0.08357684,long
Yield10 Bioscience and BioMar Aim to Grow Fish Oil on Land,"Yield10 Bioscience and BioMar Group have signed an LOI to form a long-term partnership to commercialize a Camelina crop containing enriched levels of EPA and DHA equal to fish oil. After a decade of research, this Omega-3 Camelina technology is now advancing toward market availability and has the potential to become another important, high-quality supplement to the scarce supply of marine long-chain fatty acids.","Yield10 Bioscience and BioMar Group have signed an LOI to form a long-term partnership to commercialize a Camelina crop containing enriched levels of EPA and DHA equal to fish oil. After a decade of research, this Omega-3 Camelina technology is now advancing toward market availability and has the potential to become another important, high-quality supplement to the scarce supply of marine long-chain fatty acids.",Partnerships,0.064516163,0.063096504,long
Yield10 Bioscience and Marathon Petroleum Corporation Sign LOI for Potential Investment and Offtake Agreement for Camelina Feedstock Oil for Renewable Fuels,"WOBURN, Mass., May  01, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that it has signed a non-binding Letter of Intent (“LOI”) with Marathon Petroleum Corp. (NYSE: MPC, “Marathon”) for a potential investment and offtake agreement for low-carbon intensity Camelina feedstock oil for use in renewable fuels production. Marathon is a leading, integrated downstream energy company in the U.S.","WOBURN, Mass., May  01, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that it has signed a non-binding Letter of Intent (“LOI”) with Marathon Petroleum Corp. (NYSE: MPC, “Marathon”) for a potential investment and offtake agreement for low-carbon intensity Camelina feedstock oil for use in renewable fuels production. Marathon is a leading, integrated downstream energy company in the U.S.",Partnerships,0.09122807,0.092334005,long
Yield10 Bioscience Announces Closing of $3.7 Million Public Offering,"WOBURN, Mass., Aug.  15, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the closing of its previously announced public offering of 5,750,000 units at a public offering price of $0.65 per unit. Each unit consisted of one share of common stock and one warrant to purchase one share of common stock. The warrants are immediately exercisable at an exercise price of $0.65 per share and expire five years from the date of issuance. The shares of common stock and accompanying warrants could only be purchased together in this offering but were issued separately and are immediately separable upon issuance.","WOBURN, Mass., Aug.  15, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the closing of its previously announced public offering of 5,750,000 units at a public offering price of $0.65 per unit. Each unit consisted of one share of common stock and one warrant to purchase one share of common stock. The warrants are immediately exercisable at an exercise price of $0.65 per share and expire five years from the date of issuance. The shares of common stock and accompanying warrants could only be purchased together in this offering but were issued separately and are immediately separable upon issuance.",Product / Services Announcement,0,0.007573833,long
Yield10 Bioscience Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina,-On track for commercial launch of first herbicide tolerant Camelina variety as early as 2025,-On track for commercial launch of first herbicide tolerant Camelina variety as early as 2025,Product / Services Announcement,0.030303,0.027771574,long
"Yield10 Bioscience Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina, Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market",-Findings demonstrate a key advancement in the development of proprietary Camelina varieties tolerant to application of broadleaf weed control as well as to Group 2 soil residual herbicide chemistries,-Findings demonstrate a key advancement in the development of proprietary Camelina varieties tolerant to application of broadleaf weed control as well as to Group 2 soil residual herbicide chemistries,Advisory,-0.030836975,-0.023761066,short
Yield10 Bioscience Announces Pricing of $3.0 Million Registered Direct Offering and Concurrent Private Placement,"WOBURN, Mass., May  03, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that it has agreed to sell $3.0 million of its shares of common stock (or prefunded warrants in lieu thereof) in a registered direct offering and warrants in a concurrent private placement with investors including a certain institutional investor and an existing investor.","WOBURN, Mass., May  03, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that it has agreed to sell $3.0 million of its shares of common stock (or prefunded warrants in lieu thereof) in a registered direct offering and warrants in a concurrent private placement with investors including a certain institutional investor and an existing investor.",Changes in company's own shares,0.0135135,0.021632901,long
Yield10 Bioscience Announces Pricing of $3.7 Million Public Offering,"WOBURN, Mass., Aug.  11, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the pricing of its public offering of 5,750,000 units at a public offering price of $0.65 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock. The warrants will be immediately exercisable at an exercise price of $0.65 per share and will expire five years from the date of issuance. The shares of common stock and accompanying warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance.","WOBURN, Mass., Aug.  11, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the pricing of its public offering of 5,750,000 units at a public offering price of $0.65 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock. The warrants will be immediately exercisable at an exercise price of $0.65 per share and will expire five years from the date of issuance. The shares of common stock and accompanying warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance.",Major shareholder announcements,-0.564356434,-0.560005775,short
"Yield10 Bioscience Completes Harvest of a Majority of the 2023 Winter and Spring Camelina Grain Grown Under Contract, Generating Revenue from Biofuel Production",Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform,Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform,Calendar of Events,0.030303,0.035568498,long
"Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research","WOBURN, Mass., Oct.  18, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has exercised its option to finalize an exclusive global, commercial license to advanced omega-3 production technology from U.K.-based Rothamsted Research Limited (“Rothamsted”). In 2020, Yield10 signed an exclusive collaboration agreement with Rothamsted to support Rothamsted’s Flagship Program to develop omega-3 oils in Camelina sativa (“Camelina”). As part of the collaboration agreement, Yield10 received an exclusive option to sign a global, exclusive license agreement for the technology.","WOBURN, Mass., Oct.  18, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has exercised its option to finalize an exclusive global, commercial license to advanced omega-3 production technology from U.K.-based Rothamsted Research Limited (“Rothamsted”). In 2020, Yield10 signed an exclusive collaboration agreement with Rothamsted to support Rothamsted’s Flagship Program to develop omega-3 oils in Camelina sativa (“Camelina”). As part of the collaboration agreement, Yield10 received an exclusive option to sign a global, exclusive license agreement for the technology.",Product / Services Announcement,0.193548393,0.197745418,long
Yield10 Bioscience Files Request for Regulatory Status Review under USDA-APHIS’s SECURE Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil,-Omega-3 (EPA) Camelina planted at acre-scale in US nearing maturity,-Omega-3 (EPA) Camelina planted at acre-scale in US nearing maturity,Product / Services Announcement,0.016304332,0.018434143,long
"Yield10 Bioscience to Announce First Quarter 2023 Financial Results and Host a Conference Call on Wednesday, May 10, 2023","WOBURN, Mass., May  04, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its first quarter 2023 financial results and provide a corporate update on Wednesday, May 10, 2023.","WOBURN, Mass., May  04, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its first quarter 2023 financial results and provide a corporate update on Wednesday, May 10, 2023.",Calendar of Events,0.029999971,0.0326714,long
"Yield10 Bioscience to Announce Fourth Quarter and Full Year 2022 Financial Results and Host a Conference Call on Tuesday, March 14, 2023","WOBURN, Mass., March  08, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2022 financial results and provide a corporate update on Tuesday, March 14, 2023.","WOBURN, Mass., March  08, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2022 financial results and provide a corporate update on Tuesday, March 14, 2023.",Calendar of Events,-0.027777833,-0.0280792,short
"Yield10 Bioscience to Announce Second Quarter 2023 Financial Results and Host a Conference Call on Monday, August 14, 2023","WOBURN, Mass., Aug.  11, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its second quarter 2023 financial results and provide a corporate update on Monday, August 14, 2023.","WOBURN, Mass., Aug.  11, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its second quarter 2023 financial results and provide a corporate update on Monday, August 14, 2023.",Calendar of Events,-0.564356434,-0.560005775,short
"Yield10 Bioscience to Announce Third Quarter 2023 Financial Results and Host a Conference Call on Tuesday, November 14, 2023","WOBURN, Mass., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its third quarter 2023 financial results and provide a corporate update on Tuesday, November 14, 2023.","WOBURN, Mass., Nov.  08, 2023  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its third quarter 2023 financial results and provide a corporate update on Tuesday, November 14, 2023.",Company Announcement,0,-0.00141898,short
Yield10 Bioscience to Present at the CG AgriFood Tech Innovation Virtual Forum,"WOBURN, Mass., Nov.  21, 2022  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that President and CEO Oliver Peoples, Ph.D. will present a corporate overview at the Canaccord Genuity AgriFood Tech Innovation Virtual Forum on December 1, 2022 at 1:30pm ET.","WOBURN, Mass., Nov.  21, 2022  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that President and CEO Oliver Peoples, Ph.D. will present a corporate overview at the Canaccord Genuity AgriFood Tech Innovation Virtual Forum on December 1, 2022 at 1:30pm ET.",Calendar of Events,-0.007812493,-0.004302698,short
